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Abstract 
Historically, cannabis has been used as a pharmaceutical drug for a variety of conditions 
including rheumatism, depression, convulsions, and malaria. Since the 1970s, 
randomised, controlled clinical trials have shown cannabis to be effective in the 
treatment of debilitating medical conditions including nausea and vomiting resulting 
from cancer chemotherapy, wasting syndrome associated with HIV/AIDS, and chronic 
pain. Despite scientific evidence, as of 2011, when the material for this thesis was 
collected, only 17 states of the United States (U.S.) and the District of Columbia had 
enacted medical cannabis laws allowing patients with specific medical conditions to use 
cannabis without being criminally prosecuted. This thesis examines two components of 
the medical cannabis policy: the medical cannabis policy process in five representative 
states of the U.S., and the factors influencing the formation of such a process. The first 
part of the thesis chronologically documents the passing, attempts to pass, and failure to 
pass medical cannabis policies in five U.S. states; two with a current medical cannabis 
law; one where attempts to pass a law have been made, but a law has not yet been 
passed; and two states where no or few attempts at passing a medical cannabis law have 
been made. The second part of the thesis used a questionnaire to elicit the factors 
influencing policies as perceived by three groups. Group one comprised individuals 
directly involved in the medical cannabis policy process in at least one of the five states 
referred to above and group two comprised individuals participating in research in the 
alcohol and other drug field. Group four comprised members of the International 
Society for the Study of Drug Policy (ISSDP). The study found that, despite the 
expectation that the same rules would apply to cannabis as other medicine, the medical 
cannabis process appears to be less medically and more politically driven, with 
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scientific evidence having limited influence. The results suggest that there are a number 
of interlinking factors which played a role in the passing or failure to pass medical 
cannabis laws in U.S. states, and the level of influence of these factors can vary 
according to context or conditions placed on them. Three major themes emerged in 
relation to the factors influencing policy: the role of scientific evidence, the political 
process, and the interaction between factors. It is hoped that this thesis will be viewed as 
an observation of the medical cannabis process, not only from the researcher’s point of 
view but from the views of those who participated in the process, researched the 
process, or observed the changes in medical cannabis laws over the years. 
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Chapter 1- Introduction 
Studying the origins, development, and implementation of policies allows us to 
enhance knowledge of the policy process and examine factors influencing policy 
creation and implementation, as well as the effects of policy (Birkland, 2005; Sabatier, 
1991; Weible, Heikkila, deLeon, & Sabatier, 2012). If the process by which policies are 
enacted is not analysed, important changes and improvements cannot be made (Burch, 
1999). Anderson (2003) defined policy as “a relatively stable, purposive course of 
action followed by an actor or a set of actors in dealing with a problem or a matter of 
concern” (p.2). This definition of policy will be adopted in this thesis. Policies may take 
various forms such as legislation, executive orders, or others official acts (Anderson, 
2003). 
The policy process is complex and inherently political and does not have one 
single theoretical foundation (Birkland, 2005; Choi et al., 2005; Ritter, 2011). A number 
of theories of the policy process offer insight into the process including “Institutional 
Analysis and Developmental Framework”, “Multiple Streams”, “Advocacy Coalition 
Framework”, “Policy Diffusion”, “Punctuated- Equilibrium”, and “Social Construction 
and Policy Design”  (Nowlin, 2011). Because the policy process is complex and 
multifaceted, Weible et al. (2012) argued that a single framework cannot explain all its 
facets and it is difficult to reach consensus on which is the “best” or most satisfactory 
approach (Anderson, 2003). To enable the reader to understand the process for the 
development of medical cannabis policies, this thesis will adopt the approach of the 
Institute of Medicine (IOM) (1999) study which looked at medical cannabis by 
describing what happened with no predetermined framework identified. By taking this 
approach, this thesis will provide an account of the medical cannabis policymaking 
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process, analyse the evidence and arguments offered in support of the major claims 
made for and against the medical use of cannabis, capture what happened in the states 
with medical cannabis laws, and describe and analyse the process of development of 
medical cannabis policies.    
Participants in the United States Policy Making 
Birkland (2005) outlined two categories of participants in policy making; official 
and unofficial actors. Official actors are involved in public policy and given 
responsibilities in laws or in the Constitution and therefore have the power to make and 
enforce policies. Unofficial actors include those who play a role in the policy process 
but do not have a legal authority. Unofficial actors are involved in the process because 
they have important interests to protect and promote. Interest groups are very important 
unofficial actors and the impact that they have depends on how powerful the group is, 
the control it has over resources, the influence it has on official actors, and access to 
information. The decisions in the policymaking process are the cumulative result of 
interactions between the many actors involved in the process (Wolf, 2000). The political 
process in the U.S. will be discussed in Chapter Two of this thesis.  
There is a complex interaction between the actors in the policy process and 
mixed evidence on what influences policy (Birkland, 2005; Noel, 2010). There are 
normally several actors involved in the process, involving a number of complex 
interacting elements over time (Brownson, Chriqui, & Stamatakis, 2009; Choi et al., 
2005; Sabatier, 1999). The policy process can also be long and occur at different levels 
of government (Sabatier, 1999). Public policies do not just happen through one isolated 
event but are the result of actions or patterns of action taken over time by the actors 
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involved (Anderson, 2003). One element in the mix of influences on the policy process 
is scientific evidence, which is discussed next.  
The Role of the Scientific Evidence  
Evidence-based policy is encouraged in public policy and is occurring in some 
public sectors (Brownson, Baker, Left, Gillespie, & True, 2011; Davies, Nutley, & 
Smith, 2000). The key characteristics of evidence-based policy making in public health 
include making decisions using the best available peer-reviewed evidence, using data 
and information systems systematically, applying program-planning frameworks, 
engaging the community in decision making, conducting sound evaluation, and 
disseminating what is learned (Brownson et al., 2009). Ideally, scientific evidence 
should always be incorporated in selecting and implementing programs, developing 
policies, and evaluating progress (Brownson et al., 2011). However, as the policy 
process is a political rather than scientific process no policy process relies solely on 
research evidence (Anderson, 2003; Brownson et al., 2009; Brownson et al., 2011; 
Pentz, Marers, Schinke, & Rohrbach, 2004; Ritter, 2011). Birkland (2005) and Ritter 
(2011) argued that in order for the study of public policy to be useful to the community 
as a whole, it is important to bridge the gap between what research tells us and how 
citizens and government officials use that information.  
Weiss offered seven different models of the use of research in policymaking 
(Weiss, 1977, 1979). These are (1) knowledge-driven; (2) problem-solving; (3) 
interactive; (4) political; (5) enlightenment; (6) tactical; and (7) intellectual enterprise 
(Weiss, 1979). Weiss suggested that the “enlightenment model” was the way in which 
scientific research most frequently enters the policy arena (Weiss, 1979). In the 
enlightenment model, the impact of research on policy is not direct, but research is 
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instead seen as one of several sources of information available to policymakers (Weiss, 
1977, 1979). Weiss’ enlightenment model indicates that research utilisation develops 
through a gradual shift in thinking and that the accumulation of research will influence 
policy by educating the policymakers.   
Weiss also identified ways in which the results of policy research enter the 
policy field and influence policy decisions (Weiss, 1991). The three ways described by 
Weiss are (1) research as data and findings; (2) research as ideas and criticism; and (3) 
research as arguments or briefs for policy action (Weiss, 1991). The implication of these 
for policy research is that policymakers have to get something out of research if they are 
to use it. When research is used as data or findings it is assumed that these meet the 
users’ needs and that there is no conflict between what the goal of research is and what 
is required by policymakers. Research is likely to be influential when there is consensus 
on values and goals of research and policy. When research is used as ideas, the findings 
are generalised and diffused into a simple story, altering the way that issues are 
conceptualised and problems framed. The ideas from research became absorbed into 
conventional wisdom and bring new insights into the policy process in terms of what 
needs to be done and what solutions will achieve the desired outcomes. Research as 
arguments represents research to which an advocacy position has been added; a decision 
has already been made and the policymakers and/or interest groups use research to 
support their position. When research is used as arguments, the data are selectively lost 
in order to make an argument more persuasive (Weiss, 1991).  
Weiss (1991) suggests that research as data is more likely to be influential in 
situations of consensus on values and goals, when research has been explicitly designed 
to test a limited number of alternatives and findings are clear-cut, when nobody knows 
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what the situation is or if the present conditions are unacceptable, and when decision 
makers using data are skilled in analysing it so that data are not applied beyond their 
generalisability. Research as ideas is more likely to be influential at the early stages of 
policy discussion, when existing policy is in crisis and a way out of the situation is 
needed, when there is uncertainty around what will work and ideas are needed, and in 
decentralised policy arenas where many separate bodies make a decision. Research as 
arguments is more likely to be influential when conflict is high and different sides are 
seeking justification to strengthen their own case, in legislatures where argumentation is 
the prevailing mode, and after decisions have been made and there is continuing need 
for legitimation (Weiss, 1991). In practice, while research can be used for different 
purposes by policymakers, there are also several barriers to effective use of research in 
decision making.   
Barriers to research utilisation. Weiss listed the reasons for the limited use of 
research in policymaking as weaknesses in the research itself, conflicting demands on 
policy, and the discrepancy between what knowledge is needed by policymakers and 
what is provided by researchers (Weiss, 1977, 1979). More recently, Black (2001) listed 
these reasons as (a) policymakers having their own goals for policies other than 
evidence and clinical effectiveness; (b) the dismissal of evidence as irrelevant and not 
applicable to a particular sector; (c) lack of consensus about evidence and its 
interpretations; (d) focus on other types of evidence such as personal experience; (e) a 
social environment not conductive to policy change; and (f) poor quality of knowledge 
purveyors. 
In terms of public health, Brownson et al. (2011) suggested that the potential 
barriers for use of evidence-based decision making are lack of resources, lack of 
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leadership and instability in setting a clear and focused agenda for evidence based 
approaches, lack of incentives for using evidence-based approaches, and lack of a long-
term view for program implementation and evaluation. Brownson et al. (2011) also 
suggested that external (including political) pressures can drive the process away from 
evidence, as well as inadequate training, lack of time to gather the necessary 
information and evidence, lack of evidence on the effectiveness of a specific 
intervention, and lack of information on implementation of interventions. Possible 
approaches to overcoming these barriers and improving the use of scientific evidence 
are discussed next.  
Improving the use of scientific evidence. To improve the use of scientific 
evidence by policymakers, it is necessary to consider which arguments are likely to be 
useful to policymakers (Weiss, 1991). Researchers need to understand the policymaking 
process and that their research may not be used in the way they intended, as the 
policymakers consider other factors in deciding policy. In order for research to have an 
impact, it is necessary to consider the values of the policymakers and the factors other 
than research evidence which play a role in the policymaking process (Weiss, 1991). 
Davies et al. (2000) believed it important for there to be some agreement on what counts 
as evidence in what circumstances, that there should be a strategy of creating evidence 
in priority areas, that such evidence needs to be disseminated where it is most needed 
and made available for wide use, and that strategies should be put in place to ensure that 
evidence is integrated into policy and utilised in practice.  
Bacci (2009) suggested that what needs to happen for research evidence to be 
used effectively in the process is for researchers and decision makers to collaborate 
more instead of working in isolation, and for the decision makers to be involved in all 
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stages of research. Decision makers also need to be more transparent about their aims 
and objectives and clarify what sort of information they want and how they want to use 
it, while researchers also need to make their expectations clear. Bacci (2009) also 
suggested that there needs to be more of a synthesis and summary of knowledge rather 
than a focus on single studies.   
In terms of public health, Brownson et al. (2009) argued that to overcome the 
barriers to the use of evidence, potential solutions such as increasing funding, increasing 
the understanding of the value of the evidence-based approach and identification of new 
ways of shaping organisational culture to support evidence-based decision making need 
to be considered. Brownson et al. (2009) also believed that systematic communication 
and dissemination strategies need to be implemented as well as wider dissemination of 
new and established training programs. Other solutions suggested include enhanced 
skills for efficient analysis and review of literature, increased funding for applied 
researched and dissemination of findings, and greater emphasis on building the evidence 
base for external validity (Brownson et al., 2009). It has also been recognised that 
policymakers draw lessons from the actions of their counterparts in other jurisdictions 
which is referred to as policy transfer and learning. This is discussed next.  
Policy Transfer and Learning 
The policy transfer process is described as “the process by which knowledge 
about policies, administrative arrangements, institutions and ideas in one political 
system (past or present) is used in the development of policies, administrative 
arrangements, institutions and ideas in another political system” (Dolowitz & Marsh, 
2000, p.5). As different jurisdictions are subjected to similar situations, policymakers 
are increasingly looking to other jurisdictions for knowledge and ideas they can apply to 
 Medical Cannabis in the United States     8 
 
their own jurisdictions (Dolowitz & Marsh, 2000; Wolf, 2000). According to Wolf 
(2000) “the most important trend for the future of public administration is the trend 
towards global learning processes among practitioners and experts” (p. 696).   
Wolf (2000) noted that currently there is no such thing as “best country” in 
terms of public administration, but there are instead good and better practices which 
need to be identified on the basis of national needs and the requirements for its 
adaptation to the political and administrative context in which they are to be applied. 
According to Dolowitz and Marsh (2000), policy transfer can occur at international, 
national and local levels of governance. Policymakers can also look within their own 
political systems to find possible policy solutions. In terms of what can be transferred, 
Dolowitz and Marsh (2000) refer to “policy goals, policy content, policy instruments, 
policy programs, institutions, ideologies, ideas and attitudes and negative lessons” (p. 
12). Peachment (2001) suggested that for each policy consideration the possible courses 
of action should focus on what the policy must do, what it must not do, and what it 
could do.  
A range of actors is likely to become involved in the policy transfer process, 
including elected officials, bureaucrats/civil servants, political parties, pressure groups, 
policy networks, policy entrepreneurs and experts, think tanks, transnational 
corporations, and supranational governmental and nongovernmental institutions and 
consultants (Dolowitz & Marsh, 2000; Wolf, 2000). However, policy transfer is not an 
“all or nothing” process and the type of transfer likely to occur is subject to a number of 
factors such as the actors involved, the resources and time available, and the nature of 
the problem faced (Dolowitz & Marsh, 2000). Policy transfer can be direct and indirect 
and the reasons why it occurs also vary and are affected by a range of factors, 
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illustrating the dynamic and complex nature of the policy process. Peachment (2001) 
noted that one of the constraints on policy transfer is that the historical record of policy 
development is often unclear, with much policy inherited and many statutes being very 
old and never having been tested in law.  
Overall, there appears to be a gap between what research shows as effective and 
the policies that are enacted and enforced (Birkland, 2005; Brownson, et al., 2009; 
Davies et al., 2000; Hanney, Gonzalez-Block, Buxton, & Kogan, 2003; Ritter, 2011). 
Evidence can impact on policymaking, but not necessarily in the immediate or direct 
way that would be expected by the researchers, as evidence is only one of many factors 
that affect policymaking (Black, 2001; Brownson et al., 2009). It is also not enough for 
research to be available as it needs to be research that is wanted and can be used by 
policymakers. Evidence-based policy is difficult to achieve and policies created do not 
necessarily reflect evidence (Hanney et al., 2003). Evidence can be used to make 
evidence-based policy but evidence itself may not necessarily be used by the 
participants in the process (Birkland, 2005; Brownson et al., 2009; Hanney et al., 2003). 
The extent of the involvement of researchers in the policy process has also been 
questioned. Pentz et al. (2004) argued that researchers were reluctant to get involved in 
the highly political policy process and that the lack of attention paid to evidence 
reflected historical precedent rather than deliberate inattention. In order for research to 
have an impact on policy, researchers need to have an understanding of the policy 
process and the political nature of policymaking and that science is just one of many 
elements under consideration (Davies et al., 2000; Schenkel, 2010; Pentz et al., 2004; 
Weiss, 1998).  
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Overall, it is important to analyse policies in order to obtain a better 
understanding of how the policy process works, how problems and issues are identified 
and placed on the political agenda, how and why governments choose to act or not act 
on policies, and what the effects of the policies are. One policy that has ignited debate in 
recent years is that of medical cannabis. For the purposes of this thesis, cannabis will be 
the term applied to all products derived from the plant Cannabis sativa, which has over 
400 compounds (Institute of Medicine [IOM], 1999; McPartland & Russo, 2001; Ryder, 
Walker, & Salmon, 2006).  
In 1996 California became the first state in the U.S. to legalise the cultivation, 
possession and use of cannabis for medical purposes (Marijuana Policy Project [MPP], 
2013; Zeese 1999). It was the first in a string of state medical cannabis movements in 
the U.S. Since 1996, despite federal opposition, when the material for this thesis was 
collected, 171 U.S. states and the District of Columbia have enacted medical cannabis 
laws (MPP, 2013; ProCon.org, 2014). In order to understand what happened in the 
states that enacted or did not enact medical cannabis laws, it is important to look at the 
history of drug policy in the U.S., and medical cannabis in particular. The following 
section will provide a background to the history of medical cannabis in the U.S. and 
recount the events leading up to the passage of the medical cannabis laws.  
 
 
1 Since 2011 when the material for this thesis was collected, , six more states have enacted medical 
cannabis laws. As of November 2014, 23 states and the District of Columbia have enacted medical 
cannabis laws.   
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History of Medical Cannabis in the United States 
The U.S. has a complex history of drug control policy, but the restriction of use 
and distribution of drugs at the federal level goes back approximately 100 years 
(McBride, Terry-McElrath, Harwood, Inciardi, & Leukefeld, 2009). Previous to 1914, 
any restrictions on use and distribution of drugs were at the state or local level, and it 
was thought that federal control over drug use and prescription practices by medical 
professions was unconstitutional (Musto, 1999). Drugs such as heroin, morphine, and 
cannabis were readily available and sold as part of medicines. The U.S. history of 
medical cannabis began with the first American Conference on the Medical Use of 
Marijuana in Ohio in 1860, where physicians reported its effectiveness in the treatment 
of conditions including chronic cough, gonorrhoea and pain (Grinspoon, 2000; IOM, 
1999; Ruiz, Strain, & Langrod, 2007).  
Gradually, federal commerce and tax powers were broadened by Supreme Court 
decisions and occurred in the context of major social reforms, such as the shift towards 
safe food and drugs which led to the Pure Food and Drug Act of 1906 and the Harrison 
Act of 1914 (McBride et al., 2009; Musto, 1999). The Pure Food and Drug Act required 
that any quantity of cannabis, as well as several other substances, be clearly marked on 
the label when sold to the public (Musto, 1999). After the passage of the Pure Food and 
Drug Act in 1906, campaigning for federal anti-drug laws gained momentum.  
As cannabis became widely used as a medicine, recreational use of the drug also 
increased. While cannabis use was mostly supported by the public, in the 1920s the 
federal government started giving more attention to drug use and there was political 
pressure for the federal government to regulate cannabis, amongst other drugs (Musto, 
1999). The passage of the Harrison Tax Act saw the federal government not only 
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collecting taxes and ensuring registration of drug users, but also the prosecution of 
doctors that prescribed the drugs. Since it was brought to the U.S. in the 1800s, cannabis 
was recognised as an effective medicine, and by the 1930s at least two American 
companies were selling medicines containing cannabis (Grinspoon, 2000; Mack & Joy, 
2000; Ruiz et al., 2007). During the 19th and 20th century the drug’s recreational use 
increased and it became popular among minorities, such as immigrants and African-
Americans. Fear of cannabis was seen in areas with concentrations of Mexican 
immigrants, who were feared as a source of crime and deviant social behaviour (Musto, 
1999). The end of the 1920s saw the emergence of reports of negative effects of 
cannabis, including crime and death (Mack & Joy, 2000; Marshall, 2005).  
Consequently, the U.S. Congress passed the Marihuana Tax Act of 1937, which 
imposed a $1-an-ounce tax for industrial and medicinal use of cannabis and a $100-an-
ounce tax for the drug’s recreational use (Eddy, 2010; Koch, 1999). While cannabis was 
not made illegal by this act, the prohibitive tax imposed on it made it difficult to get 
cannabis, including for medical purposes (Gieringer, Rosenthal, & Carter, 2008). As a 
result, the use of cannabis reduced significantly and doctors eventually ceased to 
prescribe it. By 1942, cannabis was no longer included in the U.S. Pharmacopeia 
(American College of Physicians [ACP], 2008; Koch, 1999). U.S. states also started 
passing laws making cannabis illegal and by 1937 cannabis use was prohibited in every 
state (Gieringer et al., 2008; Musto, 1999).  
The use of cannabis increased in the 1960s, which was also a period of 
economic growth in the U.S. (Musto, 1999). Cannabis also became a political issue, 
associated with anti-war protests and the use of the drug was no longer associated only 
with minorities (Musto, 1999). However, cannabis remained legal under federal law 
 Medical Cannabis in the United States     13 
 
until the Controlled Substances Act (CSA) of 1970 (Controlled Substances Act [CSA], 
1970; Eddy, 2010). The act was signed into law by President Nixon, at a time when 
drug use and its associated harm were increasing (Musto, 1999). The act classified all 
drugs into schedules, and cannabis was placed in the most restrictive, Schedule I 
category, together with LSD and heroin. This classification implied that cannabis had no 
accepted medical use, had a high potential for abuse, and could not be used safely even 
under medical supervision (CSA, 1970). Figure 1 outlines the history of medical 
cannabis in the U.S. since the enactment of the CSA. 2 
2 The chronological account in the original thesis ended in 2011; all events from 2011 leading up to 2014 
have been subsequently added.   
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1970 
•U.S. Congress passed the Controlled Substances Act. Cannabis classified as Schedule I 
substance 
•National Organization for the Reform of Marijuana Laws (NORML) founded 
•The National Commission on Marijuana and Drug Abuse created by President Nixon and 
led by Raymond P. Shafer  
1971 
•President Nixon declares a "War on Drugs" 
1972 
•National Organization for the Reform of Marijuana Laws (NORML) files first ever 
administrative petition  to reschedule cannabis for medical use, under the Controlled 
Substance Act 
•The Shafer Commission recommends that cannabis should be decriminalised for personal 
use. President Nixon rejects the recommendations 
1974 
•National Institute on Drug Abuse (NIDA) established, placed in charge of contracts to grow 
cannabis for research purposes 
•The U.S. Court of Appeals for the District of Columbia Circuit orders the Bureau of 
Narcotics and Dangerous Drugs to process NORML's petition  
1976 
•Federal court rules Robert Randall's use of cannabis a "medical necessity" 
1977 
•President Jimmy Carter endorses the Shafer Commission’s findings and endorses cannabis 
decriminalisation 
1978 
•Federal government IND Compassionate Use Program supplies patients with cannabis 
•New Mexico passes first state law recognising medical value of cannabis 
1981 
•Robert Randall forms organisation to help others obtain access to medical cannabis 
1985 
•Marinol approved by the Food and Drug Administration (FDA) 
1988 
•Drug Enforcement Administration (DEA) Administrative Law Judge Francis Young rules in 
favour of NORML to make cannabis a medicine 
•The Reagan administration and Department of Justice appeal Judge Young’s ruling seeking 
to uphold a total ban on cannabis 
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1991 
•San Francisco becomes the first city to pass a medical cannabis ordinance 
•  Federal Government suspends  IND Compassionate Use Medical Marijuana Program 
 
1992 
• IND Compassionate Use Program officially terminated; existing patients continue to get 
government cannabis 
1994 
•The U.S. District Court of Appeals makes a final decision in favor of the Drug Enforcement 
Administration in NORML vs. DEA 
1996 
•  California becomes first state to legalise the cultivation, possession and use of cannabis for 
medical purposes, laying the groundwork for future laws across the country 
•Arizona voters pass a medical cannabis initiative which proved ineffective 
1998 
•  Alaska, Oregon, Washington, and the District of Columbia pass medical cannabis laws 
•  Presidents Ford, Carter, and Bush urge voters to reject medical cannabis 
 
1999 
 
•Maine voters approved a medical cannabis initiative 
•  Institute of Medicine (IOM) conducts comprehensive study on medical effects of cannabis 
•  Marinol moved to Schedule III to increase availability to patients 
 
2000 
•Nevada and Colorado voters approve medical cannabis initiatives 
•Hawaii legislature passed medical cannabis legislation 
 
2001 
•Supreme Court rules that there is no medical necessity exception to the Controlled 
Substances Act in U.S. v. Oakland Cannabis Buyers’ Cooperative 
 
2003 
•U.S. House of Representatives rejects amendment to stop federal raids on medical cannabis 
patients 
2004 
•Montana voters approve a medical cannabis initiative 
•Vermont’s legislature passed medical cannabis legislation 
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Figure 1. Time chart of medical cannabis in the U.S. since the enactment of the CSA.  
2005 
•The U.S. Supreme Court upholds the power of Congress to prohibit and prosecute medical 
cannabis even in the states that permit it 
•The States’ Rights to Medical Marijuana Act introduced to 109th Congress  
2006 
•Rhode Island legislature passes medical cannabis legislation 
•FDA confirms opposition to smoked cannabis for medical purposes 
2007 
•New Mexico legislature passes medical cannabis legislation 
•DEA Administrative Law Judge recommends allowing new source of cannabis for research 
2008 
•Michigan voters approve medical cannabis initiative 
•The American College of Physicians calls for cannabis reclassification and supports non-
smoked forms of medical cannabis 
2009 
•DEA rejects judge's ruling to allow new source of cannabis for research  
•Deputy Attorney General says raids on medical cannabis clinics will not continue 
•The American Medical Association calls on the federal government to reconsider cannabis'  
classification under federal law 
2010 
•Arizona voters approve medical cannabis initiative 
•District of Columbia City Council passes medical cannabis legislation 
•New Jersey legislature passes medical cannabis legislation 
2011 
•Delaware legislature passes medical cannabis legislation 
•First ever cannabis legalisation bill introduced into the US Congress 
•U.S. Attorneys send letters to states with medical cannabis  
•DEA denies petition to initiate proceedings to reschedule cannabis 
2012 
•Connecticut legislature passes medical cannabis legislation 
•Massachusetts voters approve a medical cannabis initiative 
2013 
•New Hampshire legislature passes medical cannabis legislation 
• Illinois legislature passes medical cannabis legislation  
•The Justice Department announces that it will not challenge state cannabis laws  
•U.S. Appeals Court upholds rejection of the cannabis rescheduling petition 
2014 
•Maryland legislature passes medical cannabis legislation  
•Minnesota legislature passes medical cannabis legislation  
•New York legislature passes medical cannab is legislation  
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The 1970 CSA authorised the creation of a National Commission on Marihuana 
and Drug Abuse and President Nixon appointed Raymond P. Shafer, formerly Governor 
of Pennsylvania, to head the commission, which later became known as the Shafer 
Commission (Bonnie, 2001; Gieringer et al., 2008). Its purpose was to to undertake a 
two-year study on cannabis and the causes of drug abuse in general. The commission 
reviewed the available literature on cannabis use and its effects and also sponsored its 
own research (Bonnie, 2001). In the same year, the National Organization for the 
Reform of Marijuana Laws (NORML) was founded by Keith Stroup, a public-interest 
attorney (NORML, 2014a). The NORML was founded as a non-profit public-interest 
advocacy group to oppose cannabis prohibition and favour an end to the practice of 
arresting cannabis users.  
In a special message to the Congress on Drug Abuse Prevention and Control on 
17 June 1971, President Nixon said that drug abuse had assumed the dimensions of a 
national emergency and that he was therefore “transmitting legislation to the Congress 
to consolidate at the highest level a full-scale attack on the problem of drug abuse in 
America” (Nixon, 1971). The movement later became more commonly known as the 
“War on Drugs”. In 1972 the Shafer Commission issued its first report which found that 
“there is no evidence that experimental or intermittent use of marihuana causes physical 
or psychological harm” (as cited in Zeese, 1999, p. 344). The commission therefore 
recommended decriminalisation of possession of cannabis for personal use and casual 
distribution in private of small amounts of cannabis, but that growing and selling of 
cannabis remain a criminal offence (Bonnie, 2001; Zeese, 1999).   
While President Nixon immediately rejected the recommendations, the 
publication of the commission’s findings reflected a shift in elite opinion. The report 
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was followed by the National Conference of Commissioners on Uniform State Laws 
supporting amendments to the CSA based on the commission’s recommendations and 
the endorsement of some forms of cannabis decriminalisation by various national 
organisations (Bonnie, 2001; Caulkins, 2012). In 1977, in a message to the U.S. 
Congress, President Carter endorsed the findings of the Shafer Commission and 
decriminalisation of cannabis (Bertram, Blachman, Sharpe, & Andreas, 1996; Bonnie, 
2001). However, political and legislative support for cannabis decriminalisation was 
decreasing and the more permissive stance on cannabis decriminalisation during the 
Carter Administration led to an increase in public resistance and opposition from lobby 
groups (Bonnie, 2001). In 1982, the National Academy of Sciences came to similar 
conclusions as the Shafer Commission in relation to cannabis, and the findings were 
rejected by President Reagan (Bertram et al., 1996; Gieringer et al., 2008).  
In 1972, the NORML foundation filed the first ever administrative petition with 
the Bureau of Narcotics and Dangerous Drugs (BNDD) to move cannabis to Schedule II 
of the CSA (Koch, 1999; Zeese, 1999). This schedule encompasses drugs that have a 
strong potential for abuse or addiction but also have recognised medical use (CSA, 
1970). Substances placed in this schedule include morphine, cocaine, and oxycodone. 
The petition was rejected by the BNDD and the NORML appealed the decision. In 
1974, the U.S. Court of Appeals for the District of Columbia Circuit ordered the BNDD 
to process the NORML petition (Zeese, 1999). It wasn’t until 1986 that the Drug 
Enforcement Administration (DEA) initiated public hearings on whether cannabis 
should be rescheduled (Clark, 2000). The hearings lasted two years, and in 1988 Judge 
Francis L. Young recommended that cannabis be moved from Schedule I to Schedule II. 
However, as his ruling was a recommendation only, the final decision was left to the 
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DEA administrator (Clark, 2000). In 1989 the DEA administrator John Lawn overruled 
Judge Young’s ruling to reschedule cannabis and stated that there was no scientific 
evidence to support claims that cannabis is better than other drugs used in the treatment 
of any medical condition (Koch, 1999; Werner, 2001). Cannabis research projects are 
rarely approved due to a complicated federal approval process and the difficulty of 
obtaining research-grade cannabis; this makes it difficult for scientific evidence to be 
obtained (Marshall, 2005). Martin and Rashidian (2014) note that “the federal 
government has never approved a plant in its entirety as medicine, and it’s unlikely it is 
going to begin with the controversial cannabis plant” (p. 17).  
In 1974, the National Institute on Drug Abuse (NIDA) was established as a 
federal government research institute “for research, treatment, prevention, training, 
services, and data collection on the nature and extent of drug abuse” (National Institute 
on Drug Abuse, [NIDA], 2014b). It is the single official source of cannabis for 
medicinal research. The institute funds a wide range of research on cannabis and also 
supports a drug supply program which provides research-grade cannabis to researchers 
(NIDA, 2014a). The NIDA contracts with the University of Mississippi to grow 
cannabis for use in research and it is there that cannabis is grown, harvested, stored and 
made into cigarettes or other purified elements of cannabis. To obtain research-grade 
cannabis through the NIDA, the research must be approved by the Food and Drug 
Administration (FDA), the DEA, and the NIDA (NIDA, 2014a).  
The FDA approval process. In the U.S., before a drug can be prescribed, it 
needs to undergo the FDA’s approval process. Under the federal Food, Drug, and 
Cosmetic Act, to be approved by the FDA, the drug in question first needs to be tested 
as an Investigational New Drug (IND). Sponsors of the drug need to complete 
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preclinical testing in laboratory animals to demonstrate its effectiveness and safety and 
outline what they propose to do for human testing, following which the FDA decided 
whether it is safe for the drug to be tested in humans. This stage is followed by clinical 
trials in humans and after extensive testing showing effectiveness and safety, a potential 
manufacturer is required to file a New Drug Application with the FDA. It is then up to 
the FDA to determine whether the drug is safe and effective for its proposed use, 
whether the benefits of the drug outweigh its risks, and whether the methods used in 
manufacturing the drug and the controls used to maintain the drug's quality are adequate 
to preserve the drug's integrity, strength, quality, and purity (Federal Food, Drug, and 
Cosmetic Act, 2000). The decision is made based on clinical trials, where the drug in 
question has to be proven safe and effective for human use (Federal Food, Drug, and 
Cosmetic Act, 2000; Joy, Watson, & Benson, 1999). If the FDA determines that the 
benefits of the drug outweigh its risks, it will allow it to be manufactured (Federal Food, 
Drug, and Cosmetic Act, 2000). For cannabis, the process is made more difficult due to 
cannabis’ Schedule I classification and the fact that cannabis for research can only be 
obtained through the federal government (ACP, 2008; Joy, et al., 1999).  
In 1976, Robert Randall, a glaucoma patient, became the first person to use a 
medical cannabis necessity defence to defend himself against cannabis charges 
(Gieringer et al., 2008). With the support of his doctor, Randall argued that cannabis 
was the only drug that would prevent him from going blind (Gieringer et al., 2008). 
After the charges were dropped Randall successfully lobbied the federal government to 
allow him access to medical cannabis under the IND program, becoming the first U.S. 
citizen to receive federally supplied cannabis under the IND program. Randall also 
lobbied for cannabis’ rescheduling and in 1981 he formed the Alliance for Cannabis 
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Therapeutics to lobby state legislatures to protect medical cannabis patients from arrest 
and prosecution (Gieringer et al., 2008; Werner, 2001).  
The IND program was established in 1976 and the patients were considered to 
be participants in research on medical cannabis (Gieringer et al., 2008). As part of the 
program, a limited number of patients were approved by the FDA to receive 
government supplies of medical cannabis grown at the University of Mississippi. It was 
difficult for patents to qualify for the program and it was expanded to approximately 30 
patients until suspended in 1991 and closed in 1992 by the Bush Administration, who 
believed too many people were seeking access to medical cannabis supplies and they 
did not want to send the wrong message to the public (Clark, 2000; Werner, 2001). As 
the decision proved unpopular, it was decided that already approved program 
participants would receive cannabis for the rest of their lives while others would be 
prescribed dronabinol (distributed in the U.S. as Marinol), a synthetic form of Delta-9-
Tetrahydrocannabinol (THC) (Gieringer et al., 2008; Werner, 2001).  
First medical cannabis IND program. In 1978, New Mexico became the first 
state to pass legislation recognising cannabis as a medicine (Koch, 1999). By 1983, 34 
states had enacted legislation which allowed their health departments to conduct 
research on the effectiveness of cannabis as a medicine under the IND program (Koch, 
1999; Werner, 2001). The cannabis required for research was to be supplied by the 
federal government. However, due to its classification as a Schedule I substance, 
cannabis could only be distributed to patients through the NIDA (Werner, 2001). The 
process proved to be difficult and only six states (New Mexico, California, New York, 
Tennessee, Michigan, and Georgia) obtained research-grade cannabis for medical 
cannabis research; the other states received oral THC pills (Koch, 1999; Werner, 2001).   
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In June 1985, dronabinol (Marinol) was moved to Schedule II of the CSA 
(Werner, 2001). Marinol was approved for use in the treatment of the AIDS wasting 
syndrome, and nausea and vomiting associated with cancer chemotherapy (ACP, 2008). 
The rescheduling followed research which indicated that THC was effective in the 
treatment of nausea. Marinol was reclassified as a Schedule III substance in 1999, after 
a study found that Marinol had low abuse potential. However, it has been suggested that 
the federal government decided to make THC legally available after political pressure in 
support of cannabis and in an effort to stem medical demand for cannabis in its natural 
form (Gieringer et al., 2008; IOM, 1999; Zeese, 1999). Access to cannabis remained 
limited, and as Werner (2001) states:  
 Despite the fact that a synthesized and concentrated version of cannabis’ 
most active compound was rescheduled, the source plant was not. With 
marijuana withheld, and synthetic THC available by prescription, the 
state medical marijuana research programs slipped into dormancy. (p. 
22).  
In 1991, San Francisco activists succeeded in getting “Proposition P” on the 
ballot which passed with 79 percent of the vote (Zeese, 1999). The initiative was in 
favour of patients having access to cannabis for medical purposes. The same year, 
following an appeal to the U.S. Court of Appeals by the Alliance for Cannabis 
Therapeutics and the NORML, the Court rejected the DEA’s 1989 findings that there 
was no scientific evidence to support medical cannabis claims and reschedule cannabis 
and ordered the DEA to reconsider their position. The DEA did not change their view. 
The decision was again appealed, and after 22 years of litigation the final decision was 
rendered by the U.S. District Court of Appeals upholding the DEA’s decision to keep 
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cannabis in Schedule I (Pacula, Chriqui, Reichmann, & Terry-McElrath, 2002; Zeese, 
1999).  
After the failed litigation to reschedule cannabis, a national movement emerged. 
In 1995 activists in California gathered the required signatures for a medical cannabis 
proposition and in 1996 California became the first state to legalise the cultivation, 
possession and use of cannabis for medical purposes when it passed Proposition 215, a 
ballot initiative, with 56 percent of the vote in favour (MPP, 2013; Zeese 1999). This 
was at odds with the federal law which prohibits possession, sale and cultivation of 
cannabis. In the same year Arizona voters also passed a medical cannabis initiative but 
it was ineffective because it required medical cannabis patients to have a doctor’s 
prescription. It should be noted that using the word “prescribe” made the law 
ineffective, as doctors cannot legally prescribe an illegal substance to their patients 
(Delaney, 2010a). In 1998, voters in Alaska, Oregon, Washington and the District of 
Columbia (D.C.) passed medical cannabis initiatives similar to California (MPP, 2013). 
However, the DC initiative did not take effect until 2010 as Congress was able to 
prevent it from taking place because D.C. is a district and not a state (MPP, 2013).  
While the states were passing medical cannabis laws, in 1998 former Presidents 
Ford, Carter, and Bush released a statement urging voters to reject state medical 
cannabis initiatives (Mack & Joy, 2000). The presidents said that the state initiatives 
bypassed the FDA approval process and believed that medicine must be based on 
science and not political appeals (Mack & Joy, 2000). However, medical cannabis 
initiatives continued to be passed and in 1999 Maine voters also approved a medical 
cannabis initiative (MPP, 2013).  
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In 1999, the IOM published the findings of their comprehensive study on 
medical effects of cannabis (IOM, 1999). The study was requested by the White House 
Office of National Drug Control Policy (ONDCP) as a critical review of scientific 
evidence pertaining to medical use of cannabis (IOM, 1999; Mack & Joy, 2000). The 
report recognised that cannabis has therapeutic properties and recommended that the 
drug be made available to individuals requiring it (IOM, 1999). The 1999 IOM report 
outlined both positives and negatives of cannabis use and found evidence that cannabis 
can offer “broad-spectrum” relief from severe pain, nausea, and appetite loss associated 
with AIDS or chemotherapy patients; offered moderate promise for alleviating 
symptoms associated with muscle spasticity; and was least promising for movement 
disorders, epilepsy and glaucoma. It found no significant data showing that cannabis 
was a “gateway” drug, leading to other drug use. The report concluded that:  
The critical issue is not whether marijuana or cannabinoid drugs might 
be superior to the new drugs, but whether some group of patients might 
obtain added or better relief from marijuana or cannabinoid drugs. (p. 
153).  
In 2000, Nevada and Colorado voters also passed medical cannabis initiatives 
(MPP, 2013). The same year, Hawaii’s legislature became the first to pass a law to 
remove criminal penalties for medical cannabis. In 2001, in the first medical cannabis 
case heard by the U.S. Supreme Court, the U.S. government sued the Oakland Cannabis 
Buyers’ Cooperative, organised to distribute cannabis for medical purposes to qualified 
patients, to cease operating as their activities violated the CSA’s prohibitions on 
distributing, manufacturing, and possessing with the intent to distribute or manufacture 
cannabis (United States v. Oakland Cannabis Buyers' Cooperative, 2001; MPP, 2013). 
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The U.S. Supreme Court ruled that there is no medical necessity exception to the CSA 
and that the medical necessity defence cannot be used to avoid federal prosecution by 
third parties seeking to manufacture or distribute cannabis for others who need it 
(United States v. Oakland Cannabis Buyers' Cooperative, 2001; MPP, 2013). However, 
the question of whether individual patients charged with personal possession or 
cultivation can use the medical necessity defence was left open. It is notable that the 
CSA makes no distinction between medicinal and recreational use of cannabis. The 
second and last medical cannabis case to be heard at the federal level was “Gonzales v. 
Raich” (Gonzales v. Raich, 2005; MPP, 2013). The case followed DEA raids on two 
medical cannabis patients who argued that the federal government’s powers to regulate 
interstate commerce did not extend to their personal use and cultivation of medical 
cannabis. In 2005, the U.S. Supreme Court ruled that the Congress has the power to ban 
the use of medical cannabis even where states approve its use for medicinal purposes 
(Gonzales v. Raich, 2005). The court did not question the validity of the state laws and 
the patients remained protected under state, but not federal law.  
In 2003, during the 108th Congress, in response to DEA raids on medical 
cannabis users and providers in states with medical cannabis laws, Representative 
(Rep.) Maurice Hinchey and Rep. Dana Rohrabacher introduced a bipartisan bill 
seeking to prevent the Department of Justice from using appropriated funds to interfere 
with the operations of medical cannabis laws in states with such laws (Departments of 
Commerce, Justice, and State, the Judiciary, and Related Agencies Appropriations Act, 
2004). Between 2003 and 2007 the bill was debated and rejected five times, the 
opponents arguing that smoked cannabis is not safe and effective as medicine and sends 
the wrong message to young people (Eddy, 2010).   
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A more specific bill, the States’ Rights to Medical Marijuana Act (2005), was 
introduced in 2005 and sought to move cannabis from Schedule I to Schedule II of the 
CSA. It also sought to provide that in states with medical cannabis laws no provisions 
of the CSA or the Federal Food, Drug, and Cosmetic Act could prohibit or restrict 
prescription or recommendation of cannabis by a physician for medical use or an 
individual from obtaining and using cannabis from a prescription or recommendation of 
cannabis by a physician for medical use by such individual. The bill was never referred 
to a committee hearing (Eddy, 2010).  
In 2004, Montana voters approved a medical cannabis initiative and Vermont’s 
legislature passed medical cannabis legislation and in 2006 Rhode Island became the 
11th state to legalise medical cannabis after its legislature overrode the governor’s veto 
(MPP, 2013). In 2006, the FDA said that they opposed medical cannabis and supported 
its listing in the most restrictive CSA Schedule I (FDA, 2006). The FDA stated that 
smoked cannabis is harmful, and that no scientific evidence supports its medical use. 
They also said that there are FDA-approved medications for treatment of different 
conditions that can be used instead of cannabis. The agency also stated that if cannabis 
were to be marketed, there would need to be sufficient scientific evidence showing it is 
safe and effective to use (FDA, 2006). However, due to federal opposition to medical 
cannabis and a difficult research approval process, few controlled studies have been 
approved and conducted in the U.S. (Marshall, 2005).  
In another first for New Mexico, attempts to legalise medical cannabis were 
successful in 2007, when Democratic (D) Governor (Gov.) Bill Richardson became the 
first governor in history to enact a medical cannabis law while running for the 
presidency (Lynn and Erin Compassionate Use Act, 2007; MPP, 2013). He signed 
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Senate Bill 523 into law, making New Mexico the 12th state to allow medical cannabis 
use for qualifying patients. The House of Representatives approved the bill by a 36-31 
vote, while the Senate approved it 32-3 (MPP, 2013).  
Showing how difficult it is to obtain cannabis for research purposes, Lyle 
Craker, at the University of Massachusetts, petitioned the DEA for permission to 
cultivate cannabis to use in university-approved clinical studies on cannabis’ 
effectiveness as a medicine (Eddy, 2010; MPP, 2013). In 2007, the DEA Administrative 
Law Judge, Mary Ellen Bittner, recommended that Craker’s application be granted and 
concluded that “there is currently an inadequate supply of marijuana available for 
research purposes, that competition in the provision of marijuana for such purposes is 
inadequate…” (U.S. Drug Enforcement Administration, 2007, p. 87). The Judge also 
concluded that Craker’s registration to cultivate cannabis would be “in the public 
interest”. However, because rulings by administrative law judges are nonbinding, in 
2009 the DEA rejected Judge Bittner’s recommendation (Lyle E. Craker; Denial of 
Application, 2009). It wasn’t the first time the DEA rejected an administrative law 
judge’s recommendation, as it previously happened to Judge Young’s 1998 ruling.  
On November 4, 2008, the Michigan Medical Marihuana Act (2008), which 
allows the use of medical cannabis for qualifying patients, was approved by Michigan 
voters through a ballot initiative. The same year the ACP questioned cannabis’ Schedule 
I placement and urged a review of this (ACP, 2008). The ACP said they supported 
programs for scientific research into cannabis as a medicine, but also noted that the 
research has been limited by a difficult approval process, difficulty in obtaining 
research-grade cannabis, and the legalisation debate (Clark, 2000). The American 
Medical Association (AMA) (2009) also called for more controlled clinical studies to be 
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conducted on cannabis as a medicine and recommended a review of cannabis’ Schedule 
I classification in order to enable more research to be conducted on its potential as a 
medicine. The association also urged the National Institutes of Health (NIH) to 
implement administrative procedures which would assist in developing and conducting 
clinical trials into medicinal properties of cannabis (AMA, 2009).  
In October 2009, the Obama Administration Deputy Attorney General David 
Ogden issued a memorandum to U.S. attorneys saying that in states with medical 
cannabis laws federal resources should not focus on individuals whose actions “are in 
clear and unambiguous compliance with existing state laws providing for the medical 
use of marijuana” (U.S. Office of the Deputy Attorney General, 2009, p.2). The 
announcement followed a pledge that was made by then-candidate Obama during the 
presidential campaign (Eddy, 2010). In a subsequent memorandum in June 2011, 
Deputy Attorney General James Cole reaffirmed that medical cannabis patients should 
not be targeted and stated that “it is likely not an efficient use of resources to focus 
enforcement efforts on individuals with cancer or other serious illnesses who use 
marijuana as part of a recommended treatment regimen consistent with applicable state 
law, or their caregivers” (U.S. Office of the Deputy Attorney General, 2011, p.1). 
However, he also added that state laws or local ordinances are not a defence to civil or 
criminal enforcement of federal law with respect to individuals who are in the business 
of cultivating, selling, or distributing cannabis and are in violation of the CSA (U.S. 
Office of the Deputy Attorney General, 2011).  
In 2010 Arizona voters approved a medical cannabis initiative (MPP, 2013). 
This law used the word “certification” instead of “prescription” which made the medical 
cannabis law effective, unlike the state’s 1996 measure. The same year, New Jersey 
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legislature passed medical cannabis legislation (MPP, 2013). New Jersey became the 
first state to enact a medical cannabis law that did not provide for home cultivation but 
relied solely on medical cannabis dispensaries.  
Medical cannabis since 2010. Since 2010, there has been an increase in medical 
cannabis laws being passed through the legislative process; Delaware, Connecticut, 
New Hampshire, Illinois, Maryland, Minnesota and New York legislatures passed 
medical cannabis legislation. Since Arizona voters approved a medical cannabis 
initiative in 2010, all other state laws to date were passed by the legislature. At the time 
when the material for this thesis was collected, 173 of 50 U.S. states and the District of 
Columbia have enacted laws allowing the use of cannabis for medical purposes (MPP, 
2013; ProCon.org, 2014). Ten of the state medical cannabis laws were passed by a 
ballot initiative and seven were passed by the legislature (ProCon.org, 2014). It is 
important to note the role of state legislatures in the medical cannabis movement, as 
only 17 U.S. states and the D.C. have an initiative process under which citizens can, by 
collecting a specified number of signatures on a petition, place an issue before the 
state’s electorate (Birkland, 2005; Britannica Educational Publishing [BEP], 2010; 
Howard, 2005; Initiative and Referendum Institute [IRI], 2009; Katz, 2003). This means 
that 27 states must rely on their state legislatures to enact medical cannabis laws.  
In 2011, a first ever federal cannabis legalisation bill was introduced into the 
U.S. House of Representatives (Ending Federal Marijuana Prohibition Act, 2011). The 
bill sought to remove cannabis from the CSA schedule and remove prohibition on its 
3 Since 2011, when the material for this thesis was collected, six more states enacted medical cannabis 
laws, taking the number of states with medical cannabis laws to 23.   
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import and export; the language of the bill was similar to the changes enacted by the 
Congress to repeal the federal prohibition of alcohol (NORML, 2011). On their website, 
the NORML stated that their organisation along with representatives from the Drug 
Policy Alliance (DPA), Students for Sensible Drug Policy and the Marijuana Policy 
Project (MPP) worked closely with members of Congress in drafting the bill (NORML, 
2011). The bill was not enacted and was introduced again during the 113th U.S. 
Congress (Ending Federal Marijuana Prohibition Act, 2013).  
In 2011, the DEA also rejected a petition to reschedule cannabis in “Americans 
for Safe Access v. DEA” (2013) and the rejection of the rescheduling petition was 
upheld in federal court in 2013 (MPP, 2013; U.S. Drug Enforcement Administration, 
2011). However, in 2013 Deputy Attorney General James Cole again issued a 
memorandum to federal attorneys in which he outlined the federal law enforcement 
policy in relation to state medical cannabis laws and instructed federal attorneys and law 
enforcement to focus their resources and efforts on the enforcement priorities outlined 
in the memorandum, while emphasising that “the Department of Justice has not 
historically devoted resources to prosecuting individuals whose conduct is limited to 
possession of small amounts of marijuana for personal use on private property” (U.S. 
Office of the Deputy Attorney General, 2013, p.2). He also wrote that the federal 
government has traditionally relied on states and local law enforcement agencies to 
address cannabis activity through the enforcement of their own laws. The interplay 
between state and federal government will be further discussed in Chapter Two.   
Overall, over the years medical cannabis activists have turned to state and local 
governments in order to pass medical cannabis laws and enable patients to obtain 
cannabis for medical purposes. While the state medical cannabis laws are effective at 
 Medical Cannabis in the United States     31 
 
the state level, the laws put the states in violation of federal laws because cannabis is a 
Schedule I substance according to the CSA (Eddy, 2010; MPP, 2013). Medical cannabis 
patients, their caregivers, and cannabis providers can therefore be arrested and 
prosecuted at the federal level, although the federal government has indicated as 
recently as 2013 that prosecuting medical cannabis patients would not be their priority. 
However, what has also been created by state medical cannabis laws is what Cohen 
(2010) referred to as a “regulatory vacuum” creating an absence of appropriate state 
regulations to control the distribution and use of medical cannabis. As Cohen put it:  
It should be obvious that unless physicians adhere to their ethical and 
fiduciary responsibilities to patients, controlling the number of 
dispensaries or limiting the areas allowed for cultivation will not suffice 
to allow marijuana to be treated as a genuine medication recommended 
in good faith as part of the legitimate practice of medicine. (p.659).   
There has also been a push to reschedule cannabis from Shedule I of the CSA in 
order to permit medical use. However, the federal government has maintained its stance 
that cannabis is not safe and that no sound scientific studies supported medical use of 
cannabis (Cohen, 2010; Eddy, 2010). This has been made more difficult by restrictions 
placed on medical cannabis research, and the fact that the results of research that does 
get conducted are not always accessed by those who need to make policy-related 
decisions and are not always used as intended by scientists. Clark (2000) suggested that 
if cannabis were moved to Schedule II to be used for medical purposes, the federal 
government would be able to better regulate its use.  
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Medical cannabis advocates note that cannabis will most likely not be 
rescheduled until there is sufficient scientific evidence for its effectiveness (Marshall, 
2005). However, cannabis research projects are rarely approved (Cohen, 2010; 
Marshall, 2005). Under the federal Food, Drug, and Cosmetic Act, the FDA decides 
whether a drug is sufficiently safe and effective to enter the marketplace (Federal Food, 
Drug, and Cosmetic Act, 2000). The decision is based on clinical trials, where the drug 
in question has to be proven safe and effective for human use (Federal Food, Drug, and 
Cosmetic Act, 2000; Joy, Watson, & Benson, 1999). The drug in question is first tested 
as an IND and, after a series of tests demonstrating its effectiveness and safety, a New 
Drug Application is filed with the FDA. If the FDA determines that the benefits of the 
drug outweigh its risks, it will allow it to be manufactured for commerce (Federal Food, 
Drug, and Cosmetic Act, 2000). The process is made more difficult due to cannabis’ 
Schedule I classification and the fact that cannabis supply required for research can only 
be obtained through the federal government (ACP, 2008; Cohen, 2010; Joy, et al., 
1999).  
In spite of the impediments to conducting research on the medical use of 
cannabis, several scientific bodies have recommended such studies and have 
recommended a review of cannabis’ scheduling. However, the recommendations have 
so far been rejected by the federal agencies and the DEA has also rejected the 
recommendations of its own administrative law judges. Cohen (2010) stated that the 
approval of any drug for medical use should be based on scientific evidence rather than 
political considerations and that such evidence should be used to weigh up the risks and 
benefits of cannabis use and whether it justifies its FDA approval for medical use. 
Cohen (2009) also questioned why legislators rather than experts acted to deny cannabis 
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being recognised as a medicine at the federal level, and why the use of cannabis for 
medical purposes was legitimised through legislation, ballot initiatives and referenda 
rather than by experts qualified by scientific training and experience.  
As previously mentioned, there are many factors influencing the creation of 
public policy, and in terms of medical cannabis, while scientific evidence has played a 
part, there are other political and institutional dynamics at work in setting the policy, 
such as “presidents seeking public approval, bureaucrats seeking increased funding, 
members of Congress seeking re-election” (Bertram et al., 1996, p. 101). Cohen also 
argued that instead of being driven by scientific evidence and experts in what should 
have been a straightforward process, it has been complicated by “politics, ideology, 
prejudice, and unwarranted fear” (2009, p. 131). The understanding of the role of 
scientific evidence in the formation of medical cannabis policies will offer those 
individuals involved in research an insight into how scientific evidence can be given a 
more significant role in informing policy.  
The present research sought to (a) Identify the main issues pertaining to the 
development and formation of medical marijuana policies in the U.S. and how problems 
and issues are recognised and raised; (b) Understand factors leading to different 
outcomes in medical cannabis policy; and (c) Examine the role that scientific evidence 
plays in passing medical cannabis legislation in the U.S. and the extent to which it 
informs the policy.   
The current research focused on the following research questions:  
1. What role does scientific evidence play in medical cannabis policy making? 
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2. What factors and processes have influenced medical cannabis policy 
creation?  
3. What lead to medical cannabis policy being passed in states with current 
medical cannabis laws? 
Chapter Two of this thesis describes the political context within which medical 
cannabis laws were passed by providing an outline of the U.S. political system. Chapter 
Three discusses cannabis as a medicine and provides a review of relevant medical 
cannabis literature. Chapter Four describes, chronologically, the passing, attempts to 
pass, and failure to pass medical cannabis policies in five U.S. states; two with a current 
medical cannabis law; one where attempts to pass a law have been made, but a law has 
not yet been passed; and two states where no or few attempts at passing a medical 
cannabis law have been made. These states are Michigan, New Mexico, Illinois, 
Kentucky, and Louisiana, respectively. Chapters Five and Six discuss the research 
design, sampling and data collection procedures, the techniques used for data analysis, 
and results for study groups One, Two, and Four. Finally, Chapter Seven will present 
the discussion of the research findings, the implications of the study, and directions for 
future research. 
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Chapter 2- The United States Political System  
To understand the policy process, it is important to understand the political 
system. The political system of the U.S. is a distinctive and complex democratic system 
(Singh, 2003; Watts, 2010). Democracy is defined as government where the supreme 
power is vested in the people; exercised through their elected agents (U.S. Department 
of State, 2007). This chapter will discuss areas of the U.S. political system relevant to 
understanding policy formation, including the interaction between the two levels of 
government- federal and state.  
The U.S. Constitution 
 The U.S. government, under its Constitution, is a federal, representative, 
democratic republic consisting of 50 states and one federal district (H.R. Doc. No. 108-
94, 2003). The Declaration of Independence of 1776 and the Constitution of 1787 form 
the foundations of the U.S. government (H.R. Doc. No. 108-94, 2003; R. Harris & 
Tichenor, 2009). The Constitution assigns specific powers to the national government 
and the states, although these powers can often be intertwined (Volden, 2005). State 
governments make decisions affecting the daily life of people in their community, while 
the federal government makes decisions affecting the whole country. However, the 
powers assigned by the Constitution have been and are subject to interpretations by 
courts, the highest of which is the Supreme Court. Overall, the Constitution provides the 
people in government with enough power to effectively run the nation, but also makes it 
difficult to accumulate and abuse power (W. Storey, 2007). 
The Constitution specifies three branches of the federal government: the 
Executive Branch; the Legislative Branch; and the Judicial Branch (H.R. Doc. No. 108-
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94, 2003; W. Storey, 2007). Each branch has its own distinct responsibilities, but also 
limits the authority of others (K. Thomas, 2001). In order to prevent concentration of 
power, a series of checks and balances are written into the Constitution, permitting each 
branch to participate in and check and balance the powers of other branches. Although 
each branch is formally separate from the other two, there is also cooperation among the 
branches (Administrative Office of the U.S. Courts, 2003; Kaiser, 2001). The following 
section will describe the three levels of government in the U.S.; federal, state, and local 
government. 
Federal Government 
Executive branch. The Executive Branch of government is responsible for 
carrying out the political system’s laws or directives (BEP, 2010; H.R. Doc. No. 108-
94, 2003; Watts, 2010). It consists of the president, vice president, department heads 
(Cabinet members), and heads of various independent agencies (Dinan & Krane, 2006; 
H.R. Doc. No. 108-94, 2003; R. Harris & Tichenor, 2009). The president is the head of 
the executive branch of the federal government (Watts, 2010). The president’s term of 
office lasts four years and the president may be re-elected for only two terms (BEP, 
2010). 
Federal bureaucracy. Bureaucrats, or government employees, play an 
influential role in shaping public policy (Birkland, 2005; Kaufman, 2001; Singh, 2003). 
Those who act as advisors to a branch of the federal government also have, through the 
way they do their job, the potential to directly influence policy-makers (Kaufman, 
2001). The bureaucracy’s main functions are executing laws, creating rules, and the 
implementation of public policy. It is also responsible for adjudicating disagreements 
over laws and their interpretation (Singh, 2003). All three branches of government 
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influence the shape and role of federal bureaucrats. For example, Congress has the 
authority to establish and instruct agencies; the president has the authority to appoint 
department and agency heads; and the federal court has the authority to determine 
whether agency actions are constitutional (BEP, 2010; Singh, 2003). Also, federal, state, 
and local governments may have bureaucracies working on specific issues such as 
education or health (Singh, 2003).  
Federal Legislative branch. Congress is the legislative branch of the U.S. 
federal government (Watts, 2010). Congress consists of two chambers; the House of 
Representatives and the Senate. Between them, the two chambers are responsible for 
making federal law in the areas set out in the Constitution. They are responsible for 
deciding on taxation and how taxes should be spent, borrowing money on behalf of the 
U.S., regulating commerce, coining money, declaring war, raising and supporting 
armies, and making all laws necessary for the execution of Congress’ powers (H.R. 
Doc. No. 108-94, 2003; W. Storey, 2007). In addition, Congress acts as a watchdog 
over other branches of the federal government, the Executive and the Judiciary (H.R. 
Doc. No. 108-94, 2003).  
House of Representatives. The House of Representatives comprises 435 
Members who are elected to two-year terms from among the 50 states. In addition, 
nonvoting delegates from the D.C. and the U.S. territories are also elected to a two-year 
term. The members are distributed according to population, so that the larger the state’s 
population, the more representatives it is allocated (Cushman, 2005; H.R. Doc. No. 108-
94, 2003; Watts, 2010). Each state must have at least one house seat and each member 
has only one vote (Cushman, 2005; H.R. Doc. No. 108-94, 2003). Each chamber can 
introduce legislation on any subject, but revenue bills must originate in the House of 
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Representatives, and both chambers need to approve a bill in order for it to be passed 
(Cushman, 2005; Watts, 2010).  
Senate. The Senate is intended to provide for state representation in Congress, 
protect the interest of the states, and provide a check upon the House of Representatives 
(H.R. Doc. No. 108-94, 2003; Watts, 2010). The Senate comprises 100 members, two 
for each of the 50 states. Senators serve for six years, with a third of the membership of 
the Senate elected every two years (H.R. Doc. No. 108-94, 2003). Each senator has one 
vote (H.R. Doc. No. 108-93, 2003; Watts, 2010). 
 How a bill becomes law. A member of Congress may introduce a proposal in 
one of four forms: the bill, the joint resolution, the concurrent resolution, and the simple 
resolution (H.R. Doc. No. 108-93, 2003). The Member’s constituents also have the right 
to petition and pass on their proposal to the Member for consideration. Any Member 
can introduce a bill at any time, while the Congress is in session (Birkland, 2005). The 
following section will describe the bill passing process only, as it is relevant to this 
thesis.  
The process. Before a bill becomes law it must be approved by both chambers 
and signed into law by the president. Bills may originate in either of the chambers, 
though the Constitution specifies that all bills concerning the raising of revenue must 
originate in the House of Representatives (Birkland, 2005; H.R. Doc. No. 108-94, 
2003). Anyone may draft a bill but only members of the Congress can introduce 
legislation and therefore become the bill’s sponsor (s). After a proposal is drafted into 
bill form, it is introduced into one of the two Chambers. If the author is a Senator, the 
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bill is introduced in the Senate; if the author is a Representative, the bill is introduced in 
the House of Representatives (Birkland, 2005; H.R. Doc. No. 108-94, 2003).  
As soon as a bill is introduced it is assigned, according to the subject area, to the 
appropriate committee for its first hearing. The committee seeks the input of the 
relevant departments and agencies. During the committee hearing, the author presents 
the bill to committee, subcommittees may make reports on the bill, and testimonies in 
support or opposition to the bill may be heard. The committee votes whether to pass the 
bill on or pass with amendments. A majority vote is needed to pass the bill out of the 
committee and onto the floor of the chamber where it originated or to the next 
committee. If the bill is passed by the committee it was assigned to, it is read a second 
time on the floor of the house where it originated, and a bill analysis is prepared before 
the third reading. If the committee does not act on a bill, the bill is “dead” and does not 
progress further (Birkland, 2005; H.R. Doc. No. 108-94, 2003).  
At the third reading, the bill is read and explained, discussed by members, and 
voted on (H.R. Doc. No. 108-94, 2003). A majority vote is required for the bill to be 
passed. When the bill is approved by the house of origin, it is passed onto the other 
house where the same procedure is repeated. A bill that has been agreed to by both 
houses is sent to the president for approval, and becomes law after either presidential 
approval, failure by the president to return it with objections to the House of origin 
within 10 days, or the overriding of a presidential veto by two thirds of the vote in each 
House (Birkland, 2005; H.R. Doc. No. 108-94, 2003).  
Judicial branch. The federal Judiciary explains and applies the law and serves 
as a check on potential government abuse of power (H.R. Doc. No. 108-94, 2003; W. 
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Storey, 2007; U.S. Department of State, 2007). The Supreme Court is the highest court 
in the federal judiciary, and is also the final court of appeal. The Constitution does not 
stipulate the number of Supreme Court Justices and their number is determined by the 
Congress (Administrative Office of the U.S. Courts, 2003; Barker, 2005).  
State Government  
State and Federal governments are independent, although there is an evolving 
relationship between the two and a historical drift of power from states to the federal 
government (Babcock, 1965; Grodzins, 1960; Watts, 2010). Although the power of the 
federal government has grown significantly since the Constitution was written, states 
still have responsibility for most issues within their own borders such as education, 
health, transportation, and law enforcement (W. Storey, 2007; K. Thomas, 2001; U.S. 
Department of State, 2007). They are limited in their authority regarding regulation of 
foreign imports and exports, or the conduct of foreign affairs (K. Thomas, 2001).  
The U.S. history is marked by an ongoing debate over states’ rights versus 
federal rights and the issue us states’ rights has always been a contentious area (Drake 
and Nelson, 1999). States’ rights calls for the limitation of powers of the federal 
government, with the belief that states could best resolve pressing issues and protect the 
rights of individuals. While decision makers from two or more governments may 
cooperate with each other in one policy area, they may be have conflicting views in a 
different area (Dinan & Krane 2006; Drake and Nelson, 1999; Williams, 2009). States 
can also differ with each other over policy issues and can adopt different approaches to 
the same issue.  
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It is suggested by Dinan and Krane (2006) that the reason for national policy 
making is the lack of action by state governments. Conversely, state governments often 
engage in policy initiatives because of inactivity at the federal level in relation to a 
particular problem (Dinan & Krane, 2006). Each state has their own Constitution which 
outlines the government’s structure and responsibilities (Williams, 2009). State 
constitutions differ significantly from the federal one; they are longer, more detailed, 
and cover more topics. However, state constitutions do not and cannot contradict the 
U.S. Constitution, which can override a state constitution. Both the federal Constitution 
and federal statutes can override the state constitutional provisions. States also have to 
respect laws and court decisions in other states. Like the national government, the states 
have a separation of powers between three branches of government: executive, 
legislative, and judicial. Each branch is checked and balanced by each other, and by the 
federal government (Williams, 2009).  
Executive branch. The executive government is responsible for executing the 
laws of the state (U.S. Immigration and Naturalization Service, 1987; Williams, 2009). 
The state executive branch of government is headed by the governor. The role and 
importance of governors vary according to the individual state. The term of a governor’s 
office also varies among states, but today all but two governors serve for four years. 
Some states also have restrictions on the number of terms a governor can serve. The 
governor is responsible for advising the state legislature on laws concerning the state, 
proposing new laws, calling special sessions of the state legislature, and serving as head 
of the state’s National Guard. In all but two states, the governor also has the power to 
veto bills passed by the legislature, and in all but seven states the governor can also use 
a line-item veto which enables them to block specific sections of a bill (Watts, 2010). 
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Similar to the federal government, the Executive Branch of state government consists of 
a group of advisors who perform special duties, such as the Secretary of State and 
Attorney General (U.S. Immigration and Naturalization Service, 1987; Williams, 2009). 
The influence of a governor also depends on the extent to which they share executive 
power with other elected officials and agencies. In Michigan, for example, there are 
many state-wide elected officials and agencies and there is therefore less opportunity for 
the governor to coordinate and control the executive branch (Watts, 2010).  
Legislative branch. Every state except Nebraska has a legislative branch similar 
to that of the federal government, with two separate legislative chambers or houses 
(U.S. Immigration and Naturalization Service, 1987; Williams, 2009). Nebraska is an 
exception to this as it has a unicameral legislature (Williams, 2009). The term of office 
varies amongst the 50 U.S. states; usually the term of office in the Senate is four years, 
and two years in the House of Representatives (U.S. Immigration and Naturalization 
Service, 1987; Williams, 2009). The number of members in each house also differs, 
with each state having their own procedure for deciding the number of members. The 
procedure for making laws is seen by some as being very similar to the federal 
government, while others believe the state legislative process is more constricted and 
subject to a variety of constitutional limitations (Williams, 2009). The Legislature’s 
passing of laws can also be affected by direct democracy in the form of the initiative 
and referendum, as discussed below (Cushman, 2005; Williams, 2009).  
Judicial branch. The state Judicial Branches only hear those cases involving 
state or local law (United States Courts, n.d.). The state Judicial Branch is similar to the 
federal system and consists of a hierarchy of courts. Courts that handle specific legal 
matters (e.g. Family Court, Traffic) along with the Municipal County Magistrates Court 
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are the lowest and have a limited jurisdiction. At the next level are the state trial courts 
(e.g. District, Superior, Common Pleas). They are followed by an intermediate Court of 
Appeals, which is not found in all states. The highest court at the state level is the state 
Supreme Court (United States Courts, n.d.). 
Local Government 
Local governments are created by state governments rather than the U.S. 
Constitution and are the most common form of government in the U.S. (U.S. 
Immigration and Naturalization Service, 1987; U.S. Department of State, 2007; 
Zimmerman, 2012). The state government provides the local government with a 
“charter”, which describes its role, structure, and authority.. Local governments are 
controlled and checked by the state government, and have the power to perform only 
those functions assigned by the state. There are four levels of local governments, with 
all U.S. residents living within a local government, whether it is a municipality, a 
special district, and/or sub-state jurisdictions such as counties (known as parishes in 
Louisiana and boroughs in Alaska) (Katz, 2003; Kincaid & Steytler, 2009).  County 
governments were initially created as administrative arms of the states, but over time 
evolved into fairly autonomous governments with directly elected officials 
(Zimmerman, 2012). Connecticut and Rhode Island are the only states that do not have 
county governments. Twenty states have townships as local governments (Zimmerman, 
2012). In some states townships can assume general government powers while in others 
they have limited powers. Municipalities (or cities, owns, boroughs, or villages) are 
general-purpose governments with directly elected legislative bodies (Zimmerman, 
2012).  The functions of municipal governments can vary across the states. Special 
districts are limited governments that provide a specific service, such as housing, water-
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supply and transit boards, and school boards. Majority of all special districts only 
perform a single function (such as housing). In order to perform their functions, local 
governments receive funding from the state and federal governments and also collect 
property taxes and fees from their constituency (Sutton, 1974; U.S. Immigration and 
Naturalization Service, 1987; Watts, 2010). Local governments also have a court 
system, which deals with local issues such as traffic laws (Sutton, 1974; U.S. 
Immigration and Naturalization Service, 1987).  
Direct Legislation  
Some states provide their citizens with direct democracy through the initiative, 
referendum, and recall process (Birkland, 2005; BEP, 2010; Cushman, 2005). The 
history of direct legislation goes back to the 17th century and was primarily a result of 
social change and political reforms during the Progressive Era that span the end of the 
19th to the beginning of the 20th century (Arnon, 2008). The reform was a reaction 
against the laws and widespread corruption in the representative system, in which the 
influence of interest groups and powerful party bosses who controlled their party 
members’ voting patterns led to political dissatisfaction of the citizens. Direct 
legislation was created to act as a check on representative institutions and allow citizens 
to be involved in the legislative process (Arnon, 2008). It also allows the lawmaking 
power to be shared between the legislature and the people (Braunstein, 2004; Williams, 
2009). Out of the states discussed later in this thesis, Michigan has an initiative, 
referendum and legislative process; New Mexico has a referendum and legislative 
process; Illinois has an initiative, popular referendum and legislative referendum; 
Kentucky has a legislative process; and Louisiana has a legislative referendum 
(Cushman, 2005; IRI, 2009). The initiative process is the process by which the people 
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introduce a new legislation and vote on it at the ballot (Arnon, 2008). The popular 
referendum is the process that allows the people to place acts of their legislature on a 
ballot and vote on it (Arnon, 2008). Only the initiative process will be described in this 
section because it was the only direct democracy process utilised in relation to the 
medical cannabis policy in the states reviewed in this thesis.  
Over the past two decades, there has been an increase in initiatives in the U.S. 
(Watts, 2010). In total, 24 U.S. states and Washington D.C. have an initiative process 
under which citizens can, by collecting a specified number of signatures on a petition, 
place an issue before the state’s electorate (Birkland, 2005; BEP, 2010; Howard, 2005; 
IRI, 2009; Katz, 2003). Of the 24 states with an initiative process, 18 states allow 
initiatives to amend the state constitution and 21 states allow initiatives to propose and 
pass laws. The initiative may either be direct or indirect. In most cases, once a required 
number of signatures have been collected, the measure is brought directly to the state’s 
electorate for a vote of the people (direct initiative). Several states use the indirect 
initiative which allows the legislature to vote on the initiative first; if passed by the 
legislature, is not voted on by the electorate. However, if the proposal is not passed by 
the legislature, it is then put to a popular vote (Howard, 2005; IRI, 2009; Singh, 2003).  
The initiative process is useful in cases where law makers are unwilling to enact 
or consider a law that the citizens want (Watts, 2010). The initiative process may also 
have an indirect effect on policy making by voters approving initiatives that define how 
future legislators govern, affecting citizen behaviour, giving legislators more accurate 
information about voter preferences, increasing the number of interest groups, and 
influencing how legislators behave (Bowler & Donovan, 2004). According to Bowler 
and Donovan (2004), the initiative process has a greater impact “where it is easier to get 
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a measure on the ballot, where it can more easily circumvent the legislative process, 
and, perhaps most important, where it is used the most” (p. 359). Over 60 percent of 
initiative activity in the U.S. has occurred in Arizona, California, Colorado, North 
Dakota, Oregon and Washington, which generally have lesser signature requirements 
than other states (Watts, 2010).  
In the U.S., in 1998, $400 million was spent nationally on ballot proposition 
campaigns (Matsusaka, 2005). Much of the research on the topic has indicated that 
monetary resources and a large interest group membership assist in the success of the 
initiative process (Boehmke & Bowen, 2010; Braunstein, 2004; Magleby, 1998). It has 
also been estimated that 78 percent of ballot campaigns have been won by the side that 
spent the most money (Braunstein, 2004). Due to the money required for initiative, 
Magleby (1998) suggested that agenda-setting and campaign management in initiatives 
is primarily organised by elites, but must involve mass audiences in order to place an 
issue on the ballot and win on election day. As a result, some initiative campaigns are 
seen as battles amongst wealthy economic interest groups who are trying to secure more 
favourable policy, and use signature gathering firms to quickly and cheaply secure 
ballot measures, with little consideration given to voter engagement. This results in a 
decrease in voter interest and debate on a particular issue. Boehmke & Alvarez (2014) 
found that because the signature collection process reaches some voters and not others, 
voter participation on a particular measure can vary across voters and within states.  
Research has shown that the initiative process can lead to a greater participation 
by organised interest groups by providing them with the ability to propose legislation 
directly to voters (Boehmke & Bowen, 2010). Because the interest groups are 
traditionally disadvantaged in the legislature, the initiative process provides them with a 
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way to raise their policy concerns. An initiative process can increase the number of 
interest groups lobbying in the state by approximately 25 precent (Boehmke & Bowen, 
2010). According to Boehmke and Bowen (2010), interest groups tend to campaign 
more publicly during issue campaigns in states with an initiative process than for 
debates in the legislature, and try to recruit new members to strengthen their side. As a 
result, media coverage of the issue increases, which then increases the scope and 
intensity of conflict, leading groups to work harder to win the support of individuals and 
increase their membership (Boehmke, 2002). Groups in initiative states tend to have 
more members than groups in states with no initiative. Interest groups in states with an 
initiative process also rely more on outside lobbying tactics to influence government 
action, mobilising members, and organising public displays of support to pass an 
initiative (Boehmke & Bowen, 2010).  
Interest groups can use the initiative process to propose new legislation and to 
shape debate (Boehmke, 2008). It can also be used to influence decisions made by the 
legislature in a less direct way, by leading legislatures to choose policies that are close 
to the average voter preference to discourage interest groups from challenging policies 
by a ballot initiative (Boehmke, 2008; Bowler & Donovan, 2004). Also, the presence of 
particular measures on upcoming ballots may also encourage groups to mobilise or 
lobby. The interest groups that oppose the particular ballot measure may also start 
campaigning against the measure once the proponents show sufficient strength or their 
measure qualifies for the ballot (Boehmke, 2008). Boehmke (2008) viewed these groups 
as likely to be temporary in nature as they form in direct response to the threat posed by 
a particular measure. Once the threat is removed or fails, the opposition group is likely 
to dissolve. Therefore, the entry and exit rates of interest groups in states with the 
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initiative process are likely to be greater than in the states with no initiatives (Boehmke, 
2008). 
Initiatives also face legal challenge, as state and federal courts have in the past 
overturned the people’s vote on state or federal constitutional grounds (Magleby, 1998; 
Theodore, 2013). The judicial process can also delay implementation of an initiative. As 
Magleby (1998) puts it, “The willingness of federal courts to overturn state initiatives 
on U.S. Constitutional grounds is an important manifestation of federalism” (p. 152). 
The constitutional assertion of federal constitutional sovereignty over the people’s vote 
has in the past led to overturning of successful initiatives on issues such as the death 
penalty, abortion, homosexual rights, term limits, physician-assisted suicide, and illegal 
immigration (Magleby, 1998). As illustrated by the medical cannabis movement in the 
U.S., some state ballot initiatives can also be seen as trying to alter federal policy by 
stressing a state policy role in an area thought to be federal in nature.  
One of the more prominent criticisms of the process is that voters lack education and 
competence to make policy decisions (Burnett & Parry, 2014; Matsusaka, 2005). 
Research has shown that most voters are uninformed about public policy, politics and 
government, which raises the concern that damaging policy may be adopted as a result 
(Burnett & Parry, 2014; Hastings & Cann, 2014). In the absence of information, an 
influence on voters’ choice is the position taken by elites (Burnett & Parry, 2014; 
Hastings & Cann, 2014). Burnett and Parry (2014) found that voters rely on other 
evidence and that the governor’s endorsement of a ballot measure can have an effect on 
voter choice; voters who disapproved of the governor’s performance were significantly 
less likely to support the initiative while voters who approved of the governor’s 
performance were more likely to support the measure (Burnett & Parry, 2014). It has 
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also been suggested that the ballot wording influences voters’ choices. How the issue is 
framed also plays a role, and research has shown that even small changes in the 
presentation of an issue can produce changes in voter opinion (Druckman, 2001; 
Hastings & Cann, 2014). Another criticism is that well organised and wealthy interest 
groups may use voters’ lack of knowledge to their own benefit, especially in cases of 
well organised, wealthy interest groups.  
Informal Structures 
Even though the U.S. has a constitution, most of the electoral structure (offices, 
branches, levels, procedures) is determined and regulated by federal and state laws 
outside the Constitution (Young, 2007). For example, the political party system is not 
included in the Constitution, and the Constitution does not encompass everything in the 
legal system. Although unofficial actors are not mentioned in the Constitution, they play 
an important role in the policy process (Birkland, 2005). In this section, four informal 
groupings relevant to the medical cannabis policy process will be discussed. These are 
interest groups, political parties and the party system, independent research 
organisations, and the media. 
Interest groups. The democratic system of government in the U.S. allows for 
private associations, through which citizens can express their concerns and advance or 
defend their particular interests (Birkland, 2005; R. Harris & Tichenor, 2009; Singh, 
2003). Interest groups are independent agencies, free of governmental control; although 
they frequently seek to influence it. Interest groups can have political significance when 
they try to influence public policy, propose new laws, or persuade government officials 
to act in their interest. However, not all interest groups have a political significance or 
interests (Birkland, 2005; R. Harris & Tichenor, 2009; Singh, 2003). The approach and 
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activities of most interest groups is determined by the group’s mission, strategic goals, 
objectives, strategies and tactics (Leiden, 1995).  
Five broad types of interest groups active in the U.S. include economic interest 
groups, public interest groups, sectional groups, attitude groups, and intergovernmental 
groups (Birkland, 2005; R. Harris & Tichenor, 2009; Singh, 2003). Economic interest 
groups include a range of corporations, labour unions, agricultural groups, and 
professional bodies. Citizen, or public interest groups, are those with open memberships 
that represent the interests of the general public (Boehmke, 2002). Sectional groups 
represent concerns of a particular group of individuals and include organisations such as 
the National Organization for Women. Attitude groups advocate a specific political 
position or an ideological orientation. Lastly, intergovernmental groups include public 
officials seeking to promote a cause and pressure other government institutions (Singh, 
2003).  
The main functions of interest groups are representation (express the views of 
citizens to government); citizen participation (allow ordinary citizens to become active 
in the nation’s political life); public education (influence government and help educate 
citizens about government and its actions); agenda building (placing issues on the 
agenda and forcing decision-makers to act on specific issues); and programme 
monitoring (providing an additional check on government, making sure it is functioning 
properly) (R. Harris & Tichenor, 2009; Singh, 2003). Leiden (1995) suggested that 
many interest groups rarely make their true objectives public, and may be closely held 
by the group’s leadership or advocates.  
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Over the years, the activism and influence of interest groups has expanded, and 
they now play a significant role in the U.S. political system (Singh, 2003). While some 
see them as being a positive influence, others accuse them of compromising the 
democratic process. For example, some interest groups provide both presidential and 
congressional candidates with a large amount of money for their campaign funding, 
which is seen as promoting special interests of the wealthy (Birkland, 2005; R. Harris & 
Tichenor, 2009; Singh, 2003).  
Research has found that states with an initiative process have more interest 
groups (Boehmke, 2002). There is also a bias in the interest groups, with research 
showing that business groups and corporations tend to be overrepresented while broad-
based membership groups are underrepresented (Boehmke, 2002). Interest groups also 
take the political and economic context into account when deciding whether to become 
active. The initiative process also increases interest groups’ potential to affect policy 
and results in more groups being active in states with the initiative process. There is a 
relationship between the interest groups and initiative usage. According to Boehmke 
(2005) states with more citizen groups experience greater initiative use and states with 
more economic groups experience less initiative usage.  
Political parties and the party system. Political parties are not mentioned in 
the U.S. Constitution (Singh, 2003). The U.S. currently has a two-party political system, 
dominated by the Democratic and Republican parties (English, 2003; Singh, 2003). 
While there are more than two parties, the two major parties have been dominant since 
the Civil War (Singh, 2003). In the U.S., the parties do not have the power to choose 
who represents them in the elections for Congress as this decision is made by the voters 
in each state or district in primary elections. Primary elections take the power of 
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candidate nomination from the party leaders to the people, in turn allowing the parties to 
be made more attentive to what their constituents want, hence allowing the two parties 
to keep their dominance of the system (English, 2003; Singh, 2003). As a result, most 
elected government officials are either Republicans or Democrats. Third parties can also 
have a significant influence and, if they manage to gain sufficient support, may be able 
to influence a major party by bargaining for its votes (Birkland, 2005; Singh, 2003). 
Which party has control of the Congress can influence the passing of laws and 
other legislative functions. Congress is organised along party lines, and committee 
assignments are based on party affiliation (Birkland, 2005; English, 2003). However, 
political parties in the U.S. are weaker and more fragmented than in many other 
countries, and a party government is difficult to achieve. While there are differences 
between the ideologies of the two major parties, these differences are not fundamental; 
some Republicans have expressed Democratic sentiments, and vice versa (Krause & 
Bowman, 2005). In many cases, it is not in the interest of the party for all their members 
to vote the same way, and members must give consideration to how the voters will react 
to their actions. As party influence is not always very strong, members can often find 
that an independent stance on an issue can gain them more support from the voters 
(Birkland, 2005; English, 2003).  
In order to gain power, a party has to win majority support from all levels and 
sections of society (Krause & Bowman, 2005; Singh, 2003). There are regional 
differences in voter support for the political parties, with parties known to dominate 
certain states. Over the years, however, a decrease has been observed in the strength of 
voter-party identification, which makes voters more unpredictable at election time 
(Singh, 2003). To win support the political parties have to, amongst other things, 
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constantly change their stance on issues in order to meet the expectations and changing 
views of the electorate. Party candidates also have to be carefully selected, in order to 
gain public approval and support. Overall, political parties play a significant role in the 
government system, from framing the nature of political debate to influencing decision-
making, and providing an avenue for everyday citizens to influence the governmental 
decision-making process (Birkland, 2005; Singh, 2003). 
Independent research organisations. Independent research organisations such 
as the Brookings Institution and RAND can play a role in informing and shaping public 
policy (Birkland, 2005). The organisations consist of academic scholars and policy 
experts, and provide information that policymakers can use when forming policies. 
Many of these organisations identify with a particular ideological position, while those 
associated with universities are generally more scholarly and less ideological. Federal, 
state and local governments often rely upon university research organisations to obtain 
expert advice (Birkland, 2005).  
However, policymakers do not always have access to scientific research results 
and may turn to other sources for information (Ritter, 2009). There appears to be a 
discrepancy between the sort of information that policymakers require (simple 
summaries, policy-accessible language) and the information provided by many of the 
research organisations. Research evidence is therefore not the only factor influencing 
policy and other factors such as interest groups, legislative processes, and opportunistic 
windows can influence the decision-making process (Kaiser, 2001). 
The media. The media is believed to play an important role in the democratic 
political system (Birkland, 2005; R. Harris & Tichenor, 2009). It is essential in 
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facilitating communication between citizens and their elected officials and providing 
information to the public, its role in the political system further enhanced by the 
advances in the mass media technologies (internet, blogging). The media can also act as 
a government “watchdog”; keeping an eye on politics and policy-making activities of 
the government and reporting them to the public (Birkland, 2005; R. Harris & Tichenor, 
2009).  
While some believe that the mass media has a short-term and limited effect on 
the policy process, others believe it has a strong influence in the areas of agenda setting, 
priming, and framing (Birkland, 2005; R. Harris & Tichenor, 2009). Arguably, the 
media may not have a direct influence on the policy making process, but it can have an 
effect on the actions and attitudes of policymakers and the public (R. Harris & Tichenor, 
2009). It can help bring public attention to certain issues and can expand issues to 
broader audiences, which in turn creates more pressure for change. Interest groups also 
recognise the value of media and can gain access to it to further promote their case. 
However, it is not a flawless process. There can be biases in the media coverage, such 
as taking a particular side in the debate, which can influence policy. A decision on what 
stories to cover can also influence public opinion. Individual journalists also play a role 
as they are the ones that write the coverage of the news and events (Birkland, 2005; R. 
Harris & Tichenor, 2009). 
Medical cannabis and the federal-state relations 
Over the past decade, state officials and the public have acted on many issues 
where they felt that the federal government was not taking action or was making 
unacceptable policy decisions, in policy areas such as education, welfare and drug 
control (Ferraiolo, 2008; Hall & Degenhardt, 2003; Pickerill & Chen, 2008). In the area 
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of medical cannabis, state activism took place in the form of initiatives. State direct 
democracy measures have had an impact on federal-state relations, as cannabis is 
generally considered to be a policy area of federal concern, and have hence created a 
conflict between state and federal governments (Ferraiolo, 2008; Hall & Degenhardt, 
2003; McDonough, 2000; Pickerill & Chen, 2008). As a result of the conflict, patients, 
doctors, police, prosecutors, and public officials are placed in a difficult position as they 
still can be prosecuted at the federal level (Hall & Degenhardt, 2003; McDonough, 
2000; MPP, 2013).  
The question that this raises is whether states should be able to decide for 
themselves whether to legalise cannabis for medical use or if the federal government 
should regulate this area of policy (Pickerill & Chen, 2008). In Gonzales v. Raich 
(2005), the U.S. Supreme Court upheld the Congress’ authority under the CSA when it 
ruled that the Congress has the power to ban the use of medical cannabis even where 
states approve its use for medicinal purposes. However, the ruling did not deter states in 
passing medical cannabis laws and widening the gap between federal law and voter 
preference (Ferraiolo, 2008).  
According to Pickerill and Chen (2008), allowing a state to experiment with a 
policy allows for any potential harm or failures to be localised to that state, and that if a 
policy works other states may learn from it and choose to adopt it. They also suggested 
that allowing a state to experiment with a policy may lead to different states trying 
different ways to approach the issue and assess which approaches are more or less 
effective (Pickerill & Chen, 2008). In the states that currently have medical cannabis 
laws, the laws vary in such terms as which debilitating medical conditions cannabis is 
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allowed for, whether or not they allow dispensaries and whether patients need registry 
cards (MPP, 2013).   
Summary 
Overall, it is important to examine all levels of government as each has a 
significant role to play. The government operates in a complex multi-level system, 
based not only on the U.S. Constitution, but laws and statutes outside of it. There are 
many individuals and organisations that have not been included in the Constitution 
which can influence the political system and how the nation is governed. Most state 
agencies were created by legislative enactment, rather than by provisions of the state 
constitutions. Because the U.S. is a democratic system where the supreme power is 
vested in the people, its aim is to allow all citizens to have an equal say in decisions 
affecting them. However, there are other factors and informal structures which can play 
a role in the political system, one of them being scientific evidence. The following 
chapter will discuss cannabis as a medicine and provide a review of relevant medical 
cannabis literature. 
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Chapter 3- Cannabis as a Medicine: A Review of the Literature 
Cannabis has long been recognised for its medicinal properties and is the third 
most commonly used psychoactive substance after tobacco and alcohol in America 
(Baker, Pryce, Giovannoni, & Thompson, 2003; Eddy, 2010; Kreit, 2003; Marshall, 
2005; Russo, 2007). For the purposes of this thesis, cannabis will be the term applied to 
all products derived from the plant Cannabis sativa, which has over 400 compounds 
(IOM, 1999; McPartland & Russo, 2001; Ryder et al., 2006). Cannabis is made up of 
Phytocannabinoids, Terpenoids, and Flavonoids (McPartland & Russo, 2001). 
Phytocannabinoids (cannabinoids) are a group of compounds uniquely produced by 
cannabis and over seventy different cannabinoids have been identified (McPartland, 
2008; McPartland & Russo, 2001).   
THC is the main psychoactive ingredient in the cannabis plant (Baker et al., 
2003; Ben Amar, 2006; IOM, 1999; Russo, 2007; Ryder, et al., 2006). THC was first 
isolated, synthesised and stereochemically defined in the 1960s (Baker et al., 2003). It is 
estimated that over the past decade the THC content increased from 1-3 percent to 6-13 
percent and above, with an average of 7 percent THC content in the U.S. (Baker et al., 
2003; Russo, 2007). Cannabidiol (CBD), a non-psychoactive compound, is cannabis’ 
major constituent. It is believed to have medicinal properties and reduces THC’s side-
effects (Mather, 2005; McPartland & Russo, 2001). Cannabinoids bind to specific 
receptors of which two have been identified, the CB1 and CB2 receptors. CB1 receptors 
are mainly found in the brain and both male and female reproductive systems 
(American College of Physicians [ACP], 2008; Ben Amar, 2006; McPartland, 2008; 
Robson, 2001). These receptors mediate most of the central nervous system responses to 
cannabinoids and are believed responsible for cannabis’ euphoric effects. CB2 receptors 
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are found mostly in the peripheral nervous system and are believed to be responsible for 
cannabis’ anti-inflammatory and immunosuppressive effects (AMA, 2009; McPartland, 
2008; Robson, 2001). Several endogenous fatty-acid ligands (atoms or molecules that 
bind to another), known as endocannabinoids, have also been found (Baker et al., 2003). 
These compounds have cannabinoid receptor binding activity, but their physiological 
roles are not yet know.  
Marijuana, hashish, charas, bhang, ganja and sinsemilla are the terms used for 
different cannabis preparations, the effects of which vary with different delivery 
methods (IOM, 1999; Julien, Advokat, & Comarty, 2008; Russo, 2007). Bhang and 
marijuana are low-grade preparations taken from the dried mixture of cannabis flowers, 
leaves, and stems. Ganja and sinsemilla are the seedless unfertilised female flowering 
tops. Charas and hashish are the most potent cannabis preparations and are derived from 
cannabis resin (Julien, et al., 2008; Russo, 2007). Studies have shown that there are also 
different strains of cannabis which can have various effects (Russo, 2007).  
There are different ways of administering cannabis, with each method having 
advantages and disadvantages. Route of cannabis administration can affect the 
therapeutic benefits experienced by some patients (Clark, 2000; Grotenhermen, 2001). 
The following section will discuss different routes of cannabis administration and the 
use of synthetic cannabinoids in the U.S.  
Synthetic Cannabinoids 
What is often forgotten in the debate on medical cannabis is that there are 
currently two synthetic cannabinoids approved in the U.S., dronabinol (Marinol) and 
nabilone (Cesamet). Dronabinol is approved by the FDA for oral administration as an 
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appetite stimulant for HIV/AIDS-related wasting syndrome, along with relief of nausea 
and vomiting (Beal et al., 1997; Hazekamp & Grotenhermen, 2010; Werner, 2001). 
Nabilone is also approved by the FDA and is used primarily to treat nausea and 
vomiting resulting from cancer chemotherapy, when other medications have proven 
ineffective (National Library of Medicine, 2012). Evidence has shown that these 
compounds have medical use and they have passed the strict requirements of the FDA 
for approval as medicines for human consumption (Iversen, 2000). Research is also 
being done on other synthetic cannabinoids, such as CT-3, a synthetic derivative of a 
non-psychoactive THC metabolite called THC-11-oic acid, to determine their 
effectiveness in the treatment of some debilitating medical conditions.  
However, despite dronabinol’s positive effects, reports indicate that patients 
prefer smoked cannabis to dronabinol (Earleywine, 2002). The drug is reported difficult 
to swallow by patients with nausea and vomiting, and due to its oral administration the 
effects do not appear rapidly. Many patients claim that dosage is easier to regulate with 
smoked cannabis than with dronabinol. Dronabinol (Marinol in the U.S.) is also 
expensive, with patients paying up to $1, 000 per bottle of 60 capsules (Earleywine, 
2002; Gieringer, Rosenthal, & Carter, 2008).  
Route of Administration 
Smoking. Smoking is the most popular method of cannabis administration for 
recreational use and one of the most direct methods of ingestion (Gieringer et al., 2008; 
Iversen, 2000). Smoking cannabis rapidly delivers THC to the brain, making it easier 
for patients using the drug for medicinal purposes to control dosage and alleviate 
symptoms (Degenhardt, Hall, & Lynskey, 2003; Mack & Joy, 2000). Maximum THC 
concentration is reached within approximately five minutes and THC can be detected in 
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plasma seconds after first inhalation. Psychoactive effects are felt within seconds to 
minutes, reaching their maximum after 30 minutes, and last approximately two to three 
hours (Degenhardt, et al., 2003). A major disadvantage of smoked cannabis is that some 
chemicals found in cannabis smoke can be toxic and damaging to the respiratory tract 
(Gieringer et al., 2008). The frequency and amount of cannabis smoked by an average 
individual may differ in comparison to tobacco, but smoked cannabis contains the same 
harmful toxins present in tobacco smoke, with greater concentrations of carcinogenic 
substances (Clark, 2000; Robson, 2001). While some reports have claimed that smoking 
is a relatively ineffective route of administration because it destroys up to 70 percent of 
THC, most have found smoking to be a more efficient mode of administration (Mack & 
Joy, 2000; Russo, 2007). 
Vaporisation. The use of inhalation devices, such as vaporizers, has been 
suggested as an alternative to smoking cannabis as they allow inhalation of cannabis 
without the negative health effects of smoking (ACP, 2008; Grotenhermen, 2001). 
Vaporisation offers the same rapid delivery of THC and other cannabinoids as smoking, 
but may require more getting used to than smoking cannabis. Vaporisers may be bought 
commercially or the users can make their own (Gieringer et al., 2008). Vaporisers 
require the use of a hot plate to heat cannabis to the point where cannabinoids vaporise 
and users can then inhale the vapour (Earleywine, 2002). The disadvantage of using a 
vaporiser is that the vapour usually contains a low amount of THC and a high amount of 
cannabinol (Earleywine, 2002).  
Eating/drinking. THC is soluble in fats and alcohol so it can be extracted and 
added to various food and drinks and administered in that way (Iversen, 2000). 
Absorption occurs through the walls of the stomach and intestines and therefore gives a 
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much slower absorption and avoids the irritating effects of inhaled smoke. The effects 
of cannabis administered this way take longer to manifest than smoking, usually one to 
two hours, and peak more slowly, but the effects can last three up to four hours. 
Cannabis can also be mixed with alcohol and the tincture made into tea. This route of 
administration is considered unreliable as the dosage is difficult to titrate due to delayed 
onset of effects (ACP, 2008; Robson, 2001).  
Capsules.  Taking THC by mouth in capsule form is not very reliable as a 
method of delivering a consistent dose of the drug (Iversen, 2000). While THC is 
absorbed reasonably well from the gut, the process is slow and unpredictable and most 
of the absorbed drug is rapidly degraded by metabolism in the liver before it even 
reaches the general blood circulation. The peak blood levels of THC occur anywhere 
between one and four hours after ingestion and the overall delivery of active THC to the 
bloodstream averages less than 10 percent. The effects of oral administration can be 
affected by the acid in the stomach and gut and the presence or absence of food (ACP, 
2008; Grotenhermen, 2001). Orally-administered products have not proved consistently 
effective in their medical application as THC may be erratically or slowly absorbed into 
the bloodstream and patients suffering from nausea and vomiting have found it difficult 
to keep oral cannabinoids in their system long enough for the effects to be felt (Clark, 
2000). Difficulty in regulating dosage can result in a possible over-dosage or under-
dosage (Grotenhermen, 2001; Julien, et al., 2008).   
Suppositories. Another way of delivering the drug is in the form of rectal 
suppositories, where THC can be converted to a hemisuccinate (Julien, et al., 2008). 
Absorption can be good by this mode of administration, as it delivers the drug directly 
into the systemic circulation, bypassing the liver, and avoids the problem of liver 
 Medical Cannabis in the United States     62 
 
metabolism, which limits oral THC absorption. This mode of administration can deliver 
approximately twice as much active drug to the bloodstream as the oral route, although 
there can still be variability in drug absorption amongst individuals (Julien, et al., 2008).  
Spray. A new spray based on natural cannabis extracts has been developed in 
the United Kingdom (Gieringer et al., 2008). The oral spray, known as Sativex, consists 
of equal parts THC and CBD extracted from cannabis and is administered under the 
tongue, from where it is absorbed into the bloodstream. Sativex differs from Marinol in 
that it is a mixture of compounds derived from the Cannabis plant; incorporates CBD 
and other plant ingredients as well as THC. Its absorption is not as fast as inhalation as 
it takes several minutes for the cannabinoids to be absorbed through the membrane of 
the mouth, but it is faster than oral ingestion (Gieringer et al., 2008). The spray delivers 
a more consistent dosage because the cannabinoids are absorbed directly into the blood 
without having to pass through the digestive system. Sativex is not currently approved 
for use in the U.S.  
Topical. Topical cannabis preparations have been used as folk medicine in India 
and Latin America (Gieringer et al., 2008; Mack & Joy, 2000). Cannabis can be applied 
topically to the skin in the form of ointments, lotions, or poultices, for treatment of such 
conditions as swollen joints and skin inflammation (Gieringer et al., 2008). However, 
research is unclear on whether there is an effective method for transporting THC or 
other cannabinoids through the skin. Suppositories are thought to be a better way of 
delivering cannabinoids to the system and there is no commercially available topical 
cannabis treatment.  
 Medical Cannabis in the United States     63 
 
Intravenous. Cannabis is very difficult to administer intravenously as THC is 
extremely insoluble in water. Cannabis can be injected by adding an alcoholic solution 
of THC to a rapid intravenous infusion of saline solution, but this is rarely used 
(Iversen, 2000). The method delivers THC to the blood circulation rapidly. This mode 
of administration is very rare (Earleywine, 2002).  
Anecdotal and clinical reports have suggested cannabis could potentially be 
effective in the treatment of various debilitating medical conditions (Mack & Joy, 2000; 
Mather, 2005). The following section will review clinical trials of cannabis and 
cannabinoids in the treatment of various medical conditions and compare the results 
with conclusions reached in other influential earlier reviews of the literature. It is 
important to note that the first section does not follow standards set for systematic 
literature reviews, but the findings of systematic reviews and meta-analyses on medical 
cannabis will be discussed later in the chapter. Additionally, this review only included 
studies of cannabis plant and its natural derivatives and excluded studies that focused on 
synthetic cannabinoids such as nabilone and dronabinol. Synthetic cannabinoids 
nabilone and dronabinol are already approved by the FDA for use in the treatment of 
some debilitating medical conditions, and were excluded because the focus of the 
research in this thesis was on laws as they relate to medical cannabis, and research on 
synthetic cannabinoids was deemed beyond the remit of this study.  
Review Strategy  
For the purpose of this review, an electronic search was made in the OneSearch 
program of Edith Cowan University (ECU) library system of all literature published 
until February 2011. The search included the following keywords:  “cannabis”, 
“cannabinoids”, “marijuana”, “marihuana”, “THC”, “tetrahydrocannabinol”, “medical”, 
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“medicinal”, and “therapeutic”; or a combination of these keywords. Only full-text 
articles in peer-reviewed journals, obtained either online or through ECU or other 
university libraries, were included in the search. Other reports were identified through a 
general internet search of medical and scientific journal websites, pages devoted to 
medical cannabis, and Google Scholar. Additional reports were also identified from the 
reference lists of retrieved articles and reports. It is important to note that some studies 
were not accessed and included in this review because they could not be accessed 
through the standard university system. The search only included articles in English or 
with an English translation. Data from review articles, case reports, and where abstracts 
only were available were not included.  
Inclusion criteria. The method for assessing the quality of a clinical trial and 
the inclusion criteria were as described by the Jadad Scale (Jadad et al., 1996). The 
Jadad Scale assesses the methodological quality of studies by the presence of three key 
features: randomization; double-blinding; and accounting for all patients, including 
withdrawals and dropouts. Studies were included if they met these three key criteria, or 
had a score point of three or more on a five-point scale (Jadad, et al., 1996). One point is 
given to a study for each of the following points: randomisation, use of appropriate 
randomisation procedures, double-blinding, use of appropriate double-blinding 
methods, and a description of reasons for patient withdrawals and dropouts. Some 
critics suggest that the scale may be limiting in focusing only on three key criteria, and 
may not provide the most comprehensive measure (Armijo Olivo et al., 2008). It also 
does not allow for the studies to be divided into “low” and “high” quality. For the 
purpose of this research, the Jadad Scale was chosen for its ease of use and its known 
reliability and external validity (Armijo Olivo, et al., 2008). The scale was also chosen 
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because it assesses measures of internal validity and accounts for methodological errors 
such as the placebo effect, which can affect the results (Jadad, et al., 1996). It should be 
noted that the scale was not used only to exclude studies but to identify common 
methodological weaknesses, and raise questions that need to be addressed in medical 
cannabis research.  
Level of evidence. All of the studies included in this review are considered to be 
Level II evidence, according to the National Health and Medical Research Council 
guidelines (National Health and Medical Research Council, 1999). The levels evaluate 
the degree to which bias has been eliminated by study design; Level II grading 
encompasses evidence “obtained from at least one properly designed randomised 
controlled trial” (National Health and Medical Research Council, 1999, p. 8).  
Review Summary 
The following section will discuss the scientific evidence from clinical studies 
on the effectiveness of medical cannabis, as determined by the previously mentioned 
selection criteria. In total, 38 studies fitting the selection criteria have been identified. 
As can be seen in Table 1, this review identified 10 conditions in which studies fitting 
the selection criteria were conducted. While no study specifically examined the effect of 
medical cannabis on sleep, cannabis’ sleep-inducing properties and effects on quality of 
sleep have been mentioned in a number of studies discussed in this review. For each 
study reviewed, methodology, route of cannabis administration, treatment and control 
groups, the number of participants, drop-out rates, outcome measures, and results will 
be described. A summary of the results for each debilitating medical condition will also 
be provided.  
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Table 1 
A Summary of Studies Reviewed 
Medical Condition Number of Studies 
Range of study 
participants 
Total number of 
participants 
Pain 16 10-177 794 
Nausea and vomiting 7 9-214 474 
Spasticity 6 13-630 1, 073 
Appetite/Weight 2 67-243 310 
Gilles de la Tourette 
syndrome 2 12-24 36 
Parkinson’s disease 1 19 19 
Epilepsy 1 15 15 
Glaucoma 1 6 6 
Bladder dysfunction 1 135 135 
Schizophrenic 
psychosis 1 13 13 
Sleep* Mentioned in other studies  
TOTAL 38  2,875 
 
Pain 
A total of 16 randomised controlled clinical trials examining cannabis and its 
constituents in the treatment of pain met the inclusion criteria for this review (Abrams et 
al., 2007; Berman, Symonds, & Birch, 2004; Blake, Robson, Ho, Jubb, & McCabe, 
2006; Conte et al., 2009; Ellis et al., 2008; Johnson, Burnell-Nugent, Lossignol, Ganae-
Motan, & Fallon, 2010; Notcutt et al., 2004; Noyes, Brunk, Avery, & Canter, 1975; 
Nurmikko et al., 2007; Raft, Gregg, Ghia, & Harris, 1977; Rog, Nurmikko, Friede, & 
Young, 2005; Selvarajah, Gandhi, Emery, & Tesfaye, 2010; Wade, Robson, House, 
Makela, & Aram, 2003; Wallace et al., 2007; Ware et al., 2010; Wilsey et al., 2008). 
The four different forms of pain covered include: neuropathic or chronic pain, acute 
pain, chronic cancer pain, and rheumatic pain.
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Table 2 
(Chronic) Neuropathic Pain 
Author Methodology Route of 
Administration 
Number of 
participants  
Treatment and 
Control Groups 
Outcome 
measures 
Results Side Effects 
Abrams et 
al. (2007) 
Randomised 
placebo-
controlled 
trial 
Smoked 
cannabis (3.56% 
THC) 
54 patients 
with HIV-
associated 
neuropathic 
pain. 
 
50 (93%) 
patients 
completed the 
trial.25 in 
each group. 
27 randomly 
assigned to receive 
a cannabis cigarette. 
27 to receive an 
identical placebo 
cigarette, three 
times daily for 5 
days 
Ratings of 
chronic pain, 
percentage 
achieving >30% 
reduction in 
pain intensity, 
side effects 
Cannabis 
smoking reduced 
neuropathic pain 
significantly 
more than 
placebo (34% 
reduction to 
17% 
respectively). 
Twelve (48%) of 
patients who 
smoked cannabis 
reported a 
reduction in pain 
of more than 
30% from 
baseline to end 
of treatment, 
compared to 6 
(24%) of 
placebo 
receiving 
patients. 
Cannabis side effects 
ratings were 
significantly higher 
than those of placebo 
for anxiety, sedation, 
disorientation, 
confusion, and 
dizziness. No patient 
withdrew from the 
study due to side 
effects. 
Ellis et al. 
(2008) 
Phase II, 
double-blind, 
placebo-
controlled, 
crossover trial 
Smoked 
cannabis (1-8% 
THC) 
34 HIV-
infected 
patients.  
 
28 (82%) 
Patients were 
administered either 
smoked cannabis or 
an identical looking 
placebo cigarette 4x 
Measures of 
multiple pain 
(such as 
analgesia) and 
side effects 
Smoked 
cannabis 
significantly 
reduced 
neuropathic pain 
The frequency of 
some side-effects, 
including 
concentration 
difficulties, fatigue, 
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patients 
completed 
treatment (13 
placebo-
cannabis, 15 
cannabis-
placebo) 
daily over 5 
consecutive days. 
34 patients were 
randomised (16 
received placebo 
first followed by 
cannabis, 18 
received the reverse 
order).  
intensity in HIV-
infected patients 
compared to 
placebo and 
when taken in 
combination 
with an 
analgesic 
medication. 30% 
more patients 
achieved pain 
reduction from 
cannabis (0.46) 
than for placebo 
(0.18). 
sleepiness or sedation, 
increased duration of 
sleep, dry mouth, and 
thirst was greater for 
cannabis than placebo 
Wilsey et 
al. (2008) 
Randomised, 
placebo-
controlled, 
crossover trial 
Smoked 
cannabis; high-
dose (7% THC), 
low-dose (3.5% 
THC) 
38 patients 
with 
neuropathic 
pain. 
 
32 (84%) 
patients 
completed all 
three study 
sessions. 
During three 6-hour 
experimental 
sessions, 38 patients 
were randomised to 
receive a high-dose 
cannabis cigarette, 
low-dose cannabis 
cigarette, and a 
placebo cigarette 
(cannabinoids 
extracted) once in 
random order. 
Pain intensity, 
pain 
unpleasantness, 
neurocognitive 
effects, and 
psychoactive 
side effects 
Both low and 
high THC 
concentrations 
produced 
statistically 
significant 
analgesic effects 
compared with 
placebo. The 
difference 
between high 
and low dose 
cannabis 
cigarettes was 
not statistically 
significant. Pain 
was more 
tolerable at 
Subjects using the 
higher THC dose 
experienced 
significantly greater 
side effects than those 
using a lower dose or 
placebo. Feeling 
“high” and feeling 
“stoned” scored 
significantly greater 
for the high-dose 
group; both dose 
groups significantly 
differed from placebo. 
Feeling “impaired”, 
sedation, and 
confusion were 
significantly different 
 Medical Cannabis in the United States     69 
 
higher 
cumulative 
doses of 
cannabis than 
with placebo. 
between the two dose 
groups compared with 
placebo. 
Ware et 
al. (2010) 
Randomised, 
double-blind, 
placebo-
controlled, 
crossover trial 
Smoked 
cannabis (2.5%, 
6%, and 9.4% 
THC). 
23 patients 
with chronic 
neuropathic 
pain. 
 
21 patients 
(91%) 
completed all 
four treatment 
cycles 
Patients randomly 
assigned to groups 
receiving different 
cannabis potencies, 
over four 14-day 
periods.  
Daily average 
pain intensity, 
effects on mood, 
sleep and 
quality of life, 
side effects. 
High potency 
cannabis (9.4% 
THC) 
significantly 
reduced average 
pain intensity 
compared with 
placebo; 
increasing THC 
content led to 
improvement in 
outcomes. At the 
end of the trial, 
16 (76%) 
participants 
were able to 
correctly identify 
the 9.4% THC 
treatment, and 
13 (62%) were 
able to identify 
the placebo 
period. The 6% 
THC period was 
identified by 8 
(38%) 
participants, and 
the 2.5% THC 
No serious side 
effects. Participants 
using 9.4% THC 
reported significantly 
more drowsiness. 
Side effects increased 
with cannabis 
potency. The most 
frequent side effects 
reported by patients 
receiving 9.4% THC 
included headache, 
dry eyes, burning 
sensation, and cough. 
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period by 7 
(33%) 
participants. 
Wade et 
al. (2003) 
Randomised, 
double-blind, 
crossover, 
placebo-
controlled 
study 
Cannabis based 
medicinal 
extract  
THC (2.5mg): 
CBD (2.5mg) 
24 patients 
with  
neurogenic 
symptoms 
unresponsive 
to standard 
treatment 
 
20 (83%) 
patients 
completed the 
study (3 
withdrew 
during open-
label, 1 during 
the blinded 
phase). 
 
 
An open label 
period during which 
patients received a 
1:1 combination of 
THC (2.5 mg) and 
CBD (2.5 mg) was 
followed by an 8-
week double-blind 
phase, consisting of 
four 2-week stages 
during which 
patients were 
randomised to 
receive either 
cannabis extract 
containing THC 
(2.5 mg) only, CBD 
only (2.5 mg), a 
combination of 
both, or matched 
placebo. Treatments 
were self-
administered by 
sublingual spray in 
doses of 2.5-120 mg 
per day. 
Symptoms, 
well-being, and 
intoxication 
scores were 
recorded on a 
Visual Analogue 
Scale. Severity 
and frequency 
of symptoms, 
measures of 
disability, mood 
and cognition, 
side effects 
In comparison 
with placebo, 
both THC and 
CBD alone 
significantly 
improved pain. 
Levels of 
intoxication 
were highest 
with THC 
Side effects were 
reported by patients in 
all groups: 11 (55%) 
following THC, 10 
(48%) following 
placebo, seven (33%) 
following CBD, and  
six (30%) following 
THC:CBD 
Berman et 
al. (2004) 
Randomised, 
double-blind, 
placebo-
controlled 
Sativex 
(sublingual) 
(2.7 mg THC: 
2.5 mg CBD) 
48 patients 
with central 
neuropathic 
pain 
Over three 2-week 
treatment periods, 
patients were 
randomised to 6 
Pain severity 
score, followed 
by pain related 
quality of life 
Both THC alone 
and Sativex 
reached 
statistical 
Dizziness, 
somnolence, a bad 
taste in the mouth, 
nausea and feeling 
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trial  
45 (94%) 
patients 
completed the 
study 
 
sequences of 
receiving Sativex 
(1:1 ratio of 2.7 mg 
THC, 2.5 mg CBD), 
a THC extract (2.7 
mg), and placebo, in 
sublingual spray.  
* All patients 
remained on their 
existing 
medications. 
and treatment 
side effects 
significance in 
decreased pain 
compared with 
placebo, but did 
not reach the 
pre-determined 
level for clinical 
significance. 
*The 
researchers 
found it was 
difficult to 
guarantee full 
blinding because 
many patients 
had previous 
experience with 
cannabis 
drunk were the most 
commonly reported 
side effects. They 
were generally well 
tolerated 
Nurmikko 
et al. 
(2007) 
Randomised, 
double-blind, 
placebo-
controlled 
clinical trial 
Sativex 
(sublingual)  
(2.7 mg THC: 
2.5 mg CBD) 
125 patients 
with 
neuropathic 
pain of 
peripheral 
origin 
 
105 (84%) 
patients 
completed the 
study.  
In the 5-week study, 
patients were 
randomised to 
receive either 
oromucosal Sativex 
(63 patients) or a 
placebo (62) 
identical in 
appearance, smell, 
and taste. Doses 
were self-titrated by 
patients in order to 
optimise drug 
administration. 
* Patients remained 
Change from 
baseline of 
mean intensity 
of global 
neuropathic 
pain, allodynia, 
sleep 
disturbance, 
Pain Disability 
Index, general 
health, cognitive 
decline, side 
effects 
Reduction in 
pain from 
baseline was 
statistically 
significant for 
Sativex (reduced 
by 22%) 
compared with 
placebo (8%). 
Improvement in 
pain intensity, 
allodynia, pain 
disability, and 
impression of 
change, were 
Side effects were 
reported by 57 (91%) 
of patients in the 
Sativex group, 
compared with 48 
(77%) patients in the 
placebo group. The 
most common side-
effects of Sativex 
were dizziness (29%), 
nausea (22%), fatigue 
(21%), and dry mouth 
(17.5%) 
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on their existing 
analgesic treatment 
throughout the 
study. 
 
also significantly 
greater for 
Sativex than 
placebo.  
 
Selvarajah 
et al. 
(2010) 
Randomised, 
placebo-
controlled, 
double-blind, 
clinical trial 
Sativex 
(sublingual)   
(2.7 mg THC: 
2.5 mg CBD) 
30 patients 
with  painful 
diabetic 
neuropathy 
 
24 (80%) 
patients 
completed the 
study.  
Patients received 
daily doses of 
Sativex or placebo 
in a sublingual 
spray, up to 4 times 
a day. Doses were 
self-titrated by 
patients over 2 
weeks, followed by 
a 10-week 
maintenance phase. 
* Patients continued 
using their existing 
neuropathic pain 
treatment. 
Change in mean 
daily pain 
scores, quality 
of life, side-
effects 
An improvement 
in pain scores 
was observed in 
both groups. The 
difference 
between groups 
was not 
statistically 
significant. 53% 
of Sativex-
treated patients 
responded to 
treatment, 
compared with 
64% of placebo-
treated 
participants.  
Six patients withdrew 
from the study due to 
side effects, but side 
effects were not 
outlined by the 
authors 
Rog et al. 
(2005) 
Randomised,  
double-blind, 
placebo-
controlled, 
parallel-group 
trial 
Sativex 
(sublingual)   
(2.7 mg THC: 
2.5 mg CBD) 
66 patients 
with central 
pain associated 
with multiple 
sclerosis 
 
64 (97%) 
participants 
completed the 
study  
Over the course of 5 
weeks, patients 
were randomised to 
receive either 
Sativex (34) or a 
placebo (32) 
identical in 
appearance, smell, 
and taste to Sativex. 
Treatments were 
delivered via 
Change in 
Neuropathic 
Pain Scale and 
an 11-point 
Numerical 
Rating Scale 
scores from 
baseline to end 
of treatment, 
side effects 
Reduction in 
pain scores on 
both Numerical 
Rating Scale -11 
and Neuropathic 
Pain Scale was 
statistically 
significant for 
Sativex in 
comparison with 
placebo.   
30 patients (88.2%) 
receiving Sativex 
experienced at least 1 
side effect; 22 
(68.8%) receiving 
placebo. Most 
common Sativex side-
effects were: 
dizziness (56%), dry 
mouth (12%), 
drowsiness (9%), 
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oromucosal spray; 
doses were titrated. 
* Patients continued 
using their existing 
neuropathic pain 
treatment. 
dissociation (9%), 
nausea (9%), falls 
(9%), and weakness 
(9%) 
Notcutt et 
al. (2004) 
Randomised, 
double-blind, 
placebo-
controlled, 
crossover trial 
Sativex 
(sublingual)  
(2.7 mg THC: 
2.5 mg CBD) 
34 patients 
with chronic 
pain 
 
32 (94%) 
patients 
completed the 
study 
Used ‘N of 1’ 
methodology 
(objectively and 
systematically 
evaluating 
participants’ 
individual responses 
to treatment). 
Patients randomly 
received a different 
treatment each week 
over two 4-week 
sessions: THC, 
CBD, a combination 
of both (1:1), and a 
placebo. Titration 
was conducted 
under supervision at 
the start of each 
week. 
* Patients continued 
using their existing 
neuropathic pain 
treatment. 
Effects, 
tolerability, 
safety, and 
dosages 
Both THC alone 
and the THC: 
CBD 
combination was 
significantly 
better than 
placebo in 
providing pain 
relief, while 
CBD alone was 
ineffective. Out 
of the 28 
patients who 
obtained benefit, 
most preferred 
either THC 
alone or the 
THC: CBD 
combination.  
* 7 frequent 
cannabis users 
were offered 
THC: CBD as 
rescue 
medication 
Data on side effects 
during the baseline 
period was 
incomplete due to an 
error in data 
collection.  
Side effects were 
common and most 
frequently included  
dry mouth, 
drowsiness, 
dysphoria/euphoria, 
and dizziness 
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Table 3 
Acute Pain 
Author Methodology Route of 
Administration 
Number of 
participants  
Treatment and 
Control Groups 
Outcome 
measures 
Results Side Effects 
Wallace 
et al. 
(2007) 
Randomised, 
double-blind, 
placebo-
controlled, 
crossover trial 
Smoked 
cannabis  
(2%, 4%, and 
8% THC) 
19 healthy 
volunteers 
 
15 (79%) 
participants 
completed 
the study 
Over 4 dose-
randomised sessions, 
participants received 
1 of 3 doses of 
cannabis or a placebo 
identical in 
appearance while 
being exposed to 
capsaicin-induced 
pain.  
Pain, 
hyperalgesia, 
THC plasma 
levels, and side 
effects 
Cannabis’ 
effectiveness as an 
analgesic was 
dose-dependent. 
Low dose of 
smoked cannabis 
(2% THC) had no 
analgesic effects; a 
medium cannabis 
dose (4% THC) 
resulted in delayed 
pain relief, 
Mainly experienced 
with high doses of 
cannabis and included: 
dizziness/faintness, 
drowsiness, feeling 
cold, cognitive 
impairment, shortness 
of breath, and dry 
mouth. An increase in 
heart rate was 
experienced at all 
cannabis doses. 
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significantly 
inhibiting 
capsaicin-induced 
pain at 45 minutes 
after drug 
exposure; high 
cannabis dose (8% 
THC) produced an 
increase in pain at 
45 minutes. 
Raft et 
al. 
(1977) 
Randomised, 
double-blind, 
placebo-
controlled, 
crossover trial 
Intravenous 
THC (0.022 
mg/kg and 0.044 
mg/kg) 
10 healthy 
male 
volunteers 
undergoing 
dental 
extractions 
 
9 (90%) 
participants 
completed 
the study 
2 intravenous doses 
of THC were 
compared with 
intravenous 
diazepam (0.157 
mg/kg) and placebo. 
Participants were 
subjected to both a 
surgical experience 
and an experimental 
noxious stimulus. 
Each subject 
participated in 4 
separate trials where 
a single molar (4 
molars/patient) was 
removed following 1 
of the 4 intravenous 
treatments 
(administered on a 
random basis). 
Pain, side 
effects, 
treatment 
preference 
Statistically 
significant increase 
in pain detection 
thresholds 
observed with 
diazepam and both 
THC doses (THC’s 
effectiveness 
attributed to a 
disruption of the 
normal sensory 
signals rather than 
an analgesic 
effect). No 
evidence of 
analgesic effects 
on pain tolerance 
threshold for any 
of the treatment 
groups. Higher 
dose of THC was 
least preferred by 
participants; it was 
Lower dose THC 
reportedly produced 
euphoria/dysphoria, 
while higher THC dose 
produced anxiety 
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associated with 
most pain. 
Diazepam was 
associated with 
least pain. Lower 
dose of THC was 
preferred over 
placebo, and 
described by 
patients as good or 
excellent. 
Conte 
et al. 
(2009) 
Randomised, 
double-blind, 
placebo-
controlled, 
crossover trial 
Sativex 
(sublingual)  
(2.7 mg THC: 
2.5 mg CBD) 
18 patients 
with multiple 
sclerosis 
 
17 (94%) 
patients 
completed 
the study 
Over 8 weeks, the 
right tibial nerve was 
stimulated with 
bipolar electrical 
stimuli to measure 
whether 
cannabinoids can 
regulate the 
nociceptive system 
(which produces 
pain). Patients were 
randomly assigned to 
2 groups of 9 to 
receive Sativex-
placebo or placebo-
Sativex sequence for 
6 weeks, with a 2-
week washout period 
after the 3rd week. 
Patients self-titrated 
their daily doses up 
to a total of 48 
Changes in 
RIII reflex 
variables, 
subjective 
quality and 
intensity of 
pain (Visual 
Analogue 
Scale), 
spasticity 
(Ashworth 
scale), side 
effects 
A significant effect 
was observed on 
the pain threshold 
and reflex activity 
in favour of 
Sativex. The pain 
rating scores on the 
10-point Visual 
Analogue Scale 
also decreased in 
patients using 
Sativex, but the 
difference between 
groups was not 
significant. The 
authors concluded 
that Sativex 
showed promise in 
modulating pain 
processing and 
may be useful in 
analgesic therapy 
None of the participants 
experienced major side 
effects. Most frequent 
Sativex side effects 
were slower thinking 
(11 patients), dizziness 
and vertigo (8), and 
fatigue (6). Most 
frequent placebo-
related side effects 
were fatigue (3) and 
headache (3) 
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sprays/day. 
 
 
 
 
Table 4 
Pain (Other) 
Author Methodology Route of 
Administration 
Number of 
participants 
Treatment and 
Control 
Groups 
Outcome 
measures 
Results Side Effects 
Chronic Cancer Pain 
Noyes et 
al. (1975) 
Randomised, 
double-blind, 
crossover, 
placebo-
controlled trial 
Oral THC 36 patients 
with cancer 
pain 
 
34 (94%) 
patients 
completed the 
study 
Placebo, THC 
(10 and 20 mg), 
and codeine (60 
and 120 mg) 
were 
administered 
randomly on 
successive days 
(single oral 
dose), and were 
all identical in 
appearance. All 
patients received 
Severity of 
pain/pain 
ratings, extent 
of relief, and 
side effects 
Significant 
differences in pain 
reduction and relief 
scores were observed 
between placebo and 
20 mg THC, and 
between placebo and 
120 mg codeine. 
Lower doses of THC 
(10 mg) and codeine 
(60 mg) did not 
achieve statistical 
differences when 
Heavy sedation 
was reported by 
patients 
receiving high 
dose THC, and 
drowsiness was 
reported by 
those on a 
lower dose 
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their usual 
analgesic 
medication, and 
varying doses of 
oral codeine (60 
mg, 120 mg) 
and oral THC 
(10 mg, 20 mg 
capsules) 
compared to placebo. 
6 patients (18%) 
reported substantial 
pain relief after 
placebo; 8 (24%) 
after 60 mg codeine; 
13 (38%) after 10 mg 
THC, 16 (47%) after 
120 mg codeine and 
16 (47%) after 20 mg 
THC 
Johnson 
et al. 
(2010) 
Multicenter, 
double-blind, 
randomised, 
placebo-
controlled, 
parallel-group 
study 
Sativex 
(sublingual)  
(2.7 mg THC: 2.5 
mg CBD)  
 
and Tetranabinex 
(THC-only extract) 
177 patients 
with cancer 
pain who did 
not get 
sufficient 
relief from 
analgesic 
medication 
 
144 (81%) 
patients 
completed the 
study 
In the 2-week 
study, patients 
were 
randomised to 
receive either 
Sativex (60 
patients), 
Tetranabinex 
(58), or placebo 
(59) using a 
pump action 
oromucosal 
spray. Each 
Sativex spray 
delivered a dose 
containing 2.7 
mg THC and 2.5 
mg CBD, while 
each 
Tetranabinex 
spray delivered 
2.7 mg of THC; 
The Numerical 
Rating Scale 
pain severity 
score, use of 
opioid 
background 
medication, 
sleep quality, 
nausea, 
memory, 
concentration, 
appetite, side 
effects 
Pain was 
significantly reduced 
with the THC: CBD 
extract compared 
with placebo, but not 
with the THC 
extract. 
Approximately twice 
the number of 
patients achieved a 
greater improvement 
in pain with the 
THC: CBD (43%) 
combination, than 
those in the THC 
(23%) and placebo 
(21%) groups. 
106 patients 
(60%) reported 
experiencing 
side effects. 
Most 
commonly 
reported side 
effects of 
Sativex 
included 
drowsiness 
(13%), 
dizziness 
(12%), and 
nausea (10%). 
Most 
commonly 
reported side 
effects of the 
THC extract 
were 
drowsiness 
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patients self-
titrated to their 
optimal dose. 
(14%), 
dizziness (12%) 
and raised 
gamma GT (a 
measure of 
liver 
dysfunction) 
(9%) 
Rheumatic Pain 
Blake et 
al. (2006) 
Randomised, 
double-blind, 
placebo-
controlled, 
parallel-group 
study 
Sativex 
(sublingual) 
(2.7 mg THC: 2.5 
mg CBD) 
58 patients 
with arthritis 
not adequately 
controlled by 
other 
medication 
 
54 (93%) 
patients 
completed the 
study 
In the 5-week 
study, 31 
participants 
were randomly 
assigned to 
receive Sativex 
by an 
oromucosal 
spray (each 
spray delivered 
2.7 mg THC and 
2.5 mg CBD) 
and 27 to 
receive placebo. 
Dosing was 
titrated to a 
maximum of 6 
sprays per day 
Pain on 
movement, 
pain at rest, 
morning 
stiffness, sleep 
quality, and 
disease 
activity 
Sativex produced a 
statistically 
significant 
improvement in pain 
on movement, pain at 
rest, and pain at 
present, compared to 
placebo. 
Most frequently 
reported side 
effects of 
Sativex 
included 
dizziness 
(26%), dry 
mouth (13%), 
light-
headedness 
(10%), nausea 
(6%), and fall 
(6%). 
Palpitations 
(7%) and 
vomiting (7%) 
were the most 
commonly 
reported side 
effects of 
placebo. 
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The largest number of studies included in this review examined cannabis’ 
analgesic properties; 10 studies addressed chronic neuropathic pain, three focused on 
acute pain, and three on other pain types. The number of participants in the studies 
ranged from 10-177, with a total of 794 participants. All included studies had a 
participant retention rate greater than 75 percent. Most of the studies examined the 
effects of Sativex (cannabinoid oromucosal mouth spray) and smoked cannabis. Other 
variations of what here is termed cannabis included cannabis based extract, tetranabinex 
(THC-only extract), intravenous THC and oral THC. 
In terms of chronic neuropathic pain, nine out of 10 studies found significant 
results favouring cannabis and its components: smoked cannabis (4 out of 4 studies 
(4/4)), cannabis-based medicinal extract (1/1), and Sativex (4/5) (Abrams, et al., 2007; 
Berman, et al., 2004; Ellis, et al., 2008; Notcutt, et al., 2004; Nurmikko, et al., 2007; 
Rog, et al., 2005; Wade, et al., 2003; Ware, et al., 2010; Wilsey, et al., 2008).  
All three studies on cannabis’ effects on acute pain produced results indicating 
positive effects of the drug and its different components: smoked cannabis (1/1), 
intravenous THC (1/1), and Sativex (1/1) (Conte, et al., 2009; Raft, et al., 1977; 
Wallace, et al., 2007). However, Conte et al. (2009) noted that the difference between 
groups in pain rating scores on the 10-point Visual Analogue Scale was not significant, 
Raft et al. (1977) found no evidence of analgesic effects on pain tolerance threshold for 
any of the treatment groups, and Wallace et al. (2007) found that smoked cannabis’ 
effectiveness as an analgesic was dose-dependent. Lastly, all three studies looking at 
other types of pain (chronic cancer and rheumatic) yielded significant results in favour 
of oral THC (1/1, dose dependent) and Sativex (2//2) (Blake, et al., 2006; Johnson, et 
al., 2010; Noyes, et al., 1975).  
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A major caveat in the studies of cannabis’ therapeutic potential in the treatment 
of pain is that the data have mainly been collected on small sample sizes of healthy, 
regular cannabis users, and usually with more male than female participants.  
Psychoactive effects of cannabis also make blinding difficult; in some studies, such as 
Ware et al. (2010) subjects were able to correctly identify the treatment they were 
receiving due to feeling “high”. Durability of analgesia is also difficult to access in 
short-term studies. Therefore, more randomised controlled studies are needed to 
determine the therapeutic application of cannabis and its constituents, and an optimal 
delivery system.   
Overall, cannabis and its constituents have shown considerable potential in 
decreasing chronic pain. However, less research has been conducted on its effects in the 
treatment of acute pain. Generally, studies on cannabis’ analgesic properties have had 
low sample sizes, making them difficult to generalise. They have, however, shown that 
cannabis has short-term analgesic potential. Cannabis’ therapeutic potential in some 
pain management was no more effective than other drugs. On the other hand, studies 
such as Blake et al. (2006) have shown that cannabis may reduce pain in patients whose 
pain was not adequately controlled by other medication. Its effects might also be dose-
dependent, especially if used in smoked form.  
In acute types of pain cannabis-based medicines did not show significant results. 
However, the three studies included in this review used different routes of cannabis 
administration, so it is difficult to reach a conclusion on cannabis’ effectiveness in the 
treatment of acute pain based on the limited number of studies. Larger numbers and a 
higher degree of homogeneity are necessary in order to be able to comment on the true 
size of the analgesic effect of cannabis. 
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Relief of Nausea and Vomiting 
Seven randomised, controlled clinical trials examining the effects of cannabis 
and its constituents on nausea and vomiting met the inclusion criteria for this review 
(Chang et al., 1981; Chang et al., 1979; Duran et al., 2010; Frytak et al., 1979; Sallan, 
Cronin, & Zelen, 1980; Sallan, Zinberg, & Frei, 1975; Ungerleider et al., 1982). The 
studies were grouped by different routes of cannabis administration, and are discussed 
below.  
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Table 5 
Nausea and Vomiting 
Author Methodology Route of 
Administration 
Number of 
participants  
Treatment and 
Control Groups 
Outcome 
measures 
Results Side Effects 
Sallan et al. 
(1975) 
Randomised, 
double-blind, 
crossover, 
placebo-
controlled trial 
Oral THC 
(capsules) 
15 or 10mg/m² 
20 patients 
receiving 
chemotherapy 
 
11(55%) 
patients 
completed all 3 
courses of 
treatment 
Patients received 
either THC capsule 
or identical placebo 
capsule 3 times per 
day during three 1-
day courses; each 
patient served as 
their own control. 
* The study was 
limited in scope 
because it did not 
include a control 
group treated with 
a standard 
antiemetic 
Nausea, 
vomiting, 
appetite, and 
side effects 
A significant 
difference between 
THC and placebo in 
treating nausea and 
vomiting was 
observed; 14 out of 
20 (70%) patients 
reported an 
antiemetic effect from 
the THC, while no 
effect was observed 
in the placebo group. 
13 (81%) patients 
receiving THC 
reported feeling 
“high”; 2 (13%) 
reported 
experiencing THC 
toxicity (e.g. 
paranoia, fear, 
panic).  
Sallan et al. 
(1980) 
Randomised, 
double-blind, 
cross-over trial 
Oral THC 
(capsules) 
15 or 10mg/m² 
84 patients 
receiving 
chemotherapy 
 
57(68%) 
patients 
completed the 
study 
Patients received a 
combination of 2 
one-day treatments 
with oral THC and 
one with 10 mg 
prochlorperazine 
(PCP) (standard 
antiemetic 
treatment), OR 2 
prochlorperazine 
and one THC 
treatment.  
Nausea, 
vomiting, 
food intake, 
and feelings 
of being 
“high”. 
The rate of complete 
response (no nausea 
or vomiting) to THC 
treatment (6 complete 
responses) was 
significantly higher 
than the rate for PCP 
(1 complete 
response). 9 patients 
receiving THC had no 
response to treatment, 
and 11 had no 
response with PCP. 
All 6 patients who 
had a complete 
response to THC 
experienced feeling 
“high”, whereas 2/9 
who had no 
response reported 
feeling “high”. 
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20/25 patients, who 
were treated with 
both drugs and who 
expressed a 
preference, preferred 
THC to PCP 
Frytak et al. 
(1979) 
Randomised, 
double-blind, 
placebo-
controlled, 
parallel groups 
trial 
Oral THC 
(capsules) 15mg 
116 patients 
receiving 
chemotherapy 
 
98 (84%) 
patients 
completed the 
study 
Patients were 
randomised to 
receive oral THC 
(38 patients), oral 
prochlorperazine 
(10mg) (41 
patients) or placebo 
(37 patients). 
Placebo and PCP 
were prepared in 
the same gelatine 
capsules as THC. 
First dose was 
administered 24 
hours before 
chemotherapy, and 
subsequent doses 
were given 2 and 8 
hours after 
chemotherapy. On 
the remaining 3 
study days, 
treatments were 
given 3x a day. 
Nausea, 
vomiting, 
appetite, 
sedation, 
feelings of 
“high”, and 
side effects 
On Day 1, a 
significantly higher 
percentage of placebo 
patients experienced 
nausea and vomiting 
than patients in other 
two study groups. 
The antiemetic effects 
of oral THC were 
equivalent to those of 
PCP, and were more 
significant than 
placebo. Seventeen 
(45%) THC, 18 
(44%) PCP and 20 
(54%) placebo group 
participants reported 
experiencing repeated 
vomiting. 12 patients 
considered THC 
therapy intolerable. 
Side effects such as 
ataxia, hypotension, 
and visual 
hallucinations were 
more frequent and 
severe with THC 
(12, 32%) than PCP 
(1, 2%) and placebo 
(1, 3%)  
*18 patients 
(15.5%) dropped 
out after Day 1 due 
to side effects (10 
out of THC, 5 PCP, 
and 3 placebo 
group) 
Ungerleider 
et al. (1982) 
Randomised, 
double-blind, 
crossover 
Oral THC 
(capsules) 
(7.5-12.5 mg) 
214 patients 
receiving 
chemotherapy 
Patients were 
grouped by two 
standard 
Appetite, 
food intake, 
mood, 
No significant 
differences between 
THC and PCP were 
Side effects were 
reported by 75 
(45%) of patients 
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design trial  
139 (65%) 
patients 
completed the 
study  
chemotherapy 
regimens (98 were 
randomly assigned 
to a single-day 
regimen, 41 to a 
multiple-day 
regimen). 
Prochlorperazine 
was administered in 
a fixed dose of 10 
mg, while THC was 
administered in 
proportion to the 
body surface area. 
Both treatments 
were administered 
orally 1h before 
chemotherapy and 
every 4 hours 
thereafter, for a 
total of 4 doses/ day 
for each day of 
chemotherapy. 
activity, 
relaxation, 
interaction, 
and 
concentration 
observed in 
antiemetic response 
and effectiveness; 54 
(41%) of evaluable 
patients experienced 
less nausea when 
using THC, compared 
with 41 (31%) of 
those using PCP.   
* 2/3 of patients who 
completed the study 
were able to correctly 
identify the drug they 
received, and this 
group did 
significantly better on 
THC. 
receiving THC, 
compared to 56 
(31%) of those 
receiving PCP.  
Frequency of side 
effects was 
significantly greater 
for patients 
receiving THC than 
PCP. There were 
significant drug 
effects with THC: 
less ability to 
concentrate, less 
social interaction, 
and less activity. 
Chang et al. 
(1979) 
Randomised, 
double-blind, 
crossover, 
placebo-
controlled trial 
Oral THC (10 
mg/m²) 
 
Smoked cannabis 
(1.93 % THC)* 
only used as a 
substitute for oral 
THC in case of its 
failure/inadequacy 
15 patients with 
chemotherapy-
related nausea 
and vomiting 
 
15 (100%) 
patients 
completed the 
study 
During 6 
subsequent 
chemotherapy 
treatments (3 THC, 
3 placebo) each 
patient served as 
their own control. 
Placebo capsules 
were identical to 
THC capsules, and 
Number of 
nausea and 
vomiting 
episodes, 
appetite, side-
effects, and 
THC plasma 
concentration
s 
THC treatment 
produced a 
statistically 
significant reduction 
in the number of 
vomiting and retching 
episodes, degree of 
nausea, duration of 
nausea, and volume 
of emesis compared 
Sedation was 
reported by 12 
(80%) patients, but 
no participant 
withdrew from the 
study 
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placebo cigarettes 
had an identical 
odour and taste to 
cannabis cigarettes 
to placebo. 14/15 
(93%) patients 
reported a reduction 
of nausea and 
vomiting with THC. 
Nausea and vomiting 
decreased with 
elevation of THC 
plasma concentration.  
Smoked cannabis was 
more effective and 
reliable than oral 
THC in reaching a 
higher, therapeutic 
plasma concentration. 
Chang et al. 
(1981) 
Randomised, 
double-blind, 
crossover, 
placebo-
controlled trial 
Oral THC (10 
mg/m²) 
 
Smoked cannabis 
(1.93 % THC)* 
only used as a 
substitute for oral 
THC in case of its 
failure/inadequacy 
9 patients 
receiving 
chemotherapy 
 
8 (89%) were 
evaluable 
Each patient served 
as his or her control 
and completed 3 
paired trials of 
either the THC-
placebo or placebo-
THC 
sequence.THC or 
an identical looking 
placebo were 
administered 5 
times/day. The 
order of THC and 
placebo 
administration was 
randomised. In case 
of vomiting, the 
patient was given a 
Number of 
vomiting and 
retching 
episodes, 
volume of 
emesis, 
degree and 
duration of 
nausea, 
feelings of 
being “high”; 
and other side 
effects 
Oral or smoked THC 
did not significantly 
reduce the number of 
vomiting or retching 
episodes, volume of 
emesis, degree of 
nausea, or duration of 
nausea compared to 
placebo. 3 (38%) 
patients had a “fair” 
response to THC in 
reducing nausea and 
vomiting; 5(62%) had 
no response. Drug 
absorption was 
observed to be poor 
and highly variable 
for all scheduled 
Apart from 
euphoria (75% of 
patients) and short 
episodes of 
tachycardia, no side 
effects were 
reported 
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cannabis cigarette 
for the remainder of 
that trial. 
doses. 
Duran et al. 
(2010) 
Pilot, 
randomised, 
double-blind, 
placebo-
controlled, 
phase II 
clinical trial 
Whole-plant 
cannabis-based 
medicine (CBM) 
(oromucosal 
spray) 
THC (2.7 mg), 
cannabidiol (2.5 
mg) 
16 patients 
receiving 
chemotherapy 
 
15 (94%) 
patients 
completed the 
study 
The CBM was 
taken in 
conjunction with 
standard antiemetic 
therapies. 7 patients 
were randomised to 
receive the CBM in 
a 120 hour post-
chemotherapy 
period, and nine to 
receive a placebo. 
Response to 
treatment, 
frequency and 
duration of 
nausea and 
vomiting, side 
effects, 
impact on 
daily life, 
satisfaction 
with 
treatment  
Six (86%) patients in 
the CBM group and 
all the patients in the 
placebo group 
tolerated dose 
titration. Complete 
response to treatment 
(no nausea) was 
significantly higher in 
the CBM group 
compared with 
placebo (5, 71% 
patients in CBM and 
2, 22% in placebo 
group).  4 patients 
(57%) of patients 
receiving CBM and 8 
(88%) receiving 
placebo were satisfied 
with their treatment. 
At least one side 
effect was reported 
by six (86%) CBM 
and 6 (67%) 
placebo receiving 
participants; 
somnolence was the 
most reported 
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In the seven studies of cannabis’ antiemetic properties reviewed here, the 
number of participants ranged from 9-214, with a total of 586 participants. Four (57%) 
studies had a participant retention rate greater than 75 percent. The studies examined the 
effects of oral THC and CBM (cannabis-based medicine). Five out of seven studies 
produced results indicating positive effects of the drug and its components: oral THC 
(4/6) and CBM (1/1) (Chang, et al., 1979; Duran, et al., 2010; Frytak, et al., 1979; 
Sallan, et al., 1980; Sallan, et al., 1975).  
Only one study comparing cannabis to other antiemetic drugs found its 
antiemetic effects to be superior (Sallan, et al., 1980). Two studies found that the 
antiemetic effects of cannabis and its constituents were similar or equal to those of other 
antiemetic drugs (Frytak, et al., 1979; Ungerleider, et al., 1982). Side effects occurred 
more often with cannabinoids than with other antiemetics, but these usually occurred in 
a small number of patients and disappeared after a short period of time. 
It should be noted that only one study reviewed here has been conducted 
recently, and all others were conducted in the 1970s and 1980s, bringing into question 
their generalisability and applicability, as it is known that the THC content of cannabis 
plants has increased in past decades. None of the studies evaluated the effects of 
smoked cannabis. Comparison of the studies is also made difficult due to variability in a 
number of areas including participants, dosage, types of chemotherapy and antiemetic 
drugs administered, and number of patients who withdrew or dropped out. One of the 
potential explanations for a large number of drop outs is disease progression. Cancer 
can be a terminal illness, and patients terminating the study early may be attributable to 
the disease itself. Performing a double-blind trial may also be difficult when using 
cannabis, due to patients experiencing psychoactive drug effects. Feeling these effects 
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may enable patients to correctly identify the drug received and perform better on a 
particular treatment, as was the case with Ungerleider et al. (1982).  
Based on the number of studies reviewed here, it is difficult to reach a 
conclusion on cannabis’ anti-emetic properties, especially in terms of smoked cannabis. 
The overall consensus is that cannabis and its constituents (cannabinoids) are superior to 
placebo in the treatment of nausea and vomiting in individuals receiving cancer 
chemotherapy, especially when used together with other antiemetic drugs (Sallan, et al., 
1980). However, cannabis and its constituents did not adequately control nausea and 
vomiting in some patients due to issues with oral administration and the side-effects 
associated with orally administered drugs, such as difficulty in swallowing and titrating 
dosage. Smoking is suggested as a better route of administration for individuals 
experiencing nausea and vomiting or those that have difficulty swallowing or keeping a 
pill down, but no study included in this review examined the antiemetic effects of 
smoked cannabis.  
Further clinical trials are recommended in order for an effective dosage to be 
established as well as the most effective route of administration. As studies on the 
antiemetic properties of cannabis have often been criticised for their sample size, further 
large-sample human clinical trials comparing the action of cannabinoids with modern 
antiemetic medication are recommended.   
 
 
Spasticity 
A total of six randomised controlled clinical trials evaluating the effectiveness of 
cannabis and its constituents in the treatment of spasticity met the inclusion criteria for 
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this review (Collin, Davies, Mutiboko, Ratcliffe, & Group, 2007; Ungerleider, 
Andrysiak, Fairbanks, Ellison, & Myers, 1988; Vaney et al., 2004; Wade, Makela, 
Robson, Houre, & Bateman, 2004; Wade, et al., 2003; Zajicek et al., 2003). Spasticity is 
a chronic disorder characterised by an abnormal increase in muscle tone and resistance 
to passive movement (Collin, et al., 2007; Zajicek, et al., 2003). It is a symptom of 
conditions such as multiple sclerosis (MS) and spinal cord injury.  
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Table 6 
Spasticity  
Author Methodology Route of 
Administration 
Number of 
participants  
Treatment and 
Control Groups 
Outcome 
measures 
Results Side Effects 
Ungerleider 
et al. (1988) 
Randomised, 
double-blind, 
placebo-
controlled, 
crossover trial 
Oral THC  
(2.5-15mg/day) 
13 patients with 
MS 
 
12 (92%) 
patients 
completed at 
least two 
paired trials 
5 (38%) 
completed 
three paired 
trials  
Patients were 
divided into 2 
dosing groups 
(depending of the 
time of their most 
severe spasticity). 
One group (2 
patients) received 
their treatment at 
bedtime and the 
other group (11 
patients) received 
their treatment 
2x/day. Each group 
was randomised to 
receive 5 days of 
oral THC (2.5-15 
mg per day) 
followed by 5 days 
of placebo, or the 
reverse sequence. 
Patients were 
initiated at varying 
doses of THC 
which were later 
adjusted. 
Motor 
function, limb 
spasticity, and 
limb 
weakness 
(assessed by 
physician 
rating scales); 
spasticity and 
side effects 
(patient rating 
scales) 
Patient rating scales 
indicated a significant 
reduction in spasticity 
for 7.5 mg THC dose 
compared with 
placebo; 2.5 and 5 mg 
doses were deemed 
ineffective. The 
results indicated that 
a reduction is 
spasticity began at 7.5 
mg and continued for 
most participants at 
10 and 15 mg doses. 
The 7.5 mg THC dose 
was selected as the 
highest tolerable dose 
because 75% of 
participants who 
received the 10 mg 
dose of THC 
complained of 
intolerable side 
effects. 
Side effects were 
frequent with the 
7.5 mg THC dose 
and included dry 
mouth, weakness, 
dizziness, 
relaxation, mental 
clouding, short-
term memory 
impairment, and 
spatial-time 
distortions. 
* Authors suggested 
that side effects 
might have 
interfered with 
patient blinding 
Zajicek et 
al. (2003) 
Randomised, 
double-blind, 
Cannabis extract 
(capsules) (2.5mg 
630 patients 
with MS 
In the 15-week 
study, patients were 
Change in 
MS-related 
Treatment with 
cannabinoids was not 
A total of 50 (8%) 
participants  (12 
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parallel groups, 
placebo 
controlled trial 
THC: 1.25mg 
CBD, and less 
than 5% of other 
cannabinoids per 
capsule) 
 
 Synthetic THC 
(Marinol, 
capsules) 
 
 
611 (97%) 
participants 
completed the 
study 
randomised to 
receive: Marinol 
capsules 206 
patients), cannabis 
extract capsules 
(211 patients), or 
placebo (213 
patients). Doses 
were administered 
according to 
bodyweight, with a 
maximum 25 mg 
daily. As the 
researchers were 
unable to make the 
active treatments 
identical, each had 
its own matched 
placebo identical in 
appearance. 
spasticity ( 
using the 
Ashworth 
scale), 
mobility, 
symptoms, 
disability 
scale, side 
effects 
found effective in 
improving MS 
associated spasticity, 
as measured by the 
Ashworth scale. 
However, a 
significant reduction 
in spasticity was 
reported by patients 
receiving both 
synthetic THC (60%) 
and the cannabis 
extract (61%). 46% of 
patients receiving 
placebo reported an 
improvement in 
spasticity. 
receiving cannabis 
extract, 18 
receiving Marinol, 
20 receiving 
placebo) reported 
serious side effects 
and 558 (89%) 
patients reported 
minor side effects; 
these were 
generally found to 
be well tolerated 
Vaney et al. 
(2004) 
Randomised, 
double-blind, 
placebo-
controlled, 
crossover trial 
Cannabis extract 
(oral) (2.5 mg 
THC: 0.9 mg  
CBD per capsule) 
57 patients with 
MS 
 
37 (65%) 
patients 
completed the 
study per-
protocol 
28 patients were 
randomised to 
receive cannabis 
extract capsules for 
14 days followed 
by a placebo 
identical in shape, 
taste, and colour; 29 
received the reverse 
sequence. 
Treatments were 
administered in 12 
capsules daily, with 
Change in 
MS-related 
spasticity ( 
using the 
Ashworth 
scale), spasm 
frequency and 
symptoms, 
Rivermead 
Mobility 
index, nine-
hole peg test, 
side effects 
While not statistically 
significant, the active 
treatment produced 
favourable results for 
spasm frequency, 
mobility, and 
patients’ general 
condition. Evaluation 
by the Ashworth scale 
found no beneficial 
effects on spasticity 
unless the analysis 
was restricted to 37 
Cannabis extract 
was well tolerated 
and no serious 
adverse events were 
reported. However, 
significantly higher 
toxicity levels were 
reported during 
active treatment 
compared with 
placebo. Most 
frequently reported 
side effects 
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varying proportions 
of active treatment 
(15-30 mg of THC 
per day) and 
placebo. Patients 
continued using 
their current 
medication. 
(65%) patients who 
took 90% or more of 
the prescribed dose; 
then significant 
improvements in the 
frequency of spasms 
were observed. 
included dizziness, 
feeling “high”, and 
difficulty 
concentrating 
Wade et al. 
(2003) 
Randomised, 
double-blind, 
placebo-
controlled, 
crossover trial 
Cannabis extract 
containing THC 
(2.5mg) 
 
Cannabis extract 
containing CBD 
(2.5mg) 
 
Combination of 
both THC 
(2.5mg): CBD 
(2.5mg) 
 
(sublingual spray) 
 
24 participants 
(18 with MS, 4 
with spinal 
cord injury, 1 
with brachial 
plexus damage) 
 
20 (83%) 
patients 
completed the 
study  
 
Patients were 
randomly assigned 
to receive either 
cannabis extract 
containing THC 
CBD, a 
combination of 
THC: CBD, or 
matching placebo in 
a sublingual spray 
four times/day 
(maximum 120 
mg/24 hours) over 
four 2-week study 
periods. 
Visual 
Analogue 
Scale score 
for target 
symptoms, 
wellbeing, 
and 
intoxication. 
Severity and 
frequency of 
symptoms 
(numerical 
rating scales 
and standard 
measures of 
disability 
(Barthel 
Index)). 
In comparison with 
placebo, both CBD 
and THC extract 
significantly 
improved pain. THC 
extract also 
significantly 
improved muscle 
spasm, spasticity and 
appetite. THC: CBD 
significantly 
improved muscle 
spasm and sleep. 
While rescue 
medication was 
offered, 12 (50%) 
patients used zero or 
negligible amounts of 
it. 
Levels of 
intoxication were 
highest with THC. 
Side effects were 
reported by patients 
in all groups: 11 
(55%) following 
THC, 10 (48%) 
following placebo, 
7 (33%) following 
CBD, and  6 (30%) 
following 
THC:CBD 
Wade et al. 
(2004) 
Randomised, 
double-blind, 
placebo-
controlled trial 
Sativex 
(sublingual) 
(2.7 mg THC; 2.5 
mg CBD) 
160 patients 
with MS 
 
154 (96%) 
participants 
completed the 
Eighty patients 
were randomised to 
receive Sativex 
administered in 
sublingual spray at 
2.5-120 mg doses 
Visual 
Analogue 
Scale score 
for target 
symptoms, 
measures of 
Primary symptom 
Visual Analogue 
Scale scores were 
compared between 
groups and indicated 
that Sativex 
Side effects were 
generally mild and 
well tolerated. Most 
frequent side effects 
experienced by the 
Sativex group 
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study for a period of six 
weeks; 80 received 
placebo. The first 
dose was supervisor 
and the rest were 
titrated by patients 
at home. 
disability, 
cognition, 
mood, sleep 
and fatigue, 
side effects 
significantly 
decreased spasticity 
compared to placebo. 
There was also a 
significant 
improvement in 
patients’ assessment 
of the quality of sleep 
with Sativex. 
included dizziness 
(26, 33%), 
application site 
discomfort (21, 
26%), and fatigue 
(12, 15%). Patients 
receiving placebo 
most frequently 
reported application 
site discomfort (18, 
23%), headache 
(13, 16%), and 
dizziness (10, 13%) 
Collin et al. 
(2007) 
Randomised, 
double-blind, 
placebo-
controlled, 
parallel-group 
trial 
Sativex 
(sublingual) 
(2.7 mg THC; 2.5 
mg CBD) 
189 patients 
with MS 
 
174 (92%) 
participants 
completed the 
study 
In the 6-week 
study, participants 
were randomised   
in a 2:1 ratio; 124 
to oromucosal 
Sativex (2.7 mg 
THC, 2.5 mg 
CBD), and 65 to an 
identically 
flavoured placebo. 
Titration was 
performed as 
required, up to a 
maximum of 48 
sprays per day. 
Numerical 
Rating Scale 
for the 
severity of 
spasticity, the 
Ashworth 
scale score of 
spasticity, and 
a subjective 
measure of 
spasm, side-
effects 
A statistically 
significant decrease 
in spasticity score as 
evaluated by the 
Numerical Rating 
Scale was reported in 
the Sativex group 
compared with 
placebo. Sixty six 
(57%) participants in 
the Sativex group 
reported that their 
condition improved, 
compared with 31 
(48%) participants 
receiving placebo. 
Side effects were 
reported by 102 
(82%) participants 
receiving Sativex 
and 46 (71%) 
receiving placebo; 
majority were mild 
to moderate.  
Only 6 (4.8%) 
participants from 
the Sativex and 2 
(3.1%) from the 
placebo group 
withdrew due to 
side effects. 
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Six studies included in this review examined cannabis’ effectiveness in treating 
spasticity, with a focus on patients with MS. The number of participants in the studies 
ranged from 13-630, with a total of 1,073 participants. Five (83%) studies had a 
participant retention rate greater than 75 percent; one of the studies included in the 
count reported 92% completing at least two paired trials, with 38% completing three. 
The studies examined the effects of Sativex, THC, CBD, cannabis extract, and oral 
THC. 
Five out of six studies found significant results favouring cannabis and its 
components: oral THC (1/1), cannabis extract (1/2), THC and combination of 
THC:CBD (1/1), Sativex (2/2) (Collin, et al., 2007; Ungerleider, et al., 1988; Wade, et 
al., 2004; Wade, et al., 2003; Zajicek, et al., 2003). The effects of THC were dose 
dependant, with higher doses producing better results. Conversely, higher THC doses 
resulted in frequent side effects which led to difficulties in performing patient blinding 
(Ungerleider, et al., 1988). The side effects, however, were generally well tolerated.  
Overall, results from clinical trials are mixed but show that cannabis and its 
derivatives have the potential to reduce spasticity and objective ratings of spasticity in 
patients with MS. Results have also indicated that it might be an effective long-term 
treatment. However, more research is needed to establish the most effective mode of 
cannabis administration, and whether the therapeutic benefits outweigh the negative 
side effects associated with the drug. As no comparisons with other anti-spastic drugs 
have been made in the studies reviewed here, it is not possible to determine whether 
cannabis and its components are the most effective method of decreasing spasticity and 
for whom they might be appropriate. Also, most reports in favour of cannabis came 
from subjective scores rather than objective measurements, therefore future research 
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should look at determining the most appropriate measurement of the effects of cannabis 
and its components on spasticity. 
Appetite Stimulation/Weight Gain 
Two randomised, controlled trials examining the effectiveness of cannabis and 
its constituents on appetite stimulation met the inclusion criteria for this review (Abrams 
et al., 2003; Strasser et al., 2006). The studies are described below.  
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Table 7 
Appetite Stimulation/Weight Gain 
Author Methodology Route of 
Administration 
Number of 
participants  
Treatment and 
Control Groups 
Outcome 
measures 
Results Side Effects 
Strasser et 
al. (2006) 
Multicentre, 
phase III, 
randomised, 
double-blind, 
placebo-
controlled, 
parallel trial 
Oral THC (2.5 
mg)  
 
Cannador (an oral 
whole plant 
cannabis extract 
with 2.5 mg THC 
and 1 mg CBD) 
243  patients 
with cancer-
related 
anorexia-
cachexia 
syndrome 
 
164 (67%) 
patients 
completed the 
study 
In the 6-week 
study, patients were 
assigned to receive 
either THC (100 
participants), 
Cannador (95 
participants), or 
placebo (48 
participants) twice 
daily.  
Appetite, 
mood, nausea 
(monitored 
with a visual 
analogue 
scale), quality 
of life, 
cannabinoid-
related 
toxicity 
No significant 
differences were 
observed between the 
three study arms for 
appetite or 
cannabinoid-related 
toxicity. Increased 
appetite was reported 
by 58%, 73%, and 
69% of participants 
receiving THC, 
Cannador, or placebo, 
respectively. No 
differences between 
treatment arms in 
body weight at 
baseline or week 6 
(end of treatment) 
were reported 
No significant 
differences between 
side effects were 
observed. The most 
common side 
effects include 
nausea, fatigue, 
pain, anemia, 
dizziness, dyspnea, 
diarrhoea, and 
obstipation 
Abrams et 
al. (2003) 
Randomised, 
placebo-
controlled, 21-
day 
intervention 
trial 
Cannabis 
(smoked) (3.95% 
THC) 
 
Dronabinol (oral) 
(2.5mg) 
67 HIV-
infected 
patients 
 
62 (93%) 
patients 
completed the 
study 
Rolled cannabis 
cigarettes were 
administered to 21 
patients (1 to 3 a 
day); 25 patients 
received oral THC; 
and 21 patients 
were assigned to the 
placebo group. 
HIV RNA 
levels, CD4+ 
and CD8+ 
cell subsets, 
pharmacokine
tics, change 
in weight 
The primary aim of 
the study was to 
assess the effects of 
cannabinoids on the 
severity of HIV 
infection progression, 
but the results showed 
that participants in the 
cannabis and 
Side effects were 
generally well 
tolerated 
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Both oral THC and 
placebo were 
administered in a 
capsule; smoked 
and oral cannabis 
were administered 
on the same 
schedule. There was 
no smoked placebo 
group- the authors 
did not think they 
could successfully 
blind study 
participants to 
cannabis given their 
previous cannabis 
experience. 
dronabinol groups 
gained significantly 
more weight than 
those in the placebo 
group (an average of 
3.0 kg; 3.2 kg; and 
1.1 kg respectively). 
The short-term use of 
cannabinoids did not 
adversely affect viral 
load in individuals 
with HIV infection 
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While dronabinol (Marinol) is prescribed in the U.S. for the treatment of AIDS-
related wasting syndrome, a relatively small number of clinical, randomised, double-
blind trials have been conducted to assess its effectiveness. In the two studies included 
in this review, there were 67 participants in one study and 243 in another, with a total of 
310 participants. Only one study had a participant retention rate greater than 75 percent. 
The studies evaluated the effectiveness of smoked cannabis, oral THC, and Cannador 
(oral whole plant cannabis extract). 
Abrams et al. (2003) compared the effects of dronabinol and smoked cannabis, 
and found that participants receiving both smoked cannabis and dronabinol gained 
significantly more weight than those in the placebo group. Treatment related side effects 
were reported in all studies, but were well tolerated. No long-term study fitting the 
selection criteria has been identified, possibly due to disease progression and difficulty 
retaining participants. Strasser et al. (2006) examined the effects of oral THC and 
Cannador and found no significant differences between oral THC, Cannador and 
placebo for appetite and no differences between treatment arms in body weight at 
baseline compared to week 6 (end of treatment) were reported.  
Overall, cannabis and its derivatives have shown some potential in stimulating 
appetite and increasing weight in patients with AIDS or cancer related wasting 
syndrome. However, the side effects of cannabis constituents need to be considered in 
comparison to other appetite stimulants, which may prove more or equally beneficial 
but with less side effects. Cannabis may be useful for individuals for whom other 
appetite stimulants have proven ineffective, or for those who cannot take other 
treatments orally. However, limited research prevents any firm conclusions being drawn 
on the effectiveness of cannabinoids on appetite and more research is needed to evaluate 
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the long-term effects of cannabis and the effectiveness of different routes of cannabis 
administration, especially in comparison with other already available treatments.  
Other Conditions 
Seven studies met the selection criteria for inclusion in this review (Carroll et 
al., 2004; Cunha et al., 1980; D'Souza et al., 2005; Kavia, DeRidder, Constantinescu, 
Storr, & Fowler, 2010; M¨uller-Vahl et al., 2002; M¨uller-Vahl et al., 2003; Tomida et 
al., 2006). The conditions covered by the studies were Gilles de la Tourette syndrome, 
Parkinson’s disease, epilepsy, glaucoma, bladder dysfunction and Schizophrenic 
psychosis.  
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Table 8  
Other Conditions 
Author Methodology Route of 
Administration 
Number of 
participants  
Treatment and 
Control Groups 
Outcome 
measures 
Results Side Effects 
Gilles de la Tourette Syndrome 
M¨uller-
Vahl et al. 
(2002) 
Randomised, 
double-blind, 
placebo-
controlled, 
crossover trial 
Oral THC  
(5.0, 7.5, and 
10.0 mg) 
12 patients 
with 
Tourette’s 
syndrome 
 
All patients 
(100%) 
completed the 
study 
Patients received 
different doses of 
oral THC based on 
their age, sex, and 
prior use of 
cannabis. 6 
patients were 
randomly assigned 
to receive a single 
dose of THC 
capsule followed 
by an identical 
placebo over 2 
days; 6 received 
treatment in the 
reverse sequence. 
After a 4-week 
washout phase, 
patients were 
crossed over to the 
other treatment 
sequence 
Tic severity 
(assessed by 
the Tourette 
Syndrome 
Symptom 
List (self-
rating scale) 
and Shapiro 
Tourette-
Syndrome 
Scale 
(examiner 
ratings)). 
Using a self-rating 
scale, the results 
showed a significant 
reduction of motor 
and vocal tics, and 
obsessive 
compulsive 
behaviour. 
Examiner ratings 
showed a significant 
improvement in 
subscores in favour 
of THC; the 
differences between 
groups in overall 
global tic severity 
scores did not reach 
statistical 
significance. 
9/12 patients (75%) 
indicated that THC 
was a more 
successful treatment 
than placebo 
Side effects were 
mild and reported 
by five (58%) 
patients receiving 
THC and two (17%) 
patients receiving 
placebo. Higher 
THC doses of 7.5 
and 10.0 mg 
produced more 
significant side 
effects including 
headache, nausea, 
ataxia, and anxiety. 
Researchers 
suggested that the 
side-effects were 
likely to decrease 
after long-term 
treatment. 
M¨uller-
Vahl et al. 
(2003) 
Randomised, 
double-blind, 
placebo-
controlled 
trial 
Oral  THC (2.5 
and 5.0 mg 
capsules) 
24 patients 
with 
Tourette’s 
syndrome 
 
17 (71%) 
In the 6 week 
study, patients 
were randomly 
assigned to receive 
THC capsules or 
identical placebo. 
Tourette 
Syndrome 
CGIS 
(Clinical 
Global 
Impression 
A statistically 
significant 
difference was 
observed in favour 
of THC based on the 
CGIS scores. Using 
Side effects were 
generally mild and 
well tolerated; five 
(42%) patients 
receiving THC and 
three (25%) 
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participants 
completed the 
study 
Treatment dosage 
was titrated to the 
target of 10.0 mg 
THC, starting at 
2.5 mg per day. 
Scale), 
examiner 
ratings, self-
ratings, and a 
video-based 
rating scale 
a self-rating scale at 
10 treatment days, 
there was a 
significant 
difference between 
both groups. THC 
reached efficacy 
after approximately 
three weeks of 
treatment; this 
efficacy persisted or 
increased after more 
than four weeks up 
to the end of the 
study 
receiving placebo 
reported mild side 
effects. 
Parkinson’s disease 
Carroll et 
al. (2004) 
Randomised, 
double-blind, 
placebo-
controlled, 
crossover trial 
Cannador 
(ethanolic 
cannabis extract) 
(2.5 mg THC: 
1.25 mg CBD per 
capsule) 
19 patients 
with 
Parkinson’s 
disease 
 
17 (89%) of 
patients 
completed the 
study 
Ten patients were 
randomised to 
receive Cannador 
followed by 
placebo; nine the 
reverse sequence. 
The treatment dose 
was administered 
based on weight 
(maximum 0.25 
mg/kg of THC). 
Each treatment 
phase lasted 4 
weeks, with a 2-
week washout 
period. 
Effects on 
Parkinson’s 
disease 
severity and 
duration of 
dyskinesia, 
adverse 
effects, and 
dosing 
schedules 
Results indicated 
that Cannador had 
no significant effect 
on dyskinesia and 
had no pro- or anti-
parkinsonian effects. 
However, 11 
patients (65%) did 
not attain the target 
dose on Cannador 
and 9 (53%) on 
placebo. 
 
No serious adverse 
effects were 
reported. Mild side 
effects were 
reported by both 
groups, but were 
more common with 
Cannador (37 
reported adverse 
events) than placebo 
(15). Main side 
effects included 
drowsiness/lethargy, 
dry mouth, and 
detachment 
Epilepsy 
Cunha et al. 
(1980) 
Randomised, 
double-blind, 
Cannabidiol 
(CBD) (oral) 
15 epileptic 
patients who 
Participants 
continued using 
Absence of 
convulsive 
3 patients receiving 
CBD showed an 
4 patients receiving 
CBD and 1 
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parallel 
groups, 
placebo-
controlled 
trial 
did not obtain 
satisfactory 
results with 
their 
prescribed 
anticonvulsant 
medication 
 
12 (80%) 
patients 
completed the 
study  
their prescribed 
anticonvulsant 
medication and 
were randomly 
assigned to two 
groups; one group 
(7 patients) was 
administered CBD 
(200-300 mg 
daily) and the 
other (8) placebo 
in capsule form for 
up to 4 ½ months. 
The patients were 
instructed to take 2 
or 3 capsules daily 
*One patient 
receiving placebo 
was transferred to 
the CBD group 
after one month 
crises, 
neurological 
examination 
and EEG, 
clinical and 
laboratory 
examinations, 
clinical 
evaluation of 
treatment 
improvement in the 
EEG pattern. 2 
patients receiving 
placebo had an 
improved EEG 
pattern on one 
occasion only. 
Improvements in 
clinical evaluation 
scores were 
observed in both 
groups in the 1st 
week; from the 2nd 
week all but one 
placebo patient 
returned to their 
previous clinical 
state. 4 patients 
receiving CBD 
remained convulsion 
free throughout the 
treatment; 3 showed 
partial 
improvement. 1 
patient receiving 
placebo showed an 
improvement in 
their condition; 7 
showed no 
improvement. 
receiving placebo 
reported 
somnolence. 1 CBD 
patients complained 
of painful gastric 
sensations after 
taking the drug; 
symptoms 
disappeared after 
taking antacid. 
Glaucoma 
Tomida et 
al. (2006) 
Randomised, 
double-blind, 
placebo-
controlled, 4 
Oral THC (5 mg)  
 
Oral CBD (20 mg 
or 40 mg) 
6 patients with 
ocular 
hypertension 
or early 
Patients received a 
single dose of 5 
mg THC, 20 mg 
CBD, 40 mg CBD, 
Intraocular 
pressure, 
visual acuity, 
vital signs, 
Results indicated 
that two hours after 
administration of 5 
mg THC the 
Side effects were 
generally mild and 
well tolerated. Only 
one patients 
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way crossover 
trial 
 primary angle 
glaucoma 
 
All patients 
(100%) 
completed the 
study 
or placebo. psychotropic 
effects 
intraocular pressure 
was significantly 
lower than after 
placebo, returning to 
baseline levels after 
four hours. No 
significant 
therapeutic effects 
were observed with 
either of the CBD 
doses. In contrast, 
the 40 mg dose of 
CBD led to an 
increase of 
intraocular pressure 
at four hours after 
administration. 
experienced a panic 
like reaction after 
receiving THC 
Bladder dysfunction 
Kavia et al. 
(2010) 
Randomised, 
double-blind, 
placebo 
controlled, 
parallel-group 
trial 
Sativex 
(sublingual) (2.7 
mg THC: 2.5 mg 
CBD) 
135 patients 
with MS 
 
118 (87%) 
patients 
completed the 
study 
 
*86 (64%) 
patients were 
included in 
per-protocol 
analysis of 
efficacy 
In the 10-week 
trial, 67 patients 
were randomised 
to receive 
oromucosal 
Sativex and 68 to 
receive placebo. 
Patients self-
titrated to their 
optimal dose 
(maximum 48 
sprays per day). 
Daily number 
of urinary 
incontinence 
episodes, 
incidence and 
urgency of 
nocturia, 
bladder 
condition, 
quality of 
life, and 
patient’s 
impression of 
change 
Sativex marginally 
reduced the daily 
number of urinary 
incontinence 
episodes compared 
to placebo, but 
statistical 
significance was not 
reached. A statistical 
difference was 
reached in the 
decrease of number 
of episodes of 
nocturia, number of 
voids per day, 
patient impression 
of change, and 
Sativex-related side 
effects were 
generally mild or 
moderate. Main 
Sativex side effects 
were dizziness 
(12%), headache 
(6%), vomiting 
(6%), disorientation 
(6%), and 
dissociation (6%). 
Dizziness (6%) and 
urinary tract 
infection (6%) were 
the main placebo-
related side effects 
 Medical Cannabis in the United States     105 
 
overall bladder 
condition. 
Schizophrenic psychosis 
D’Souza et 
al. (2005) 
Randomised, 
double-blind, 
placebo-
controlled 
trial 
Intravenous THC 
(2.5 mg or 5 mg) 
13 stable, 
antipsychotic 
drug treated 
schizophrenia 
patients 
 
9 (69%) 
participants 
completed all 
three test days 
Over 3 test days, 
patients were 
randomised to 
receive 2.5 mg or 
5 mg THC, or 
placebo in a 
counterbalanced 
order. Tests days 
were separated by 
at least one week. 
Safety and 
cognitive, 
behavioural, 
motor, and 
neurochemical 
effects 
THC transiently 
increased a range 
of positive and 
negative 
schizophrenia 
symptoms, 
learning and recall 
deficits, perceptual 
alterations, and 
medication side 
effects associated 
with 
schizophrenia. It 
failed to produce 
any obvious 
“beneficial 
effects”. 
No serious long or 
short term side 
effects were 
reported, but a 
comparison found 
patients with 
schizophrenia were 
more vulnerable to 
THC effects on 
learning and 
memory than 
healthy subject 
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Two studies, comprising a total of 36 participants, evaluated the effects of oral 
THC on Gilles de la Tourette syndrome (M¨uller-Vahl, et al., 2002; M¨uller-Vahl, et al., 
2003). Gilles de la Tourette syndrome is a neurological condition characterised by rapid 
movements and sounds (called tics), and a range of behavioural and cognitive features 
(M¨uller-Vahl, et al., 2003). Both studies produced results indicating positive effects of 
oral THC; a significant reduction of motor and vocal tics, obsessive compulsive 
behaviour, and an improvement in the Tourette Syndrome Clinical Global Impression 
Scale (CGIS) scores was reported. However, it is difficult to draw a conclusion on the 
effectiveness of cannabis constituents from the results of two trials with relatively small 
samples, one of which used only single-dose THC. While preliminary, the results are 
promising and suggest that oral THC has the potential to reduce tics associated with 
Tourette’s syndrome without serious side effects. Further research is needed to establish 
the optimal dosage and compare oral THC to other routes of administration in order to 
determine the most effective one. Larger-scale and longer studies are also necessary to 
determine the long term effects of cannabis and its constituents and evaluate their 
potential in treatment of tics in Tourette’s syndrome.  
One study of 19 participants examined the effects of Cannador on patients with 
Parkinson’s disease (Carroll, et al., 2004). The cannabis derivatives did not demonstrate 
an anti-Parkinsonian effect in a controlled clinical setting (Carroll, et al., 2004). Lack of 
significant effect in the Carroll et al. (2004) study could be attributed to failure in most 
patients to attain a recommended treatment dose, although this conclusion is difficult to 
make due to low number of participants, route of administration, and the complexity of 
the disease. The results so far have not been promising and indicate that cannabinoids 
are not very effective in the treatment of dyskinesia nor do they have anti-Parkinsonian 
effects. 
 Medical Cannabis in the United States     107 
 
One study of 15 epileptic patients who did not obtain satisfactory results with 
their prescribed anticonvulsant medication found that cannabidiol treatment led to 
improvement in the EEG pattern (Cunha, et al., 1980). While the results were 
encouraging, a major caveat of the study is that no tests of significance were conducted. 
Since 1980, no further clinical trials that fit the inclusion criteria for this review have 
been conducted in order to confirm the results reported by Cunha et al. (1980). While 
cannabis may have anticonvulsant properties, one study is insufficient to draw firm 
conclusions. In the study described here, patients continued using their prescribed 
anticonvulsant medication, which makes it difficult to determine whether CBD 
potentiated the effects of anticonvulsant treatments or worked independently. Further 
studies are therefore required in order to explore the therapeutic potential of cannabis 
and its derivatives on epilepsy.  
While anecdotal evidence has suggested that cannabis is effective in the 
treatment of glaucoma, the number of randomised controlled studies which have 
assessed the effectiveness of cannabis and its extracts on treatment of intraocular 
pressure is very limited. One study assessed the efficacy of THC and CBD in the 
treatment of glaucoma in six patients with ocular hypertension or early primary angle 
glaucoma (Tomida, et al., 2006). Results indicated that THC could be beneficial in the 
treatment of intraocular pressure, but effects were dose-dependent; two hours after 
administration of 5 mg THC the intraocular pressure was significantly lower than after 
placebo. However, valid conclusions cannot be drawn from one small-scale study and 
more research into the appropriate dosage benefits and risks of cannabis use in 
treatment of glaucoma is needed before conclusions can be made.  
One study assessed the efficacy of Sativex as an add-on treatment for bladder 
dysfunction in 135 patients with MS (Kavia, et al., 2010). Sativex marginally reduced 
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the daily number of urinary episodes, but statistical significance was not reached. A 
statistical difference was reached in the decrease of number of episodes of nocturia, 
number of voids per day, patient impression of change, and overall bladder condition. 
Due to the limited number of studies, a valid conclusion on the effectiveness of Sativex 
or other cannabis derivatives in treating bladder dysfunction cannot be reached. The 
results reported here, however, are promising and warrant further research into the 
effects of cannabis and its constituents in treatment of bladder dysfunction. 
One study examining the effects of cannabis constituents in patients with 
schizophrenic psychosis met the inclusion criteria for this review. A 3-day study by 
D’Souza et al. (2005) examined the effect of intravenous THC administration on 13 
stable, antipsychotic drug treated schizophrenia patients. The data from the study were 
compared with effects in healthy subjects reported by other studies, but the results failed 
to produce any obvious beneficial effects. Due to the limited number of studies, low 
number of participants, and a low retention rate, it can be concluded that THC did not 
show promise in the treatment or management of schizophrenia symptoms. 
Sleep. While no study of cannabis and its constituents has been identified in 
which sleep was the primary disorder, cannabis’ sleep-inducing properties and effects 
on quality of sleep have been mentioned in a number of studies discussed in this review 
(Berman, et al., 2004; Blake, et al., 2006; Notcutt, et al., 2004; Wade, et al., 2004; 
Wade, et al., 2003; Zajicek et al., 2005). In a study of 48 patients with neuropathic pain, 
Berman et al. (2004) found that both THC (2.7 mg in sublingual spray) and a 
combination of THC and CBD produced statistically significant improvements in sleep 
quality. Similar results were reported by Notcutt et al. (2004) who found that sleep 
quality was significantly better in a subjective assessment of 34 patients receiving THC 
alone, CBD alone, and a THC/ CBD combination compared with placebo.  
 Medical Cannabis in the United States     109 
 
Zajicek et al. (2005) found that synthetic oral THC (Marinol) capsules and 
cannabis extract (2.5 mg THC and 1.25 mg CBD) produced a statistically significant 
improvement in subjective ratings of sleep quality in a study of 630 patients with MS. 
In another study of 18 patients with MS, Wade et al. (2003) reported a statistically 
significant improvement in sleep quality with a combination of THC (2.5 mg) and CBD 
(2.5 mg) compared with placebo. Wade et al. (2004) conducted a study of 160 patients 
with MS and found a statistically significant subjective improvement in sleep quality 
with a cannabis extract (2.7 mg THC and 2.5 mg CBD) compared to placebo. Lastly, 
Blake et al. (2006) reported that Sativex use led to a statistically significant 
improvement in sleep quality in a study of 58 patients with arthritis.  
The secondary outcome measures from the studies discussed in this review 
indicate that cannabis has sleep-inducing properties and can potentially improve sleep 
quality. However, a study primarily on cannabis’ sleep-inducing properties has not been 
identified by this review. While encouraging, the current results are limited and further 
research is needed in this area. Future studies should aim to specifically focus on 
cannabis’ potential to improve the quality of sleep, its effectiveness in the treatment of 
sleep disorders, and the viability of such use.   
Systematic Reviews and Meta-analyses  
This literature review also identified nine systematic reviews and three meta-
analyses on cannabis and cannabinoids in the treatment of some debilitating medical 
conditions (Campbell et al., 2001; Cotter, 2009; Iskedjian, 2007; Lakhan & Rowland, 
2009; Lynch & Campbell, 2011; Machado Rocha, Dos Santos Júnior, Stefano, & Da 
Silveira, 2014; Machado Rocha, Stéfano, De Cássia Haiek, Rosa Oliveira, & Da 
Silveira, 2008; Martín-Sánchez, Furukawa, Taylor, & Martin, 2009; Tramer et al., 
2001). A systematic review by Tramer et al. (2001) and a systematic review and meta-
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analysis by Machado Rocha et al. (2008) were excluded as they only reviewed studies 
of synthetic cannabinoids and as such were beyond the scope of this thesis.  
Campbell et al. (2001) completed a systematic review of nine studies of 
cannabis given by any route of administration with any analgesic or placebo in patients 
with acute, chronic, non-malignant, or cancer pain. However, no studies of smoked 
cannabis were included in the review. Campbell et al. (2001) evaluated nine studies; 
five related to cancer pain, two to chronic and non-malignant pain, and two to acute 
postoperative pain. Campbell et al. (2001) found that cannabinoids had a moderate 
effect on pain, but were no more effective than codeine in controlling pain. The study 
concluded that due to their adverse effects, cannabinoids were unlikely to be useful in 
acute pain.  
Martín-Sánchez et al. (2009) completed a systematic review and meta-analysis 
of 18 double-blind, randomised controlled trials to assess the efficacy and harms of 
cannabis preparations in the treatment of chronic pain. Five of the reviewed studies 
examined Sativex, four examined TCH capsules and oromucosal spray, and eight 
examined synthetic cannabinoids. Similarly to the review completed in this thesis, the 
systematic review conducted by Martín-Sánchez et al. (2009) found evidence of 
efficacy in the use of cannabis therapy for patients with chronic pain. The meta-analysis 
found that cannabinoids reduced visual analogue scale scores of pain by -0.61 (-0.84 to 
-0.37), but the authors concluded that effects may be offset by potentially serious harm. 
In terms of efficacy, the results indicated a positive and moderate short-term trend 
toward a reduction in the intensity of pain in chronic patients, but the authors questioned 
the long-term effectiveness of cannabis due to a high number of adverse effects reported 
by patients.  
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More recently, Lynch and Campbell (2011) conducted a systematic review of 18 
randomised controlled trials of cannabinoids in management of chronic pain; four trials 
examined smoked cannabis, seven examined oromucosal extracts of cannabis based 
medicine, and eight studies examined synthetic cannabinoids. The review found modest 
analgesic effects in non-chronic non-cancer patients. Similarly to this literature review, 
several trials reviewed by Lynch and Campbell (2011) reported significant 
improvements in sleep. There were no serious adverse events reported, with most 
common adverse effects being sedation, dizziness, dry mouth, nausea and disturbances 
in concentration. Adverse effects were generally described as being well tolerated, 
transient, and mild to moderate. The main limitations to findings by Lynch and 
Campbell were short trial duration, small sample sizes, and modest effect sizes. As a 
result, Lynch and Campbell (2011) called for larger trials of longer duration so that 
efficacy and safety of cannabinoids can be examined over the long term and in greater 
numbers of patients.  
A meta-analysis by Iskedjian (2007) examined the efficacy and safety data of 
cannabinoid-based drugs for neuropathic and MS related pain. Data were extracted from 
four studies looked at Sativex, five at cannabidiol, and three dronabinol. Iskedjian found 
statistically significant lowering of pain scores; some patients did not obtain relief while 
others responded very well. However, the analysis was limited by a small number of 
trials and patients, and assumption that pain in MS and any neuropathic pain would be 
affected in the same manner (Iskedjian, 2007).  
Cotter (2009) reviewed 10 clinical trials of smoked and oral synthetic THC in 
order to ascertain whether they are effective in the treatment of chemotherapy-induced 
nausea and vomiting. Cotter found that cannabis and synthetic oral THC were more 
effective than placebo in treating nausea and vomiting. Smoked cannabis and oral 
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synthetic THC were found to be equally effective in controlling symptoms of nausea 
and vomiting when compared to traditional antiemetics. However, side effects of both 
were greater when compared to placebo and other antiemetics. The review also found 
that patients did not have significant preference for oral THC capsules as opposed to 
traditional antiemetics. Some patients were unable to tolerate cannabis smoke and it was 
deemed unacceptable to many patients. As such, Cotter (2009) suggested the addition of 
cannabinoids to existing antiemetic regimens may provide increased relief of 
chemotherapy-induced nausea and vomiting.  
Similarly to the review completed for this thesis, Lakhan and Rowland (2009) 
conducted a systematic review of six studies of whole plant cannabis extract in the 
treatment of spasticity in MS. The studies were reviewed for treatment dosage and 
duration, objective and subjective measures of spasticity, and reports of adverse effects. 
The review found evidence that combined extracts of THC and CBD may reduce 
symptoms of spasticity in patients with MS. However, subjective measures of spasticity 
were found to be significant while objective measures failed to show significant 
changes. Adverse health effects were reported in each trial in which patients received 
active treatment, and varied greatly depending on dosage. The review found some 
evidence that combined extracts of THC and CBD may reduce the side effects of THC 
alone.  
Lastly, Machado Rocha et al. (2014) completed a systematic review of literature 
on clinical and experimental trials of antitumor effects of cannabinoids on gliomas 
(primary tumours originating in the glial cells). Machado Rocha et al. (2014) reviewed 
35 studies; one study was a pilot phase I/II clinical trial done on human participants, and 
the remaining were experimental studies of patients with gliomas, laboratory animals, 
and glioma cells in in vitro experiments. In all experimental studies reviewed, 
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cannabinoids showed antitumoral activity in vitro and/or antitumoral evidence in vivo in 
several models of tumour cells and tumours. The review concluded that cannabinoids 
show promise in the treatment of gliomas, especially on account of present scarcity of 
effective resources to treat some types of cancers (Machado Rocha et al., 2014). 
Because the review completed for this thesis only included randomised controlled trials, 
it is difficult to compare the findings of the two reviews, but Machado Rocha et al. 
(2014) review results appear encouraging and indicate that there are perhaps conditions 
which cannabis can be used for that research has not yet explored.  
Reports 
As well as controlled trials and reviews, the medical uses of cannabis and its 
derivatives have been reviewed and recommendations made by various bodies including 
the U.S. IOM, the British House of Lords Select Committee on Science and 
Technology, the AMA, the American College of Physicians, and the New South Wales 
Working Party on the Use of Cannabis for Medical Purposes (Working Party) (ACP, 
2008; AMA, 2009; Center for Medicinal Cannabis Research, 2010; House of Lords, 
1998; IOM, 1999; Working Party on the Use of Cannabis for Medical Purposes 
[WPUCMP], 2000). The 1999 IOM report recognised that cannabis has therapeutic 
properties and recommended that the drug be made available to individuals requiring it 
(IOM, 1999). The report also found evidence to show that cannabis can be effective for 
the treatment of pain, nausea and vomiting, and weight loss associated with HIV/AIDS. 
It found no significant data showing that cannabis was a “gateway” drug, leading to 
other drug use. Similarly to the findings of the review in this thesis, the IOM report 
inferred that there were no significant benefits of cannabis use in the treatment of 
glaucoma compared to other already available medicines. The report concluded that:  
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The critical issue is not whether marijuana or cannabinoid drugs might 
be superior to the new drugs, but whether some group of patients might 
obtain added or better relief from marijuana or cannabinoid drugs. (p. 
153).  
The Working Party (WPUCMP, 2000) report concluded that there was evidence 
for cannabis’ use for the treatment and management of the wasting syndrome; pain 
unrelieved by conventional treatments; neurological disorders, including but not limited 
to, multiple sclerosis, Tourette’s syndrome, and motor neurone disease; and 
chemotherapy-related nausea and vomiting. The Working Party report, however, called 
for further controlled trials in order to examine the benefits of cannabis and its 
constituents and their effectiveness in the treatment of the abovementioned medical 
conditions. Smoking was also not the preferred method of administering the drug, and 
further research into other routes of cannabis administration was recommended 
(WPUCMP, 2000). 
Britain’s House of Lords concluded that cannabis had potential medical benefits 
and could assist patients for whom other conventional medicines have proven 
ineffective (House of Lords, 1998). The report found that there was sufficient evidence 
to suggest that cannabis has potential to relieve pain or the symptoms of MS; enough to 
justify legalising cannabis’ medical use. The House of Lords recommended research 
into effective modes of cannabis administration other than smoking, and encouraged 
further clinical trials evaluating the drug’s medicinal properties.  
The AMA (2009) also called for more controlled clinical studies to be conducted 
on cannabis as a medicine and recommended a review of cannabis’ Schedule I 
classification in order to enable more research to be conducted on its potential as a 
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medicine. The association also urged the NIH to implement administrative procedures 
which would assist in developing and conducting clinical trials into medicinal properties 
of cannabis (AMA, 2009).  
Overall, the conclusions made by these reports were not uniform. For example, 
in terms of debilitating medical conditions, three reports concluded that there were 
adequate data from controlled trials to support cannabis’ anti-nausea effects (House of 
Lords, 1998; IOM, 1999; WPUCMP, 2000). Similarly, three reviews concluded that 
there was reasonable scientific evidence supporting the effectiveness of cannabis and its 
constituents in appetite stimulation, while the House of Lords report concluded that the 
evidence was unclear (AMA, 2009; House of Lords, 1998; IOM, 1999; WPUCMP, 
2000). The House of Lords (1998) report raised concern for use of cannabis in AIDS, 
due to the drug’s immunosuppressive effects. However, the other side to this argument 
is whether patients with terminal illnesses should be prevented from using cannabis if it 
helps them and in the absence of other effective medication, even with its long-term 
effects being unclear. Evidence also suggests that cannabis can be an effective 
antiemetic, even superior to some antiemetic drugs, but the issue of its side effects in 
comparison to other antiemetics needs to be further explored. While the review 
undertaken for this thesis concluded that cannabis may have anti-emetic properties, 
further studies were recommended. Similarly to the reports, the review undertaken for 
this thesis indicated that cannabis does have therapeutic potential as an analgesic.  
The House of Lords (1998) report concluded that there was strong anecdotal 
evidence for cannabis’ therapeutic potential in the treatment of MS-related symptoms, 
and recommended urgent clinical trials of cannabis’ effectiveness for the treatment of 
MS. In comparison to the review presented in this thesis, these results seem generous. 
While the House of Lords referenced anecdotal reports, the review completed in this 
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thesis covered only randomised, double-blind human trials which indicated that the 
clinical evidence on the use of cannabis in multiple sclerosis and chronic conditions 
involving spasticity was promising but required further study. In terms of Tourette’s 
syndrome and motor neurone disease, the number of studies identified and included in 
this review was deemed too low to make valid conclusions. 
The overall consensus appears to be that cannabis and its derivatives do have 
therapeutic benefits, with the evidence being the strongest for chronic pain, appetite 
stimulation and weight gain, and MS. However, there are issues with some of the 
evidence such as low numbers of participants, different routes of administration and 
dosages used, as well as differences between conditions and patient demographics. 
While this review only focused on clinical trials, both anecdotal and clinical reports 
have suggested cannabis could potentially be effective in the treatment of various 
debilitating medical conditions (Mack & Joy, 2000; Mather, 2005). In terms of this 
review, the strongest evidence came from studies on cannabis’ effect on pain, nausea 
and vomiting, and spasticity. The review completed for this thesis excluded synthetic 
cannabinoids and focused on the cannabis plant and its natural derivatives, which may 
explain the contrast in some of the findings. The following table summarises the 
findings for the review undertaken for this thesis, per debilitating medical condition, in 
comparison to the five reports on medical cannabis discussed here. 
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Table 9 
A Summary of Findings per Medical Condition 
Medical 
Condition 
This 
Review 
IOM House 
of 
Lords 
AMA American 
College of 
Physicians 
Working 
Party 
Campbell 
et al. 
(2001) 
Martín 
Sánchez 
et al. 
Lynch 
and 
Campbell 
(2011) 
Iskedjian 
(2007) 
Cotter 
(2009) 
Lakhan 
and 
Rowland 
(2009) 
Machado 
Rocha et 
al. (2014) 
Pain ×××× 
Chronic 
×× Acute 
×××× 
Chron
ic 
×× 
Acute 
×××× 
Chronic 
 
×××× 
Chronic 
 
×××× ××× Chronic 
×× Pain 
management 
x xxx xx xxxx 
Neuropathic 
and MS 
related  
   
Nausea and 
vomiting 
××× ×× N/A ×  ×××× ××××     xxxx   
Spasticity ××× ×× ×××× 
MS 
××× ××× ××      xxx  
Appetite/ 
Weight 
×× ×××× N/A ×××× ×××× ×××        
Gilles de la 
Tourette 
syndrome 
×× ××× N/A N/A N/A ×××        
Movement 
disorders 
Parkinson’s 
disease 
Dystonia 
× × N/A N/A ××× ××        
Epilepsy × × × N/A × ×        
Glaucoma ×× × × × × ×        
Bladder 
dysfunction 
×× N/A N/A N/A N/A N/A        
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Sleep ×× N/A N/A N/A N/A N/A   xx     
Other             xx 
Gliomas 
××××  Recommended- strong supporting evidence 
×××  Encouraging- some supporting evidence, might have a role, further research needed 
××  Promising, but further research is needed  
×  Not recommended- very limited or no supporting evidence 
N/A Not available
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When evaluating cannabis’ effectiveness in the treatment of some debilitating 
medical conditions, it is important to consider the side effects of cannabis use and 
determine whether the benefits outweigh the risks for patients. The adverse effects are 
discussed next.  
Adverse Effects of Cannabis Use  
Generally, THC is considered a very safe drug, both acutely and on long-term 
exposure (Iversen, 2000). It is estimated that a fatal human dose of THC is between 15g 
and 70g, which is much higher than that smoked by a heavy user (Hall & Degenhardt, 
2009). However, it is cannabis’ psychoactive effects that give the greatest concern in 
considering it for medical use. Patients who have not had any prior experience with 
cannabis often find the intoxicant effects disturbing, while others do not like 
experiencing the feeling of “high”. The drug also affects short-term memory and other 
aspects of cognition, and can impair psychomotor skills. Although cannabis is generally 
safe for moderate use, the likelihood of adverse effects increases with long-term, heavy 
use (Gieringer et al., 2008). There is also growing recognition that both tolerance and 
dependence can occur in some chronic users of the drug (Iversen, 2000). Research has 
also raised concerns about cannabis and psychosis, although there are currently no data 
on the extent of risk for psychotic symptoms among medical cannabis users 
(Degenhardt & Hall, 2008). The epidemiological data on the long-term effects of 
cannabis is still scarce and long-term studies are encouraged.  
More specifically, there are also concerns over the use of the drug by smoking. 
While smoking can be an efficient way of titrating dosage and delivering an appropriate 
dose of THC to the patient, the method of delivery is not considered to be safe. 
Cannabis smoke is very similar in chemical composition to tobacco smoke, which 
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contains more than 6000 chemical constituents, with thousands more present in trace 
amounts. Cannabis joints have also been shown to deliver at least four times as much tar 
to the lungs as tobacco cigarettes of equivalent weight (Mack & Joy, 2001). Due to its 
similarity to tobacco smoke, cannabis can have possible links to chronic respiratory 
disease and cancer. Because of its potential for harm, it is unlikely that smoked cannabis 
will ever be approved by the FDA for the long-term treatment of any illness where its 
use needs to be regular. On the other hand, it could be argued that in patients with 
terminal illness or with reduced life expectancy because of illness, the long-term health 
effects of cannabis are irrelevant and smoked cannabis could be a viable option for them 
if their illness does not respond to conventional medicine.  
In terms of medical cannabis, this literature review identified one systematic 
review of 31 studies with published adverse effects of medical cannabinoid use (23 
randomised controlled trials and eight observational studies) (Wang, Collet, Shapiro, & 
Ware, 2008). No randomised controlled trials of medical cannabis administered by 
smoking were included in the review. Wang et al. (2008) excluded studies that focused 
on adverse effects of cannabis occurring in combination with other agents and those that 
involved synthetic cannabinoids. Respiratory (16.5%), gastrointestinal (16.5%), and 
nervous system disorders (15.2%) were the most frequently reported categories of 
serious adverse events among those patients assigned to receive cannabinoids, while 
nervous system disorders (30%) was the most frequently reported adverse event among 
controls. There was no evidence of a higher incidence of serious adverse events 
following medical cannabis use compared with controls. In 23 controlled clinical trials 
reviewed, nervous system disorders were the most frequently reported non-serious 
adverse event for both groups. In the eight observational studies, nervous system 
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disorders were the most frequently reported category for both serious and non-serious 
adverse events.  Psychiatric disorders were the second most frequently reported 
category. Overall, incidence rate of non-serious adverse events was significantly higher 
among subjects assigned to cannabinoid therapy than among those assigned to control 
groups (Wang et al., 2008).  
Long-term adverse effects were not well defined in clinical trials and 
observational studies reviewed by Wang et al. (2008), therefore more high-quality trials 
of long-term exposure were deemed necessary. Wang et al. (2008) cautioned against 
assuming that the adverse effects commonly reported in recreational cannabis use can 
be expected to occur with medical use of cannabis, as “the amounts used, the existence 
of comorbidities and the methods of drug delivery are different in the two populations, 
which should therefore be evaluated separately” (p. 1676).  
While much of what is known about the long-term effects of cannabis use comes 
from recreational users, the long-term effects of medical use of cannabis are unclear 
(Degenhardt & Hall, 2008). According to Degenhardt and Hall (2008), we “know 
nothing of the risks of incident cannabis dependence in the context of long-term 
supervised medical use” (p. 1686). While short-term use of cannabinoids for medical 
purposes has an acceptable safety profile, more research is needed on the adverse effects 
of long-term use of cannabinoids for medical purposes, especially in those patients who 
smoke cannabis for medical purposes (Degenhardt & Hall, 2008). Because the effects of 
cannabis depend on the dose received, the route of administration, the users previous 
experience with the drug and the setting in which it is used, future research will need to 
take these factors into consideration if we are to get a clearer picture of the long-term 
effects of medical cannabis use.   
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Discussion 
Overall, the research evidence reviewed here has shown that cannabis and its 
constituents have therapeutic potential for a number of conditions, some for which the 
evidence is mixed and unclear. Most of the research evidence supports the use of 
cannabis in the treatment of chronic pain, spasticity, nausea and vomiting, and as an 
appetite simulant for AIDS-related wasting syndrome.  
Although the research on nausea and vomiting is relatively old, a substantial 
amount of research has been conducted on the topic to suggest cannabis may have 
therapeutic potential. However, this review excluded studies on synthetic cannabinoids 
such as the already available dronabinol and nabilone, which have already been 
approved by the FDA for this purpose. The studies reviewed here showed encouraging 
results in terms of the antiemetic effects of oral THC and CBM, but no study focused on 
smoked cannabis which has now been legalised in 17 U.S. states. The question that this 
raises is whether any more anti-emetic cannabis derivatives are needed with two already 
legally available? The other issue is that some patients, especially those with nausea and 
vomiting, struggle with taking oral tablets, and therefore may benefit from other modes 
of administration. However, with no studies completed on smoked cannabis in the 
treatment of nausea and vomiting included in the review undertaken for this thesis, it is 
impossible to draw a conclusion on its effects based on scientific evidence.  
While conclusions on cannabis’ analgesic effectiveness are somewhat mixed, its 
effectiveness in the treatment of chronic neuropathic pain is well documented. The 
same, however, cannot be said for acute pain. Systematic reviews on cannabis’ 
analgesic properties found that cannabis had a moderate to significant effect on pain, 
depending on dosage and patient, but there were concerns over its adverse effects 
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(Campbell et al., 2001; Iskedjian, 2007; Lynch & Campbell, 2011; Martín-Sánchez et 
al., 2009). Overall, research included in this review has indicated that cannabis does 
have therapeutic potential as an analgesic medication, but further research is needed to 
evaluate the extent of cannabis’ therapeutic potential and the effects of its long-term 
therapeutic use. 
Cannabis’ therapeutic role in the treatment of spasticity is also relatively well 
documented but is mainly based on subjective ratings by the participants, which makes 
it difficult to draw valid conclusions regarding its clinical efficacy. A systematic review 
by Lakhan and Rowland (2009) found evidence that combined extracts of THC and 
CBD may reduce symptoms of spasticity in patients with MS, but similarly to this 
review significant findings were obtained from subjective measures of spasticity while 
objective measures were not.  However, cannabis in the treatment of spasticity does 
show potential in both long and short term treatment and further research in the field is 
warranted.  
Only one randomised, double-blind study on glaucoma fitted the inclusion 
criteria for this review. While THC did show some short-term potential in the treatment 
of intraocular pressure, further research exploring different methods of cannabis 
administration and long-term studies are needed before valid conclusions can be drawn. 
Results for other less researched conditions such as insomnia, epilepsy, and Tourette’s 
syndrome warrant further research. 
While cannabis and its derivatives have been found to have therapeutic potential, 
they also produce some unwanted side-effects. Some of the possible side-effects of 
cannabis include an increase in heart rate; decrease in blood pressure; impairment of 
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short-term memory, attention, motor skills, reaction times; fatigue; vertigo; euphoria; 
dysphoria; hallucinations; and the organisation and integration of complex information. 
Smoked cannabis also contains many of the same compounds of tobacco smoke, and 
can lead to cancer and lung damage (ACP, 2008).  
Short term effects such as feeling the psychoactive effect of the drug, anxiety, 
panic, paranoia, and feelings of impending doom, are not considered as a serious 
limitation to cannabis’ medical use because they can be controlled by dosage, and can 
also be experienced with other conventional medication. Long term effects are difficult 
to assess and may include effects on cognitive performance, respiratory disorders, and 
lung cancer due to smoking. Possible tolerance may make medical use of the drug 
difficult, although this can be experienced with other conventional medication and is not 
considered a major problem in the medical use of cannabis. While the research so far 
has identified the potential side effects of cannabis use, it should be acknowledged that 
other conventional medicines also have recognised side effects, which need to be 
weighed against their benefits. For conditions such as multiple sclerosis, which aren’t 
always successfully treated by other medicines, medical cannabis may be a beneficial 
addition to treatment or management of the condition (Zajicek, et al., 2003).  
Optimal doses and routes of cannabis administration have not yet been 
established through scientific research (Robson, 2001). Different routes of 
administration appear to be appropriate for different medical conditions and an accurate 
titration of effects and reliability is necessary. Smoking is generally not the 
recommended route of administration, and further research is therefore necessary in 
order to establish an alternative route of administration, with both short and long term 
safety and efficacy (House of Lords, 1998; Robson, 2001; WPUCMP, 2000). However, 
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it may take years to develop effective alternative methods or devices for delivering THC 
(WPUCMP, 2000). 
As suggested by this review, there is evidence supporting cannabis’ therapeutic 
use for some medical conditions. In the U.S., at the time when the material for this 
thesis was collected, 17 states and the District of Columbia had enacted laws allowing 
smoked cannabis to be used for medicinal purposes (NORML, 2010). While there are 
promising results in terms of cannabis’ potential in treating some debilitating medical 
conditions, more studies are urgently needed to test the effectiveness of different routes 
of administration. In this literature review of 38 studies, only six studies (16%) 
evaluated smoked cannabis; four in the treatment of chronic pain, one in treatment of 
acute pain, and one in appetite stimulation. The long-term effects of medical cannabis 
use also remain relatively unknown and urgently need to be researched. However, Wang 
et al. (2008) cautioned against comparing the adverse effects of recreational and 
medical cannabis users as the way in which they use the drug differs, therefore long-
term studies of medical smoked cannabis use are required.  
 While there is undoubtedly evidence for cannabis’ potential as a medicine, the 
question arises of how much of a role scientific evidence played in influencing 
policymakers and leading to change in state laws to allow for medical cannabis use? 
While many would disagree on the interpretation of the medical cannabis literature, one 
would assume that reasoned scientific debate would play an important part in public 
health policy development. Why did laws in the 17 states focus on smoking as the mode 
of administering medical cannabis as opposed to other modes of administration? What 
factors played a role in the 17 states that led to the medical cannabis laws being passed? 
In order to understand what happened in this policy process it is important to determine 
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the role scientific evidence plays in public health policy making and identify factors it 
contends with in the sometimes arduous policy making process (Birkland, 2005; Ritter, 
2009).  
It is also important to understand how the context in which these policy changes 
took place and the process that occurred before medical cannabis laws came to be 
enacted in 17 of 50 U.S. states and the District of Columbia. For the purpose of this 
thesis, two representative states were chosen as examples of how medical cannabis laws 
came to be passed. Michigan was chosen as a representative state for medical cannabis 
laws passed by ballot initiative, while New Mexico was chosen as a representative state 
for medical cannabis laws passed by the legislative process. The states were chosen 
because they were the most recent states to pass a medical cannabis law at the time of 
writing this thesis.  
Three other representative states (Illinois, Kentucky, and Louisiana) were 
chosen. Illinois was chosen as a state which is considering medical cannabis laws, but 
has not passed one to date4. Kentucky was chosen as a state which has no medical 
cannabis laws and has not considered one, while Louisiana is a state which has not 
considered passing a medical cannabis law, but has an ineffective, symbolic, medical 
cannabis law on its books.  
The chronological accounts in the following chapter will outline what happened 
in each of the representative states in terms of medical cannabis and the use of media 
4 Illinois became the 20th state in the U.S. to legalise medical cannabis in July 2013, after this thesis was 
submitted.  
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available to the general public will allow the reader to see how the issue was framed in 
those particular states.
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Chapter 4- Medical Cannabis in Five Representative States 
For the purpose of this thesis, two representative states were chosen as examples 
of how medical cannabis laws came to be passed. Michigan was chosen as a 
representative state for medical cannabis laws passed by ballot initiative, while New 
Mexico was chosen as a representative state for medical cannabis laws passed by the 
legislative process. The states were chosen because they were the most recent states to 
pass a medical cannabis law at the time of writing this thesis. 5 
Three other representative states (Illinois, Kentucky, and Louisiana) were 
chosen. Illinois was chosen as a state which is considering medical cannabis laws, but 
has not passed one to date. 6 Kentucky was chosen as a state which has no medical 
cannabis laws and has not considered one, while Louisiana is a state which has not 
considered passing a medical cannabis law, but has an ineffective, symbolic, medical 
cannabis law on its books.7  
The chronological accounts in the following five chapters were generated 
through a review of publicly available literature including government publications, 
newspaper articles, parliamentary proceedings, court documents, and press releases. A 
general internet search using Google as a search engine was also made with the use of 
the keywords including the name of the state in question and “cannabis”, “marijuana”, 
“marihuana”, “medical”, “medicinal”, and “therapeutic”, “law”; and/or a combination 
5 The study was completed in 2011 and thesis submitted for examination in 2012.    
6 At the time of writing this thesis, Illinois did not pass a medical cannabis law. Illinois subsequently 
passed a medical cannabis law on August 1, 2013.  
7 At the time of writing this thesis Kentucky and Louisiana did not consider medical cannabis law. Since 
then, there have been activities in both states in relation to medical cannabis. 
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of these keywords. Additional newspaper reports were also identified through the Media 
Awareness Project website, http://www.mapinc.org/.  
Michigan  
On November 4, 2008, the Michigan Medical Marihuana Act, which allows the 
use of medical cannabis for qualifying patients, was approved by Michigan voters 
through a ballot initiative (Michigan Medical Marihuana Act, 2008). The act took effect 
on December 4, 2008, and allows patients with specific debilitating medical conditions 
to acquire, possess, cultivate, manufacture, use, deliver, transfer or transport medical 
marijuana and paraphernalia relating to marijuana administration, in order to treat or 
alleviate a debilitating medical condition (Michigan Medical Marihuana Act, 2008). A 
qualifying patient is only allowed to have one caregiver, while a caregiver can care for a 
maximum of five patients. Specifically, a debilitating medical condition is defined by 
the act as one or more of the following: cancer, glaucoma, positive status for human 
immunodeficiency virus, acquired immune deficiency syndrome, hepatitis C, 
amyotrophic lateral sclerosis, Crohn’s disease, agitation of Alzheimer’s disease, nail 
patella, or symptoms of conditions such as cachexia or wasting syndrome. The patient 
or their carer can legally possess up to 2.5 ounces (70.9g) of usable marijuana, and 
grow, in an enclosed, locked facility, up to 12 plants. The law does not specify how the 
seedlings or plants are to be obtained by the patient or their caregiver in order for them 
to be grown (Michigan Medical Marihuana Act, 2008).  
In order to qualify for the program, individuals meeting the specific criteria are 
required to obtain an identification card from the Michigan Department of Community 
Health (MDCH) in which the act vested responsibility for medical cannabis program 
implementation and administration (Michigan Medical Marihuana Act, 2008). In order 
to qualify, patients must also have a recommendation from their physician saying that 
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they will benefit from the use of medical marijuana. According to the act, the physician 
will be exempt from arrest, prosecution or penalty in Michigan. 
At the state level, qualifying individuals and their carers can also assert medical 
reasons for using cannabis as a defence to any prosecution involving their cannabis use 
and/or possession. The defence is not limited to registered patients only, and, while it 
does not protect a patient from arrest, it requires the charges to be dropped if the patient 
can prove that a doctor has stated they will benefit from marijuana use, they did not 
possess more than the necessary amount, and that the possession, manufacture or 
delivery of the drug was done for the purpose of treating the patient (Michigan Medical 
Marihuana Act, 2008). 
In the following section, Figure 2 will chronologically review the history of 
medical cannabis in Michigan, followed by a chronological description of the process 
by which the act was passed.   
 
 
 Medical Cannabis in the United States     131 
 
 
1979 
•Michigan Liutenant Governor signs legislation authorising a therapeutic cannabis program 
for cancer and glaucoma patients 
1980 
•Reports of shortage of federally grown cannabis 
•Physicians start reporting patient complaints regarding quality of federally-supplied 
cannabis  
1982 
•Michigan's Public Health Code section allowing cannabis use for therapeutic research 
expires and is not renewed 
1997 
•Peter McWilliams, a cancer and AIDS patient,  announces he is attempting to set legal 
precedent in Michigan by using medical necessity as a defence on a posession charge 
•Judge denies McWilliams' medical necessity defence   
•Suggestions that some anti-drug groups are softening their anti-medical cannabis stance 
1999 
•Michigan newspapers publish a summary of the IOM report 
•Executive vice president of the Partnership for a Drug Free America says the organisation 
supports the report's recommendations 
•Activists propose a "Personal Responsibility Amendment" allowing individuals with 
debilitating medical conditions "personal amount" of cannabis  
2000 
•Libertarian party petitions to prevent Ann Arbor Police from charging individuals who use 
cannabis for medical reasons  
2001 
•Second petition drive to place the "Personal Responsibility Amendment" on the 2002 ballot 
occured 
•Michigan NORML joins "Adopt-A-Highway" program to counter negative perceptions of 
NORML 
•Michigan senators speak against medical cannabis legislation 
2002 
•  Detroit Coalition for Compassionate Care starts city-based petition to amend city charter in 
relation to allow medical cannabis use 
2004 
•Ann Arbor activists place medical cannabis ordinance change proposal on city ballot 
•Governor Granholm reported as the biggest opposition to Ann Arbor ordinance change 
initiative  
•Ann Arbor voters pass medical cannabis ordinance amendment; Police Chief instructs 
officers to continue enforcement of all cannabis-related offences 
•Detroit voters pass medical cannabis ordinance amendment 
•"Love. The Anti-Drug" launched in Detroit by director of the ONDCP 
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Figure 2. Time chart of medical cannabis history in Michigan. 
2005 
•Ferndale and Traverse City pass medical cannabis ordinance amendment 
•Activist group "Win-The-War" starts circulating petitions to amend state constitution to 
legalise cannabis use and regulate it like alcohol  
•Bruce Mirken from the MPP  says  U.S. Supreme Court ruling would not deter medical 
cannabis efforts in Michigan and other states  
•Medical cannabis bill HB 5470 introduced in the Michigan House of Representatives; 
Deputy Director of the ONDCP asks for the bill to be rejected 
2006 
•HB 5470 dies at the end of the legislative session 
•"Medical and Recreational Peace" (MRP) group proposes making cannabis legal for those 
over 18 years of age 
•Michigan NORML announce they will try to get a bill similar to HB 5470 on the 2008 
ballot but not in conjunction with MRP proposal  
2007 
•Flint city voters pass change to the city ordinance legalising use of medical cannabis 
•Medical cannabis bill HB 4038 introduced to the House of Representatives  
•Spokesperson for the ONDCP says medical cannabis laws would not help sick individuals 
•Michigan Coalition for Compassionate Care (MCCC) announce they will launch a 
Michigan Medical Marihuana Act initiative  
2008 
•MCCC publish a poll on their website indicating 67% of Michigan voters support 
legalising cannabis for medical use  
•Michigan State Medical Society announce they oppose medical cannabis, except for use in 
controlled studies  
•Detroit News article revealed that MCCC spent over $1.1 million on campaigning, with 
most money coming from MPP  
•Citizens Protecting Michigan's Kids is formed, opposing medical cannabis law 
•Chair of Workplace Law Practice Group issues a memorandum opposing medical 
cannabis proposal  
•Director of the ONDCP goes to Detroit to speak against medical cannabis proposal  
•A group of local law enforcement agencies issue a statement opposing the medical 
cannabis initiative  
•Proposal 1 passed by 62.7% of votes on November 4, 2008.  
2009 
•The first draft of rules for the medical cannabis program resulted in protests from patients 
and advocates  
•The debate on whether the law should or should not have been passed still active 
•Judge Robert Turner says the medical cannabis law was ambiguous 
2010 
•Ongoing debates over the medical cannabis law’s ambiguity 
•Confusion regarding the law resulted in local governments passing their own ordinances 
2011 
•Calls for the legislature to make the medical cannabis law workable 
•Six bills passed during the 2011-2012 legislative session to tighten regulations on medical 
cannabis  
•Reports that, in the first two years of the medical cannabis law, over 100,000 Michiganders 
registered to use medical cannabis and the Michigan government made a profit of $8 
million profit  
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2008 Michigan Medical Marijuana Act: Chronological account. In the 
1970s, Michigan was one of the first states to authorise cannabis use for therapeutic 
purposes (Drug Enforcement Administration [DEA],  n.d.; MPP, 2013). In 1978 Roger 
D. Winthrop, who organised the Michigan chapter of the NORML and lobbied the 
Michigan legislature on issues including Michigan drug policy reforms, asked Senator 
Jerry Hart (Democrat [D]) to sponsor cannabis-related legislation (DEA,  n.d.). The 
legislation sought to make cannabis available for glaucoma and cancer patients, and 
those undergoing neurological therapies. Hart agreed, and the legislation was introduced 
at the start of the 1979/1980 legislative session. Senator Hart had previously introduced 
a bill aimed toward decriminalising general cannabis use, which was defeated at the end 
of the 1977/1978 legislative session. He intended to reintroduce the bill with an added 
section for medical cannabis use (DEA, n.d.). 
At the same time, Senator Steve Monsma (D) wanted to introduce medical 
cannabis legislation separately from Senator Hart’s (DEA, n.d.). Senator Monsma was 
concerned that being linked with general cannabis decriminalisation would jeopardise 
the medical initiative (DEA, n.d.). According to Winthrop, when Senator Hart’s bill was 
heard before the Senate Judiciary committee, there was vigorous debate regarding the 
part of the bill aimed at cannabis decriminalisation, while there was significant public 
and political support for the drug’s medical use. Subsequently, Senator Monsma’s bill 
was introduced, and was modelled on New Mexico’s 1978 medical cannabis legislation 
(DEA, n.d.).  
As patients were called upon to share their medical cannabis experiences with 
the legislature, press coverage also grew (DEA, n.d.). According to Winthrop, it was 
clear that the issue of medical cannabis and general cannabis decriminalisation had to be 
separated, which resulted in Senator Hart agreeing to let Senator Monsma’s bill take 
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priority. At the same time, the FDA threatened to block the medical cannabis program 
implementation by withholding cannabis supplies. Afterward, Senator Monsma 
proposed an amendment to the bill, which, if passed would have allowed the use of 
confiscated cannabis for treatment of patients if the necessary supply was not received 
from federal sources. A spokesperson for the FDA also said that, if Michigan 
conformed to regulations, the federal government would supply the cannabis (DEA, 
n.d.).  
On June 25, 1979, the Michigan senate passed Senator Monsma’s bill by a 29-5 
vote. The bill was then moved on, and on October 3, 1979, the House Public Health 
Committee unanimously passed it (DEA, n.d.). On October 10, the bill went for a House 
hearing, and was passed by a 100-0 vote of the House. On October 22, 1979, Lieutenant 
Gov. James Brickley signed the legislation requiring the Michigan Department of Public 
Health to operate a therapeutic cannabis program for physician-recommended cancer 
and glaucoma patients, as Public Act 125 of 1979  (Public Health Code Act, 1978).  
In 1980, it was advised that there was a shortage of federally grown cannabis 
(DEA, n.d.). Physicians also started reporting patient complaints regarding federal 
cannabis quality. According to Winthrop, cannabis supplied to the Michigan therapeutic 
research program was lower in quality than the mandatory standards. It was suspected 
that the federal government had cannabis of better quality, but did not provide it for 
Michigan (DEA, n.d.). The Michigan Public Health Code’s section, allowing cannabis 
use for therapeutic research expired on November 1, 1982, and has not been renewed 
since. This took away the health department’s responsibility for establishing a 
therapeutic cannabis research program (Public Health Code Act, 1978). 
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Following the expiration of the medical cannabis legislation in 1982, no media 
reports focusing on medical cannabis were reported in Michigan until October of 1997 
when PR Newswire, issued a press release announcing that a cancer and AIDS patient, 
Peter McWilliams, was attempting to set a legal precedent in Michigan by using 
medical necessity as a defence on a cannabis possession charge (“McWilliams Hopes”, 
1997). The following day, the judge in the case, Tina Green, allowed Mr McWilliams’ 
lawyer to base his defence on the use of cannabis for medical purposes. However, Judge 
Green then changed her mind after reviewing the law and advised that McWilliams did 
not meet the criteria for such a defence because McWilliams not using cannabis would 
not result in death or serious bodily harm (Cain, 1997; “Judge Denies Author's Medical 
Defense”, 1997). His attempt was unsuccessful, but there followed an increase in media 
reports on medical cannabis (“McWilliams Hopes”, 1997). McWilliams’s house was 
raided by DEA in December 1997, on apparent suspicion that McWilliams was 
cultivating or dealing drugs (Farmanfarmaian, 1998). McWilliams alleged that the DEA 
was interested in the material he was collecting for a book he was writing on medical 
cannabis (Farmanfarmaian, 1998). 
The year 1999 saw the publication of the IOM report (IOM, 1999). The Detroit 
Free Press published a summary of the report, which found that cannabis has medical 
benefits (McFarling, 1999). The article also reported that some anti-drug groups 
appeared to be softening their anti-medical cannabis stance, and quoted Steve Dnistrian, 
of the Partnership for a Drug Free America, as saying that the organisation supported 
the report’s recommendations as they did not want to contradict what doctors and 
scientists said (McFarling, 1999).  
After the IOM report was published, a “Personal Responsibility Amendment” 
was proposed to the Michigan constitution to allow individuals with debilitating 
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medical conditions to grow a “personal amount” of cannabis (“Activists Promote 
Legalized Marijuana”, 1999). This was specified as being no more than three mature 
plants, seedlings, and 3 ounces (85g) of dried cannabis. The initiative, started by 
Gregory Schmid from the Michigan branch of the NORML, required 302,711 signatures 
in order to be put on the November 2000 ballot (“Legalized Marijuana”, 1999). 
However, the organisation encountered difficulties in organising a petition drive and did 
not manage to collect enough signatures (Trahan, 2001). This was the first attempt at 
passing medical cannabis legislation in Michigan since the 1980s.  
A second petition drive to place the “Personal Responsibility Amendment” on 
the 2002 ballot occurred at the annual Ann Arbor ‘Hash Bash’, where people gather to 
protest cannabis prohibition (Restivo, 2001; Trahan, 2001). Gregory Smith, who 
organised the previous year’s petition, said he was confident enough signatures would 
be gathered despite having limited funding (Trahan, 2001). Articles were published in 
support of medical cannabis and encouraged people to vote for it (“Just Say Yes”, 2001; 
“Marijuana- Leave Room”, 2001). The Michigan NORML chapter also joined 
Michigan’s Adopt-A-Highway program, committing to pick up litter on a 2-mile stretch 
of road, in order to counter negative perceptions people might have of the NORML 
(“Pro-Marijuana Group Sponsors”, 2003).  
Despite the “Personal Responsibility Amendment” failing, the issue of medical 
cannabis continued to be discussed in the media and both opponents and proponents of 
medical cannabis were making their opinions heard. Michigan Senator Bill Bullard Jr. 
(Republican [R]) spoke out against medical cannabis legislation in the state, arguing 
that it promoted recreational use of the drug and said that the legislature would not 
approve such legislation, which would leave petitioning as the only way to get medical 
cannabis on the ballot and this required money and organisation (Crimmins, 
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2001).Another senator, John Schwarz (R), said he opposed the legislation because 
cannabis was already available in tablet form (Marinol) (Crimmins, 2001). Robert 
Sharpe, the program officer for the Lindesmith Centre Drug Policy Foundation, 
responded to the senator’s comments by stating that cannabis has been used as a 
medicine for thousands of years, and should be legalised and regulated (Sharpe, 2001). 
Movements towards medical cannabis legislation at the state level also coincided with 
attempts at city-level changes.  
Changes at the city level. Although largely symbolic, local medical cannabis 
laws have the potential to influence priorities of local law enforcement officers and 
prosecutors (Eddy, 2010). Ann Arbor led the way at the local level, with a petition 
initiated by the Libertarian party aiming to prevent Ann Arbor Police from charging 
people who used cannabis for medical reasons (Wahlberg, 2000). However, some of the 
movement was not solely to do with medical cannabis and James Tudler of the 
Libertarian party said that the organisation aimed for the legalisation of all drugs, 
starting with medical cannabis (“Activists Promote Legalized Marijuana”, 1999; 
Wahlberg, 2000). The Libertarian party failed to submit their petition on time and the 
amendment was not put on the city ballot (Hoffman, 2000; Meehan, 2000).  
However, in 2004, activists from the Washtenaw Coalition for Compassionate 
Care managed to collect 7,000 signatures on a petition seeking support for amendments 
to the Ann Arbor ordinance (Charter for the City of Ann Arbor, 1956; Tomkie, 2004). 
The amendments were designed to decrease the fines for cannabis use and prohibit the 
local police from fining medical cannabis patients for its possession (Charter for the 
City of Ann Arbor, 1956; Tomkie, 2004). There was a suggestion that, if passed, Ann 
Arbor’s ordinance amendment would set the trend towards decriminalisation of 
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cannabis (“Medicinal Marijuana Could Lead”, 2004; “A Possible Model for Medical 
Marijuana”, 2004).  
The press reported that Scio Township Trustee Charles Ream, who led the Ann 
Arbor drive by collecting 7,000 petition signatures, paid $1 for each voter signature 
using $5,000 of his own money, while the MPP donated $4,000 (Tee, 2004). According 
to the Michigan Daily, Ream decided to rely on newspaper articles and editorials to 
make people aware of the initiative (Tee, 2004). As was also the case in Detroit, the 
media reports indicated that the biggest opposition to the initiative came from Gov. 
Jennifer Granholm (D), who publicly said she did not approve of medical cannabis use 
(Tee, 2004). Despite opposition, on November 2, 2004, approximately 75 percent of 
Ann Arbor voters passed the ballot proposal (Rott, 2004). The following day, Ann 
Arbor Police Chief Dan Oates released a written statement saying he had instructed his 
officers to continue enforcement of all cannabis-related offences (Davis, 2004).  
At the same time as Ann Arbor, there was also activity in Detroit. The Detroit 
Coalition for Compassionate Care (DCCC) started a city-based petition in order to 
amend the city charter to make medical cannabis possession the lowest law enforcement 
priority (O'Brien, 2002). According to Tim O’Brien, the advertising and media 
consultant for the DCCC, even though a city charter is superseded by state and federal 
laws, changing Detroit’s charter could still make an impact. He believed a change could 
be possible as the responsibility for enforcement of cannabis possession offences fell to 
the local police. The proposal came under scrutiny in part because, according to the 
opposition, it did not specify the conditions and symptoms for which the drug could be 
used (O'Brien, 2002).  
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While the support for the initiative was strong and supporters raised $30,000 in 
campaign funds, there was strong opposition from the Partnership for a Drug-Free 
Detroit (Angel, 2004). It was alleged in the media that the opposition was receiving 
funds from the federal government in order to fight against the amendment to the city 
code (P. Smith, 2004). Partnership for a Drug-Free Detroit stated in a published 
memorandum that the medical cannabis initiative should be opposed because (a) the 
drug was dangerous and hurt AIDS patients; (b) safer evidence-based treatments could 
be used instead of cannabis; and (c) the initiative was deceptive and based on politics, 
rather than facts (P. Smith, 2004). Despite the opposition from Gov. Granholm and 
suggestions that the ordinance change was only symbolic and would not guarantee that 
patients would not be prosecuted, the DCCC initiative appeared on the August 3 ballot 
and was passed (“Detroit Okays Medical Use”, 2004; Gantert, 2004; “Medical Pot 
Victory”, 2004).  
Ferndale and Traverse City joined the medical cannabis movement, and both 
passed a medical cannabis ordinance amendment in November 2005 (Flesher, 2005; 
McConnell, 2005; McCray, 2005). The Traverse City amendment did not make medical 
cannabis use legal, but made it the lowest law enforcement priority (Flesher, 2005). In 
February 2007, Flint Coalition for Compassionate Care, which received a $7,500 grant 
from the MPP, succeeded in their aim to change the city ordinance, with Flint voters 
supporting measures legalising the use of medical cannabis with doctor’s approval 
(“Flint Legalizes”, 2007; Rook, 2006; “State Should Allow”, 2006). 
Increase in medical cannabis debate. Changes at the local level were followed 
by an increase in the medical cannabis debate across the state. In the same year the 
Detroit ordinance was changed, a national ad campaign, “Love. The Anti-Drug”, which 
urged parents to take a stand against youth drug use, was launched in the city by John 
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Walters, director of the ONDCP (“A Talk With Drug Czar”, 2004). In May of 2005, the 
Detroit Free Press reported that there was again movement towards amending the state 
constitution to legalise the use of medical cannabis. A group called Win-The-War, 
headed by Bruce Ritchie, started circulating petitions for a proposal seeking to legalise 
general cannabis use and regulate it in the same way as alcohol (“Marijuana Petition 
Drive for 2006”, 2005; Range, 2005). According to news reports, the group was 
working on limited funds and had $3,000 to $4,000 available to fund the campaign. 
Ritchie said he hoped that they would get more funding from the MPP (Range, 2005). 
The group’s efforts were unsuccessful.  
In 2005, Bruce Mirken from the MPP said that the U.S. Supreme Court ruling 
which found that federal agents could arrest medical cannabis users in the states that 
have legalised medical cannabis would not deter medical marijuana efforts, but would 
instead strengthen the movement in Michigan and other states (“Buzz Over Medical 
Marijuana”, 2005). The same year, House Bill HB 5470 was introduced by Rep. LaMar 
Lemmons III (D) in the Michigan House of Representatives. The bill sought to allow 
licensed physicians to prescribe small cannabis amounts to patients with debilitating 
medical conditions, such as cancer and glaucoma (Bell, 2006; H.R. Rep. No. 5470, 
2005). The introduction of the bill saw both sides of the debate speaking out. Scott 
Burns, Deputy Director of the ONDCP urged the House Government Operations 
Committee to reject the legislation, because smoked marijuana was not safe or effective 
and legalising it would be bad for patients and society (Bell, 2006). Prominent medical 
cannabis users testified in support of the bill, but the committee took no action, letting 
the bill die at the end of the 2006 legislative session (Andrews, 2006; Cain, 2006). The 
following year, another medical cannabis bill, HB 4038, was unsuccessfully introduced 
to the House of Representatives. It sought to allow use of medical cannabis for 
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individuals with specific medical conditions, with a referral from their physician (H.R. 
4038, 2007).  
This was followed by a new petition by Medical and Recreational Peace (MRP) 
that proposed making cannabis legal for those older than 18 years, as long as they were 
using or growing cannabis on private property (“Marijuana Petition Drive for 2008”, 
2006). Tim Beck, then the Executive Director for Michigan NORML, distanced his 
organisation from the MRP and said that the NORML would also try to get a proposal 
similar to HB 5470 on the 2008 ballot, but not in conjunction with the MRP proposal. 
He said the MRP proposal sought to legalise marijuana for general use and came out of 
nowhere (Aisner, 2006; Rook, 2006). The medical cannabis movement drew opposition 
from Raphael Lematrie, spokesperson for the ONDCP, who said that medical cannabis 
laws would not help sick individuals (D. Storey, 2007). Both proposals were 
unsuccessful.  
Proposal 1. The opposition did not deter the newly established Michigan 
Coalition for Compassionate Care (MCCC), founded by Tim Beck. In May 2007 they 
announced the launch of the Michigan Medical Marihuana Act initiative to legalise 
medical cannabis in the state. Using both volunteers and paid signature collectors, the 
organisers planned to collect 550,000 signatures within 6 months to get the petition on 
the 2008 ballot (Guyette, 2007; Kozlowski, 2007). The initiative received opposition 
from law enforcement figures such as Ingham County Sheriff Gene Wrigglesworth, who 
said it was a mistake and would be difficult to enforce and regulate (Andrews, 2007a). 
Meanwhile, Dianne Byrum, a former state legislator, worked with the MCCC to get the 
measure on the ballot and discussed the benefits of medical cannabis in the media. 
Michigan NORML’s Executive Director Rev. Steven Thompson declined to discuss the 
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specifics of the MCCC initiative, but expressed his support (Andrews, 2007a; Czarnik, 
2007). 
Some of those using cannabis for medicinal purposes were active in sharing their 
stories and experiences, appearing in articles across different newspapers (Andrews, 
2007a; Czarnik, 2007; Guyette, 2007). Support was also received from the former U.S. 
Surgeon General Joycelyn Elders and Howard J. Wooldridge, a retired police detective 
campaigning against prohibition. Wooldridge said that the reluctance to adopt new drug 
laws came mainly from the pharmaceutical industry’s concern that they would suffer 
significant monetary loss should cannabis be legalised (Andrews, 2007a; R. E. Martin, 
2007).  
By November 2007, the necessary signatures were collected by the coalition 
(McVicar, 2007). The opposition spoke out, with Ingham County Sheriff Wriggelsworth 
indicating he did not support the proposal because it would require an increased police 
presence and open the door for general cannabis use (McVicar, 2007). State Senator 
Tom George (R) said that legalising smokeable cannabis would have no benefits and 
would make determining the right dose difficult (Killian, 2008a). Senate majority Floor 
Leader Alan Cropsey (R) also spoke out against the proposal. The senator believed that 
the legislature was unlikely to enact the law and would let the initiative go to ballot 
instead (Andrews, 2007b). The legislature did not enact the law and the initiative, 
known as Proposal 1, was set to go before voters on November 4, 2008 (Bell, 2008a). 
The MCCC published on their website a March 2008 poll, which found that 67 percent 
of Michigan voters supported removing criminal penalties for the medical use of 
cannabis (Michigan Coalition for Compassionate Care [MCCC], 2008).  
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One of the issues raised by opponents was that patients would have to obtain 
cannabis from someone, who would be committing a felony by selling it to them, 
because the proposal did not provide for a legal supply network (Citizens Research 
Council of Michigan, 2008; Killian, 2008b). The Michigan State Medical Society also 
announced that they opposed medical cannabis, except for use in controlled studies 
(Doty, 2008). The MDCH representative James McCurtis said that they could not 
legally take a stand on the proposal, but saw both sides of the argument (Roltsch, 2008).  
While there were individuals speaking out in opposition of medical cannabis in 
the state, until September 2008 there was no specific organised group opposed to 
medical cannabis laws. Then, according to the State of Michigan (2008) on September 
23, Citizens Protecting Michigan’s Kids (CPMK) was formed. CPMK consisted of 
medical, law enforcement and anti-drug organisations (Leubsdorf, 2008). They were set 
to launch their campaign in five cities: Southfield, Lansing, Grand Rapids, Traverse 
City and Saginaw (Citizens Protecting Michigan's Kids [CPMK], 2008). On their 
webpage, CPMK declared that they were formed in order to urge voters to vote against 
Proposal 1 (CPMK, 2008). Michigan Court of Appeals Judge Bill Schuette spoke on 
behalf of the CPMK in opposition to the proposal and was supported by the Howell 
Chief of Police George Basar (Leubsdorf, 2008). Ron Schafer, Ionia County 
Prosecuting Attorney, also joined in the opposition, reasoning that the proposal had a 
gap which would allow people to drive under the influence of cannabis and increase 
danger on the roads (CPMK, 2008).  
The debate intensified in October 2008 when the CPMK started airing a 
television advertisement showing a storefront called “Cannabis Company” and talking 
about the hundreds of pot-smoking clubs which opened in California after voters 
approved the use of medical cannabis in 1996 (Van Dussen, 2011). The announcer says 
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that “They grow pot there. They smoke it there in every neighbourhood just blocks from 
schools”. At this point, MCCC staff posted a blog on their website responding to the 
television advertisement which they believed was misleading, lied to the public and was 
just using scare tactics (MCCC, 2008a). The MCCC also started running advertisements 
featuring Dr George Wagoner who helped his wife by obtaining cannabis to ease her 
symptoms of chemotherapy (YesOnProp1, 2008). It was also reported that through to 
October 20 that year, the MCCC raised more than 10 times the amount Proposal 1 
opponents raised, $1.5 million to $125, 500 (Oosting, 2008).  
A memorandum was also issued to Michigan employers by Steven J. Fishman, a 
chair of the Workplace Law Practice Group, opposing the proposal and claiming that 
there was no scientific evidence that smoking cannabis was safe or effective, and that 
because it is not FDA approved, employers would not be able to monitor its use 
(Fishman, 2008). Fishman reasoned that, as Michigan was a state with a high 
unemployment rate and among the least attractive for business, it could not afford to 
have cannabis in the workplace (Fishman, 2008). MCCC spokeswoman Dianne Byrum, 
together with Bruce Mirken, responded to Fishman’s claims saying that the MCCC did 
not believe that Proposal 1 would affect workplaces (Bell, 2008b). Byrum said she was 
not aware of any cases of workplace problems with medical cannabis in states that have 
already adopted such laws. Fishman’s memorandum, however, had an impact on the 
Chamber of Commerce, who previously adopted a neutral position on the proposal but 
said Fishman’s memorandum raised significant and previously unconsidered points 
(Bell, 2008b; CPMK, 2008).  
Less than a month before the election, Judge Bill Schuette and Michigan State 
Medical Society’s House of Delegates speaker Daniel Michael wrote a number of 
articles against Proposal 1 (Schuette & Michael, 2008a, 2008b). Similarly to the CPMK 
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advertisements, they suggested that California’s medical cannabis law resulted in chaos 
and that the same would happen in Michigan should Proposal 1 be passed (Schuette & 
Michael, 2008a, 2008b). While claiming the proposal was bad because it did not require 
a prescription for cannabis, they strongly urged voters to vote no on the proposal 
(Schuette & Michael, 2008a). Judge Schuette and members of the Michigan Sheriff’s 
Association also joined the deputy drug czar Scott Burns in Grand Rapids to campaign 
against Proposal 1, while Oakland County Sheriff Michael Bouchard, prosecutor David 
Gorcyca and Southfield Police Chief Joe Thomas held a press conference and spoke 
against the proposal (CPMK, 2008; “Deputy Drug Czar Will”, 2008).  
One of the more high-profile opponents, John Walters, Director of the ONDCP, 
went to Detroit to speak against the proposal he called the first step towards legalising 
drugs (“Drug Czar Visits”, 2008). He said that its proponents did not have any facts but 
relied on the sympathy of the voting public. Following Walters’s arrival, a joint 
statement opposing the initiative was released by a group of local law enforcement 
agencies (Kloosterman, 2008). The statement said that medical cannabis (a) was a 
Trojan horse for legalising the drug itself and making it available with disregard for 
scientific evidence; (b) had no scientific base; (c) was dangerous; and (d) could have a 
staggering effects on families and children (Kloosterman, 2008). Afterwards, Howell 
Police Chief George Baser encouraged voters to vote no on the proposal which he 
believed would lead to more people, including children, using cannabis (Totten, 2008). 
He said that, if the drug were truly for medical use, the proposal would include a 
requirement for physicians’ prescription (Totten, 2008). Donald Allen, Director of the 
Michigan Office of Drug Control Policy, was also quoted as saying that medical 
cannabis was not in the public health interest (Satyanarayana, 2008a). 
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In response to the opposition’s comments, Dianne Byrum presented the 
argument that cannabis legalisation was not the goal of Proposal 1 but providing options 
for patients in pain (Totten, 2008). Campaigners such as Dr. George F. Wagoner and 
Reverend Steve Thompson of Benzie County NORML wrote to different newspapers 
relating experiences with medical cannabis and voicing support for the initiative 
(Wagoner, 2008a, 2008b). Thompson alleged that CPMK only posted half-truths and 
said it was not clear who stood behind them. In response to claims that legalising 
medical cannabis was just a step towards legalising cannabis in general, Thompson said 
that the NORML wanted the drug completely legalised, for both recreational and 
medical use, and that was why they took a back seat to the MCCC, whose goal was 
legalisation for medical purposes only (Coates, 2008).  
In October, CPMK spokespersons stopped in Battle Creek to speak against 
Proposal 1, calling the initiative preposterous and a con (“Medical Marijuana a Hot 
Issue”, 2008). Following the group’s visit to Battle Creek, David Headings from the 
Battle Creek Police Department and Al Byam, Sheriff of Calhoun County, wrote a letter 
to the Battle Creek Enquirer, strongly opposing medical cannabis (Headings & Byam, 
2008). They said that the initiative could make drugs available to children under the 
guise of medical use and that advocates of cannabis legalisation played on people’s 
emotions by presenting cases of sick patients who have benefited from the use of the 
drug (Headings & Byam, 2008). 
While the MDCH previously took no stance on the medical cannabis issue, at 
the end of October, Janet Olszewski, the department’s director, stated in the Detroit Free 
Press that legalising cannabis for medical purposes was not the right answer for treating 
pain (Olszewski, 2008). She said that major public health organisations did not support 
medical cannabis and that there was no need for it, as Marinol (dronabinol) was 
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available and had medical value. According to Olszewski, the proposal had loopholes 
that could cause legal confusion and drug enforcement problems (Olszewski, 2008).  
On October 30, prominent figures, including Macomb County Sheriff Mark 
Hackel and prosecutor Eric Smith, joined Bill Schuette at Macomb County to urge 
voters to vote against Proposal 1 (Wilczynski, 2008). Schuette said that wealthy 
millionaires from New York, Washington D.C., and California were spending millions 
to promote the medical cannabis initiative, with the aim ultimately being general 
cannabis legalisation (Wilczynski, 2008). Matt Resch, spokesman for the CPMK, said 
the opposition was slow to start their campaign, but were busy in October airing 
television commercials (Bell, 2008c).  
At the start of November, the Detroit Free Press indicated the polls showed 
strong support for the proposal (Bell, 2008c). Debates over the issue were evident 
across newspapers leading up to the election, with both supporters and opponents 
presenting their views (Panian, 2008; Satyanarayana, 2008b). Then, on November 4, 
2008, voters passed the proposal (Michigan Department of State, 2008a). The 
information from the Department of State showed that Proposal 1 received majority 
‘yes’ votes in every one of the 83 Michigan counties; 3,006,820 (62.7%) voted in favour 
of the proposal and 1,790,889 (37.3%) voted against (Michigan Department of State, 
2008a).   
Funding. On Tuesday, November 4, 2008, the co-chairs of CPMK Judge Bill 
Schuette and Jim Barrett released a statement on CPMK’s website following the passing 
of Proposal 1, stating that the organisation campaigned on a limited budget (CPMK, 
2008). This section will outline the funds and expenditures for both MCCC and CPMK 
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during 2008 and the election cycle, as reported in the Michigan Department of State 
documents. 
The documents indicated that, in 2008, MCCC processed 99 separate donations, 
yielding a total of $69,563.48 (Michigan Department of State, 2008b). The MPP made 
12 separate donations, totalling $67,475.84 for 2008, and a cumulated total of 
$1,240,460.07 worth of donations for the election cycle. In 2008, MCCC spent a total of 
$36,159.35; a large proportion of which was spent on political consultations and legal 
fees. Examples of other expenses included printing, signature verification, federal taxes, 
state taxes, and classified advertisements in the Flint Journal and the Kalamazoo 
Gazette. Total MCCC expenditures for the election cycle cumulated to $1,105,927.04.   
According to the Michigan State documents, CPMK was officially formed on 
September 23, 2008 (Michigan Department of State, 2008c). From October 21, 2008 to 
November 24, 2008, the CPMK received $184,030.71 worth of donations and a 
cumulative total of $309,520.71 for the election period. Major donators to CPMK 
included the presidents of Alticor and R.D.V. Sports; Richard M. DeVos, a 
businessman; Save Our Society from Drugs; Robert Thompson, a retiree; the Dow 
Chemical Corporation; and DTE Political Action committee. On October 7, 2008, 
Michigan Health and Hospital Association donated $100,000. Total expenditures from 
October 21, 2008 to November 24, 2008 were $215,288.69, with a cumulative total of 
$276,632.11 for the election period. In total, CPMK spent $198,596.58 for media and 
television advertising and approximately $5,265 on consulting services (Michigan 
Department of State, 2008c).  
Post-Proposal 1. After the law was passed, the Bureau of Health Professionals, 
under the MDCH, had 120 days to draft and finalise rules for the medical cannabis 
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program (Kinstle, 2008). The registry program was to be completed by April 14, 2009. 
However, questions were raised regarding the new law’s so called vague language and 
how cannabis was to be obtained by patients (Merion, 2008). Dianne Byrum attempted 
to dispute the concerns regarding the law and stated it was well structured, well written 
and very limited (Merion, 2008).  
In January of 2009, the first draft of rules for the medical cannabis program, 
created by the MDCH, resulted in protests from patients and medical cannabis 
advocates (McNamara, 2009). They argued that the MDCH was, in some instances, 
contradicting the law passed by voters by seeking to restrict access to medical cannabis. 
Karen O’Keefe, a lawyer for the MPP, said the MDCH was overstepping its boundaries 
and took the draft rules further than it was assigned to do. According to O’Keefe, the 
department was only given the duty of setting up a patient registry and overseeing the 
list of diseases that would allow patients to register for the medical cannabis program 
(McNamara, 2009).  
The Michigan medical cannabis law received criticism from Judge Robert 
Turner who said it was the worst legislation he had seen, after he dismissed felony 
charges against a couple who were charged with intent to manufacture cannabis 
("People v. Redden," 2010). The couple had their physician’s letter of recommendation 
but did not possess the MDCH issued ID cards, which were due to be issued five days 
after the couple’s arrest. Their lawyers argued that physician recommendation was 
sufficient grounds for cannabis use while the prosecution contended that defendants 
were required to abstain from cannabis use until they were able to obtain an 
identification card and that they did not have a bona fide physician-patient relationship 
with their doctor. Defendants argued that the plain language of the medical cannabis act 
did not require possession of a card ("People v. Redden," 2010). Judge Turner said the 
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medical cannabis law was ambiguous, as it did not specify the exact amount of cannabis 
a registered patient was allowed to possess, leaving judges to determine what a 
reasonable amount was. In 2010, the Michigan Court of Appeals affirmed the circuit 
court’s decision to reinstate the charges against the defendants, but Judge Peter D. 
O’Connell also wrote:  
No system of regulation can succeed without a clear set of rules. Those wishing 
to use marijuana need to know when, how, and under what conditions they can 
legally do so. Providers need to know under what conditions they can legally 
grow, harvest, and distribute their product, and the operators of the new medical-
marijuana clinics that appear to be springing up on every corner need to know if 
they are in fact set up to dispense marijuana to the public legally (para.223).  
The confusion regarding the law resulted in local governments passing their own 
ordinances, to accommodate or restrict medical cannabis dispensaries (Bukowski, 2010; 
Householder & Martin, 2010; Steber, 2013). However, this resulted in inconsistencies in 
local laws, some of which also conflicted with the interpretations of the medical 
cannabis act (Steber, 2013). Steber (2013) suggested that political preferences of the 
municipalities also played a role in influencing local laws regarding medical cannabis, 
as it appears that the more liberal cities were permitting medical cannabis dispensaries 
and were more likely to facilitate patients’ access to medical cannabis.  
During the 2011-2012 legislative session, the Michigan legislature passed six 
bills amending the state’s medical cannabis act (MPP, 2014). House Bill 4856 (2012) 
was passed to amend the medical cannabis act for medical cannabis patients and 
caregivers to keep cannabis in a case in the trunk of their vehicle or enclosed in a case 
that is not readily accessible if the vehicle does not have a trunk, when transporting 
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cannabis. House Bill 4834 (2011) provided that patients and caregivers will need to 
renew their registry cards every two years. House Bill 4851 (2011) requires doctors who 
recommend cannabis to patients to first establish a “bona fide physician-patient 
relationship” by the doctor reviewing the patient’s medical records and completing a 
full assessment of the patient’s medical history, creating and maintaining records of the 
patient’s condition, having an expectation that they will provide follow-up care, and 
notifying the patient’s primary care physician of the patient’s condition and use of 
medical cannabis. The bill also changes the definition of “enclosed, locked facility” 
where patients can grow cannabis to say that it must be “stationary” and “fully 
enclosed”. The bill also permits outdoor cultivation as long as the plants are not visible 
from adjacent property and are grown in a stationary and enclosed structure. The other 
House Bill 4853 (2011) applied the state’s criminal sentencing guidelines to the crime 
prohibited by the original act. The two senate bills passed during the 2011-2012 
legislative session specified that medical cannabis or related expenses are not required 
to be covered by insurance companies and that employers are not required to reimburse 
their employees for medical cannabis treatment (MPP, 2014). There are currently 30 
pending bills related to medical cannabis in the state’s legislature (MPP, 2014).  
New Mexico 
New Mexico’s attempts to legalise medical cannabis were successful in 2007, 
when, on March 13, Gov. Bill Richardson, a Democrat, became the first governor in 
history to enact a medical cannabis law while running for the presidency (Lynn and Erin 
Compassionate Use Act, 2007; MPP, 2013). He signed SB 523, known as the “Lynn 
and Erin Compassionate Use Act”, into law, making New Mexico the 12th state to allow 
medical cannabis use for qualifying patients. The House of Representatives approved 
the bill by a 36-31 vote, while the Senate approved it 32-3. The bill took effect on July 
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1, 2007. The New Mexico Department of Health (NMDH) finalised the rules for the 
medical cannabis program in January 2009. The New Mexico legislature also passed a 
non-binding resolution which urged the federal government to allow doctors to 
prescribe cannabis to patients. The resolution did not change the state policy, but was 
significant because it officially stated the legislature’s position on the issue (MPP, 
2013). 
Not all of the currently included debilitating medical conditions were included in 
the original bill. Following amendments in January and April of 2009, the following 
conditions were specified as enabling patients to qualify for the New Mexico medical 
cannabis program: severe chronic pain; painful peripheral neuropathy, intractable 
nausea/vomiting; severe anorexia/cachexia; hepatitis C infection currently receiving 
antiviral treatment; Crohn’s disease; Post-traumatic Stress Disorder; Amyotrophic 
Lateral Sclerosis (Lou Gehrig’s disease); cancer; glaucoma; multiple sclerosis; damage 
to the nervous tissue of the spinal cord with intractable spasticity; epilepsy; HIV/AIDS;  
inflammatory autoimmune-mediated arthritis; hospice patients; and any other condition 
subject to approval by the NMDH (Lynn and Erin Compassionate Use Act, 2007; MPP, 
2013). In order to qualify, patients have to be residents of New Mexico, and be 
diagnosed by a medical practitioner as having one or more of the specified debilitating 
medical conditions, including a statement from their practitioner that, in their opinion, 
the potential health benefits of using medical cannabis would outweigh the health risks 
for the patient. The length of New Mexico residency before a patient can apply for 
participation in the program is not specified. The practitioners are exempt from arrest or 
prosecution for recommending medical cannabis to a patient with specified medical 
conditions (Lynn and Erin Compassionate Use Act, 2007). 
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The NMDH is responsible for issuing identification cards to eligible patients and 
caregivers (Lynn and Erin Compassionate Use Act, 2007). Patients may legally possess 
six ounces of usable medical cannabis, four mature plants and 12 seedlings. However, if 
they have their physician’s approval, patients can apply to the Medical Advisory Board 
to possess more than 6 ounces of useable cannabis. State regulations also authorised 
non-profit facilities to apply to produce and dispense medical cannabis, with state 
licensed producers permitted to grow up to 95 mature plants at one time (Lynn and Erin 
Compassionate Use Act, 2007; New Mexico Register, 2008). At the state level, patients 
are also able to use a medical necessity defence, should they be prosecuted for an 
offence involving cannabis, as long as they are in possession of no more than the 
necessary amount of cannabis needed to relieve their pain and ensure an uninterrupted 
supply of the drug. The defence is not limited to registered patients only, and while it 
does not protect a patient from arrest, it requires the charges to be dropped if the 
specified conditions are met (Lynn and Erin Compassionate Use Act, 2007). 
New Mexico’s law was the first in the country to specifically instruct the state to 
develop and implement a cannabis production and distribution system, in order to assist 
patients in obtaining the drug (Lynn and Erin Compassionate Use Act, 2007; MPP, 
2013). This meant that patients could register to grow their own cannabis, or non-profit 
businesses wanting to produce and distribute the drug could apply for their licence 
through the NMDH. A Medical Advisory Committee consisting of eight medical 
professionals was also created, to assist the NMDH with program development and give 
advice on rules governing the Medical Cannabis Program (“Local Doctors”, 2007; New 
Mexico Department of Health [NMDH], 2007b). The committee is required to meet at 
least twice a year to hold public hearings and evaluate patients’ petitions to add 
conditions to the list of qualifying medical conditions.  
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In the following section, Figure 3 will chronologically outline the history of 
medical cannabis in New Mexico, followed by a chronological description of the 
process that took place before the Lynn and Erin Compassionate Use Act was passed.  
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1978 
•New Mexico becomes the first U.S. state allowing therapeutic cannabis research program 
•As a result of the act, the Controlled Substances Act was amended to allow cannabis 
possession to qualifying patients participating in the program 
1983 
•By 1983, 180 patients had participated in the program 
•A report by the Behavioral Health Services Division found that 75% of the patients showed 
a positive response to the treatment they received as part of the program 
1986 
•Program ends in 1986 after the Legislature decided not to renew its annual funding of the 
program  
•Medical cannabis remained legal for therapeutic research purposes in New Mexico 
1996 
•New Mexicans for Compassionate Use is created  
1997 
•Bryan Krumm, founder of New Mexicans for Compassionate Use , spoke in front of New 
Mexico Board of Pharmacy to gain support to reschedule cannabis  
1999 
•1999 Gov. Johnson  suggests that the federal government should consider 
decriminalisation of drugs  
•U.S. drug czar Barry McCaffrey visited New Mexico in order to counter Gov. Johnson’s 
statements on drug legalisation  
•Activists announce potential lawsuit to reinstate the 1978 therapeutic program 
•Alex Valdez, Secretary of the New Mexico Department of Health told medical cannabis 
activists he would move to reinstate the medical cannabis law 
•Alex Valdez, acting on Gov. Johnson's instructions, drafts a measure aimed at reviving 
the the medical cannabis law 
2000 
•Gov. Johnson successfully uses his power of line-item veto to remove a provision banning 
the use of budget money on promotion of drug legalisation and decriminalisation  
•Gov. Johnson said that cannabis should be legalised 
•Alex Valdez suggests replacing the old medical cannabis law with one modelled on 
Hawaii's medical cannabis program  
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2001 
•The Drug Policy Advisory Group, created by Gov. Johnson, recommends the reform of 
the Lynn Pierson Act to allow for patient access to medical cannabis  
•The group recommends New Mexico's medical cannabis law should be modelled on 
Oregon and Hawaii's program  
•Reports that the advisory group was created by Gov. Johnson using private money 
•Reports that Gov. Johnson plans to propose eight drug-reform bills to the state 
Legislature, including decriminalisation of possession of small cannabis amounts, and 
legalising cannabis use for medical purposes  
•Opposition vocal in the media, saying Gov. Johnson is sending a bad message to people 
•NORML begins airing radio advertisements supporting drug law changes  
•Two medical cannabis bills introduced,  one in the House of representatives and one in 
the Senate 
•Opposition lobbying lawmakers to reject some of Gov. Johnson's drug reform bills 
•Poll finds that 61% of participants support medical cannabis  
2002 
•Following Supreme Court ruling, Gov. Johnson waters down a medical cannabis bill from 
previous versions  
•New medical cannabis bill introduced in the Senate by Sen. Maes  
•The bill's proposition that patients should grow and dispense cannabis draws criticism  
•NMDH spokesperson supports cannabis as a medicine 
2003 
•Compassionate Use Medical Cannabis bill introduced again and defeated in the House of 
Representatives  
•Gov. Johnson replaced by Gov. Richardson  
2005 
•Sen. McSorley announces that he would sponsor a medical cannabis bill 
•Media reports that the pharmaceutical industry contributed more than $97,000 to New 
Mexico political campaigns 
•Legislative support for medical cannabis decreased since Gov. Johnson was replaced by 
Gov. Richardson   
•Senate passes three medical cannabis bills  
•Gov. Richardson says that if the House passes a medical cannabis bill he would sign it 
2006 
•Gov. Richardson announces he would include a medical cannabis bill on his agenda 
•House Speaker asks the governor not to include the bill on his agenda as there is not 
enough time for it to be heard 
•Another medical cannabis bill introduced in Senate by Sen. McSorley; legislative session 
ended before the bill could get a house floor vote 
•Patients speak in support of the medical cannabis bill  
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Figure 3. Time chart of medical cannabis history in New Mexico.  
2007 Lynn and Erin Compassionate Use Act: Chronological account. In 
1978, New Mexico was the first U.S. state to pass a law allowing a therapeutic cannabis 
research program, which involved receiving cannabis supplies from the federal 
government (Behavioral Health Services Division [BHSD], 1983). The act was passed 
by the Legislature, and was renamed in 1979 the Lynn Pierson Therapeutic Research 
Program (LPTRP), in honour of Lynn Pierson, a cancer patient, who lobbied for 
medical cannabis in New Mexico. It was administered by the then Health and 
Environment Department, run through the University of New Mexico, and sought to 
2007 
•Lynn and Erin Compassionate Use Act introduced in the Senate by Sen. Ortiz y Pino  
•Opponents say the bill runs contrary to federal law  
•Erin Armstrong, a cancer patients, speaks in support of the bill  
•Lynn and Erin Compassionate Use Act defeated and replaced by the Compassionate Use 
Medical Marijuana Act  
•Gov. Richardson says that signing the bill would be the right thing to do  
•Gov. Richardson signs SB 523 known as the "Lynn and Erin Compassionate Use Act" into 
law on April 2, 2007 
•Allegations that Gov. Richardson used medical cannabis issue to gain support for his 
presidential campaign  
•Gov. Richardson received monetary contributions from medical cannabis activists 
•NMDH starts accepting applications from medical cannabis patients on July 1, 2007 
•Eight medical professionals appointed to a Medical Advisory Committee 
•Gov. Richardson sends a letter to President Bush asking him to end the priority placed on 
arresting and prosecuting state workers involved in the medical cannabis program 
 
2008 
•Reports that there are approximately 200 medical cannabis users in the state 
•NMDH Medical Advisory Board holds a public hearing to discuss adding new debilitating 
medical conditions to the program's list 
2009 
•NMDH finalises regulations for the registry identification cards and a production/distribution 
system  
2011 
•By October 2011 there were 5, 495 enrolments in the state's medical cannabis program 
•The state's medical cannabis program used as a model for other states  
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provide cannabis and delta-9-THC to cancer chemotherapy patients suffering from 
nausea and vomiting caused by their therapy (BHSD, 1983). As a result of the act, the 
Controlled Substances Act was amended to allow cannabis possession to qualifying 
patients participating in the LPTRP. However, due to federal law superseding state law, 
starting the LPTRP required approval from the FDA, the DEA, and the NIDA. After 
these agencies approved the program, the first shipment of the required drugs arrived 
and the program began in January 1979 (BHSD, 1983).  
By 1983, 180 patients had participated in the program, and another 51 applied 
but did not enter it (BHSD, 1983). Half of the patients were administered cannabis, 
which was inhaled; the other half received delta-9-THC, which was ingested in capsule 
form. A report by the Behavioral Health Services Division found that 75 percent of the 
patients showed a positive response to the treatment they received as part of the 
program, with inhalation found to be superior to ingestion. The report noted that the 
LPTRP implementation was successful, with no recorded misuse or abuse of the drug, 
and no problems with approving patients for participation (BHSD, 1983). 
Despite its reported success in treating patients, the LPTRP ended in 1986 after 
the Legislature decided not to renew its annual funding of the program (Jadrnak, 1999; 
T. Smith, 1997). Even though the program became defunct, medical cannabis remained 
legal for therapeutic research purposes in New Mexico, although this was largely 
symbolic and no therapeutic research program has been run since 1986. Since it ended, 
medical cannabis advocates have attempted to revive the LPTRP, first through the 
Board of Pharmacy, and then, as of 2001, in the State Legislature (Baker, 2006).  
After the LPTRP became defunct in 1986, no significant efforts to revive it were 
noted until, in 1997, Bryan Krumm, founder of New Mexicans for Compassionate Use, 
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was set to address the New Mexico Board of Pharmacy at their monthly public meeting 
seeking assistance to re-assign cannabis to Schedule II (T. Smith, 1997). New Mexicans 
for Compassionate Use was created in 1996, with the aim of make changes to cannabis’ 
status at the state level, making it more accessible to people who need it. Krumm said 
that he was hoping to get Gov. Gary Johnson (R) to introduce law changes at the next 
legislative session, in order to reclassify cannabis. However, Richard W. Thompson, the 
board’s executive director, said that there was little chance medical cannabis would 
become legal in New Mexico in the near future (T. Smith, 1997). Thompson said that 
legalising cannabis was unnecessary as Marinol was already available although Krumm 
said that he did not think Marinol worked as well as cannabis. Krumm also suggested 
that it was the pharmaceutical companies who stood in the way of legalising medical 
use of cannabis, for fear of profit loss. Jerry Montoya, chief drug inspector for the Board 
of Pharmacy, disagreed with this statement and claimed that pharmaceutical companies 
make most of their money on anti-depressants (T. Smith, 1997).  
In 1999 Gov. Johnson admitted to using cannabis and cocaine while in college, 
and suggested the Federal Government should consider decriminalisation of drugs 
(Janofsky, 1999). He said that the campaign against drugs had left courts and prisons 
overwhelmed. Gov. Johnson’s statements were considered controversial and drew 
criticism from both sides, including the ONDCP. In October of 1999, U.S. drug Czar 
Barry McCaffrey visited New Mexico in order to counter Gov. Johnson’s statements on 
drug legalisation and Gov. Johnson said that he did not expect much support from law 
enforcement organisations (“Drug Debate Fizzled”, 1999; Janofsky, 1999). While his 
views got him national attention, it was suggested in the media that Gov. Johnson’s past 
office record countered his drug legalisation views, as he had previously consistently 
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vetoed such programs when they were presented to him by the legislature (“Drug 
Debate Fizzled”, 1999).  
The same year, Bryan Krumm and Ed McWilliams were announced in the media 
as potential plaintiffs in a class-action lawsuit, requesting that the 1978 medical 
cannabis program be reinstated (Jadrnak, 1999). In October of 1999, Alex Valdez, 
secretary of the NMDH, told the medical cannabis activists he would move to reinstate 
the program, and they delayed filing the lawsuit. He said that the program was not his 
priority for the fiscal year budget, but he was informed by the DEA about what federal 
requirements he must fulfil to reinstate the program. According to Jadrnak (1999), 
Valdez stated he wanted to make it clear that his interest in the medical cannabis 
program was not related to Gov. Johnson’s discussion on cannabis legalisation, as he 
did not want people to think medical cannabis was the first step to general legalisation 
of the drug.  
In November of the same year, Alex Valdez, acting on Gov. Johnson’s 
instructions, drafted a measure aimed at reviving the 1978 medical cannabis law 
(“Legislature to Study”, 1999). Allegedly, Valdez started studying the law after threats 
of a class-action lawsuit. Earlier in the month, Valdez was sued by attorney Charlie 
Knoblauch on behalf of Tony Cognetto, for not providing his sick client with cannabis. 
Bryan Krumm and Ed McWilliams also threatened to sue. It was alleged that it was the 
governor who pushed Valdez towards reviving the medical cannabis program, after he 
said it was not going to be his priority (“Legislature to Study”, 1999).  
The following year, Gov. Johnson successfully used his power of line-item veto 
(deleting a particular provision of a bill enacted by legislature) to remove a provision 
banning the use of budget money on promotion of drug legalisation and 
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decriminalisation (Fecteau, 2000a; Watts, 2010).  He said that removing criminal 
penalties from drugs such as cannabis and heroin would reduce drug use because it 
would allow for the substance to be controlled, regulated and taxed. The governor also 
pledged to continue to push for a public debate on drug-related issues until the end of 
his time as a governor, despite the fact he was aware his popularity would decline as a 
result (“60 Minutes to Air”, 2000; Fecteau, 2000a). He was also to discuss drug reform 
and legalisation of some drugs on CBS’s “60 Minutes” program (“60 Minutes to Air”, 
2000).  
Following the airing of the “60 Minutes” program with Gov. Johnson, in which 
he advocated legalisation of both cannabis and heroin, the governor said that he thought 
cannabis should be legalised, and that he intended to support general cannabis 
legalisation even after he left office (Fecteau, 2000b). The governor said his opinion had 
changed since he filmed the “60 Minutes” program in December of 1999 and said that 
talking about heroin scared people, which led him to decide to separate the two drugs 
and only focus on cannabis legalisation (Fecteau, 2000b). Alex Valdez also spoke in 
support of medical cannabis and suggested the state replace its old medical cannabis law 
with one modelled on Hawaii’s medical cannabis program (Fecteau, 2000c). 
In 2001, the Drug Policy Advisory Group, created by Gov. Johnson, 
recommended the reform of the Lynn Pierson Act to allow for patient access to medical 
cannabis for people with serious medical conditions for which it has been shown to 
decrease pain and suffering (New Mexico Governor's Drug Policy Advisory Group, 
2001). The report stated that since the act was enacted in 1979 the medical 
appropriateness of cannabis has been established for a variety of medical conditions and 
that many states have enacted medical cannabis laws. The group recommended that 
New Mexico’s program be modelled on Oregon and Hawaii’s programs. The group also 
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recommended amendment of existing criminal statutes to remove the criminal penalty 
for personal possession of cannabis and to allow for civil penalties, rather than criminal 
penalties, for use of cannabis in public places (New Mexico Governor's Drug Policy 
Advisory Group, 2001). According to a newspaper article, the advisory group was 
created by Gov. Johnson using private money (Mahesh, 2001a).  
In January of 2001 it was reported that, after recommendations from the Drug 
Policy Advisory Group, Gov. Johnson planned to propose eight drug-reform bills to the 
state Legislature, including decriminalisation of possession of small cannabis amounts, 
and legalising cannabis use for medical purposes (McClannahan, 2001). State Rep. Ron 
Godbey (R) spoke in opposition and said that he thought Gov. Johnson would send a 
bad message to people and that he was appalled at what the governor was trying to do. 
Rep. Godbrey said he was especially concerned with the push to legalise cannabis for 
medical purposes, as other medicines that could be used in its place were already 
available. He also expressed his belief that the push for medical cannabis legalisation 
did not come from the medical community, but from the “druggies” (McClannahan, 
2001). Rep. Ted Hobbs (R) also opposed medical cannabis and said that it was a step 
towards general legalisation. Matt Sandoval, president of the New Mexico District 
Attorneys Association, said that the proposal amounted to legalisation and would lead to 
higher drug use (Mahesh, 2001a).  
Senator (Sen.) Cisco McSorley (D) and Rep. Joseph Thompson (R) agreed to 
sponsor two cannabis-related bills proposed by Gov. Johnson (Mahesh, 2001b). Sen. 
McSorley, together with Sen. Roman Maes (D), were to introduce Senate Bill 315, a 
medical cannabis bill allowing cannabis use for people with specific medical conditions, 
while Rep. Thompson was to introduce House Bill 431 in the House of Representatives 
(H.R. 431, 2001; Mahesh, 2001b; S.B. 315, 2001). Thompson said he did not find a 
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House co-sponsor for his medical cannabis bill, but that, at that point, a lot of 
representatives indicated they would vote for it. McSorley also agreed to sponsor a bill 
which aimed to decriminalise possession of up to an ounce of cannabis for personal use 
(Mahesh, 2001c). Around the same time, the NORML began airing radio 
advertisements in support of the drug law changes (NORML, 2014b). The two week 
campaign of radio spots was intended to help build support for Gov. Johnson’s call to 
legalise cannabis and ran approximately 150 times on two Albuquerque stations and one 
Santa Fe station (NORML, 2014b).  
Two medical cannabis bills, part of Gov. Johnson’s drug-reform package, were 
approved by Senate Committees in February of 2001, despite some law enforcement 
groups voicing their disapproval (Terrell, 2001). Senate Bill 315 (2001) then cleared the 
Senate on a 29-12 vote, and was due to be considered by the House. In March, House 
Bill 431 (2001), sponsored by Rep. Joe Thompson, cleared the house by a 35-32 vote. 
While the bill proposed to make cannabis available to those suffering from cancer, 
HIV/AIDs, glaucoma, neuro-muscular conditions, and other severely debilitating 
illnesses, it also included a sunset provision, which meant that, if passed, it would 
expire on July 1, 2005, when the legislature would have had the option of extending it 
(Mahesh, 2001d).  
Thirteenth Judicial District Attorney, Lemuel Martinez, said members of the 
New Mexico District Attorneys Association were lobbying lawmakers and testifying 
before the Legislature to reject some of Gov. Johnson’s drug reform bills (Pawloski, 
2001). Reasons Martinez gave for opposing Gov. Johnson’s proposals included sending 
a negative message to children, an increase in cannabis-impaired drivers on the streets, 
and disadvantaging those trying to complete drug rehabilitation programs by 
“undermining incarceration” (i.e. removing the threat of incarceration which the drug 
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courts often use as a threat to those wo do not comply with the “rehabilitation” 
program). Katherine Huffman, director of the New Mexico Drug Policy Project of the 
Lindesmith Center (now the Drug Policy Alliance), disagreed with Martinez’s claims, 
and said the bill would not legalise cannabis for everyone (Pawloski, 2001).  
In March 2001, a study was commissioned by the Lindesmith Center, and was 
conducted by Research and Polling, Inc. (Research and Polling, 2001). As part of the 
study, 504 registered voters in New Mexico were randomly selected and interviewed 
over the telephone about their attitudes and opinions on issues relating to drug use and 
drug laws in New Mexico. The study found that 61 percent of participants strongly 
supported making cannabis available to seriously ill or terminal patients, while 17 
percent somewhat supported the idea (Research and Polling, 2001). 
Meanwhile, Gov. Johnson continued to promote his proposals, and spoke at the 
annual NORML convention, where he vowed to keep fighting for drug law reform in 
New Mexico (Coleman, 2001). He also spoke at the Lindesmith Center’s international 
conference at Albuquerque about cannabis legalisation (Jojola, 2001). Governor 
Johnson said cannabis legalisation was needed, as well as a move from a criminal model 
to a medical model approach to drug-related issues. Ethan Nadelmann, the Lindesmith 
Center’s executive director, praised the governor and his commitment to the drug 
reform issue (Jojola, 2001). 
When three out of his eight drug-reform bills died during 2001, Gov. Johnson 
said he would not give up and would introduce more drug-reform legislation in 2002 (B. 
Smith, 2001). His views continued to cause controversy and raised questions over why 
Gov. Johnson did not make his position on drug use clear until his second term as a 
governor (Zeleny, 2001). However, when Gov. Johnson made his position on drug use 
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clear his approval rating dropped by 11 points and three members of his 
administration’s anti-drug task force resigned. There was also a political aspect to the 
debate and a newspaper article quoted a professor of political science at the University 
of New Mexico who said the Democrats used the controversy Gov. Johnson’s views 
created to paint the Republicans as being pro-vice and pro-sin (Zeleny, 2001). In 
October of 2001, Gov. Johnson spoke at a forum along with former Gov. Toney Anaya 
(D), who was paid by the Lindesmith Center to lobby for Gov. Johnson’s drug reform 
package before the legislature (B. Smith, 2001). According to Anaya, some Democrats 
in the Legislature did not support Gov. Johnson’s bills because they were proposed by a 
Republican governor (B. Smith, 2001).  
After the 2001 medical cannabis bills failed to clear both houses, and following 
the Supreme Court decision which ruled that patients can still be arrested under federal 
law even if their state allows the use of medical cannabis, Gov. Johnson watered down a 
medical cannabis bill from previous versions (B. Smith, 2002). The 2001 bill proposed 
that the NMDH should grow and distribute cannabis for qualifying patients 
(Compassionate Use Medical Cannabis Act, 2002) . This provision was removed in the 
2002 bill, and introduced in the Senate by Sen. Roman Maes (D) as the Compassionate 
Use Medical Cannabis Act (2002). Lawmakers on the Senate committee considered the 
bill, but disagreed about who should grow and dispense cannabis. The bill’s proposition 
that patients should grow their own cannabis drew criticism from lawmakers who feared 
some patients may abuse this (Mahesh, 2002). Some senators, such as Sen. Mary Jane 
Garcia (D), said they would prefer physicians to prescribe cannabis to patients, instead 
of patients growing their own. The committee members therefore voted 6-2 to amend 
the bill to remove the provision allowing patients to grow cannabis, while Sen. Rod 
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Adair (R) recommended having a state agency or a university grow and distribute the 
drug (Mahesh, 2002).  
After the bill was introduced, Steve Jenison, from the NMDH, suggested 
cannabis could effectively be used as a medicine in certain cases, in place of other 
medications that people do not find beneficial (Jenison, 2002). Jenison stated that he 
supported cannabis use for certain debilitating medical conditions, and therefore 
supported the Compassionate Use Medical Cannabis bill which was introduced by Sen. 
Roman Maes (D). He also responded to claims that medical cannabis is unnecessary as 
Marinol was already available by saying that Marinol did not help some individuals, 
while smoking small amounts of cannabis did. Jenison encouraged people to support the 
bill and said a distinction had to be made between cannabis as a medicine and as a 
recreational drug (Jenison, 2002). The bill was not successful and was introduced again 
in 2003 and defeated in the House of Representatives by a 46-20 vote (“Medical 
Marijuana Bill Fails in New Mexico”, 2003). District attorneys and law enforcement 
groups opposed the medical cannabis proposal and Lemuel Martinez, president of the 
New Mexico District Attorneys Association, said he expected the group to continue 
opposing medical cannabis use (Massey, 2005).  
In 2005, Sen. Cisco McSorley (D) sponsored the Lynn Pierson Compassionate 
Use Act (2005), which included a provision whereby the NMDH would oversee a 
program providing cannabis to qualifying patients. Senator McSorley said that no 
lawmaker ever lost their seat because of the medical cannabis issue, and they should 
therefore not fear to vote for it (Massey, 2005). In March 2005, the Senate passed Sen. 
McSorley’s bill and two other medical cannabis bills, each of them establishing a 
program run by the state NDMH (Compassionate Use Medical Marijuana Act, 2005; 
Lynn Pierson Compassionate Use Act, 2005; Medical Therapeutic Use of Cannabis Act, 
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2005). Senator Steve Komadina (R) sponsored the Medical Therapeutic Use of 
Cannabis Act (2005) which required cannabis to be of pharmaceutical grade in order to 
obtain a consistent and regulated dosage. However, smoking of the drug was to be ruled 
out. The Compassionate Use Medical Marijuana Act (2005) was sponsored by Sen. 
Shannon Robinson (D) and sought to allow people with specific medical conditions to 
use cannabis topically, such as in patches and creams. Senator Robinson and Sen. 
Komadina’s bills did not contain a medical necessity provision and did not provide for 
patients to grow their own cannabis (Compassionate Use Medical Marijuana Act, 2005; 
Medical Therapeutic Use of Cannabis Act, 2005). The opposition raised questions over 
the sort of message that would be sent out to children if any of the bills were passed 
(Baker, 2005).  
Governor Richardson, who succeeded Gov. Johnson in 2003, said that if the 
House passed a medical cannabis bill, he would sign it. While the pharmaceutical 
industry had not been visible active in opposing medical cannabis legislation, the New 
Mexican newspaper reported that in 2002 the pharmaceutical industry contributed more 
than $97,000 to New Mexico political campaigns, including $40,000 to new Governor 
Bill Richardson (Terrell, 2005a). The more visible opposition came from law 
enforcement, with Mike Bowen, a lobbyist for police organisations, saying his 
organisation would most likely oppose the 2005 medical cannabis bills, mainly because 
they were against federal law, and there were not enough controls in them (Terrell, 
2005a). It was also noted that the legislative support for medical cannabis appeared to 
have decreased since Gov. Johnson was no longer the governor (Terrell, 2005a).  
All three medical cannabis bills passed through the Senate with bipartisan 
approval, and were sent to the House of Representatives (Terrell, 2005b). Sen. 
McSorley’s (D) bill passed on a 27-11 vote; Sen. Komadina’s (R) bill passed on a 29-11 
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vote; and Sen. Robinson’s (D) bill was passed on a 31-9 vote (Terrell, 2005b). Two 
patients with debilitating medical conditions, Essie Debonet and Erin Armstrong were 
constantly present at the House session in order to hear the medical cannabis bills being 
discussed (Andersen, 2005). Erin Armstrong, a cancer survivor and the daughter of state 
Aging and Long-Term Services secretary, Debbie Armstrong, also spoke in support of 
medical cannabis, and described her struggle with cancer and the cost of her treatments 
(Massey, 2005; Terrell, 2005a). 
The bill introduced by Sen. McSorley, the chairman of the Judicial Committee, 
was due to be heard, but was stalled due to a dispute involving an unrelated bill. It was 
alleged that Rep. Dan Silva (D) experienced difficulties getting his bill heard in the 
Senate Judiciary Committee, and therefore tried to delay the medical cannabis bill 
(Terrell, 2005c). McSorley said Silva believed his bill was more important than others, 
and said he would not give special consideration to legislation in order to have his own 
bill passed. Representative Henry Saavedra (D) carried the bill for McSorley in the 
House, but was also a co-sponsor of Silva’s bill (Terrell, 2005c). 
This resulted in some controversy, and the bill did not end up passing the House 
(Polly, 2005). It was sitting for days on the House calendar, until its supporters 
attempted to pass it in the last minutes of the House session (Terrell, 2005d). The bill 
was stopped by House Speaker Ben Lujan (D), who said the bill was too controversial, 
would need a three-hour debate, and there was not enough time to discuss it before the 
session’s end (Polly, 2005; Terrell, 2005d). It was also alleged that Rep. Henry 
Saavedra, who carried the bill in the House, asked for it to be passed over (Terrell, 
2005d). Reena Szczepanski, director of New Mexico’s DPA, said it was not due to lack 
of votes that the bill did not pass, but because it was trapped in the middle of a game. 
Szczepanski had been lobbying for the bill during the legislative session and said that 
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the legislators were sending a bad message to sick individuals by holding up the bill and 
not passing it, and held Rep. Silva responsible for the hold-up (Polly, 2005).  
The following year, a new medical cannabis bill was due to be introduced and, 
according to Reena Szczepanski, Gov. Richardson received hundreds of letters from 
medical cannabis supporters, which the DPA believed made him consider the 
importance of the issue (Terrell, 2006a). Governor Richardson also announced that he 
would include a medical cannabis bill on his agenda for the 2006 legislative session 
(Terrell, 2006a). The governor said that he decided to put the bill on the agenda after 
speaking with many sick New Mexican patients. However, before the session started, 
House Speaker Rep. Ben Lujan (D) said he asked the governor not to include the bill on 
his agenda, as there was not enough time for it to be heard (Terrell, 2006a). 
Democratic Sen. Cisco McSorley, who sponsored a failed medical cannabis bill 
in 2005, was sponsoring it again in 2006, making it the fifth time the legislature was 
considering a medical cannabis bill in six years (Tiffin, 2006). Cancer, glaucoma, 
multiple sclerosis, spinal cord injuries, epilepsy and HIV were included in the bill as 
debilitating conditions for which qualifying patients may use cannabis (Lynn Pierson 
Compassionate Use Act, 2006). The bill also included a provision for licensed growers 
certified by the state, who would provide patients with the required cannabis (Lynn 
Pierson Compassionate Use Act, 2006). The bill was unanimously passed by the Senate 
Public Affairs Committee who heard from patients with debilitating medical conditions 
in support of medical cannabis (Baker, 2006; Rubel, 2006; Terrell, 2006b). Erin 
Armstrong was also at the hearing and asked the committee to recommend the bill. The 
opponents who testified at the hearing were from law-enforcement. Law enforcement 
groups voiced their disapproval of the bill, saying it clashed with the federal law and, 
 Medical Cannabis in the United States     170 
 
according to some, passing of the bill would have led to an increase in criminal activity 
in the state (Tiffin, 2006).  
After the bill passed the Senate on a 34-6 vote, it was sent to the House 
Agriculture and Water Resources Committee, which had never heard such a bill before, 
and was known to be generally disapproving of medical cannabis (Drug Policy Alliance 
[DPA], 2007; “New Mexico Medical Marijuana”, 2006). It was alleged by Rep. Joseph 
Cervantes (D) that the bill was sent to that specific committee in order to be killed. 
According to the media, one of the testimonials that the members of the committee were 
reportedly swayed by was that of Errol Chavez, director of the New Mexico High 
Intensity Drug Trafficking Area, who opposed the bill and testified that cannabis use 
and growth increased in California after its medical cannabis law was passed (“New 
Mexico Medical Marijuana”, 2006). After the bill was rejected on a 4-3 vote, the 
supporters successfully prompted the House Speaker Lujan (D) to pull it out of the 
Agriculture Committee and into the House Judiciary Committee, which subsequently 
passed it (DPA, 2007). However, the legislative session ended before the bill could get a 
house floor vote (DPA, 2007). 
After many failed attempts at passing a medical cannabis bill, attempts were 
made again in 2007, the first of which was the Lynn and Erin Compassionate Use Act 
(2007a), introduced by Sen. Gerald P. Ortiz y Pino (D). The bill sought to enact and 
amend provisions of the Controlled Substances Act, in order to allow medical cannabis 
use for alleviating symptoms caused by certain debilitating medical conditions. 
Debilitating medical conditions included were cancer; glaucoma; multiple sclerosis; 
damage to the nervous tissue of the spinal cord with intractable spasticity; epilepsy; 
positive HIV/AIDS status; and any other medical condition as approved by the NMDH. 
It also provided for cannabis producers, licensed by the NMDH to produce, possess, 
 Medical Cannabis in the United States     171 
 
distribute and dispense cannabis to qualifying patients (Lynn and Erin Compassionate 
Use Act, 2007a).  
The bill was approved by the Senate, and then sat on the House calendar for six 
days before it was heard (Nash, 2007). Opponents said the bill ran contrary to federal 
law, with several Republican representatives proposing amendments to it. At first, the 
vote on the bill resulted in a tie (Alba, 2007a). However, as three members were absent 
from the House chamber, Majority Floor Leader Ken Martinez (D) brought the measure 
back for a second vote. In the second round of votes, some of the members changed 
their original votes, and the three previously absent lawmakers cast theirs (Alba, 2007a). 
Reportedly, the original House vote tied at 33-33, over protests by Rep. Al Park (D) that 
his yes vote was not recorded (Baker, 2007a). When the measure was considered again, 
it lost when 33 lawmakers voted for it and 36 against (Baker, 2007a).  
Representative Larry Larranga (R) spoke in opposition of the bill and said it was 
a way for people to obtain illegal drugs and would result in the state losing federal 
crime-fighting money. In response, Rep. Antonio Maestas (D), who carried the bill in 
the House for Ortiz y Pino (D), said none of the other states with a medical cannabis law 
had experienced issues with federal funding (Nash, 2007). Erin Armstrong also spoke to 
lawmakers and reporters in support of medical cannabis (Nash, 2007). Despite Ortiz y 
Pino’s bill failing to pass the House, Armstrong and other advocates said they would 
continue working on medical cannabis measures until one was approved by the 
legislature (Nash, 2007). The governor said that he was also meeting with lawmakers in 
an effort to bring back the medical cannabis bill, which he believed it was important to 
pass (Baker, 2007a). 
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After the Senate Bill 238 Lynn and Erin Compassionate Use Act (2007a) was 
defeated by a 36-33 margin, it was substituted by Senate Bill 523 (2007). Originally, 
Senate Bill 523 was known as the Compassionate Use Medical Marijuana Act and only 
focused on topical use of cannabis, such as in ointments and patches. However, after 
Senate Bill 238 died on the House floor, Sen. Robinson (D), who sponsored the bill, 
agreed for his bill to become a substitute for the Lynn and Erin Compassionate Use Act 
(Peacock, 2007). The Senate Bill 523 was now to be known as the Lynn and Erin 
Compassionate Use Act. The bill proposed that, due to research showing that cannabis 
is effectively used in the treatment of a range of conditions, state law should make a 
distinction between the drug’s medical and non-medical use. The medical conditions 
specified by the proposed act included one or more of the following: cancer; glaucoma; 
multiple sclerosis; damage to the nervous tissue of the spinal cord, with objective 
neurological indication of intractable spasticity; epilepsy; positive HIV/AIDS status; 
admittance into hospice care; and any other medical condition as approved by the 
NMDH (Lynn and Erin Compassionate Use Act, 2007b). In order to qualify for the 
program, patients had to be residents of New Mexico and be diagnosed by a medical 
practitioner to have one or more of the specified debilitating medical conditions, 
including a statement from their practitioner that, in their opinion, the potential health 
benefits of using medical cannabis would outweigh the health risks for the patient. The 
bill also proposed that a medical board, consisting of seven medical professionals, be 
appointed to assist with the program. It also included provisions for a medical necessity 
defence, should patients or their caregivers be prosecuted for an offence involving 
cannabis (Lynn and Erin Compassionate Use Act, 2007b). 
The bill passed the Senate on a 32-3 vote, and cleared the House Judiciary 
Committee with a 10-3 vote. Once the bill went to the House, Gov. Richardson said that 
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he had spoken to some representatives who had previously voted against medical 
cannabis bills, in order to persuade them to change their minds (Peacock, 2007; Terrell, 
2007a). According to media reports, Sen. Carol Leavell (R) and Sen. Rod Adair (R) 
voiced their disapproval of the bill, suggesting it was hard to understand and sent the 
wrong message. District Attorney Matthew Chandler also opposed the bill, and 
questioned the necessity of using cannabis as a medicine while, according to him, there 
was no research suggesting it was effective for terminally ill patients (Peacock, 2007). 
On the other hand, Rep. Keith J. Gardner (R) supported the bill as it was written, and 
believed it to be very controlled, with a low margin of error (Peacock, 2007).  
After rejecting a medical cannabis bill a week earlier, the House passed the Lynn 
and Erin Compassionate Use Act with a 36-31 vote, with the bill set to return to the 
Senate for approval of minor amendments (Alba, 2007b; Miles, 2007). The House made 
an amendment to the bill to state that medical cannabis cannot be distributed within 300 
feet of churches, schools, or day care centres. According to media reports, legislators 
raised the same arguments as they did with the previous medical cannabis bill, arguing 
that passing of the measure would suggest to children that lawmakers support illegal 
drug use (Alba, 2007b). Three representatives, John Heaton (D), James Strickler (R) and 
Manuel Herrera (D) questioned the bill’s effectiveness, and suggested it sent the wrong 
message to children. In response, Rep. Antonio Maestas, who carried the bill to the 
House, said cannabis’ effectiveness has been proven, and patients should have the right 
to try it (Miles, 2007). The governor said that he was busy lobbying House members to 
vote for the bill, as it provided much needed relief to patients with specific medical 
conditions (Alba, 2007b; Miles, 2007). 
According to the media, as Gov. Richardson was due to sign the medical 
cannabis bill, he said he knew that if he was to run for president his actions could 
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become an issue (Baker, 2007b). However, Gov. Richardson stated that signing the bill 
would be the right thing to do, as it assisted people in great pain. The article suggested 
the White House urged Gov. Richardson not to sign the bill. Thomas Mann, a policy 
analyst at the Brooking Institution in Washington, said that signing the bill was not 
something that is done to earn great political support, as it was a very controversial issue 
(Baker, 2007b). Lonna Atkeson, professor of political science at the University of New 
Mexico agreed, and added that she was surprised at the governor’s support of medical 
cannabis, as it was a risky move. If he were to sign the bill, Gov. Richardson would be 
the first ever presidential candidate to publicly support and sign medical cannabis 
legislation (Baker, 2007b). 
On April 2, 2007, Gov. Bill Richardson signed the Lynn and Erin 
Compassionate Use Act into law, making New Mexico the 12th state to legalise the 
medical use of cannabis (Baker, 2007c; Lynn and Erin Compassionate Use Act, 2007). 
The law, named in part after Lynn Pierson, a medical cannabis lobbyist who lobbied for 
the 1978 medical cannabis research program, took effect on July 1, 2007, and included a 
mandate for the NMDH to set up a system to license medical cannabis providers, and 
distribute the cannabis to qualified patients itself (Baker, 2007c; Del Mauro, 2007a; 
Lynn and Erin Compassionate Use Act, 2007). Its passing was set to make New Mexico 
the first state in which the state NMDH distributed cannabis to qualified patients (Del 
Mauro, 2007a; MPP, 2013).  
Before the bill was passed, Attorney General Gary King voiced his concerns and 
suggested that, even with the passing of the state law, cannabis would still be illegal 
under federal law, which would leave the state employees involved in the medical 
cannabis program with no protection from federal prosecution (Bacon, 2007; Del 
Mauro, 2007a). John Walters, the White House drug czar, had reportedly asked Gov. 
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Richardson not to sign the medical cannabis bill, and criticised him after he had done 
so, as Walters believed the law would worsen New Mexico’s illegal drug use and would 
result in the same problems as California had been experiencing. Walters also suggested 
Richardson was only trying to get donations from wealthy medical cannabis advocates 
for his presidential campaign (Baker, 2007c).  
Reena Szczepanski, from the DPA of New Mexico, who worked on getting the 
medical cannabis bill passed, said that she believed that Americans would stand behind 
Gov. Richardson as he sought the 2008 Democratic nomination, as, according to her, 
Americans would stand behind those who believe in providing sick patients with relief 
(Baker, 2007c; Parker, 2007). According to the New Mexican newspaper, in 2006 the 
DPA contributed $50,000 to Gov. Richardson’s campaign (Del Mauro, 2007a). 
Governor Richardson’s campaign reporting documents, which were later brought up by 
those opposing medical cannabis, indicated that he received $25, 000 from the DPA 
Network on the 20th of July 2006, and on 24th of July 2006 received another $25,000 
from George Soros, who has been linked to the DPA (New Mexico Secretary of State, 
2007). 
The NMDH started accepting applications from medical cannabis patients on 
July 1, 2007, in order for them to take part in the medical cannabis program (NMDH, 
2007a; Parker, 2007). The law specified medical cannabis required for registered 
patients was to be solely obtained from an intrastate source (Lynn and Erin 
Compassionate Use Act, 2007). However, despite what was originally believed, Debra 
Busmeyer, a spokesperson for the NMDH said patients would have to obtain cannabis 
on their own, as the department would not be distributing the drug. The law-
enforcement community disagreed with this move, as they believed there would be a 
problem due to lack of quality control, and the move was contrary to what was 
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originally discussed at the legislative session when the medical cannabis measure was 
passed (Del Mauro, 2007b). Reena Szczepanski said the legislation was very specific in 
who could obtain medical cannabis, but as the legislation did not specify where the drug 
would come from, patients would have to obtain it on their own. Szczepanski also said 
that selling the drug from shops would only confuse the issue (Parker, 2007). The 
legislation originally established an October 1st deadline for NMDH to form a plan for 
distributing medical cannabis to patients (Baker, 2007d; Parker, 2007).  
As different legal implications were considered, the NMDH also consulted the 
New Mexico Attorney General’s Office to determine the best way to proceed with 
medical cannabis distribution and to determine whether its employees could be federally 
prosecuted if the program went ahead (Baker, 2007d; NMDH, 2007a). When the bill 
was passed, the Attorney General did not support the plan to distribute cannabis (Bacon, 
2007). In response to the department’s inquiry as to the best way to proceed with 
implementing the second phase of the state law, the Attorney General cautioned that the 
NMDH and its employees involved in the medical cannabis program could be 
prosecuted under federal law (Baker, 2007e). He also said he would not be authorised to 
defend the NMDH or its employees, should prosecution occur (Baker, 2007e).  
After receiving the Attorney General’s advice, the NMDH decided they would 
not pursue the second part of the law, concerning the dispensing of medical cannabis, as 
they did not want to subject the department’s employees to federal prosecution (Del 
Mauro, 2007c). It was said that King warned lawmakers during the 2007 legislative 
session about putting the NMDH in charge of overseeing cannabis growers and 
distributors. Reena Szczepanski said there were other options for production and 
distribution entities other than the department, such as private companies or volunteer 
groups, but this depended on King’s further legal advice (Del Mauro, 2007c). 
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Meanwhile, Gov. Richardson, who was running for the Democratic presidential 
nomination, instructed the NMDH to continue planning for the production and 
distribution of cannabis by the department, as was originally planned by lawmakers 
(“Medical Marijuana: Drug Bust”, 2007). 
Before the NMDH decided to allow patients to grow their own cannabis, the 
department invited various law-enforcement associations to come to a meeting 
discussing how to implement the new law. Reportedly, most law-enforcement 
associations refused to participate. Director of the State Sheriffs’ and Police 
Association, Jim Burelson, said that, like most other law enforcement associations, they 
refused to participate in the NMDH initiated meetings to discuss how to implement the 
new law for fear they would be legally implicated in distribution of a controlled 
substance (Del Mauro, 2007b). In response to criticism, Dr. Steve Jenison, medical 
director of New Mexico’s Medical Cannabis Program, said that even if the measure 
allowing state-licensed production and distribution centres was put in place, patients 
would still be allowed to grow their own cannabis plants (Del Mauro, 2007b).  
On August 17, 2007, Gov. Richardson sent a letter to President Bush asking him 
to end the priority placed on arresting and prosecuting state workers involved in medical 
cannabis programs, as well as patients using the drug (Gallegos, 2007). He said the 
federal government should be trying to deal with “real criminals” and not people in pain 
and those trying to help them. The press release alleged that the Bush administration 
earlier in the year threatened to target New Mexico state officials with federal 
prosecution, if the proposed medical cannabis bill was passed by the legislature. 
According to reports, Gov. Richardson promised to defy the federal government and use 
available state resources to fully implement the state medical cannabis law (Gallegos, 
2007). It was reported in the media that, in the states with medical cannabis laws, eight 
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Democratic presidential candidates pledged to stop federal raids on patients (Terrell, 
2007b). Santa Fe County Commissioner Harry Montoya, a Democrat, said he was 
breaking party lines by opposing the medical law, which he had publicly opposed since 
1997. He also mentioned it was not a secret that Gov. Richardson received $50, 000 
from the DPA (Haywood, 2007). 
In July 2007, eight medical professionals were appointed to a Medical Advisory 
Committee, whose purpose was to help guide the new Medical Cannabis Program by 
advising the NMDH on rules governing the program (“Local Doctors”, 2007; NMDH, 
2007b). The committee was also responsible for holding public hearings twice a year, 
where they evaluate patients’ petitions to add conditions to the list of qualifying medical 
conditions (NMDH, 2007b). However, by September 2007, it was still unclear how 
registered medical cannabis patients were going to obtain the drug, which they could 
now legally use (Vorenberg, 2007). The legislature told the NMDH to find a way to 
produce and distribute medical cannabis; however, as they were later advised by the 
Attorney General Gary King, doing so would subject the department’s employees to 
federal prosecution. According to reports, the legislature wanted patients to not have to 
grow their own cannabis or have to go to drug dealers in order to obtain the drug. 
Despite some of the obstacles, Alfredo Vigil, secretary of the NMDH, said the 
department would continue the patient certification process for as long as possible. He 
also said the distributions system idea was originally a way to break new ground for 
medical cannabis, but turned out to be impossible to put into place. According to Vigil, 
the only way for the department to distribute cannabis would be for the Congress to 
consider changing the federal law to allow for medical cannabis production (Vorenberg, 
2007).   
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After the law took effect on July 1, 2007, by the end of September 2007, 50 
patients with debilitating medical conditions had qualified for the program (Del Mauro, 
2007d). New rules for the program were proposed, and the public had a chance to 
express their views at a hearing organised by the NMDH (Del Mauro, 2007d). The first 
rule concerned the patient identification card system. Under a temporary provision, 
expiring in October, qualifying patients and their caregivers were allowed to possess up 
to six ounces of cannabis, four hemp plants and three seedlings. The proposed rules 
aimed to change that amount to six ounces of cannabis, four hemp plants and four 
seedlings. The other rule concerned the Medical Advisory Board, and aimed to allow 
the board to approve other medical conditions to be included in the qualifying 
guidelines, with the health secretary having the final say (Del Mauro, 2007d).  
The NMDH’s Medical Advisory Board held a public hearing in Albuquerque to 
discuss adding new debilitating medical conditions to the medical cannabis program’s 
list (“State to Hold Medical”, 2008). The department had already started receiving 
petitions to add medical conditions such as Crohn’s disease and hepatitis C to the list 
(“State to Hold Medical”, 2008). It took until January 2009 for the NMDH to finalise 
regulations for the registry identification cards and a production/distribution system for 
its medical cannabis program (New Mexico Register, 2008; “State Finalizes Medical”, 
2009). After the amendments in January 2009 passed and more were added in February 
of the same year, the following are the debilitating medical conditions qualified for the 
NM medical cannabis program: severe chronic pain; painful peripheral neuropathy; 
intractable nausea/vomiting; severe anorexia/cachexia; Hepatitis C infection; Crohn’s 
disease; Post-traumatic Stress Disorder; Amyotrophic Lateral Sclerosis (Lou Gehrig’s 
disease); cancer; glaucoma; multiple sclerosis; damage to the nervous tissue of the 
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spinal cord with intractable spasticity; epilepsy; HIV/AIDS; and hospice patients 
(NMDH, 2009). 
By November 2008, there were approximately 200 medical cannabis users in 
New Mexico (Riley, 2008). Reena Szczepanski said it had been difficult to make 
medical cannabis legal and accessible to patients. However, she said the NMDH was 
discussing a proposal to license patients and non-profit organisations for cannabis 
production and distribution.  Szczepanski said the DPA was in support of the 
regulations but wanted to add another provision to the law (Riley, 2008). This would 
ensure that patients living in apartment buildings in a town with no non-profit medical 
cannabis distributors could have their carer grow the drug for them (Riley, 2008).  
When demand for medical cannabis outpaced the supply, patients complained 
that the NMDH wasn’t approving producers fast enough (Hamming-Green, 2010; 
Haywood, 2011). Patients also complained that they had trouble renewing their 
identification cards, issued yearly. As a result, it was reported that some patients were 
buying cannabis from unregulated sources (Hamming-Green, 2010; Major Holmes, 
2010). Deborah Busemeyer, communications director for the NMDH, said the problems 
were arising due to the NMDH’s rigorous screening of applicants and a long list of 
regulations (Hamming-Green, 2010; Korte, 2009). She also said that the process was 
slow because cannabis is illegal under federal law and therefore needed more 
consideration (Hamming-Green, 2010).   
Despite the issues, by October 2011 there were 5,495 enrolments in the medical 
cannabis program, out of which 4,310 patients were active at that point (NMDH, 2011). 
There were also 25 non-profit producers licensed to sell cannabis as part of the program. 
The top five conditions of patient enrolment in the program, as reported by the NMDH, 
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were post-traumatic stress disorder, chronic pain, cancer, painful peripheral neuropathy, 
and HIV/AIDS. The July-September 2011 quarterly data also showed that $80,887.59 in 
taxes was collected during that period (NMDH, 2011).  
A 2011 newspaper article suggested that the state’s medical cannabis program 
was used as a model for other states (Haywood, 2011). Tamar Todd, a staff attorney for 
the DPA, said the combination of patient-grown and state-regulated dispensaries was 
ideal for patients. Todd said that state-approved dispensaries provided more assurance 
for patients than buying the drug from unregulated sources. Additionally, Catherine 
Torres, secretary of the NMDH, stated that the department planned to issue a request for 
proposals for a system testing the quality of cannabis supplied to patients (Haywood, 
2011).  
Illinois 
Illinois is one of the states that has considered but not passed a medical cannabis 
law (MPP, 2013).8 It is also a state with a ballot initiative process in its constitution, but 
initiatives rarely appear on the state ballot due to a limited and difficult to implement 
process (IRI, 2009). Further, questions related to medical cannabis cannot be placed on 
the ballot in Illinois, as the constitution only allows for ballot initiatives changing the 
function or structure of the government (MPP, 2013). While there have been attempts to 
pass a medical cannabis law in Illinois, at the time of writing this thesis, no such bills 
were passed in the state. The following section will chronologically review the history 
of medical cannabis in Illinois (see Figure 4) and discuss the attempts made at passing 
medical cannabis legislation.  
8 Illinois passed a medical cannabis law on August 1, 2013, after this thesis was submitted.  
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1978 
• Illinois passes a medical cannabis therapeutic research law 
•Bill's sponsor says that there is evidence cannabis is effective in reducing eye pressure for 
glaucoma patients and relieving negative chemotherapy side-effects 
•Bill's co-sponsor is Sen. Sangmeister, a cancer patient  
•The law becomes ineffective due to heated political debate and restrictions placed on the 
law 
2001 
•Brenda Kratovil seeks to use a medical necessity defence at her trial, drawing upon the 1978 
law  
2004 
•Court finds that Kratovil had other alternatives to cannabis and was not entitled to a 
medical necessity defence 
•First attempt at passing medical cannabis legislation with Medical Cannabis Act 
•Medical cannabis bill draws media attention and opponents and proponents start speaking 
out  
•Representative McKeon, who sponsored the bill, who suffered from HIV and nausea for 20 
years, sees  cannabis as a cure for his pain  
•City activity- Chicago Mayor supports issuing fines to individuals found to be in posession 
of small amounts of cannabis instead of filing criminal charges 
•Dr Barthwell from the ONDCP tours the state speaking against medical cannabis  
2005 
•The Medical Cannabis Act dies at the Health Care Availability and Access committee 
without being voted on  
•Medical Cannabis Act again filed by Rep. McKeon  
•Dr Bartwell holds seminars speaking against medical cannabis  
•Medical cannabis patients testify in favour of the medical cannabis bill  
•ONDCP director John Walters arrives in Illinois to testify against medical cannabis 
legislation  
•Law enforcement groups oppose the medical cannabis bill  
•The bill gets rejected by the Human Services committee  
 
2006 
•Michael Steelman of NORML says that medical cannabis legislation may be more than a 
decade away in the state 
•New Medical Cannabis Act introduced in the Senate  
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Figure 4. Time chart of medical cannabis history in Illinois. 
2007 
• Increase in media reports on medical cannabis  
•Medical cannabis bill introduced in Senate by Sen. Cullerton  
•Medical Marijuana Policy Advocacy Project (MMPAP) speak in support of medical 
cannabis  
•Reports that church leaders were speaking out in support of medical cannabis  
•Small step towards change- passing of an ordinance change in Peoria Heights to give police 
officers an option of treating posession of small amounts of cannabis as a violation and 
issuing a fine  
•Medical cannabis documentary by Jed Riffe screened in the Southern Illinois University 
Carbondale Student Center  
 
2008 
•Dan Linn from NORML active in responding to opposition 
•Two medical cannabis bills introduced, one in the House of Representatives and one in the 
Senate  
•Survey shows that 68% of surveyed Illinois voters support legalising medical cannabis use 
2009 
•Barack Obama assuming office  as the new U.S. President sparks optimism in medical 
cannabis supporters 
•City activity- Springfield changes its ordinance to allow cannabis posession of less than 
2.5g to be prosecuted as an ordinance violation rather than criminal penalty 
•Compassionate Use of Medical Cannabis Pilot Program bill introduced in Senate, a 
companion bill introduced in the House of Representatives  
•Cook County Board votes in favour of passing a change in the city ordinance which allows 
police officers to issue fines to those in possession of small amounts of cannabis 
2010 
•Politicians from both parties indicate that they would consider allowing cannabis for 
medical purposes  
•Suggestions that some lawmakers did not want to make politically risky votes and were 
worried about how they were portrayed  
•Compassionate Use of Medical Cannabis Pilot Program bill dies at House of 
Representatives 
2011 
•Compassionate Use of Medical Cannabis Pilot Program re-filed, subsequently died on the 
House floor in 2013 
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In 1978, along with 34 other states, Illinois passed a medical cannabis 
therapeutic research law which allowed physicians to administer cannabis to glaucoma 
and cancer chemotherapy patients (Lichtenberg, 2009). According to the Alliance for 
Cannabis Therapeutics (1999), the Illinois medical cannabis therapeutic research bill 
was passed in September 1978, on a 140-16 House vote, and a 45-4 Senate vote. Prior 
to the bill, Illinois law only had provisions allowing limited use of cannabis for persons 
conducting research (Lichtenberg, 2009). The bill’s sponsor was Rep. Joseph B. 
Ebbesen (R), who said there was evidence that cannabis was effective in reducing eye 
pressure for glaucoma patients, and in relieving negative chemotherapy side-effects 
(“Medicinal Pot Use Legal”, 1978). Senator George Sangmeister (D), the bill’s co-
sponsor who was diagnosed with cancer prior to his involvement with the bill and used 
cannabis to help with his treatment, played a key role in passing the bill (Ciccone, 
1978). Governor James R. Thompson (R) showed his support for the bill as he signed it 
into law, calling it a “step forward in the practice of medicine”. He also asserted that the 
bill was not a step towards general cannabis legalisation, and said that he did not want 
children to experiment with the drug (“Marijuana Approved for Glaucoma”, 1978). The 
bill was due to take effect on January 1, 1979 (“Marijuana Approved for Glaucoma”, 
1978). According to a statement made by Sen. Cullerton (D) in 2007, the 1978 Illinois 
medical cannabis law became ineffective due to heated political debate at the time and 
restrictions placed on the law itself (Huffstutter, 2007).  
The Illinois Cannabis Control Act (2005) still contains a provision allowing the 
Department of Alcohol and Substance Abuse to authorise (a) possession, (b) production, 
(c) manufacture, and (d) delivery of cannabis-containing substances by individuals 
taking part in a research program. Under the act, if an individual’s doctor authorised 
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them to participate in the research program by certifying such participation was 
medically necessary for the treatment of glaucoma or side effects of chemotherapy or 
radiation, that patient was then exempt from state-level prosecution. Registered medical 
professionals were allowed to apply for federal registration to conduct a medical 
cannabis research program in a treatment setting, with written permission from State 
Police (Cannabis Control Act, 2005). However, the program is ineffective as the law 
requires the participants to be registered with the federal government in order for the 
government to supply medical cannabis, and the drug is illegal at the federal level, with 
the exception of patients receiving it through the NIDA as part of medicinal research 
(Lichtenberg, 2009; Werner, 2001).   
Since the law was passed, no person had participated in using cannabis as a 
medicine under its provisions, nor was any cannabis obtained from the federal 
government for therapeutic research purposes (Lichtenberg, 2009). According to Bryan 
Brickner from Illinois NORML, the “War on Drugs” was responsible for the failure of 
the Illinois program by allocating authority for the program to the Illinois Department of 
Alcohol and Substance Abuse (M. Harris, 2003). Brickner thought that the move 
resulted in medical cannabis research falling under “substance abuse”, and therefore 
being illegal (M. Harris, 2003).  
The issue of medical cannabis drew public attention in 2001, when the house of 
Brenda Kratovil in Waukegan, Illinois was searched by the Metropolitan Enforcement 
Group, after a neighbour reported seeing cannabis plants in her backyard (M. Harris, 
2003). The search was allegedly conducted without a warrant and three months later 
resulted in Kratovil being charged with cannabis possession. Kratovil claimed that 
cannabis helped her with glaucoma, which she had suffered for over 20 years. She was 
also legally blind and diagnosed with multiple sclerosis. Kratovil’s lawyer, David 
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Stepanich, sought to use a medical necessity defence at her trial, drawing upon the 1978 
Illinois medical cannabis research law (Cannabis Control Act, 2005; M. Harris, 2003; 
People v. Kratovil, 2004).  
On June 4, 2003 Kratovil’s doctor Michael Savitt testified that Kratovil’s 
glaucoma case was severe and that the best treatment option for her would be laser 
surgery (People v. Kratovil, 2004). He also testified that the benefits of cannabis in 
glaucoma treatment are only temporary and that there was not significant evidence for 
its effectiveness in relation to glaucoma (People v. Kratovil, 2004). The court found that 
Kratovil had other alternatives to cannabis for treating her condition, and was therefore 
not justified in breaking the law or in using the defence (People v. Kratovil, 2004). 
Kratovil claimed that under section 11 of the Cannabis Control Act, she had the right to 
possess cannabis (Cannabis Control Act, 2005; People v. Kratovil, 2004). The court, 
however, found that she was not entitled to a medical necessity defence under the act as 
(a) she did not participate in medical research; (b) her doctor was not involved in 
medical research, and (c) no authorisation was obtained from the Illinois Department of 
Health (IDOH). Kratovil was found guilty of unlawful cannabis possession and 
sentenced to 12 months’ conditional discharge and 30 hours of community service 
(People v. Kratovil, 2004).  
Following Kratovil’s trial, the first attempt at passing medical cannabis 
legislation in Illinois was the Medical Cannabis Act (2004a). It was introduced in the 
House of Representatives in February of 2004 by Rep. Angelo Saviano (R), was 
sponsored by Rep. Larry McKeon (D), and co-sponsored by Rep. Susana Mendoza (D) 
(Medical Cannabis Act, 2004a). The bill sought to amend the Cannabis Control Act in 
order to allow individuals diagnosed with a debilitating medical condition to use 
cannabis for medical purposes. Debilitating medical conditions specified by the bill 
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included cancer, glaucoma, HIV/AIDS, cachexia or wasting syndrome, severe pain, 
severe nausea, seizures including epilepsy, severe and persistent muscle spasms 
including those characteristic of multiple sclerosis or Crohn’s disease, and any other 
condition approved by the IDOH. The bill would have allowed patients and their 
primary caregiver to possess up to six cannabis plants and one ounce of dried, useable 
cannabis, without state-level prosecution (Medical Cannabis Act, 2004a).  
The first medical cannabis bill received media attention, and both opponents and 
proponents spoke out. While critics said there were other drugs available in place of 
cannabis, Bruce Mirken from the MPP maintained cannabis was effective in assisting 
some patients with specific debilitating medical conditions, such as the side effects of 
cancer therapy or AIDS medication (McKinney, 2004). Opponents also claimed the bill 
would be hard to enforce and would increase drug use (Griffy, 2004). Representative 
Patricia Bellock (R) spoke against the bill and stated that it was not up to the electorate 
or the General Assembly to decide what is considered medicine, but up to professionals 
(S. Miller, 2004). Deputy Director of the White House’s ONDCP, Dr. Andrea 
Barthwell, also spoke in Springfield against the proposed medical cannabis legislation 
(McKinney, 2004). On her tour of Illinois Dr. Barthwell said there were no proven 
medical benefits for cannabis, only short and long term risks. She also said that medical 
cannabis would (a) affect the whole society; (b) would make the drug available to 
children; and (c) would result in an increase in drug addiction (Griffy, 2004). 
Support for medical cannabis legislation came from Richard J. Rawlings from 
the Illinois Marijuana Party (IMP) who said he believed doctors should not be 
criminally prosecuted for prescribing cannabis to their patients if they believe it to be 
necessary (Rawlings, 2004). Rawlings said that prohibition, not cannabis, was a 
gateway to use as it resulted in a rise in all illegal drug use. However, Greg Sullivan, 
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executive director of the Illinois Sheriff’s Association, thought that such a law would 
increase the illegal flow of cannabis (Rawlings, 2004). 
The bill was assigned to the Health Care Availability and Access committee, 
where it died in January of 2005 without being voted on (Illinois General Assembly, 
n.d.-d). An identical bill was introduced in the Senate in February 2004 by Sen. Carol 
Ronen, but it also failed to pass (Medical Cannabis Act, 2004b). It was expected that the 
medical cannabis bill would be introduced again in the next legislative session (A. L. 
Smith, 2004). The bill’s sponsor Rep. Larry McKeon (D) said he would not give up on 
the bill despite opposition in the legislature (S. Miller, 2004). Representative McKeon 
suffered from HIV and nausea for 20 years and saw cannabis as a cure for his pain (S. 
Miller, 2004). He said that the legislation was not about expanding the drug’s 
availability on the street, but helping sick individuals (S. Miller, 2004).  
In January 2005 a Medical Cannabis Act was again filed by Rep. Larry McKeon 
(D), this time with changes in the amount of cannabis an individual was allowed to 
possess (Illinois General Assembly, n.d.-b). The bill also sought to allow non-profit 
organisations to grow limited amounts of cannabis for registered patients (Illinois 
General Assembly, n.d.-b). When the bill was introduced, Dr. Barthwell was touring 18 
Illinois cities holding seminars opposing cannabis legalisation, including medical 
cannabis (Bowen, 2005). Representative McKeon said that he believed Barthwell’s 
seminars were a smear campaign against his medical cannabis proposal and challenged 
Dr. Barthwell to a public debate on the issue (Massingale, 2005). McKeon’s debate 
challenge was refused by Dr. Barthwell, who said she did not engage in “street theatre” 
(Massingale, 2005). At the same time it was reported in the media that Dr. Barthwell 
was considering a run for the U.S. Senate, representing Illinois (Hahn, 2005).   
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Richard Rawlings from the IMP suggested that Dr. Barthwell was spreading 
drug war propaganda (Rawlings, 2005). He said that drug prohibition did not work and 
that the government had to focus on “harder” drugs rather than cannabis, while 
organisations such as the MPP and the NORML were trying to change unfair laws 
(Rawlings, 2005). Barthwell denied that her Illinois tour was related to the introduction 
of a medical cannabis bill in the state but said that there was no “compelling” scientific 
or medical evidence for cannabis’ effectiveness. Barthwell also said that while she was 
compassionate to sick individuals, she believed cannabis did more harm than good 
(Bowen, 2005). Bruce Mirken from the MPP disagreed with Barthwell and said many 
things she was stating were not true. He opposed her claims and expressed his support 
for Rep. McKeon’s bill, while adding that the FDA had no role in regulating personal 
use of a drug (Bowen, 2005).  
The start of 2006 saw a new medical cannabis bill introduced in the Senate by 
Sen. John Cullerton (D) (Medical Cannabis Act, 2006). The bill sought to allow 
individuals diagnosed by their doctor as having a debilitating medical condition and 
their caregivers to legally possess up to 12 cannabis plants and two and a half ounces of 
dried, useable cannabis (Medical Cannabis Act, 2006). The bill was assigned to the 
Health & Human Services Committee, where it died in January of 2007 (Illinois 
General Assembly, n.d.-h). A newspaper article suggested that the medical cannabis 
debate was only getting started in Southern Illinois (Morelli, 2006). However, Michael 
Steelman of the NORML said that medical cannabis legislation may be more than a 
decade away in the state. Steelman said that while there was some support in the 
legislature, people were generally unwilling to talk about the medical cannabis issue and 
were not progressive (Morelli, 2006).  
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The year 2007 saw an increase of media articles on medical cannabis and 
suggestions that the federal government should not waste tax dollars on failed policies 
and should allow more research into medical cannabis if they claim not enough 
scientific evidence on the drug’s medicinal effectiveness was available (Sharpe, 2007; 
“Truth and Medical Marijuana”, 2007). In February of 2007, a new medical cannabis 
bill was introduced by Sen. John Cullerton (D) (S.B. 0650, 2007). It sought to allow 
individuals diagnosed with a specific debilitating medical condition and their caregivers 
to legally possess no more than twelve cannabis plants and two and a half ounces of 
useable cannabis (S.B. 0650, 2007). The bill was assigned to the Public Health 
Committee where it passed on a 6-4 vote in March 2007 (Illinois General Assembly, 
n.d.-f). However, the bill died on the Senate floor on a 29-22 vote in May of the same 
year (Illinois General Assembly, n.d.-f). Senator Cullerton (D) said that he was 
disappointed the bill was not passed as it was overwhelmingly supported in the 
community (Potter, 2007). 
In March of 2007, Dr. David Ostrow, co-founder of the Howard Brown Health 
Research Center of Chicago and founder of the Medical Marijuana Policy Advocacy 
Project (MMPAP) said that there was significant evidence for the effectiveness of 
cannabis in the treatment of a number of debilitating medical conditions, including 
HIV/AIDS (Ostrow, 2007). An increase in religious denominations speaking out in 
favour of medical cannabis was also observed in 2007. It was reported that dozens of 
pastors and church leaders in Illinois spoke out in support of medical cannabis, 
suggesting that lawmakers had a moral responsibility to allow seriously ill patients to 
use medical cannabis (Huffstutter, 2007). They sent an email to Illinois senators in 
March asking them to remove criminal sanctions from doctors recommending cannabis 
to patients and from patients using cannabis for debilitating medical conditions. They 
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also questioned whether it should be up to the government to decide on medical issues 
or up to those in research and medical fields (Huffstutter, 2007). Meanwhile, Calvina L. 
Fay, Executive Director of the Drug Free America Foundation (DFAF), a national drug 
policy group, disagreed with the medical cannabis legislation and said that religious 
leaders could not necessarily judge an issue such as medical cannabis (Huffstutter, 
2007). 
In November of 2007, a documentary on medical cannabis by Jed Riffe screened 
in the Southern Illinois University Carbondale Student Center (Rodriguez, 2007). The 
documentary followed patients who used cannabis to help with their medical conditions 
as well as parents who had lost their children to addiction, as Riffe said he believed in 
showing both sides of the argument. Dan Bernath, assistant director of communications 
for the MPP, supported the documentary and said it was a good way to start a discussion 
on the topic (Rodriguez, 2007).  
In February 2008 one medical cannabis bill was introduced in the House of 
Representatives and one in the Senate (Alternative Treatment Act, 2008; Medical 
Marijuana Pilot Program, 2008). A Medical Marijuana Pilot Program (2008) bill was 
introduced in the Senate by Sen. John J. Cullerton (D) and it sought to allow patients 
diagnosed by their doctor as having a debilitating medical condition to obtain an IDOH-
issued identification card. The card would then allow the patients and their caregivers to 
possess no more than 12 cannabis plants and two and a half ounces of dried, useable 
cannabis. The bill was referred to the Public Health Committee which amended it to 
include a provision stating that qualified patients in possession of allowed amounts of 
cannabis, their caregivers and physicians would not be subject to prosecution (Illinois 
General Assembly, n.d.-i). The bill passed the committee and was sent to the senate 
floor. The second amendment came in the Senate in November 2008, and added a 
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sunset clause to the bill which meant it would expire three years after taking effect. The 
amendment also changed the maximum number of plants allowed to be in patient’s 
possession to seven. However, the bill died in the Public Health Committee in January 
of 2009 (Illinois General Assembly, n.d.-i). The second bill was introduced in the House 
by Rep. Angelo Saviano (R) and was the same as the bill introduced in the Senate 
(Alternative Treatment Act, 2008). It was assigned to the Health Care Availability and 
Access Committee on 11th March of 2008 where it was amended (Illinois General 
Assembly, n.d.-e). However the bill failed to pass as amended on a 9-3 vote and 
subsequently died in committee (Illinois General Assembly, n.d.-e). 
Prior to the bills’ failure, Sen. Cullerton said his bill was about preventing 
patients from suffering and not about the law being abused to obtain cannabis 
(Mehrotra, 2008). However, Sen. Dale Righter (R) disagreed and said medical cannabis 
legalisation was a bad idea (Mehrotra, 2008). Laimutis Nargelenas, director of the 
Illinois Association of Chiefs of Police, said there were better ways of legalising 
cannabis than using sick people as a cover up for the drug’s legalisation (Mehrotra, 
2008). Nargelenas said he had no objections to medical cannabis but believed those 
attempting to legalise the drug for general use were hiding behind sick people and 
medical cannabis (Radosevic II, 2008). He also mentioned that the measure sent a 
mixed message to children. According to reports, the Illinois State Police opposed the 
bill as it believed its wording would create a loophole allowing motorists to drive while 
under the influence of cannabis (Radosevic II, 2008). 
Dan Linn, from the NORML, was very vocal throughout 2007, writing 
numerous articles to the state newspapers in favour of legalising cannabis, as well as 
responding to opposition arguments. He also spoke in favour of general cannabis 
legalisation and suggested taxation and regulation of the drug (Linn, 2008a; Linn, 
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2008b; Linn, 2008c; Linn, 2008d; Linn, 2008e). Linn said the move would raise 
revenue for the government and would regulate the market (Linn, 2008b). He also 
maintained that it was cruel to keep sick people away from something that could help 
them ease their suffering and that studies had shown cannabis was not a ‘gateway drug’ 
(Linn, 2008c). In November of 2008, Linn said that Illinois made a lot of progress 
during the 2008 legislative session (Linn, 2008f). He said that Illinois needed a medical 
cannabis law and that the decision of what medicine is the best for an illness should be 
left to the patient and their doctors, not law enforcement personnel (Linn, 2008f). He 
urged the lawmakers to pass Sen. Cullerton’s bill as cannabis was a safe, natural 
medicine, which doctors should be able to recommend to their patients (Linn, 2008g). 
With an increase in individuals and organisations voicing their support for 
medical cannabis legislation, a survey was conducted by Mason-Dixon Polling and 
Research Inc. in 2008 (Radosevic II, 2008). It found that 68 percent of 625 registered 
Illinois voters surveyed favoured legalising medical cannabis use by seriously or 
terminally ill patients (Radosevic II, 2008). The results also showed that 49 percent of 
respondents would be more likely to vote for their state legislators if they supported and 
voted for a medical cannabis measure (MPP, 2008). The MPP initiated the survey and 
its spokesman, Dan Bernath, said the results were not surprising as the issue of medical 
cannabis was becoming more of a health issue rather than a political one (Radosevic II, 
2008). Also sparking optimism in medical cannabis supporters was seeing Barack 
Obama assume office in 2009 as the new U.S. President. Medical cannabis advocates 
such as Dan Linn hoped this would lead to a change in medical cannabis laws (Linn, 
2009a).  
New attempts. On 11th February 2009, Sen. William R. Haine (D) introduced 
the Compassionate Use of Medical Cannabis Pilot Program Act (2009a) which sought 
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to enable those diagnosed by their doctors as having a debilitating medical condition to 
obtain an identification card from the IDOH. The card was to enable the holder and their 
caregiver to possess no more than seven cannabis plants and two ounces of useable 
dried cannabis without prosecution at the state level. The bill specified that a distinction 
would be made between the medical and non-medical use of cannabis by the State in 
order to protect patients with debilitating medical conditions. Some of the debilitating 
conditions specified by the bill included glaucoma, HIV/AIDS, epilepsy and other 
ailments. Consistent with the amendment made to the 2008 bill, Sen. Haine’s bill 
included a sunset clause stating the act would expire after three years from the day it 
took effect (Compassionate Use of Medical Cannabis Pilot Program Act, 2009a). 
Senator Haine was a former state’s attorney and it was believed by some that he could 
better address the issues raised by law enforcement regarding medical cannabis 
(Colindres, 2009). The media also speculated that because Sen. John Cullerton (D), who 
had sponsored a medical cannabis bill previously, became the Senate president, the 
medical cannabis bills might pass through the Senate more easily as a result of Sen. 
Cullerton’s role (Colindres, 2009). 
The bill’s supporters claimed its purpose was to help the seriously ill (Colindres, 
2009). Dan Linn said that it was trying to protect those using cannabis with their 
doctor’s recommendation and for medical purposes (Colindres, 2009; Nave, 2009). 
Speaking in opposition, Laimutis Nargelenas said the law enforcement community had 
compassion towards very sick individuals, but that those who were trying to get high 
and were not seriously ill could abuse the medical cannabis law. Nargelenas said that 
calling cannabis a medicine was sending a bad message to children (Colindres, 2009).  
On 20th February 2009, a companion bill to Sen. Haine’s (D) Compassionate 
Use of Medical Cannabis Pilot Program Act, sponsored by Reps. Lou Lang (D) and 
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Angelo Saviano (R), was introduced in the House (Compassionate Use of Medical 
Cannabis Pilot Program Act,  2009b). The bill sought to allow patients diagnosed by 
their doctor as having a debilitating medical condition to obtain an identification card 
from the IDOH, entitling them to possess medical cannabis without state-level 
prosecution. The bill would allow patients and their primary caregivers to possess up to 
seven cannabis plants and two ounces of dried, useable cannabis. It also included a 
provisional clause which specified the act would end after three years of taking effect 
(Compassionate Use of Medical Cannabis Pilot Program Act, 2009b). The bill’s 
sponsor, Rep. Lou Lang (D), said people were suffering needlessly while cannabis had 
the potential to ease their pain (Wills & Schott, 2009). He stated that a medical cannabis 
bill was a difficult one to pass, even with a three year sunset clause (Wills & Schott, 
2009). The bill was assigned to the Human Services Committee in February where it 
was passed on a 4-3 vote (Illinois General Assembly, n.d.-c). It was then sent to the 
House floor, from which it was re-referred to the Rules Committee. The bill died in 
House in 2011, without ever being called for a vote (Illinois General Assembly, n.d.-c). 
Speaking in opposition to medical cannabis, Rep. Patricia Bellock (R) said that 
the bill could be misused by those who did not have a debilitating medical condition 
(Wills & Schott, 2009). She also wondered whether the bill would open the door for 
general cannabis legalisation in Illinois (Wills & Schott, 2009). Representative Robert 
Pritchard (R) said he voted against the legislation, as he believed it was not a pilot 
program but an experiment which could result in places selling cannabis without 
regulation (Wills & Schott, 2009). Senator Chris Lauzen (R) spoke against the bill, but 
said that as he aged he was more conflicted about it (Bonner, 2009). In his opinion, 
Marinol was effective and already available in place of cannabis. Raising a common 
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issue, Rep. Kay Hatcher (R) said the Illinois bill was loosely written and would send a 
wrong message to children (Bonner, 2009; Griffith, 2009b).  
Opponents of the medical cannabis legislation were also speaking out against 
several pro-medical cannabis advertisements produced by the MPP (Griffith, 2009b; 
MPP, 2013). Dr. Andrea Barthwell, by now chief executive officer of the Human 
Resource Development Institute (HRDI), said the advertisements were spreading 
misinformation and that the health and welfare of children as well as community safety 
would be affected as a result. Judy Kreamer, president of Educating Voices, said her 
organisation’s efforts to oppose medical cannabis could not match those of the MPP. 
The television commercials were introduced in April and ran in Chicago, Peoria, and 
the Decatur/Springfield/Champaign areas. They featured testimonials from two Illinois 
medical cannabis patients, Lisa Lange Van Camp and Lucie Macfarlane (MPP, 2013). 
Senator Haine said he hoped the lawmakers would realise there were many patients who 
would benefit from medical cannabis legislation. He also said the introduced legislation 
included many safeguards and differed from California’s in order to avoid problems 
experienced by that state. In response to opponents’ claims that cannabis was a gateway 
drug, Sen. Haine said they should read his bill, as most of those who would be using 
medical cannabis were people who were dying (Griffith, 2009b). 
Senator Haine’s bill was assigned to the Public Health Committee in February of 
2009 where it was passed on a 6-2 vote (Illinois General Assembly, n.d.-g; M. Thomas, 
2009). In May of 2009, the Senate passed the Compassionate Use of Medical Cannabis 
Pilot Program Act by a vote of 30-28. The bill was then sent to the House and assigned 
to the Human Services Committee, which passed it on a 4-3 vote in May of 2009. 
Senator Haine (D) said it was an important step for those who were suffering, and who 
relied on medical cannabis (Griffith, 2009a). In October 2009 the bill was waiting for its 
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final reading and a vote on the House floor, and was given a final action deadline of 30th 
November 2009 (Illinois General Assembly, n.d.-g). Discouragingly for the supporters, 
Rep. Lou Lang (D), who previously sponsored a medical cannabis bill which died in the 
House, said he was unsure how far any medical cannabis measure would go in the 
House of Representatives (“Senate Approves Medical Marijuana”, 2009). 
The law enforcement agencies maintained their opposition to medical cannabis 
(Griffith, 2009c). Madison County Sheriff Robert Hertz said he could not speak on 
behalf of all law enforcement but was personally against the bill. Hertz said he worried 
cannabis would be hard to control once it was legalised for medical purposes. He 
questioned whether, if cannabis was legalised, cocaine and methamphetamine would be 
next. Sen. Haine (D), however, said he believed in the bill and the positive impact it 
could have on people, and that received more letters for the bill than against it. 
However, he admitted that, overall, he did not receive a lot of mail on the subject, and 
interpreted this as people not caring about the issue (Griffith, 2009c). Reportedly, Haine 
also stated that he worried that the legislation would send a wrong message to children, 
which is why most people would not be supportive of it. Despite this, he said no one 
should live in pain (Griffith, 2009c).  
While the Compassionate Use of Medical Cannabis Pilot Program Act passed 
two House committees, in April 2010 it had still not been brought up for a House vote 
(Illinois General Assembly, n.d.-c). Representative Lang (D) said that some officials 
chose to vote against it and their own beliefs for political reasons (Thompson, 2010). He 
said that he had to be careful when to put the bill to a vote because he could not afford it 
to fail, as many legislators would only vote for such a bill once. Because he believed 
people were scared of problems resulting from a medical cannabis law, Lang said that 
he made the bill controlled and restrictive. Senator Linda Holmes (D) said that she 
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voted against the 2008 medical cannabis bill because she was up for re-election and did 
not want to be seen as a supporter of drugs. In May 2009, however, she voted “yes” on 
the medical cannabis bill and said the reaction of her constituents was more positive 
than negative (Thompson, 2010).  
In 2010, news reports indicated that politicians from both parties said that they 
would consider allowing cannabis for medical purposes (Frick Carlman, 2010; 
O'Connor, 2010). Some, like Sen. Linda Holmes (D), had personal reasons for 
supporting the bill. Senator Holmes, one of 12 sponsors of the medical cannabis bill and 
an MS sufferer, said she supported medical cannabis legislation because it could help 
bring MS sufferers relief from pain and spasticity and stimulate appetite (O'Connor, 
2010). However, there were also those who believed that medical cannabis legalisation 
would lead to general legalisation of the drug (Frick Carlman, 2010; O'Connor, 2010). 
Overall, 2010 saw the debate continue, with opponents claiming that cannabis is a cover 
for other illegal activity and proponents suggesting that, apart from medical benefits, 
cannabis was a safe drug, especially when compared to other drugs it replaced. There 
were also suggestions made by the proponents that medical cannabis legislation would 
generate tax revenue for the state (D. Miller, 2010).  
In April 2010, Rep. Lang (D) announced to the media that he was short of the 60 
votes needed for the bill’s approval in the House of Representatives (Patterson, 2010). 
He said he was told by some members that they hoped the bill would pass, but they did 
not plan on voting for it. It was suggested that some lawmakers did not want to make 
politically risky votes and were worried about how they were portrayed (Patterson, 
2010). As a result, Lang said he would not call for a vote until he knew that the measure 
would pass (Olsen, 2010). He was considering bringing the bill up for discussion in the 
House of Representatives in January, before the new legislators took their seats at the 
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General Assembly (Huchel, 2010). A late year session would have required 71 votes for 
the bill to pass, while in January session it would take only 60 votes (Huchel, 2010).  
Medical cannabis advocates said that they would continue to push for the 
legislation (Olsen, 2010). However, despite efforts, the 2010 medical cannabis failed to 
pass the House (Hess, 2011; Lester & Riopell, 2010). The bill received 56 votes in its 
favour, but needed 60. In response, Dan Linn said there were a lot of politics involved 
(Lester & Riopell, 2010). The bill’s sponsor, Rep. Lang (D) said he would continue to 
push for medical cannabis legislation (Hess, 2011). The bill known as the 
Compassionate Use of Medical Cannabis Pilot Program Act was filed again as House 
Bill 30 (Illinois General Assembly, n.d.-a).  
In 2011, Rep. Tom Cross (R) changed sides to support medical cannabis 
legislation (Brownfield, 2011a; Wilson, 2011). He said that he had a change of heart 
after being approached by several constituents. Representative Lang indicated that he 
thought that this time, with the support of Rep. Cross, he could pass the bill which the 
sponsors were trying to make the most restrictive law out of all the states (Wilson, 
2011). Rep. Lang hoped that putting more restrictions into this bill would get additional 
votes (Brownfield, 2011a). The proposed legislation would not allow patients to grow 
their own cannabis, but would have to buy it from a state-licensed dispensary. The bill 
would also legalise cannabis for medical purposes for three years, after which the law 
would have to be renewed (Wilson, 2011).  
The bill was placed on postponed consideration after failing to get enough votes 
to be passed by the House of Representatives (Morse, 2011). The bill received 56 votes 
in its favour out of the 60 required for it to be passed, but this was enough for it to be 
placed on postponed consideration so that it can be voted on again in the future 
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(Brownfield, 2011b; Morse, 2011). Representative Lang said he would seek another 
vote on the bill if he could find more votes in favour of it. He pointed out that the bill 
was about health care and not about drugs, including cannabis. However, Rep. Jim 
Watson (R), who voted against the bill, said that every local law enforcement official 
called on him to oppose it (Brownfield, 2011b). It was also said by the opposition that 
the bill was a very bad piece of legislation, which opposed the federal law (Morse, 
2011).  
Changes at the city level. The same year the Medical Cannabis Act was 
introduced, there was also some activity reported at the city level when Chicago Mayor, 
Richard Daley, said that he embraced an idea to issue fines to individuals found to be in 
possession of small amounts of cannabis instead of filing criminal charges (“Daley: Just 
Ticket Marijuana”, 2004). Bryan Brickner, a chairman of the Illinois chapter of the 
NORML, said the plan was a turning point (Goze, 2004). However, his concern was that 
Chicago was focusing on generating revenue with fines of between $250-$1,000, which 
Brickner predicted could significantly affect poor and minority residents (Goze, 2004). 
Amongst reports that Mayor Daley was considering such a plan it was reported that 
most North Shore (Chicago) police agencies had already been doing something similar 
for nearly 25 years (Goze, 2004). Wilmette Police Chief George Carpenter said the 
village had an ordinance by which officers had the option to issue fines of $100 to 
individuals in possession of ten grams or less of cannabis. It was created in August 1978 
as a way of dealing with high rates of cannabis use and an overloaded court. He said the 
ordinance was a more sensible approach to minor violations and did not mean cannabis 
was decriminalised. Kenilworth, a village in Cook County, also had a similar ordinance 
(Goze, 2004).  
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In May 2007 an ordinance change was due to take effect in the village of Peoria 
Heights (Haney, 2007). It was set to give police officers an option of treating possession 
of small amounts of cannabis as a violation and issuing a fine rather than criminally 
charging individuals (Haney, 2007). Possession of less than 2.5 grams of cannabis 
would result in a $200 fine; between 2.5 and 10 grams, a $300 fine; and between 10 and 
30 grams, a $400 fine (Haney, 2007). At the same time Dan Linn, Executive Director of 
the Illinois NORML, suggested changes should be made to the Illinois cannabis law and 
said that lawmakers should legalise and tax cannabis as a form of revenue raising (Linn, 
2007). Linn said it made more sense than arresting people and advised that Illinois 
should stop wasting tax dollars and start making money by taxing cannabis use by 
adults (Linn, 2007). 
In February of 2009, a small change in relation to cannabis occurred in 
Springfield (Poole, 2009). The city changed its ordinance to allow cannabis possession 
of less than two and a half grams to be prosecuted as an ordinance violation resulting in 
a fine, rather than a criminal penalty (Poole, 2009). Cities with similar ordinances 
included Joliet, Aurora, Bloomington, Champaign and Urbana. It was reported that 
Springfield’s ordinance change was a way of raising revenue for the city, which 
reportedly faced a $12.5 million budget deficit (Poole, 2009). Dan Linn suggested that 
cannabis could be a good way of tax and revenue raising and said government could 
make even more money if cannabis was made legal (Linn, 2009b).  
In July of 2009, the Cook County Board voted in favour of passing a change in 
the city ordinance which allows police officers to issue fines to those in possession of 
small amounts of cannabis. This then results in a misdemeanour charge instead of 
criminal prosecution (Kadner, 2009). The ordinance change gave police officers an 
option of issuing a $200 fine to those caught with 10 grams of cannabis or less. At that 
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point, however, Cook County Sheriff Tom Dart said he was not sure what he thought of 
the change (Kadner, 2009). 
Dan Linn, of Illinois NORML, said the organisation supported Cook County 
changing their ordinance (Linn, 2009c). However, he said the problem was the potential 
for discriminatory arrests, as it would be up to police officers to decide whether to fine 
or arrest individuals (Linn, 2009c). His suggestion was that cannabis should generally 
be legalised and regulated like alcohol and tobacco (Linn, 2009c).  Reverend Alexander 
Sharp, executive director of Protestants for the Common Good, said he also supported 
the ordinance change (Sharp, 2009). He said the local government needed all the money 
it could get and fining those possessing small amounts of cannabis would raise revenue. 
Reverend Sharp also said he was not advocating cannabis use, but believed people 
needed to change their way of thinking in regards to drugs (Sharp, 2009). 
Kentucky 
Unlike the 36 states that have had some form of medical cannabis law since 
1978, Kentucky has never had such a law or consideration of such laws on its political 
agenda (MPP, 2013)9. As Kentucky does not have a ballot initiative process, passing a 
medical cannabis law remains an issue dependent on the state legislature or the 
executive which had, at the time of writing this thesis, not shown significant interest in 
the topic (IRI, 2009). According to the 2002 Kentucky Drug Threat Assessment report, 
cannabis was rated as the most widely available illicit drug in the state and the leading 
crop grown for sale (National Drug Intelligence Center, 2002).The report suggested that 
9 Since the writing of this thesis, there has been consideration of a medical cannabis law in the state of 
Kentucky.  
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the central and eastern parts of Kentucky were the areas of largest cannabis cultivation. 
Kentucky was also named as one of top five cannabis producing states in the nation.  
In accordance with state laws, cannabis possession, cultivation, sale, or use, are 
criminal offences in Kentucky while research on industrial hemp is authorised (Ky. Rev. 
Stat. § 218A.010, 1992; Ky. Rev. Stat. § 260.853, 2001). Hemp refers to a fibre derived 
from certain species of cannabis that contains minimal amounts of THC (Hollister, 
2001). Hemp fibre can be used in the making of rope, clothes, paper, and other products. 
As Kentucky has no medical cannabis law, the following section will chronologically 
review (see Figure 5) the history of the brief but unsuccessful attempts made at passing 
such legislation. 
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Figure 5. Time chart of medical cannabis history in Kentucky.  
1990s 
•Focus on hemp- separating hemp from general cannabis use  
•Movement to separate cannabis use from other drugs 
2001 
•Governor Paul Patton signs into law a bill allowing research on hemp 
2004 
•Supporters of cannabis legalisation organise a rally 
2005 
•Supreme Court's ruling on medical cannabis restarts debate 
•Reports from law enforcement that cannabis trade is a big problem in Kentucky  
•Kentucky a leading state in cannabis cultivation  
2006 
•Student action- dozens of students gather for a rally held by the University of Kentucky (UK) 
chapter of NORML  
•UK NORML say they were established in 2005 but didn't have funds to organise big events  
•Western Kentucky University's president of the Campus Activities Board organises a debate 
on cannabis legalisation 
•Approximately 30 students advocating cannabis legalisation gathered at UK to promote the 
university’s NORML chapter  
•Dispute over medical cannabis  on religious grounds  
2007 
•Students at University of Louisville host a debate on cannabis legalisation 
•Religious leaders join the medical cannabis debate 
2009 
•Cannabis debate reignites  
•Student Activities Board of UK organises a debate on cannabis legalisation  
•Gatewood Galbraith, medical cannabis advocate, holds lectures describing how smoking 
cannabis helped cure his asthma  
•Galbraith  said that he predicts that President Obama would decriminalise cannabis use and 
that Kentucky could make money by making cannabis legal  
2010 
•Newspaper article suggests that the Kentucky state government should consider legalising the 
use of cannabis for medical purposes as a way of raising state revenue 
•Republican gubernatorial candidate Phil Moffett says he supports legalising  industrial hemp 
production, but is not in favour of cannabis legalisation   
2011 
•Galbraith to run for governor as an independent  
•NORML says they are not advocating smoking cannabis but its medicinal and industrial use  
2012 
• Galbraith dies 
•Jonathan Miller, Kentucky politician, says it is time for the state to legalise cannabis use  
•A bill to legalise cannabis' use for medical purposes introduced in the Kentucky State Senate 
and is known as the Gatewood Galbraith Memorial Medical Marijuana Act 
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  In the late 1990s, the focus in Kentucky was on separating hemp from general 
cannabis use rather than medical cannabis (“Victory for Hemp?”, 1997). In Kentucky, 
supporters of general cannabis legalisation attempted to make the legalisation 
movement stronger by separating cannabis use from other drugs such as heroin 
(“Victory for Hemp?”, 1997). In March of 2001, Kentucky Governor Paul Patton (D) 
signed into law a bill allowing research on hemp to be conducted at Kentucky 
universities (“Kentucky Governor Signs”, 2001; Ky. Rev. Stat. § 260.853, 2001). Joe 
Hickey, head of a Hemp Growers Cooperative, said that hemp was a way of 
compensating for the loss of revenue Kentucky tobacco farmers were facing, and was 
not an attempt at cannabis legalisation (“Kentucky Governor Signs”, 2001).  
Following the passage of hemp research legislation, cannabis and its medical use 
did not get a significant mention until May 2004, when supporters of cannabis 
legalisation organised a rally through downtown Lexington (“Cures, Not Wars”, 2004). 
The rally was organised by Gatewood Galbraith, a Kentucky politician and lawyer 
(“Cures, Not Wars”, 2004; Galbraith, 2004). Galbraith ran for governor of Kentucky in 
1999 as a member of the Reform Party; for Congress in 2000 as a Reform Party 
candidate and again as an independent in 2002; and for Commissioner of Agriculture in 
1983 as well as Attorney General in 2003 (B. Thomas, 2006). Galbraith said cannabis’ 
use as a medicine spanned over thousands of years and was the basis for over 50 
medicines (Galbraith, 2004). At the rally, some speeches discussed the benefits of 
cannabis as a medicine in the treatment of some medical conditions, while others 
suggested that legalising the medical use of the drug would help Kentucky’s budget and 
health-care crises (“Cures, Not Wars”, 2004).   
Following the rally, there was some mention of medical cannabis and its benefits 
for some individuals with debilitating medical conditions, but this occurred mainly in 
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student newspapers (Adkins, 2004). However, after brief mentions of it in 2004, there 
was no movement on the medical cannabis front until mid-2005, when the Supreme 
Court’s ruling on medical use of cannabis re-started the debate (Slider, 2005). 
Supporters started writing to newspapers in support of medical cannabis and in 
disagreement with the war on drugs (Rector, 2005; Slider, 2005). While some tried to 
discuss cannabis’ medical benefits, Capt. Lisa Rudzinski, spokeswoman for the 
Kentucky State Police, discussed the number of cannabis plants seized in the state 
(Covington, 2005). Cheyenne Albro, director of the Pennyrile Narcotics Task Force, 
said cannabis trade was a big problem in Kentucky and one the police tried to get under 
control. According to police reports, in the period between 2000 and 2005, an average 
of more than 450,000 cannabis plants were found and destroyed annually by Kentucky 
law enforcement agencies. Despite this, Kentucky remains one of the leading states in 
cannabis cultivation (Covington, 2005).  
Student action. The following year, in April of 2006, dozens of students 
gathered for a rally held by the University of Kentucky (UK) chapter of the NORML 
(B. Thomas, 2006). The university’s NORML president, Drew Duncan, said the 
organisation had been around since 2005 but did not have enough financial support to 
organise big events. Gatewood Galbraith was invited by the UK NORML to speak to 
students in an attempt to increase NORML membership (B. Thomas, 2006).  He spoke 
to students about cannabis legalisation and their rights in relation to possession of the 
drug. Opinions on Galbraith were mixed, with some believing he would increase 
NORML membership, while others believed his presence was an attempt to get votes 
for his next attempt at public office (B. Thomas, 2006).  
A week after the NORML event at the UK, Daniel Trujillo, president of the 
Campus Activities Board at Western Kentucky University organised a “Heads vs. Feds” 
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debate on cannabis legalisation (Keene, 2006). Steven Hager, editor-in-chief of High 
Times magazine, represented supporters of cannabis legalisation while Bob Stutman, a 
retired DEA agent, represented the side advocating the continued criminalisation of the 
drug. Event organisers said its purpose was to inform students about cannabis and give 
them both sides of the cannabis legalisation debate (Keene, 2006).  
In November of 2006, approximately 30 students advocating cannabis 
legalisation gathered at UK to promote the university’s NORML chapter (Troutman, 
2006). Gatewood Galbraith was once again the guest speaker at the gathering, during 
which he voiced his support for medical cannabis and the hemp industry (Troutman, 
2006). Following on the same topic, it was reported in a newspaper article that groups 
advocating cannabis legalisation such as the DPA and the NORML argue that cannabis 
eradication programs such as the one operating in Kentucky are “a waste of money, 
doing little to cut the supply of pot while helping keep prices artificially high on the 
black market” (Estep, 2006). It was also claimed that the potency of cannabis grown in 
Kentucky has increased over the years, making it a prized drug outside of the state 
(Estep, 2006).  
March of 2007 again saw student involvement when the University of Louisville 
Properties (ULP), which offer student housing for University of Louisville on campus 
students, hosted a debate on cannabis legalisation (Shastry, 2007). Sergeant Steve 
Salyers from the Louisville Police Narcotics/Vice Department moderated the debates. 
The debates were co-ordinated by Lamont Johnson, assistant community manager for 
ULP, and were aimed at presenting students with both sides of the cannabis legalisation 
debate. Medicinal and economic benefits gained from cannabis legalisation were 
emphasised by the pro-legalisation side, while the opposing side argued that cannabis 
was a gateway to “harder” and more dangerous drugs (Shastry, 2007).  
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In 2009, the Student Activities Board of UK organised a debate on cannabis 
legalisation on campus (Coovert, 2009; Hurt, 2009). As in earlier years, the debate 
called “Heads vs. Feds” occurred between Steve Hager and Bob Stutman. When 
questioned, Hager said his magazine, High Times, promoted cannabis legalisation but 
was not involved in any illegal activities. Despite disagreements on the topic, Stutman 
said that he and Hager were personal friends and that he hoped students would hear a 
rational and intelligent presentation from both sides. During the debate, Hager spoke 
about the medical benefits of cannabis and suggested it should be legalised because it is 
a cheap medication (Coovert, 2009; Hurt, 2009). Meanwhile, Stutman claimed cannabis 
was bad for people’s health and was not the benign drug people thought it was (Coovert, 
2009; Hurt, 2009). However, both sides seemed to agree that cannabis use was about 
responsibility (Hurt, 2009).  
Religious stance. September of 2006 saw religion become involved in the 
cannabis debate, with Dr. Ted Beam, Senior Pastor of the United Methodist Church, 
writing against cannabis legalisation (Beam, 2006). He said that removing illegal drugs 
from the community would have a positive effect and disagreed with statements which 
suggested God intended for people to use cannabis (Beam, 2006). In response, Rev. 
Meril Draper said he disagreed with Dr. Beam’s sentiments as he was not interpreting 
scripture correctly (Draper, 2006). Reverend Draper said he spoke on the topic of 
medical cannabis from personal experience, as his grandfather used the drug while 
suffering from cancer. He questioned whether or not Dr. Beam would go out and start 
smoking cannabis if it were legalised, to which he believed the answer was no. 
Reverend Draper then asked why Dr. Beam believed everyone else would do so 
(Draper, 2006). Dr. Beam’s letter proved somewhat controversial and caused more 
individuals to write to newspapers to dispute his claims on religious grounds, question 
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the war on drugs, but also suggest that cannabis is a gateway drug and that its 
legalisation wold lead to legalisation of other drugs such as cocaine (Givens, 2006; 
McLaurine, 2008; N. Miller, 2008a; N. Miller, 2008b; Ryan, 2007).  
Debates. In 2009, the cannabis debate was again reignited when UK organised a 
debate on cannabis, which was followed by Gatewood Galbraith holding lectures in 
Kentucky in which he described how smoking cannabis helped cure his asthma (Reed, 
2009). He said that earlier in history, America learnt that cannabis was the number one 
plant for all uses, but that the forming of chemical industries led to the criminalisation 
of the drug. Galbraith argued that cannabis had a variety of uses and was not bad for 
people’s health. Galbraith predicted that President Obama would decriminalise cannabis 
use and that Kentucky could make money by making cannabis legal (Reed, 2009).  
Galbraith wasn’t the only one to suggest that money could be made from 
cannabis legalisation, with a 2010 newspaper article suggesting that the Kentucky state 
government should consider legalising the use of cannabis for medical purposes as a 
way of raising state revenue (“Why Not Medical Marijuana”, 2010). The article stated 
that a medical cannabis bill would create jobs, generate revenue, and provide relief for 
tens of thousands of individuals suffering from a debilitating medical condition. The 
article suggested that the Federal government was forbidden from saying anything 
positive about cannabis by the Controlled Substances Act of 1970, and that the only 
good thing the federal government did was to decide not to interfere with medical 
cannabis users, doctors and providers as long as they abide by the state law. The article 
concluded that proposing a medical cannabis bill would be beneficial to legislators, as it 
would make the voters think the legislators were prepared to make a change (“Why Not 
Medical Marijuana”, 2010). 
 Medical Cannabis in the United States     210 
 
Kentucky Republican gubernatorial candidate Phil Moffett said he supported 
legalising industrial hemp production, but was not in favour of cannabis legalisation (P. 
Smith, 2010). He said he opposed medical cannabis use on an “official level”, but 
would personally not “get in the way” of someone dying of cancer and smoking the 
drug for comfort. Moffett believed there was a humanitarian aspect to allowing cannabis 
use for seriously ill individuals such as terminally ill cancer patients (P. Smith, 2010). 
Despite mentions of the medicinal properties of cannabis and its possibility of 
increasing Kentucky’s revenue, no medical cannabis bill was introduced in the 
legislature at the time of writing, nor was any such law passed. 
In 2011 Gatewood Galbraith was set to run for governor as an independent 
(Brockman, 2011). In February of the same year, he spoke to students at the Eastern 
Kentucky University, in a meeting organised by the NORML. Ashley Sharp, the 
executive director of NORML, said that they wanted Galbraith to speak to students in 
order to raise awareness of what the organisation’s mission is. Sharp also mentioned 
that the NORML was not advocating smoking cannabis, but its medical and industrial 
use (Brockman, 2011).  
Follow-up. In January 2012 it was announced that Galbraith had died, five 
months after running his campaign for governor (Blackford, 2012; Gerth, 2012). 
Following his death, Jonathan Miller, a Kentucky politician, declared that it was time 
for the state to legalise cannabis use (J. Miller, 2012). Miller expressed his belief that 
cannabis was not as addictive as alcohol, tobacco, and some other drugs, as well as that 
there was evidence for its medical use. He also said that cannabis was Kentucky’s 
“number one cash crop” and would have economic benefits if it was legalised (J. Miller, 
2012).  
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At the start of February 2012, a bill that would legalise cannabis’ use for 
medical purposes was introduced in the Kentucky State Senate (“Medical Marijuana 
Comes”, 2012). The bill known as the Gatewood Galbraith Memorial Medical 
Marijuana Act was introduced by Sen. Barry Clark (D) and sought to make cannabis a 
Schedule II drug. It also sought to give doctors the ability to prescribe up to five ounces 
of cannabis per month to their patients, or allow them to cultivate up to five cannabis 
plants (S.B. 129, 2010). However, by March 2012, the bill was stalled in the Senate 
Judicial Committee when its chair Sen. Tom Jensen (R) refused to call the measure 
before the committee, which meant that the bill could be dead for the 2012 legislative 
year (Clarke, 2012).  
Louisiana 
Like Kentucky, Louisiana is a state that has no effective medical cannabis law 
and is not in the process of considering such a law (MPP, 2013).10 The difference 
between these two states is that Louisiana has an existing medical cannabis law, enacted 
in 1978 and amended in 1991, which has remained ineffective and purely symbolic (La. 
Rev. Stat. § 40:1046, 1991; Loh-Harrist, 2002; MPP, 2013). The 1978 Therapeutic Use 
of Marijuana law allowed cancer and glaucoma sufferers to receive a cannabis 
prescription from their doctor. The law was amended in 1991 to include patients with 
spastic quadriplegia (La. Rev. Stat. § 40:1046, 1991). The law, however, remains 
ineffective as it does not include a way for doctors or patients to obtain cannabis, and 
federal drug laws made it available only for research programs (MPP, 2013).  
10 Since this thesis was submitted, there has been consideration of a medical cannabis law in the state of 
Louisiana. 
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Cannabis possession, cultivation, sale, or trafficking, are a criminal offence in 
Louisiana (La. Rev. Stat. § 40:966, 1972). Penalties for possession of any amount of 
cannabis, even for a first offence, include a fine and possibly a term in prison. Despite 
the ineffective medical cannabis law, the state has not legalised cannabis use for 
medical purposes, and such use remains a criminal offence (La. Rev. Stat. § 40:966, 
1972).  As Louisiana does not have a ballot initiative process, the legislature is 
responsible for proposing law changes in the state (IRI, 2009). However, at the time of 
writing this thesis, the state’s legislature had not attempted to pass a medical cannabis 
law since 1991 (Brumble, 2009). As Louisiana does not have an effective medical 
cannabis law, the following section will chronologically review the history of attempts 
made to pass medical cannabis legislation in the state.  
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1978 
•Louisiana Governor Edwin Edwards signs a bill to let doctors prescribe cannabis to assist 
glaucoma and cancer patients  
•The word "prescribe" made the law ineffective as doctors cannot legally prescribe an 
illegal substance 
1981 
•Amended version of the 1978 bill signed into law but remained ineffective 
1991 
•A law similar to that passed in 1978  is signed by Goveror Roemer but no action was taken 
and law remained ineffective   
2002 
•Arrest sparks debate- Wesley Sarradet arrested for cultivating and using cannabis he 
alleged was for medical problems 
•NORML says the reason there were no good clinical trials on the effectiveness of cannabis 
is the fact that the federal government kept tight control over cannabis 
2003 
•Dr Robert Goidel from the Public Policy Research Lab says that there is little interest in 
medical cannabis in the Southern states 
•Gubernatorial candidates Kathleen Bloanco and Bobby Jindal both oppose legalising 
cannabis for general use  
•Bruce Mirken, of the MPP, says that if a Louisiana governor was to consider a medical 
cannabis law, recommendations should be made to ensure the law was passed on a model 
that had proven workable in other states with an active medical cannabis law  
2005 
•City-level action- Cannabis Action Network (CAN) collects enough signatures to get a 
cannabis initiative onto parish-level ballot 
•Louisiana State University chapter of CAN holds parties to promote cannabis legalisation  
•DPA announce the organisation would begin a lobbying initiative in Louisiana 
2006 
•Media frenzy follows the arrrest of country music star Willie Nelson for cannabis 
posession  
2008 
•Matthew Zugsberger, California medical cannabis patient, arrested in Louisiana on a 
cannabis posession charge  
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Figure 6. Time chart of medical cannabis history in Louisiana.  
In 1978, Louisiana Governor Edwin Edwards signed a bill to let doctors 
prescribe cannabis to assist glaucoma and cancer patients (Loh-Harrist, 2002). It should 
be noted that using the word “prescribe” made the law ineffective, as doctors cannot 
legally prescribe an illegal substance to their patients (Delaney, 2010a). The law 
required a Marijuana Prescription Review Board to be formed to determine who would 
be eligible to legally receive cannabis. However, the board was never formed and the 
law remained ineffective. Then, in 1981 an amended version of the 1978 bill was 
introduced and signed into law by Gov. David Treen, but again remained ineffective. A 
similar medical cannabis bill was signed into law by Gov. Buddy Roemer in 1991 (Loh-
Harrist, 2002). Gov. Roemer again appointed a board to oversee the implementation of 
the law, but no action was taken and the board was dismissed in 1992 (Delaney, 2010a). 
Bobby Delaney, from the Louisiana chapter of the NORML, attributed the law’s failure 
to its conflict with federal cannabis laws (Delaney, 2010a).  In Delaney’s opinion, it was 
unclear why Louisiana’s legislature passed such legislation, which ultimately proved to 
be useless (Delaney, 2010a).  Since 1991, there has been very little political discussion 
2009 
•Reports that cannabis arrests on university campuses had increased 
•Announcement made by President Obama’s attorney general, who said that the federal 
government would not prosecute medical cannabis clinics that comply with state laws, 
discussed in the media  
•Zugsberger makes headlines when appearing in a Louisiana court to face cannabis 
posession charges  
•Louisiana newspaper reports that cannabis research was conducted by LSU Health 
Sciences Centre in New Orleans 
•Supporters say that that it would take a lot of advocacy to pass medical cannabis 
legislation in Louisiana  
2010 
•NORML becomes more active in Louisiana and states that  it will only focus on medical 
cannabis 
•By the end of the year it is reported that Louisiana NORML is not very active due to 
conflict among the executive board 
•Protests against cannabis legalisation continue to be held across Louisiana 
•New Orleans city cuncil reclassifies cannabis posession to municipal offence  
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on the topic of medical cannabis (Brumble, 2009). In 2002, Wesley Sarradet, who 
suffered from spastic cerebral palsy and cultivated and used cannabis to help ease his 
condition, was arrested by agents from the River West Narcotics Task Force (RWNTF) 
(Loh-Harrist, 2002). He was charged with two drug felonies and a misdemeanour. 
While Sarradet maintained he had cultivated and used cannabis solely for medical 
purposes, RWNTF director Maj. Jerome Fontenot said he did not believe Sarradet’s 
claims. James Johnson, one of the arresting officers, said Sarradet most likely did have 
medical problems. However, Johnson said he had a duty to uphold the law. In his 
defence, Sarradet said he had tried using medication such as Vicodin and morphine 
patches to help ease his pain and various other drugs to assist with other symptoms, but 
found cannabis to be cheaper, more effective, and to have fewer side effects than other 
drugs. Sarradet also believed he would not have been convicted had he been allowed to 
use his medical records and use medical necessity as his defence (Loh-Harrist, 2002).  
A brief discussion of medical cannabis in the media followed Sarradet’s arrest 
and sentencing. Dr. John Cole, an oncologist at the Ochsner Cancer Institute, said there 
were no good clinical trials which looked at the effectiveness of cannabis in treating 
medical conditions (Loh-Harrist, 2002). He also added that it could not be said with 
certainty that cannabis was better than other medications. However, Dr. Cole agreed 
that Marinol was not an effective anti-nausea medication and said he generally avoided 
prescribing it. If it were legal do so, Dr. Cole said he would probably prescribe cannabis 
to his patients. He also did not object to his patients using cannabis to help treat their 
medical conditions (Loh-Harrist, 2002).  
In response to Dr. Cole’s statement, the NORML spokesman, Paul Armentano, 
said the reason there were no good clinical trials on the effectiveness of cannabis was 
the fact that the federal government kept tight control over the drug (Loh-Harrist, 2002). 
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Armentano was of the opinion that the federally produced cannabis, grown for research 
purposes, was of poor quality and would most likely skew tests conducted on the drug’s 
effectiveness. He also pointed out that the pharmaceutical industry appeared to oppose 
legalisation of any medicine that could be grown by patients for themselves (Loh-
Harrist, 2002). Robert Sharpe, a program officer for the DPA, agreed with Armentano 
and added that there was a need for state-level medical cannabis distribution programs 
the federal government would not intrude upon (Sharpe, 2002).  
Media articles on the issue decreased until November 2003, when gubernatorial 
candidates Kathleen Blanco (D) and Bobby Jindal (R) were both said to oppose 
legalising cannabis for general use (Alford, 2003). Jindal also firmly opposed medical 
cannabis and said he would not sign such legislation. He attributed his stance to his 
experience at the state Department of Health and Hospitals, where he said experts 
believed cannabis was a gateway drug. Meanwhile Blanco, who was later elected 
governor, said she was always taught that cannabis was a gateway drug and did not 
believe in legalising it for general use. However, she believed that cannabis should not 
be denied to patients with some debilitating medical conditions if the drug could help 
alleviate their pain. Commenting on the issue, Bruce Mirken, of the MPP said that if a 
Louisiana governor was to consider a medical cannabis law, recommendations should 
be made to ensure the law was passed on a model that had proven workable in other 
states with an active medical cannabis law (Alford, 2003). In 2003, Dr. Robert Goidel, 
co-director of the Public Policy Research Laboratory in Baton Rouge said he was 
surprised medical cannabis was not a more popular topic in Louisiana (Alford, 2003). 
He said that he came to the conclusion that there was little interest in medical cannabis 
in the Southern states.  
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A city-level attempt. Following the gubernatorial election, no significant 
discussion on the topic of medical cannabis was noted in the media until April of 2005 
when Daniel Williams, a member of the Cannabis Action Network (CAN), discussed 
his organisation in an article published by the Advocate, the primary newspaper of 
Baton Rouge (Ventura, 2005). The CAN aimed to collect enough signatures to get a 
cannabis initiative on the East Baton Rouge parish-level ballot. Williams said the 
organisation opted for a parish-level ballot initiative as they did not have a lot of 
funding or political influence. The initiative’s aim was to change the city’s ordinance to 
decrease cannabis possession penalties, so that a person caught in possession of the 
drug, no matter what offense, would only receive a fine (Ventura, 2005). The city’s 
assistant chief administrative officer, Alfred Williams, said he would oppose any such 
initiative as he believed it would only make cannabis more available to youth (Ventura, 
2005). 
A representative of Louisiana’s Partnership for a Drug Free America chapter, 
Janice Williams, disagreed with CAN’s initiative as she believed cannabis was a 
gateway drug which led to more harmful and deadly substances (Ventura, 2005). Mary 
Roper, a special assistant in the Parish Attorney’s office, looked at the proposed 
initiative and concluded that even if an ordinance change were passed, the local police 
would still be able to choose whether or not to follow the local or the state law. She 
believed passing such an ordinance change would lead to the city government losing 
money. While the CAN attempted to collect enough signatures for their initiative, 
Michael Blain, a spokesman for the DPA, announced the organisation would begin a 
lobbying initiative in Louisiana (Ventura, 2005). Blain said that Louisiana’s cannabis 
sentencing was overcrowding the state’s prisons and the state therefore needed to look 
at decreasing sentences for cannabis offenses (Ventura, 2005). First movement at the 
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city level came when the New Orleans city council reclassified cannabis possession to a 
municipal offense, allowing police the option to issue a summons rather than make an 
arrest (Eggler, 2010). 
In April of 2006, the Louisiana State University (LSU) chapter of CAN was 
publicising its efforts to legalise cannabis (Alexander & Broussard, 2006). The 
organisation held yearly parties to promote its cause and set up information tables at 
various venues such as nightclubs and taverns in order to recruit new members and sign 
petitions (Alexander & Broussard, 2006; Ventura, 2005). However, by the end of 2006, 
CAN was no longer an official student organisation but the issue continued to be 
discussed in student newspapers (Alexander & Broussard, 2006; “Anti-Marijuana 
Laws”, 2008; Blake, 2006; Ruchalski, 2006).  
Arrests draw attention to the issue. Media frenzy followed the arrest of 
country music star Willie Nelson, who was charged with misdemeanour drug possession 
(Brown, 2006; “Willie Nelson”, 2006). The musician was an active advocate for 
cannabis legalisation and was in possession of the drug at the time of his arrest in Saint 
Martin Parish, Louisiana. In 2007, he made news headlines again, when a Louisiana 
court sentenced him to six months of probation after he pleaded guilty to a cannabis 
possession charge (Burges, 2007). 
In 2008, Matthew Zugsberger, a California resident, was arrested in Louisiana 
on a cannabis possession charge (Campo, 2008; Legendre, 2008). Zugsberger had a 
doctor’s letter and a California-issued medical cannabis patient card. He said it was not 
his intent to break the state law as he only used cannabis to ease severe nausea caused 
by a spinal cord injury (Campo, 2008; Legendre, 2008). He decided to fight the charges 
but said he did not want to fight the system, only help refine it. Zugsberger’s aim was to 
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prove that his California licence for using cannabis as a medicine should be recognised 
in Louisiana and the rest of the U.S. states (Legendre, 2008).  If deemed necessary, he 
planned to take the matter to the Supreme Court, but held hope that a Louisiana judge 
would change the state’s stance on medical cannabis (Campo, 2008).  
In April of 2009, it was reported that cannabis arrests on university campuses 
had increased (Bove, 2009). According to one article, the LSU Police Department 
spokesman, Maj. Lawrence Rabalais, said the department’s goal was preventing 
students and other citizens from using the drug again. Rabalais, who was personally 
against cannabis legalisation, wondered what drug would be next if cannabis were 
legalised and where drug legalisation would stop (Bove, 2009). The topic of cannabis 
legalisation continued to be debated, but largely at the student level, with both 
proponents and opponents writing to the student newspapers to voice their opinions on 
the issue (Albright, 2009; Bove, 2009; Freeman, 2009; Macmurdo, 2009).  
In May of 2009, Ronald Fraser, who writes for a civil liberties organisation, the 
DKT Liberty Project, discussed an announcement made by President Obama’s attorney 
general, who said that the federal government would not prosecute medical cannabis 
clinics that comply with state laws (Fraser, 2009). As a result of the announcement, 
Fraser suggested that lawmakers were free to decide whether or not cannabis use for 
medical purposes would become legalised. The author said that thousands of ill 
individuals could testify that cannabis assisted them with their medical condition, while 
the federal government maintained that the drug had no medical properties. He therefore 
said it was up to the state legislature to decide whether or not medical cannabis would 
be legalised in Louisiana (Fraser, 2009).  
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Matthew Zugsberger continued to make headlines when he was scheduled to 
appear in a Louisiana court to face cannabis possession charges (Legendre, 2009). 
Zugsberger argued that cannabis helped ease his pain better than other medication did. 
The prosecution disputed this argument and stated Zugsberger’s prescription was 
invalid in Louisiana. His court case was the first such case ruled upon in Louisiana. 
Zugsberger alleged that the Lafourche District Attorney’s Office was stalling the case, 
as it did not want to be responsible for legalising medical cannabis in Louisiana. In 
response, Lafourche District Attorney Cam Morvant II said Zugsberger’s claims were 
not true. When asked to comment on the case, NORML’s executive director, Allen St. 
Pierre, said that illnesses did not change due to geographic location (Legendre, 2009). In 
August 2011, Matthew Zugsberger pled guilty to felony charges after three years of 
prosecution and received a suspended jail sentence (Gorman, 2011).  
The week of Zugsberger’s trial, an article in a Louisiana newspaper reported that 
cannabis research was conducted by LSU Health Sciences Centre in New Orleans 
(Brumble, 2009). The research was funded by the NIDA and looked into the effects of 
cannabis on people affected by HIV and AIDS. However, Rep. Richard Burford (R) 
said there appeared to be no interest in passing medical cannabis legislation, and if there 
were, he would not be in favour of it. Malone thought the same, and said it would take a 
lot of advocacy from reputable and knowledgeable medical cannabis users and 
supporters in order to pass medical cannabis legislation in Louisiana (Brumble, 2009).  
The year 2010 saw NORML become more active in Louisiana, when the 
organisation’s state chapter held its second Medical Cannabis Rally in Monroe (Kelly, 
2010). The organisation was also set to have a booth at the Bluegoose Music Festival in 
August of 2010, where people could obtain NORML merchandise and sign up to 
become members of the organisation (Delaney, 2010f). The event’s organisers and 
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guest speakers, including Bobby Delaney, declared the Monroe event a success and 
were impressed by the support the cause was receiving (Delaney, 2010d). Delaney said 
a number of people wanted to share their personal experiences with medical cannabis 
and stories about loved ones who suffered from debilitating medical conditions. He said 
most of the sick patients refused to use cannabis, even with doctors’ recommendations, 
as they did not want to break the law. Delaney said that stories like these were the 
reason NORML Louisiana was formed (Delaney, 2010d). In his NORML Louisiana 
blog, Delaney encouraged medical cannabis supporters to write letters to newspaper 
editors in support of medical cannabis and provided a step-by-step guide on how to do 
so most effectively (Delaney, 2010b).  
Louisiana NORML’s website stated that their mission is to obtain “safe and 
legal access to medical cannabis for suffering patients” (Delaney, 2010e). Unlike 
national-level NORML, the organisation’s Louisiana chapter said that they solely focus 
on medical cannabis. Delaney maintained that separating medical cannabis from general 
cannabis legalisation was important and a moral obligation they had to patients. 
Delaney also said that religious leaders were the organisation’s valuable allies (Delaney, 
2010c).  
By the end of 2010, it was reported that the Louisiana NORML chapter wasn’t 
very active due to conflict among the executive board (John, 2010). However, protests 
against cannabis prohibition, organised by Legalize Louisiana, continued to be held in 
various cities across Louisiana (Doughty, 2012; Duvernay, 2011).  Legalize Louisiana 
was founded by Donnie Griffith, who was of the belief that cannabis should be used for 
medical purposes to help those suffering from medical conditions (Doughty, 2012).  
Discussion  
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Following the federal government’s establishment of the NIDA and the IND 
Compassionate Use Program for medical cannabis, several states including Michigan, 
New Mexico, Illinois and Louisiana passed laws that addressed the use of medical 
cannabis. Illinois and Louisiana laws became ineffective the same year they were 
passed, due to political debate and the threat by the federal government to remove a 
doctor’s power to prescribe controlled substances if they prescribed cannabis. This 
restricted the doctors in prescribing cannabis for medical purposes, making the laws 
referring to a prescription by a doctor ineffective. Before the IND program ended, there 
were reports of shortage of federally grown cannabis and patients complaining about its 
quality. Subsequently, some states tried to revive medical cannabis laws, while others 
opted for new ones. It was an important change in drug control policy, with states 
choosing to take the lead and enact medical cannabis laws, against the federal 
government’s wishes. Following the early research in the 1980s, the medicinal effects of 
cannabis were more widely discussed and in 1996 California took the lead and passed a 
medical cannabis law. In relation to the representative states discussed in this chapter, a 
number of issues emerged. The following section will discuss the factors that led to 
passing of medical cannabis legislation and will provide a chronological outline of 
major events that occurred at the federal level and the five representative states (Table 
10).
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Table 10 
Chronological Account of Medical Cannabis Related Events at the Federal and State Level  
 
Year Federal-level Michigan  New Mexico Illinois Kentucky  Louisiana 
1978 Federal government 
IND Compassionate 
use program starts 
supplying patients 
with medical 
cannabis 
 New Mexico passes first 
state law recognising 
medical value of 
cannabis and allowing for 
therapeutic research into 
medical cannabis  
Illinois passes a 
medical cannabis 
therapeutic research 
law  
The law becomes 
ineffective due to 
heated political 
debate and 
restrictions placed 
on it  
 Gov. Edwin Edwards 
signs bill to let 
doctors prescribe 
cannabis to assist 
glaucoma and cancer 
patients  
1979  Michigan passes 
medical cannabis law 
and therapeutic 
research law  
    
1980  Reports of shortage of 
federally grown 
cannabis 
Patients complaining 
about quality of 
federally-supplied 
cannabis  
    
1981      Amended version of 
the 1978 bill signed 
into law but remained 
ineffective  
1988 DEA 
Administrative Law 
Judge rules in 
favour of NORML 
to make cannabis a 
medicine  
 Medical cannabis 
therapeutic research 
program ends 
Cannabis remains legal 
for therapeutic research 
purposes  
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1991 Federal government 
suspends IND 
Compassionate Use 
Medical Marijuana 
Program  
    A law similar to that 
of 1978 is signed but 
remained ineffective  
1996   New Mexicans for 
Compassionate Use is 
created  
   
1997  Peter McWilliams 
attempts using medical 
necessity defence and 
is denied 
Suggestions that anti-
drug groups are 
softening their anti-
medical cannabis 
stance  
Bryan Krumm from New 
Mexicans for 
Compassionate Use 
speaks in front of New 
Mexico Board of 
Pharmacy to gain support 
to reschedule cannabis  
   
1999 IOM study findings 
published  
 
Marinol moved to 
Schedule III of the 
CSA 
Summary of the IOM 
report published in 
Michigan newspapers  
Partnership for a Drug 
Free America supports 
the report’s 
recommendations  
Activists propose 
“Personal 
Responsibility 
Amendment” allowing 
individuals with 
debilitating medical 
conditions “personal 
amount of cannabis” 
Gov. Johnson suggests 
that federal government 
should decriminalise 
drugs  
Drug czar visits New 
Mexico to counter Gov. 
Johnson’s statements 
Activists announce 
potential lawsuit to 
reinstate the 1978 
therapeutic program, 
Alex Valdez of New 
Mexico Department of 
Health says he will move 
to reinstate the law, based 
on Gov. Johnson’s 
instructions  
   
2000  Libertarian party starts Gov. Johnson uses line-    
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petition in Ann Arbor 
to stop police charging 
individuals using 
medical cannabis  
item veto to remove a 
provision banning the use 
of budget money on 
promotion of drug 
legalisation and 
decriminalisation 
Gov. Johnsons says 
cannabis should be 
legalised   
Alex Valdez suggests 
modelling medical 
cannabis program on 
Hawaii’s program 
2001 Supreme Court rules 
there is no medical 
necessity exception 
to the CSA in U.S. 
v. Oakland 
Cannabis Buyers’ 
Cooperative  
Second petition drive 
to place “Personal 
Responsibility 
Amendment” on ballot  
Michigan NORML 
organises activity to 
counter negative 
perceptions of the 
organisation  
Michigan senators 
speak against medical 
cannabis legislation  
Drug Policy Advisory 
Group recommends 
reform of the Lynn 
Pierson Act and that the 
state’s medical cannabis 
law should be modelled 
on Oregon and Hawaii’s 
program 
Gov. Johnson supports 
medical cannabis law 
Opposition vocal in the 
media, saying Gov. 
Johnson is sending a bad 
message and lobbying 
lawmakers to reject some 
of Gov. Johnson’s drug 
reform bills  
NORML begins airing 
radio advertisements  
Two medical cannabis 
bills introduced  
Poll finds majority 
Brenda Kratovil 
seeks to use a 
medical necessity 
defence at her trial, 
drawing upon the 
1978 law  
Gov. Patton signs 
into law a bill 
allowing research 
on hemp  
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support for medical 
cannabis  
2002  Detroit Coalition for 
Compassionate Care 
starts city-based 
medical cannabis 
petition  
Gov. Johnson waters 
down a medical cannabis 
bill following a Supreme 
Court ruling  
New medical cannabis 
bills introduced in the 
Senate  
NMDH spokesperson 
supports cannabis as a 
medicine  
  Arrest sparks debate- 
Wesley Sarradet 
arrested for 
cultivating and using 
cannabis, alleges it 
was for medical 
problems  
NORML says the 
reason behind o good 
medical cannabis 
clinical trials is 
federal government’s 
tight control over 
cannabis  
2003 U.S. House of 
Representatives 
rejects amendment 
to stop federal raids 
on medical cannabis 
patients  
 Compassionate Use 
Medical Cannabis bill 
introduced in the House 
of Representatives and 
defeated  
Gov. Johnson replaced by 
Gov. Richardson  
  Dr Robert Goidel 
from Public Policy 
Research Lab says 
there is little interest 
in medical cannabis 
in the Southern states 
 
Gubernatorial 
candidates oppose 
legalising cannabis 
for general use  
MPP say Louisiana 
cannabis laws should 
be modelled on a law 
proven workable in 
other states  
2004  Ann Arbor medical 
cannabis ordinance 
change placed on city 
 Court finds that 
Kratovil had other 
alternatives to 
Supporters of 
medical cannabis 
legislation 
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ballot  
 
Governor Granholm 
opposes Ann Arbor 
Ordinance change  
 
Detroit voters pass 
medical cannabis 
ordinance amendment  
 
“Love. The Anti-Drug” 
launched in Detroit by 
director of the ONDCP  
cannabis and was 
not entitled to a 
medical necessity 
defence  
 
First attempt at 
passing medical 
cannabis legislation 
with Medical 
Cannabis Act  
 
Medical cannabis 
bill draws media 
attention and 
proponents and 
opponents start 
speaking out  
 
Representative 
McKeon say that he 
sees cannabis as a 
cure for his HIV 
related pain  
 
City activity- 
Chicago Mayor 
supports issuing 
fines to individuals 
found to be in 
possession of small 
amounts of cannabis  
 
Dr Barthwell of the 
ONDCP tours the 
state and speaks 
organise a rally  
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against medical 
cannabis  
2005 The U.S. Supreme 
Court upholds the 
power of Congress 
to prohibit and 
prosecute medical 
cannabis  
Ferndale and Traverse 
City pass medical 
cannabis ordinance 
amendments  
 
Activists start 
circulating petitions to 
legalise cannabis and 
regulate it like alcohol  
 
MPP say the Supreme 
Court ruling will not 
deter medical cannabis 
efforts in Michigan and 
other states  
 
Medical cannabis bill 
introduced in the 
House of 
Representatives, the 
ONDCP ask for it to be 
rejected  
Media reports that the 
pharmaceutical industry 
contributed money to 
New Mexico political 
campaigns  
 
Legislative support for 
medical cannabis 
decreased since Gov. 
Johnson was replaced by 
Gov. Richardson  
 
Senate passes three 
medical cannabis bills  
 
Gov. Richardson says 
that if the House passes a 
medical cannabis bill he 
would sign it  
Medical cannabis 
bill dies at a 
committee without 
being voted on, bill 
filed again  
 
Dr Barthwell holds 
seminars speaking 
against medical 
cannabis, the 
ONDCP director 
arrives in Illinois to 
testify against 
medical cannabis 
legislation   
 
Medical cannabis 
patients testify in  
favour of medical 
cannabis  
 
Law enforcement 
groups oppose 
medical cannabis 
legislation  
 
Medical cannabis 
bill rejected by the 
Human Services 
committee  
Supreme Court 
ruling on medical 
cannabis restarts 
debate  
 
Reports from law 
enforcement that 
cannabis trade is a 
big problem in 
Kentucky, a 
leading state in 
cannabis 
cultivation  
CAN gather enough 
signatures to put 
cannabis initiative 
onto parish-level 
ballot  
 
CAN hold parties at 
Louisiana State 
University to 
promote cannabis 
legalisation  
 
DPA announce they 
wold begin a 
lobbying initiative in 
Louisiana 
 
 
2006 FDA confirms 
opposition to 
smoked cannabis for 
Medical cannabis bill 
dies  
Activist group 
Patients speak in support 
of medical cannabis  
 
NORML say that 
medical cannabis 
legislation in Illinois 
Students gather at 
a medical cannabis 
rally organised by 
Media frenzy follows 
the arrest of country 
music star Willie 
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medical purposes  proposes making 
cannabis legal for 
those over 18 years of 
age  
 
NORML announce 
they will try to get a 
medical cannabis bill 
on the 2008 ballot but 
distance themselves 
from the cannabis 
legalisation proposal  
Gov. Richardson 
announces he will 
include a medical 
cannabis bill on his 
agenda, House Speaker 
asks the governor not to 
include the bill on his 
agenda  
 
Medical cannabis bill 
dies on Senate floor  
may be a decade 
away  
 
New medical 
cannabis bill 
introduced in the 
Senate  
Kentucky chapter 
of NORML  
 
Medical cannabis 
debate organised at 
Western Kentucky 
University  
 
Students gather to 
promote 
University of 
Kentucky’s 
NORML chapter  
 
Dispute over 
medical cannabis 
on religious 
grounds  
Nelson for cannabis 
possession  
2007 DEA 
Administrative Law 
Judge recommends 
allowing new source 
of cannabis for 
research  
Flint City voters pass 
medical cannabis 
ordinance change  
 
Medical cannabis bill 
introduced in the 
House of 
Representatives 
 
ONDCP say medical 
cannabis laws would 
not help sick 
individuals   
 
MCCC announce they 
will launch a Michigan 
Medical Marihuana 
Lynn and Erin 
Compassionate Use Act 
introduced in the Senate  
Opponents say medical 
cannabis bill contradicts 
federal law   
 
Lynn and Erin 
Compassionate Use Act 
defeated and replaced by 
another ac  
 
Gov. Richards says that 
signing the bill would be 
the right thing to do  
 
Allegations that Gov. 
Increase in media 
reports on medical 
cannabis  
 
Medical cannabis 
bill introduced in 
Senate  
 
MMPAP speak in 
support of medical 
cannabis  
 
Church leaders 
speak in support of 
medical cannabis 
 
Ordinance change in 
Students at 
University of 
Louisville debate 
medical cannabis 
legislation 
 
Religious leaders 
join the medical 
cannabis debate  
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initiative  Richardson used medical 
cannabis to gain support 
for his presidential 
campaign  
 
Gov. Richardson signs 
the Lynn and Erin 
Compassionate Use Act 
into law 
Peoria Heights for 
possession of small 
amounts of cannabis   
 
Medical cannabis 
documentary 
screened in Southern 
Illinois University  
 
2008 American College 
of Physicians calls 
for cannabis 
reclassification and 
supports non-
smoked forms of 
medical cannabis  
MCCC poll reveals 
67% of Michigan 
Voters support medical 
cannabis  
 
Michigan State 
Medical Society 
oppose medical 
cannabis, except for 
use in controlled 
studies  
 
Newspaper reports 
MCCC spent over $1.1 
million on 
campaigning, with 
most money coming 
from MPP 
 
Citizens Protecting 
Michigan’s Kids is 
formed, opposing 
medical cannabis law  
 
Director of the 
ONDCP speaks against 
 NORML active in 
the media, 
responding to 
opposition  
 
Two medical 
cannabis bills 
introduced  
 
Survey shows that 
majority of Illinois 
voters support 
medical cannabis  
 Medical cannabis 
patient from 
California arrested in 
Louisiana on a 
cannabis possession 
charge  
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medical cannabis in 
Detroit  
 
A group of local law 
enforcement agencies 
issue a statement 
opposing medical 
cannabis proposal  
Michigan voters 
approve medical 
cannabis initiative  
2009 DEA rejects ruling 
to allow new source 
of cannabis for 
research  
 
AMA calls on the 
federal government 
to reconsider 
cannabis’ 
classification under 
federal law  
 
Deputy Attorney 
General says raids 
on medical cannabis 
clinics will not 
continue  
  President Obama 
assuming office 
sparks optimism in 
medical cannabis 
supporters  
 
City activity- 
Springfield and 
Cook County 
change ordinance in 
relation to cannabis 
possession  
 
Two medical 
cannabis bills 
introduced  
Cannabis debate 
reignites  
 
Cannabis 
legalisation debate 
organised at 
University of 
Kentucky  
 
Gatewood 
Galbraith holds 
lectures on 
medical cannabis  
 
Galbrait says he 
predicts that 
President Obama 
will decriminalise 
cannabis use and 
that Kentucky 
could make money 
by making 
cannabis legal  
Reports that cannabis 
arrests on university 
campuses increased  
 
Deputy Attorney 
General’s statement 
discussed in the 
media  
 
Medical cannabis 
research conducted 
by LSU Health 
Science Centre  
 
Supporters say it 
would take a lot of 
advocacy to pass 
medical cannabis 
legislation in 
Louisiana  
2010    Politicians from Suggestions that NORML becomes 
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both parties indicate 
they would consider 
medical cannabis 
bills  
 
Suggestions that 
some lawmakers 
were worried about 
making politically 
risky voters  
 
Medical cannabis 
bill dies  
Kentucky should 
consider legalising 
cannabis for 
medical cannabis 
as a way of raising 
state revenue  
 
Republican 
gubernatorial 
candidate says he 
supports legalising 
industrial hemp, 
but is not in favour 
of cannabis 
legalisation  
more active in 
Louisiana and state 
they will only focus 
on medical cannabis, 
however NORML 
less active by the end 
of the year due to 
conflict among the 
executive board  
 
Protests against 
cannabis legalisation 
held across Louisiana  
 
New Orleans city 
council reclassifies 
cannabis possession 
to municipal offence   
2011    Medical cannabis 
bill re-introduced  
Galbraith set to run 
for governor as an 
independent. 
 
NORML say they 
are not advocating 
smoked cannabis 
but its medicinal 
and industrial use  
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The role of scientific evidence. A 2010 report on medical cannabis concluded 
that “it is widely believed that science should rule when it comes to medical issues” 
(Eddy, 2010, p.46). However, based on the reviews of representative states in this 
chapter, this is often not the case, there being a discrepancy between what the evidence 
tells us and how this is reflected in current medical cannabis laws. The research 
evidence reviewed has shown that cannabis and its constituents have therapeutic 
potential for a number of conditions including chronic pain, spasticity, nausea and 
vomiting, and as an appetite simulant for AIDS-related wasting syndrome. The laws in 
New Mexico and Michigan cover these and other conditions. Use of smoked cannabis is 
generally not the recommended route of administration, but all the medical cannabis 
state laws provide for the use of smoked cannabis (House of Lords, 1998; Robson, 
2001; WPUCMP, 2000).  
Ideally, scientific evidence should always be incorporated in selecting and 
implementing programs, developing policies, and evaluating progress but the review of 
the medical cannabis laws has shown the situation to be otherwise (Brownson, Baker, 
Left, Gillespie, & True, 2011). The policy process is primarily a political rather than 
scientific process which does not rely solely on research evidence (Anderson, 2003; 
Brownson et al., 2009; Brownson et al., 2011; Pentz, Marers, Schinke, & Rohrbach, 
2004; Ritter, 2011).  
It can also be seen that scientific evidence was presented to the general public, 
but mostly filtered through the media. While proponents and opponents were active in 
putting forward their opinions, researchers were not featured prominently in the medical 
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cannabis debates.  According to Weiss’ (1979) “enlightenment model”, the impact of 
research on policy is not direct, but research is instead seen as one of several sources of 
information available to policymakers; a gradual shift in thinking over time and 
accumulation of research will influence policy by educating the policymakers. While 
those involved in the field have called for more research into medical cannabis, based 
on the evidence reviewed in this thesis it cannot be said that further research will play a 
bigger role in influencing medical cannabis laws.  
“Cherry-picking”: the selective use of evidence. Weiss identified ways in which 
the results of policy research enter the policy field and suggested that research can be 
used to support positons already adopted. That is, policymakers and/or interest groups 
use research to support their position (Weiss, 1991). While scientific evidence may not 
directly inform medical cannabis policy development, the findings of the research 
presented in this thesis suggest that it still plays a role in the process, just not a direct 
one. However, scientific evidence, regardless of its quality, appears to rarely enter the 
debate except when it is used as ammunition. Both opponents and proponents of 
medical cannabis tend to use research findings as a means of attacking or defending 
their arguments, rather than as the key to deciding whether cannabis should be available 
as a medicine for specific conditions or not. For example, the IOM (1999) review 
outlined both positives and negatives of cannabis use and provided ammunition for both 
proponents and opponents to use in the medical cannabis debate. Medical cannabis 
supporters focused on the report’s findings that cannabis has medicinal properties and 
that there was no convincing evidence for the “gateway” theory. Opposition, 
meanwhile, mainly focused on the report’s findings that cannabis smoke can be toxic.  
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As Weiss (1991) suggested, research being used to argue a position is more 
likely to be influential when conflict is high and different sides are seeking justification 
to strengthen their own case and in legislatures where argumentation is the prevailing 
mode (Weiss, 1991). In Michigan and New Mexico, for example, once the findings of 
the IOM report were published they were used by both sides to support their arguments. 
Most debate in Michigan occurred in the months prior to the medical cannabis bill going 
on the ballot, and in New Mexico the debate intensified following the IOM report and 
the 2001 Supreme Court ruling that there is no medical necessity exception to the CSA.  
Public opinion. Public opinion is particularly influential in states passing a law 
through a ballot initiative. For example, Michigan’s law was passed through a ballot 
initiative and there was much focus on getting public support, convincing the public, 
and portraying the issue as being ether detrimental to the public or in its best interest. In 
Michigan particularly, medical cannabis opponents frequently appealed to the public 
and portrayed their cause as being about preventing “wrong messages” from getting to 
the public or to certain groups. It can be difficult to argue against a vague concept such 
as “sending the wrong message”; in Michigan there was little questioning of what these 
wrong messages were and what sort of an effect they would have. In Michigan, medical 
cannabis opponents also accused the proponents of relying on the sympathy of the 
voting public, creating policies which were not in the public’s best interest, and called 
shutting down of medical cannabis dispensaries “a matter of public safety”. New 
Mexico did not experience the same amount of public debate or attempts at influencing 
public opinion as Michigan did. Illinois did experience significant public response 
regarding the medical cannabis issue, but since questions related to medical cannabis 
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cannot be placed on a ballot initiative in this state, the attempts at influencing public 
opinion were somewhat futile (IRI, 2009; MPP, 2013).  
That is not to say that public opinion does not influence policy in states 
attempting to pass a law through the legislative process, as public opinion has been 
identified as one of the major factors politicians take into account when making policy-
related decisions. Public opinion can be of importance to politicians as it is the public 
who determines whether the politician stays in power or not. Amongst other things, 
politicians are therefore concerned with what they think the public wants. This raises the 
question of how much of a role public opinion plays when a politician is not up for re-
election.  
Local governments. Over the years, local governments have become more 
representative of the communities they serve; this has made it easier for the electorate to 
raise issues and voice their opinions; and sometimes act more quickly at the local level 
than the state and federal governments do (Katz, 2003; U.S. Immigration and 
Naturalization Service, 1987). In Michigan, cities led the movement towards medical 
cannabis legislation. The first movement occurred in 2004, when Detroit voters passed 
an initiative to legalise medical cannabis in the city, despite opposition from Gov. 
Granholm. Ann Arbor followed, with approximately 75 percent of voters supporting 
amendments to the ordinance to decrease fines for cannabis use and prohibit local police 
from fining medical cannabis patients for possession. Ann Arbor has a history of 
passing cannabis ordinances dating back to 1972 (Cannabis laws in Ann Arbor, 
Michigan, n.d.). Despite opposition, in 2005 both Ferndale and Traverse Cities passed 
medical cannabis related ordinance changes. There was also city-level activity in Illinois 
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and Louisiana and movements towards medical cannabis legislation at the state level 
also coincided with attempts at city-level changes. 
The people as legislators: Influence of direct democracy. Initiatives give the 
electorate a more direct input to the enactment of laws that were originally created as 
means of directly enacting public policy (Kousser & McCubbins, 2005). However, 
Kousser and McCubbins (2005) claimed that in the recent years the initiative process 
has been used as a check on the legislature and a way of pressuring it into adopting 
certain policies. The findings in this study indicate that using the initiative process 
helped pass medical cannabis laws initially in some states and helped them gain 
momentum in other states, eventually leading to legislatures passing such laws. Starting 
with California, the first seven state medical cannabis laws were passed by a ballot 
initiative. To date, 10 of the state medical cannabis laws were passed by a ballot 
initiative and 7 were passed by the legislature (ProCon.org, 2014).   
Michigan’s medical cannabis law was passed through the initiative process. 
While there were attempts to pass medical cannabis laws via the legislature, those 
attempts proved unsuccessful. The findings also indicate that there may be some 
differences between the factors which play a role in passing medical cannabis laws in 
states with the initiative process and those without. For example, two key factors, both 
external to the state legislative and executive branches, were important in moving 
Michigan towards its medical cannabis law. These were the actions of several cities to 
enact their own policies and the use of the ballot initiative. The medical cannabis cause 
in Michigan received more attention from national organisations such as the MPP and 
NORML, and also received more funding for the cause. There was also more activity in 
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Michigan, in terms of promoting the issue, media attention, and the number of organised 
state-based support groups.  
The initiative process can be a powerful agenda-setting tool which can be used 
by interest groups, politicians and occasionally political parties to drive an issue onto 
the national agenda because of the widespread media attention given to some initiatives 
(Magleby, 1998). Even when defeated at the polls, attention can still be drawn to a 
particular issue, leading decision makers to discuss and comment on it. Magelby (1998) 
highlighted that because proponents need to meet the signature requirements to place 
their issue on a ballot, which requires either a large number of volunteers or funds to 
hire signature collectors, the initiative process is becoming less a “grass-roots 
phenomenon” and more dominated by large and well organised interest groups. He also 
highlighted the importance of campaigns in defining what the issue means for voters 
and said that initiative campaigns are “largely fought in thirty- and sixty-second 
commercials using attention-getting advertisements” that motivate citizens to either care 
about the issue or create doubts about the initiative (Magleby, 1998, p. 149).  
Interest groups prefer to use direct initiatives to indirect and often propose and 
finance initiatives in multiple states to attract national attention to their issue and 
advance their interests (Hastings & Cann, 2014; Magleby, 1998). Getting a proposition 
on the ballot is a costly and time-consuming process (Cushman, 2005). Requirements 
for putting a proposal on the ballot vary among states, but in some states more than 500, 
000 signatures in support of the initiative are required. It has been argued that this 
process can put well-funded special interest groups at an advantage because of their 
access to campaign professionals, access to donor lists, and media strategies (Birkland, 
2005; Braunstein, 2004; Cushman, 2005; Magleby, 1998).  
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Organised interest groups. While organised interest groups are more likely to 
have a greater access to resources and make campaign contributions in order to advance 
their desired outcomes, money is very important as it enables the groups to do so 
(Birkland, 2005; Boehmke & Bowen, 2010). Much of the research on the topic has 
indicated that monetary resources and a large interest group membership assist in the 
success of the initiative process (Boehmke & Bowen, 2010; Braunstein, 2004; Magleby, 
1998). There has been a growth in the “initiative industry” that specialises in services 
such as petition circulation and polling. As can be seen by the Michigan reports, interest 
groups paid money for voter signature collection in order to place medical cannabis on 
the ballot. It has been estimated that 78 percent of ballot campaigns have been won by 
the side that spent the most money (Braunstein, 2004).  
Interest groups are very important in the policy process and are an effective way 
for people to express their desires for policy (Birkland, 2005). Advocacy groups have 
been very active in states such as Michigan, where they had a persistent and prominent 
involvement. Michigan also experienced significant involvement from national 
organisations such as the MPP, the Open Society Foundation (founded by George 
Soros), and NORML, who played a major role in raising public awareness of the issue. 
Not only were advocacy groups influential in passing legislation, they also influenced 
what sort of legislation was passed. In his assessment of interest group influence on 
U.S. policy change, Grossman (2012) found that since 1945, policy historians credited 
385 out of 790 significant policy enactments to factors related to interest groups, mainly 
general support and lobbying by advocacy organisations.  
The extent to which advocates for both sides of the debate are organised may 
have contributed to the successful enactment of medical cannabis laws. For example, in 
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Michigan, MCCC successfully lobbied for medical cannabis over a period of time, 
while there was no specific organised opposition group until 2008, shortly before the 
issue was due to be voted upon. This could have given medical cannabis supporters the 
advantage, as the opposition only had months to prepare their stance and get actively 
engaged in lobbying against the initiative. The supporters also had a chance to carefully 
set out a strategy, and through the use of media spread their message to a wider 
population. But this is not the case in New Mexico, where no specific group was 
formed. Whether or not this was due to the process taking place predominantly within 
the political system, there being no ballot initiative, is a point worthy of further 
consideration.  
Allocation of money. Another issue which can affect the policy process is the 
allocation of money to support either side of the argument. As New Mexico does not 
have a ballot initiative process, the medical cannabis debate occurred within the 
political system, and little external money was spent there (IRI, 2009). Michigan, 
meanwhile, has a ballot initiative process, which resulted in the debate occurring in the 
public as well as the political arena. In Michigan, in 2008 alone, the MCCC processed 
99 separate donations and a large proportion of external money was spent on the media 
and increasing public awareness of the issue. However, money is not always used to 
support an issue, but can also be used to oppose it, or prevent a law from being passed. 
Because New Mexico does not have an initiative process, instead of money being 
donated to the medical cannabis cause, it was found that, in 2002, the pharmaceutical 
industry contributed money to new Governor Bill Richardson, which he stood to lose if 
cannabis became a legal treatment.    
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Politicians and political parties. Politicians play an important role in the 
enactment or non-enactment of medical cannabis policy. In states with no ballot 
initiative process, medical cannabis laws were passed by the legislature. While it is 
important to have support from politicians, the support does not come easily as there are 
many factors politicians need to take into account when making policy-related 
decisions. If the aim is to make policy making more evidence-based and educate 
politicians, then scientists should be aware of the political process and the factors, apart 
from scientific evidence, that are important to politicians and that politicians need to 
take into account.  
A very important factor is getting re-elected. As previously mentioned, 
politicians need to carefully consider the timing of their decisions to support or oppose 
particular legislation. Politicians also need to consider the impact and benefit of their 
decisions, and what happens in the future. Other factors include, but are not limited to 
campaign funding (who provides support for their re-election and how the decision to 
support or oppose particular legislation will impact fund raising); how they are 
perceived; international standing; lobby, pressure, and interest groups; political 
ideology; what happened and is happening in other states; public opinion; scientific 
evidence; and the policy advice they receive. Scientists interested in informing policy 
need to consider these factors and create the sort of evidence that fits in with what 
politicians need and are looking for.  
Politicians also need to take into account their party ideology. The two major 
parties have, over the years, become distinct in their ideologies and positions they 
assume on a range of issues (Birkland, 2005; Singh, 2003). Generally, the Democrats 
have typically preferred to centralise policymaking, seek to promote equality, and 
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support government intervention to deal with important problems. The Republicans 
generally wish to decentralise policymaking authority, and tend to support fiscal 
prudence and limiting government intervention. The Democrats are generally seen as 
being more liberal while the Republicans are seen as conservative. In terms of medical 
cannabis, the general notion is that the dominant Democrat position is to support 
medical cannabis, while the dominant Republican position is to oppose it (Pickerill & 
Chen, 2008). However, some of the states, such as New Mexico, neither support for nor 
opposition to medical cannabis were clearly defined amongst political parties. What the 
parties attempted to do was use the opponents’ positions as campaign issues, while not 
taking a clearly defined stance themselves. The state’s two last governors, one of whom 
was a Republican, were supporters of medical cannabis, with Gov. Johnson being very 
vocal on not only medical cannabis legalisation, but general cannabis legalisation as 
well. This was in opposition to most medical cannabis activists attempting to separate 
medical cannabis from general cannabis legalisation. 
High-profile politicians. While there were high-profile organisations 
supporting medical cannabis, the issue also drew opposition from some sections of the 
public and some politicians, including the White House. While the ONDCP and the 
DEA were also active in voicing their anti-medical cannabis stance, their influence was 
counteracted by high-profile state politicians who supported medical cannabis. In New 
Mexico, two governors supported medical cannabis laws, even though they came from 
opposite sides of the political fence. The influence that support from high-profile 
politicians can have on passing legislation should not be underestimated, especially in 
states such as New Mexico, where there is no ballot initiative. There was also no 
significant support from high-profile individuals in Kentucky and Louisiana, where 
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public support was lower than in other states and there was no significant involvement 
from high-profile organisations.  
Decoupling. Making a clear distinction between medical cannabis and the 
broader aim of decriminalisation or legalisation of cannabis for recreational as well as 
medical use has played a major role in the medical cannabis debate. In both Michigan 
and New Mexico, medical cannabis advocates made it clear that their main, limited aim 
was legalising cannabis for medical use only. In Kentucky and Louisiana, however, the 
distinction was not as clear. Decoupling has political importance, as one of the main 
arguments used by the opposition is that medical cannabis is a step towards legalising 
cannabis use in general. Making a clear distinction between these counteracts the 
opponent’s arguments and makes medical cannabis legalisation more generally 
acceptable.  
However, it is not always as straightforward in terms of who supports what. 
Some medical cannabis advocates have made it clear that their only aim is to make 
cannabis legal for medical purposes. Other organisations, however, have failed to make 
a clear distinction and sometimes tend to fluctuate between being medical cannabis 
supporters only and supporting general cannabis legalisation. For example, while 
Michigan NORML campaigned for medical cannabis legislation, one NORML 
representative said that the organisation wanted the drug legalised for both recreational 
and medical use. The MPP, on the other hand, have consistently maintained that their 
efforts were aimed towards making cannabis legal for medical purposes only, and that 
medical cannabis was not a step towards general cannabis legalisation.  
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Having no uniform stance on the issue has the tendency to confuse the public 
and raises a question of what the real goal of such organisations is. It can also influence 
how the public perceives medical cannabis advocates and whether or not the issue 
garners enough support. The advocate organisation may therefore need to compromise 
in order for an issue to be passed. In Michigan, for example, because the two 
organisations had conflicting messages, NORML took a back seat to the MCCC to 
counter the claims that legalising medical cannabis was a step towards legalising 
cannabis in general, because MCCC made it clear that their sole goal was legalisation 
for medical purposes only.   
Use of anecdotal evidence and personal experience. While scientific evidence 
plays some role in the policy process, it can also be argued that the process is influenced 
more by anecdotal reports than by scientific evidence. The majority of evidence on 
cannabis as a medicine comes from personal and historical accounts (Mack & Joy, 
2000). Throughout the medical cannabis debate in the states reviewed in this thesis, 
patient accounts and personal experience have frequently been mentioned. Patient 
testimonies were most prominent in New Mexico, where the medical cannabis law was 
passed by the legislature. Michigan also saw its share of patient testimonies, but most 
were presented in the media, either as accounts of their experience with the drug, or as 
letters written to the media. The opposition also used individuals and their personal 
experience to testify against medical cannabis bills.  
There have also been a number of anecdotal reports published, especially in the 
case of cannabis’ use in the treatment of glaucoma. This may have influenced the 
inclusion of glaucoma in the list of debilitating medical conditions cannabis can be used 
for in the states with a medical cannabis law, despite limited scientific evidence 
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supporting the use of cannabis in the treatment in intraocular pressure (ProCon.org, 
2014). Only two states do not specifically include glaucoma in the list of the conditions, 
these being Delaware and Vermont. Interestingly, both states passed their laws through 
the legislature.  
Anecdotal reports also have the potential to inspire further research, as was the 
case with the House of Lords (1998) report, which found that there was strong anecdotal 
evidence for cannabis in the treatment of MS and recommended urgent clinical trials. In 
their examination of the role of anecdotal evidence in public scientific controversies, 
Moore and Stilgoe (2009) found that anecdotal evidence can be used as a guide towards 
further investigation of an issue. Findings from this thesis indicate that politicians listen 
to anecdotal evidence and can sometimes base their decisions on it, more so than on 
scientific evidence. This could be due to the fact that anecdotal evidence is considered 
by some as a representation of public concerns. Anecdotal evidence also admits public 
involvement in development of research programs. Anecdotal evidence is also a more 
localised form of understanding, based on individual experience and knowledge of 
specific, local conditions that are not necessarily “typical” circumstances (Moore & 
Stilgoe, 2009).  
Media. How an issue is framed in the media, or how facts and ideas are 
assembled into messages, can also shape how individuals interpret and evaluate the 
issue  (Lee, McLeod, & Shah, 2008). Research also suggests that the way an issue is 
framed can not only direct the kind of knowledge that is activated in the person reading 
but also how individuals then weigh such issues as relevant attitudes and beliefs, based 
on what they were exposed to (Lee et al., 2008). Geographical location also plays a role 
in terms of the media attention given to a particular issue. In terms of medical cannabis, 
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one study found that in both the Southeast and the Midwest of the U.S., the news 
sources paid the least amount of attention to medical cannabis, comparing to the 
Northeast (Pickerill & Chen, 2008). 
Policy research has not been clear whether media is a just a channel used to 
convey information or a major contributor to the policy process (Gerstl-Pepin, 2007; 
Shanahan, Mcbeth, Hathaway, & Arnell, 2008; Speck, 2010). In terms of medical 
cannabis policy, media acted as a sort of battle arena where the debate occurred, and 
both sides got to present their opinions. There was a tendency for two different sets of 
views to be presented. On one side, cannabis was presented as a harmless drug with 
medicinal properties, while, on the other, it was portrayed as a harmful drug which 
should continue to be prohibited for both recreational and medical use (Strang, Witton, 
& Hall, 2000). Media can also serve as a link between the people and the government 
and can help determine which issues are discussed and which issues the public and 
advocacy organisations get involved in. As a result, the media kept the public actively 
involved in the issue, especially in states such as Michigan, which has a ballot initiative 
process.  
Organisations such as MPP and NORML have used media to draw attention to 
the issue, and have encouraged medical cannabis supporters to contact media and write 
letters of support. Medical cannabis opponents have been less active in using the media 
to promote their stance, but this could also be attributed to the funds available to them. 
Interestingly, the number of media reports on medical cannabis was very high in 
Michigan and New Mexico, but they were fewer in Louisiana, and even more scarce in 
Kentucky. The “hot topic”, or the topic media focused on the most, was different 
amongst the states too. For example, in Kentucky the focus was on hemp over medical 
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cannabis, in New Mexico it was general cannabis legalisation, while in Michigan the 
main focus was on medical cannabis. Speck (2010) argued that the media had the power 
to decide what they want to portray and how, and what they think is newsworthy, 
influencing what the general public sees.  
Findings also indicate that media can filter scientific evidence, and can be 
selective as to what is or is not put forward to the public. As is the case in the review of 
the media articles in the five representative states in this chapter, Shanahan et al. (2008) 
found that there is limited use of science in media articles, and that the information 
presented is mostly based on “interest groups, elected officials, judges, governmental 
agencies, and business/individual citizens” (p. 131).  
Overall, it can be said that the media is an integral part of politics, acting as a 
watchdog and an important check and balance on the political system (Gerstl-Pepin, 
2007). It is the main way the public receives information on political issues and can 
influence how an issue is portrayed and what the focus is on. Media can also be used as 
a tool, enabling supporters and opponents to be persistent and active in promoting their 
cause. However, care needs to be taken as to how media is used, as it can be either 
detrimental or beneficial to a particular issue. In terms of the goal of creating evidence-
based policies, scientists need to consider ways to disseminate the evidence in a way 
that it is picked up by the media, or go directly to the public and those who make policy 
decisions if there are misinterpretations and misrepresentations in the media.  
The findings from the state by state review conducted in this chapter indicate 
that a number of factors influenced the passing and failure to pass medical cannabis 
laws in the five states under review. Scientific evidence is one factor, but this is often 
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not used in the manner scientists would prefer but rather as ammunition to support an 
already adopted position by those involved in the debate. Anecdotal reports of those 
who have or could potentially benefit from medical cannabis are important, as is the 
role of organised and well-funded advocacy groups. While the support of powerful 
politicians can be important, as in the case of New Mexico, lack of such support does 
not prevent laws being enacted, as the case of Michigan illustrates. It should also be 
noted that the decoupling of medical cannabis from wider moves to decriminalise or 
legalise cannabis use is important. The findings also indicate that the allocation of funds 
(how they are allocated, where, and by whom) can influence whether or not a law is 
passed, as can the level of public support for the issue in a particular state. Lastly, it is 
important to consider the state political system and ways of passing legislation. 
The second part of the thesis (see Figure 7), as discussed in the following two 
chapters, used questionnaires to elicit the factors influencing policies as perceived by 
four groups of participants. The questions asked were derived from the literature review 
presented in Chapter Three and the review of five representative states presented in 
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Chapter Four. 
 
Figure 7. Explanatory study design. 
Chapters Five and Six will describe the four study groups and will discuss the 
research design, sampling and data collection procedures, and the techniques used for 
data analysis for each group. Group One comprised individuals directly involved in the 
medical cannabis policy process in at least one of the five states referred to in the state 
by state review. Group Two comprised individuals participating in research in the 
alcohol and other drug field; Group Three comprised individuals currently participating 
in the political field in one of the five U.S. states; and Group Four comprised selected 
members of the International Society for the Study of Drug Policy (ISSDP).
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Chapter 5- Group One and Group Two Study 
This chapter will outline in detail how the Group One and Group Two studies 
was undertaken, provide details of the study design, and present findings. Group One 
participants were active participants in the medical cannabis debate described in 
Chapter Four of this thesis. Group Two participants were individuals participating in 
research in the alcohol and other drug field in one of the five U.S. states under review in 
this thesis.  
A multimethod approach was employed, combining both closed-ended and 
open-ended questions. The multimethod approach was used in order to obtain relevant 
demographic information and basis statistics, while gaining an understanding of the 
participants’ opinions, attitudes, and involvement in the medical cannabis process (Ellett 
& Beausang, 2002). While priority was given to the qualitative component to allow the 
exploration of participants’ opinions on what they perceived to be the main factors that 
played a role in the passing or failure to pass medical cannabis laws in the states 
reviewed in this thesis, each method was used for a specific purpose in order to achieve 
an overall comprehensive understanding of the complex medical cannabis policy 
process.  
Sample 
Group One participants were selected through a non-random sampling method. 
They were identified as active participants of the medical cannabis movement in at least 
one of the five representative states, as described in Chapter Four. Any one individual 
who participated in the debate was invited to be a participant in the research and their 
opinions on what happened in the representative states they were active in were sought 
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to further explore the medical cannabis movement in those states and the main factors 
that played a role. As such, selection bias might have resulted, and will be addressed in 
more detail later.  
Group One participants were all from the U.S. and were actively or previously 
involved in the medical cannabis debate. Their backgrounds included government 
officials, lobbyists, medical professionals, and other individuals. A total of 172 
participants identified by the review were invited to participate; 147 were contacted via 
email and invited to complete an online Qualtrics (www.qualtrics.com) survey, and 25 
were contacted by mail and sent a printed questionnaire. Of those, approximately 12 
emails were undeliverable, and four participants advised that they would be unable to 
participate. Overall, 31 (18%) of the identified participants responded to and completed 
the survey. Of those, 24 completed both quantitative and qualitative portions, while five 
completed only the first (quantitative) portion. The results of the five participants were 
included in the analysis of quantitative data only. 
Group Two participants were also selected through a non-random sampling 
method. Group Two participants were researchers who were currently conducting 
research funded by either the National Institute on Alcohol Abuse and Alcoholism 
(NIAAA), the NIDA, or the Substance Abuse and Mental Health Service 
Administration (SAMHSA) in one of the five states under review in this thesis. The 
participants were selected as it was expected that they would provide a more objective 
perspective on the medical cannabis movement. 
Group Two participants were identified using the National Institutes of Health’s 
reporter website (http://projectreporter.nih.gov/reporter.cfm), which provides names and 
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contact details of researchers receiving funding in specific states. The list of potential 
participants was created by narrowing the numbers down to those working with or 
funded by organisations relevant to the alcohol and other drug field (i.e. NIDA, 
NIAAA, and SAMHSA). A total of 209 participants fitting the selection criteria were 
identified and were contacted via email and invited to complete the online Qualtrics 
survey. Of those, 23 (11%) responded to the survey and 22 completed both quantitative 
and qualitative portions of the questionnaire. The results of the one participant who 
completed only the quantitative section were included in the quantitative only. Four 
individuals declined to participate because they felt that they could not be of any 
assistance.  
Procedure 
Approval for the study was obtained from the ECU Human Research Ethics 
Committee prior to commencing the research. The following section will describe the 
procedures used in the development of questions and questionnaire design and how the 
questionnaires were distributed. The data collection period for Group One spanned from 
11th October 2010 to 14th January 2011, and involved two data collection methods: an 
online questionnaire and a mailed/printed questionnaire. It was anticipated that 
utilisation of different collection methods would increase the number of respondents 
and produce a rich source of data. The data collection period for Group Two spanned 
from 16th November 2010 to 16th January 2011, and utilised an online questionnaire as a 
data collection method.  
Data collection methods. Online questionnaires have been increasingly used for 
a wide range of research topics (Van Selm & Jankowski, 2006). The use of primarily 
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online questionnaire surveys was deemed the most appropriate method of addressing the 
research questions, as it was in most cases the only form of contacting the participants. 
Online questionnaires allow access to a wide range of participants, especially when they 
are distributed across a large geographic region (Van Selm & Jankowski, 2006). Due to 
participants residing in the U.S., this form of data collection was deemed suitable. Using 
online questionnaires also allowed the participants enough time to complete the 
questionnaire at a time suitable to them, therefore minimising inconvenience (Van Selm 
& Jankowski, 2006). No identifying information apart from the respondents’ IP address 
was recorded from the questionnaire in order to offer participants anonymity (O'Leary, 
2004). A self-administered online questionnaire also avoids potential errors of data 
entry, as the data were automatically transferred into an Excel database. 
Mailed questionnaires were deemed appropriate for those participants without an 
email address, or whose email address could not be found. Mailed questionnaires also 
allowed access to participants from different states and allowed the participants enough 
time to complete the questionnaire at their own leisure (O'Leary, 2004). 
Questionnaire design. Group One. In the state by state review part of this 
study, journal articles, newspaper articles, parliamentary proceedings, and court 
documents relating to medical cannabis policies were analysed for emerging themes. 
These themes were then used to develop a questionnaire which was sent to Group One 
participants (see Appendix A). The questionnaire was divided into two sections. 
Participants were provided with an introduction to each section, as well as instructions 
on how to answer specific questions. The first section requested demographic 
information from the respondents, and asked questions related to participants’ opinions 
on the medical cannabis debate in their state of residence. The questions covered 
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participants’ opinions on medical cannabis, scientific evidence, and the importance of 
factors such as advocacy groups, politicians, and money in determining whether 
medical cannabis legislation is enacted or not. Participants were also asked to rate 
factors identified through the state by state review in terms of their level of influence on 
medical cannabis legislation. A Likert five-point scaling was used in the first part of the 
questionnaire. Likert scales offer a range of responses in a sequence and allowed 
respondents to indicate their level of agreement with a specific statement. It was 
implemented in order to assess participants’ opinions in relation to medical cannabis 
and factors affecting medical cannabis policy (O'Leary, 2004).  
The second section contained open-ended questions and provided respondents 
with an opportunity to address any other issues not covered in the first section, and 
voice more of their own opinions (Van Selm & Jankowski, 2006). No limit was set on 
the length of answers in section two. Section two contained general questions relating to 
the medical cannabis debate and the factors influencing medical cannabis legislation, as 
well as specific questions relating to factors influencing the medical cannabis debate in 
the five representative states. 
The questionnaire was kept as short as possible and divided into sections, as 
research has generally found that participants are less likely to respond to large 
questionnaires (Van Selm & Jankowski, 2006). All participants were allowed up to 
three months to answer the questionnaire. Two emails were sent to participants who 
opted for the online questionnaire, reminding them of the questionnaire closing date; 
one a month after the questionnaire was emailed, and one two weeks before the 
questionnaire closed. The message was sent to everyone in the selected sample 
population and no personal data were retained. The participants were therefore advised 
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that the researcher was unable to identify whether or not they had already completed the 
questionnaire, resulting in everyone receiving a reminder email. 
Group Two. The Group One questionnaire was replicated for Group Two 
participants. However, because Group Two participants were not identified through the 
state by state review as directly participating in the medical cannabis policy process, 
they were asked additional questions relating to their involvement or lack of 
involvement in the process, the form and amount of involvement, and their awareness of 
the issue (see Appendix B).  
Questionnaire administration. Group One. Once they were identified and their 
contact details obtained, each Group One participant (n= 172) was sent an email or a 
mailed letter inviting them to voluntarily complete an online or paper-based survey 
regarding medical cannabis policy being passed or not passed in the U.S. The 
participants were provided with an information email outlining the nature of the study, 
and were advised that they were free to withdraw their consent and cease their 
involvement in the study at any time (Appendix C). One of the limitations of 
questionnaires is the fact participants cannot seek clarification (O'Leary, 2004). In turn, 
participants were provided with contact details of the researcher, two supervisors, and 
an independent contact (ECU Research Ethics Officer) in case they had any questions 
about the study. Participants contacted by mail were sent a printed questionnaire along 
with the information letter, and were asked to mail back their written consent along with 
the questionnaire if they agreed to participate (Appendix D). A coupon was included in 
the envelope to cover the cost of a stamp and envelope, so that participants could return 
the questionnaire without incurring a charge. Participants contacted by email were asked 
to indicate their willingness to participate in the research by sending an email to the 
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researcher stating their agreement. After the email confirming their willingness to 
participate in the research was received, participants were advised that they were free to 
access the online questionnaire. The hyperlink to the online questionnaire was included 
in the information email sent to participants.  
The questionnaire was available online for three months, and participants did not 
have to answer the questionnaire all at once (i.e. they were able to save the 
questionnaire and continue at another time). A progress indicator was also used in order 
to indicate the length of the questionnaire and encourage participants to persist in their 
attempt to complete it (Van Selm & Jankowski, 2006). After the questionnaires were 
closed for access, the data were downloaded and stored in a password locked computer 
in the researcher’s office at ECU. The mailed questionnaires received were manually 
entered into the online questionnaire and combined with those completed online. Hard 
copies of mailed questionnaires were kept in a locked cabinet located in the researcher’s 
office. Only the researcher had access to mailed questionnaires and raw data stored in 
the computer. All participants were assigned numerical codes based on the group they 
belonged to and the order that they completed their interview in. For example, a Group 
One participant who was the fifth to complete the questionnaire was assigned the code 
“G1-5”. 
Group Two. The Group One questionnaire administration procedure was 
replicated for Group Two participants. Once they were identified and their contact 
details obtained, each Group Two participant (n= 209) was sent an email inviting them 
to voluntarily complete an online questionnaire regarding medical cannabis policy being 
passed or not passed in the U.S. The questionnaire was available online for two months.  
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Analysis 
Data were analysed using basic descriptive statistics. The use of descriptive 
statistics assists with organising and summarising data and establishing a background 
for later findings and interpretations (Given, 2008; McHugh & Villarruel, 2003). In 
terms of Group One data, descriptive statistics were used to summarise demographic 
information and participants’ opinions on medical cannabis policy and factors 
influencing it. The analyses were performed manually.  
For the qualitative part of the questionnaire, thematic data analysis was 
implemented. Thematic analysis is a widely used qualitative analytic method for 
“identifying, analysing and reporting patterns (themes) within data” (Braun & Clarke, 
2006, p. 79). It involves the identification of themes through reading and re-reading of 
the data and coding of recurring themes appearing throughout (Liamputtong & Ezzy, 
2005). According to Braun and Clarke (2006), “a theme captures something important 
about the data in relation to the research question, and represents some level of 
patterned response or meaning within the data set” (p. 82). Thematic analysis was 
chosen due to its flexibility, allowing the researcher to play an active role in identifying 
patterns within the data and selecting those which capture something important in 
relation to the research questions (Braun & Clarke, 2006). It also allows the researcher 
to describe and present data in rich detail. Group One thematic analysis was driven by 
the open-ended questions asked in the survey as well as the research questions, and the 
prevalent issues and themes are reported here. 
The analysis was conducted in six phases, as described by Braun and Clarke 
(2006). The first phase involved getting to know the data through reading and re-reading 
of the survey responses, and noting down initial thoughts and ideas. Phase two involved 
 Medical Cannabis in the United States     258 
 
generating initial codes and allocating data to a particular code. Phase three involved 
searching for themes and assigning or grouping codes into potential themes. Phase four 
involved reviewing themes, and checking whether or not they work or are of relevance. 
Phase five involved defining and refining themes. The last phase involved pulling 
everything together, relating the analysis back to the research question, and producing a 
report of the analysis (Braun & Clarke, 2006).  
An audit trail consisting of how codes and themes were developed was kept to 
enhance the credibility of the research (Liamputtong & Ezzy, 2005). All themes and 
sub-themes were reviewed and discussed with the supervisors of the project. Providing 
an audit trail ensures the rigour of the study, which clearly and accurately documents 
how the data were collected and analysed and how interpretations were made.  
Results 
The quantitative data from Groups One and Two are summarised in both 
narrative and tabular form. Findings from the qualitative data are examined, and themes 
derived from the content analysis are outlined and discussed.  
A total of 31 (18%) out of 172 Group One participants approached answered the 
survey. Four (13%) respondents actively participated in the medical cannabis debate in 
Michigan; eight (26%) in New Mexico; 10 (32%) in Illinois; one (3%) in Kentucky; six 
(19%) in Louisiana. Two (7%) respondents resided or participated in the medical 
cannabis debate in more than one state. A total of nine (31%) Group One participants 
personally used cannabis for medical purposes, 22 (76%) knew someone who did, and 
eight (28%) indicated that they had used cannabis for recreational purposes. Overall, 14 
(48%) of participants described their political affiliation as Democrat, seven (24%) as 
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Republican, and eight (28%) as “other” (Independent, Green Party, Libertarian, non-
affiliated).  
A total of 23 (11%) of 209 Group Two participants answered the questionnaire. 
In total, five (22%) respondents indicated that they currently conducted alcohol and 
other drug related research in Michigan; one (4%) in New Mexico; 11 (48%) in Illinois; 
five (22%) in Kentucky; and one (4%) in Louisiana. Four (17%) participants stated that 
they were very aware of the medical cannabis debate in their state and 14 (61%) that 
they were somewhat aware. Four (17%) participants were somewhat unaware of the 
debate; one (4%) was very unaware. In terms of their level of involvement in the 
medical cannabis debate no participant classified themselves as very involved; one (4%) 
as somewhat involved; eight (35%) classified themselves as neither involved nor 
uninvolved; two (9%) as somewhat uninvolved, and 12 (52%) as very uninvolved.  
No (0%) Group Two participant personally used cannabis for medical purposes, 
seven (30%) knew someone who did, and 11 (48%) indicated that they had used 
cannabis for recreational purposes. Overall, 19 (83%) of participants described their 
political affiliation as Democrat, none (0%) as Republican, and four (17%) as “other” 
(Independent, Libertarian, and no voting rights).  
Opinions on medical cannabis laws. Respondents were asked to indicate 
whether or not they “strongly agree”, “agree”, “disagree”, “strongly disagree”, or “don’t 
know” (Table 11) with statements relating to cannabis and medical cannabis. Upon 
analysis, the items were combined so that “agreement” represented both “strongly 
agree” or “agree” responses, and “disagreement” represented both “strongly disagree” 
and “disagree”. Due to the low number of responses, tests of significance were not 
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performed. Participant responses, concerning cannabis and medical cannabis, are 
grouped according to the statements used in the questionnaire.  
 A large majority of participants in both groups indicated that they supported 
legislation to make cannabis legally available for medicinal purposes; 22 (71%) Group 
One and 16 (69%) Group Two respondents. Twenty three (75%) Group One and 20 
(87%) Group Two participants indicated that they believed that cannabis can be used 
effectively as a medicine. Despite believing that cannabis can be used as a medicine, 28 
(90%) Group One and all Group Two participants indicated that they believed that more 
research is needed on cannabis as a medicine. However, more Group One (71%) than 
Group Two (61%) participants believed that scientific evidence plays an important role 
in the passing of medical cannabis legislation.  
While the most common argument used by medical cannabis opponents is that 
cannabis is a gateway to the use of other illicit drugs, only ten (33%) of Group One and 
seven (31%) of Group Two participants agreed with this statement. A larger percentage 
of Group One (71%) than Group Two (65%) participants believed that laws to allow the 
use of cannabis as a medicine should be implemented in all U.S. states. More 
participants in both groups believed that the laws to allow the use of cannabis as a 
medicine should be implemented at the federal level. Lastly, 68% of Group One and 
78% Group Two participants indicated that they believed that it is important to separate 
medical cannabis legalisation from the broader drug legalisation agenda.  
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Table 11 
Group One and Group Two Opinions on Cannabis and Medical Cannabis Laws  
 
         
 
 
 
Statement Agree 
% 
Disagree 
% 
Don’t know 
% 
Support medical cannabis legislation 71 26 3 
69 27 4 
Cannabis can be used effectively as a 
medicine 
75 22 3 
87 9 4 
Cannabis is a gateway drug 33 64 3 
31 65 4 
More research is needed on medical cannabis 90 7 3 
100 0 0 
Scientific evidence is important 71 23 6 
61 39 0 
Medical cannabis laws in all states 71 26 3 
65 26 9 
Medical cannabis laws at the federal level 81 16 3 
69 22 9 
Important to separate medical cannabis 
from legalisation 
68 29 3 
78 22 0 
 Group One 
  Group Two 
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Factors influencing medical cannabis legislation. Participants were also 
presented with a number of factors influencing medical cannabis policy, as described in 
Chapter Four. They were asked to consider how important each factor was in 
determining whether medical cannabis legislation is enacted or not. Participants were 
asked to indicate whether or not a factor mentioned was “very important”, “somewhat 
important”, “somewhat unimportant”, “very unimportant”, or “don’t know” (Table 12). 
The items were combined so that “importance” represented both “very important” and 
“somewhat important” responses, and “unimportance” represented both “very 
unimportant” and “somewhat unimportant”.  
The largest percentage (97%) of Group One participants, who participated in the 
medical cannabis debate, indicated that media and the support of the legislative branch 
of the state government play an important role in determining whether media cannabis 
legislation is enacted or not. Meanwhile, all (100%) Group Two participants thought 
that public support plays a very important or somewhat important role in determining 
the success or failure of medical cannabis legislation, while 28 (90%) Group One 
participants also indicated that public support plays a very important or somewhat 
important role. Twenty nine (93%) Group One participants thought that the support of 
the executive branch of the state government was important in determining whether 
medical cannabis legislation is passed or not, while 20 (87%) of Group Two participants 
thought the support of the executive branch was important. However, 23 (74%) Group 
One participants indicated that politicians were important in determining whether 
medical cannabis legislation is enacted or not, while more (96%) Group Two 
participants thought that politicians played an important role.   
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Twenty seven (87%) Group One participants believed that advocacy groups 
were important in passing medical cannabis legislation, and 26 (84%) of the participants 
believed that the extent to which advocacy groups are well organised was of 
importance. Most (92%) Group Two participants believed that advocacy groups were 
important and 20 (87%) believed that the extent to which advocacy groups are well 
organised was of importance. The amount of money available to both advocates and 
opponents was reported as being of importance by 22 (96%) Group Two respondents, 
but a lesser number of Group One respondents (71%) thought money was important.  
Testimonies from people who have used cannabis as a medicine were considered 
important by 25 (81%) of Group One and 17 (74%) of Group Two participants. Media 
and the support of the legislative branch were considered important by 21 (91%) of 
Group Two participants.  
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Table 12 
Level of Importance of Factors Influencing Medical Cannabis Legislation  
Factor Important 
% 
Unimportant 
% 
Don’t Know 
% 
Advocacy groups 87 7 6 
92 4 4 
How well organised advocacy 
groups are 
84 10 6 
87 4 9 
Politicians 74 20 6 
96 4 0 
Money available to advocacy 
groups 
71 19 10 
96 0 4 
Testimonies from medical 
cannabis users 
81 16 3 
74 26 0 
Support of the executive branch 93 3 3 
87 4 9 
Support of the legislative branch 97 0 3 
91 0 9 
Public support 90 6 3 
100 0 0 
Media 97 0 3 
91 4 4 
   
        
  Group Two 
 Group One 
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Participants were also asked to rate factors in terms of the level of influence they 
believed the factor has on medical cannabis legislation (Table 13). The 10-point rating 
scale was used with 0 representing no influence, 5 representing some influence, and 10 
representing very high influence. A total of 29 Group One and all (23) Group Two 
participants completed this section. Group One participants rated support in the 
legislature (8.28 average score) as having the highest level of influence, followed by 
advocacy groups (7.97) and public support (7.97). Other factors, in order of influence, 
included money, lobbyists, patient testimonies, media support, high-profile individuals, 
and opposition groups. Group Two participants rated money (8.35 average score) as 
having the highest level of influence, followed by support in the legislature (8.22), 
public support (7.87), media support (7.70), and lobbyists (7.65). Other factors, in order 
of influence, included opposition groups, high-profile individuals, advocacy groups, and 
patient testimonies. 
Table 13 
The Average Rating of Factors Influencing Policy on a 0-10 Scale of Influence 
 
The following section will present themes derived from the qualitative part of 
the questionnaire.  
Factor Group 1 
Rating 
Group 2 
Rating 
Support in the legislature 8.28 (1st) 8.22 (2nd) 
Advocacy groups 7.97 (2nd) 6.35 (8th) 
Public support 7.97 (2nd ) 7.87 (3rd) 
Money 7.76 (3rd) 8.35 (1st) 
Lobbyists 7.76 (3rd) 7.65 (5th) 
Patient testimonies 7.66 (4th) 6.22 (9th) 
Media support 7.59 (5th) 7.70 (4th) 
High-profile individuals 7.48 (6th) 7.09 (7th) 
Opposition groups 6.86 (7th) 7.35 (6th) 
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The role of scientific evidence. While it is widely believed that science should 
play a major role in public health policy, as discussed in Chapter Four, this is not 
always the case. The state by state review concluded that while scientific evidence was 
presented in the medical cannabis debate, it was mostly filtered through the media and 
was selectively used by the proponents and opponents of medical cannabis. The impact 
of scientific evidence tends to be diluted and a number of other factors play a role in 
influencing policy. When asked if scientific evidence played a role in the medical 
cannabis debate in their state, Group One’s responses could be divided into two themes: 
1) strength and recognition of the scientific evidence, and 2) how the scientific evidence 
is used. A consensus was hard to reach as the respondents’ opinions were divided on the 
role scientific evidence played and continues to play in the medical cannabis debate, but 
12 out of 24 Group One respondents who answered the question believed that the 
scientific evidence plays no role (or does not play a significant enough role) in the 
medical cannabis policy process. Respondents indicated that when scientific evidence 
does play a role, it is in informing the public and gaining support for the cause. As some 
of the participants stated: 
“I think it plays an important role in the process, even here [U.S.], where 
many people are fond of hearing horror stories about gateway drugs, the 
medical and scientific community are given great weight, which is as it 
should be” (G1-24, Illinois).  
 “Yes. If there is no evidence, I would not support any efforts” (G1-10, 
Louisiana). 
 Medical Cannabis in the United States     267 
 
Group Two participants were slightly more optimistic when discussing the role 
of scientific evidence, with nine out of 15 participants believing it plays a role, 
especially in informing the public.  
“Scientific evidence plays the largest role. The public needs to be 
confident that the benefits outweigh the risks and this can only be 
provided through scientific research” (G2-9, Illinois).  
“The public needs to be confident that the benefits outweigh the risks 
and this can only be provided through scientific research” (G2-7, 
Illinois). 
However, some respondents believed that anecdotal evidence usually takes 
precedence over scientific evidence, and that as a result scientific evidence rarely enters 
the debate, despite the fact that it is generally expected that it should play a role.   
“No, it was completely ignored. They listened to anecdotal evidence to 
make their decisions” (G1-4, New Mexico).  
 “Very little- it is mainly predicated on the sick patient scenarios 
expounded to the legislature” (G1-27, Illinois).  
“I wish it did, but unfortunately the science rarely comes into the 
debate” (G2-1, New Mexico).  
Group Two participants also indicated that the public sometimes does not 
understand the available scientific evidence and that the merits of scientific evidence 
can often be lost on politicians and the public. 
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It is critical that there be sound evidence but the relative merits of 
evidence is [sic] often lost with politicians and the public” (G2-6, 
Kentucky).  
“I don’t think scientific evidence plays much of a role in any debate. 
People don’t understand statistics and how that supports evidence” (G2-
20, Kentucky).  
 The results also indicated that the respondents believed that scientific evidence 
should play more of a role than it does, and attributed its insufficient use to a number of 
causes such as money, education, and lack of recognition of the available scientific 
evidence by politicians, health professionals, and the media.  
“Not enough. As long as government spends billions of dollars per year 
disseminating lies and refusing to recognize the growing scientific 
evidence, and medical schools refuse to train their students in 
Cannabinoid Medicine, and big Pharma [sic] keeps promoting addictive 
opiate analgesics, the debate will not be influenced adequately by the 
mounting and irrefutable scientific evidence” (G1-1, Illinois).  
“The single biggest influence, either way, is a scientific ignorance, 
public and health care professional, of cannabis and the 
endocannabinoid system” (G1-17, Louisiana).  
As the literature review conducted for this thesis indicated, the available 
evidence on medical cannabis is not as clear as it may first appear, especially when 
considering the smoked route of medical cannabis administration. Further to this, some 
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participants believed that even if the evidence was available, the policymakers may not 
necessarily respond to it and it may not play as much of a role as may be expected. 
“Scientific evidence is valuable, but the necessary research is often 
lacking. Even in the face of evidence the social and political forces may 
not respond to this” (G2-2, Illinois).  
“I am not fully informed on this topic. However, I would have to say it 
[scientific evidence] plays a role, but it is difficult to get ideologues to 
listen to science” (G2-5, Illinois).  
Mixed and inconclusive research evidence. Based on the literature review 
presented in Chapter Three, the research evidence shows that cannabis and its 
constituents have therapeutic potential for a number of conditions, some for which the 
evidence is mixed and unclear. Most of the research evidence supports the use of 
cannabis in the treatment of chronic pain, spasticity, nausea and vomiting, and as an 
appetite simulant for AIDS-related wasting syndrome. A substantial amount of research 
has also been conducted on cannabis in the treatment of nausea and vomiting to suggest 
cannabis may have therapeutic potential. All other conditions, the literature review 
concluded, would require further research to be conducted before the use of cannabis as 
a medicine could be recommended.  
The general consensus between research participants was that cannabis can be 
used effectively as a medicine, but the evidence can be contradictory. An overwhelming 
majority of participants also agreed that further research on cannabis as a medicine was 
needed, particularly research addressing different routes of administration, appropriate 
dosage, side effects, and long-term effects. Participants also believed that the scientific 
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evidence available at the present time was contradictory or insufficient, and as such did 
not influence the medical cannabis debate or policy making. It was also argued that if 
the scientific evidence, especially for smoked cannabis, was stronger, it would be easier 
to pass medical cannabis legislation.  
“If we can get some comprehensive research studies, by independent 
researchers, that can conduct a longitudinal meta analysis, the debate 
would be led more by facts rather than opinion” (G1-10, Louisiana).  
“The scientific evidence for smoking cannabis as an effective medicine is 
contradictory. If it were stronger, it would be easier to pass the 
legislation...I support legalization for many reasons, but the evidence is 
that smoked cannabis is not an effective medication (the side effects 
including lung damage and addiction potential far outweigh the 
benefits)” (G2-3, Illinois).  
“I still think that there is insufficient scientific evidence to convince 
people outside of science which stems from problems funding this type of 
research” (G2-12, Kentucky).  
Need for a change in federal cannabis laws. While there has been a push to 
reschedule cannabis from Shedule I of the CSA in order to permit medical use, the 
federal government has maintained its stance that cannabis is not safe and that no sound 
scientific studies supported medical use of cannabis (Cohen, 2010; Eddy, 2010). 
Medical cannabis advocates note that cannabis will most likely not be rescheduled until 
there is sufficient scientific evidence for its effectiveness (Marshall, 2005). Three 
respondents also believed that the issue of medical cannabis will only come to 
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prominence with changes to federal laws, and that there was need to reschedule 
cannabis. 
 “I do know that keeping cannabis as a Schedule I narcotic is WRONG 
and should be changed a.s.a.p. by the FDA and the DEA...” (G1-13, 
Kentucky).  
How the scientific evidence is used. How the scientific evidence is used in the 
medical cannabis debate was also a common theme amongst respondents. As discussed 
in the state by state review in Chapter Four of this thesis, while the scientific evidence is 
not directly used in the medical cannabis debate, it mostly enters the debate as 
“ammunition”. Both opponents and proponents of medical cannabis tend to use the 
research findings as a means of attacking or defending their arguments, rather than as 
the key to deciding whether a policy should be adopted or not. The respondents in both 
groups indicated that individuals participating in the medical cannabis debate may not 
necessarily always use scientific evidence, or may use it for a specific purpose. Also, 
the evidence is not necessarily always used in its purest form (as published) but can be 
changed to suit a particular purpose.  
“It provides a platform for proponents but opponents essentially ignore 
the information and argue other points such as that it is a slippery slope 
that will lead to legalization of all drugs” (G2-21, Illinois). 
“...it is skewed in the direction of whichever lobby is trying to use it to 
support their case” (G2-1, New Mexico).  
 The respondents agreed that the way in which the available evidence (or lack 
of) is used in the process can have an influence on the outcome. One way the scientific 
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evidence could be used is as a way of refuting the opposition’s claims and in supporting 
an argument.  
“Primarily as something advocates can use to rebut opposition” (G1-22, 
New Mexico).  
“...it allowed us to refute many of the oppositions’ claims” (G1-6, New 
Mexico).  
“It plays a role in that it makes the argument possible, and enables the 
support of many medical and public health organizations” (G1-9, 
Illinois).  
Decoupling. Separation of medical cannabis from the issue of general cannabis 
decriminalisation or legalization for recreational purposes, or decoupling, was another 
major theme identified in the state by state review. Twenty one Group One and 11 
Group Two participants discussed the separation of medical cannabis from general 
cannabis legalisation. Fourteen Group one and four Group Two participants felt that 
separating the two was beneficial to passing medical cannabis legislation and played a 
role in helping the medical cannabis issue move forward. The participants believed that 
legislation legalising cannabis for general use is more difficult to pass than medical 
cannabis, and had less public support. As such, keeping medical cannabis separate from 
cannabis legislation helped make medical cannabis more generally acceptable.  
“Full legalization is a non-starter among legislators and less supported 
by the public. Keeping them separate is the only way to get medical 
cannabis passed” (G1-9, Illinois).  
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“I think it is more palatable if sold as an effort to improve medical 
options” (G1-24, Illinois).  
“The U.S. is not ready for drug legalization of any sort. It is too 
conservative. With cannabis, it is crucial that the medicalization [sic] be 
separated from its abuse potential for it to have viability in any state (or 
the county) as acceptable policy” (G2-6, Kentucky).  
“If they are separated medical cannabis will have a better chance of 
passing” (G2-10, Louisiana).  
However, some respondents were not so sure of the impact of separation, and 
believed that the impact of separating medical cannabis from general cannabis use 
depended on which other factors were at play. 
“Our bill had nothing to do with cannabis legalization, which helped it 
move forward. Under a previous administration however, the two were 
linked and it almost passed even then. So it depends on the political 
players, their level of support, and their level of courage” (G1-6, New 
Mexico).  
As discussed in Chapter Four, it is not always clear who supports what, and even 
some advocates fail to make a clear distinction between medical cannabis and general 
cannabis legalisation and sometimes tend to fluctuate between being medical cannabis 
supporters only and supporting general legalisation. As two respondents also indicated, 
the national organisations went through a lot of effort to make a clear distinction 
between general cannabis legalisation and medical cannabis and selectively funnelled 
their support for organisations that were able to keep the two issues separate. 
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“The federal organization funding the statewide [sic] efforts were very 
keen about keeping the broader legalization efforts quiet. Basically, to 
the point of bringing myself (who was the main legalization voice for 
cannabis in IL [Illinois]) on as a grant recipient to work on the medical 
and not legalization” (G1-12, Illinois).  
“Since both MPP and NORML advocate legalizing cannabis in general, 
their support for the legalization of medicinal cannabis in IL and other 
states can have both negative and positive effects to the extent that their 
support is funnelled through individuals and groups who are able to keep 
the two issues separate and not give fodder to anti cannabis groups that 
claim that the medical cannabis movement is just a cover for the 
legalization of cannabis” (G1-1, Illinois).  
However, due to public perception, it is often difficult to separate the two issues. 
This is also made more difficult by medical cannabis opponents, who attempt to portray 
the two issues as one and the same. 
“Opponents say they’re connected, we combat that. We’re usually able 
to win” (G1-3, Michigan).  
“The way the bill was introduced and written it was simply a gateway to 
legalize cannabis in the future” (G1-14, Illinois).  
“People in the general public see these two things as almost the same” 
(G2-12, Kentucky). 
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The influence of politicians. The majority of Group One participants believed 
that politicians played a major role in the medical cannabis debate, but Group Two 
participants believed that the politicians had some influence and that there were a 
number of factors that influenced the support or opposition of politicians. According to 
respondents, politicians could have a major influence on the passage or the failure to 
pass medical cannabis legislation as they have the ability to carry bills and pass 
legislation, therefore controlling the fate of the issue. However, in order for medical 
cannabis legislation to pass, it is important to have the support of politicians, especially 
in states with no initiative process.  
“If the majority of legislators are in favour, it’s easy to pass. If a 
majority is opposed, it’s next to impossible. It’s also important to have 
key legislators on board such as committee chairs and those in 
leadership positions” (G1-5, Louisiana).  
“They control the fate of the issue; our state does not have a ballot 
referendum or initiative process. So we have been working for so long on 
it that we were actually advised to register as lobbyists, and thus I  
registered a patient advocacy association so that we could legally lobby 
our legislators to pass medical cannabis legislation” (G1-12, Illinois). 
 “They are important, and a few small advocacy groups are working 
with them” (G2-2, Illinois).  
While the respondent believed that medical cannabis legislation is easier to pass 
if there is support from the politicians, especially those well known to the public, the 
difficulty arises when legislators are unresponsive, or unwilling to introduce the 
 Medical Cannabis in the United States     276 
 
legislation. This can occur either because they are not in favour of the legislation or 
because there are other factors that they need to take into account. 
“I have spent more than 2 years writing politicians all over our state, 
and of the few who have responded, not one supports safe and legal 
access to medical cannabis” (G1-21, Kentucky).  
 “Most legislators I’ve contacted don’t reply or are afraid to tackle 
medical cannabis. Our legislature is stuck on creationism in class, which 
indicates their level of sophistication” (G1-20, Illinois).  
“Politicians from the rural portions of the state will block any effort to 
pass medical cannabis laws” (G2-3, Illinois).  
 “Politicians in my state are largely quite conservative and generally not 
supportive of legalization given the dire economic situation in our state 
and nation; legalization is a very low priority right now” (G2-12, 
Kentucky).  
Influences on politicians’ decision making. Factors such as getting re-elected, 
how they are perceived, political ideology and funding are very important in influencing 
politicians’ decision of whether or not to support specific legislation. As suggested by 
the respondents, the influences may differ between the political players, but include 
personal opinion and perceived disapproval or approval by the public, political 
ideology, political timing, or fear and unwillingness to tackle a difficult issue. 
“Most are conflicted by their own opinions vs. perceived disapproval by 
the constituents or fearful of Federal (DEA) backlash if they support the 
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legislation but we are forever hopeful that we will succeed in this battle” 
(G1-1, Illinois).  
 “It is hard for politicians to support something like legalization of 
marijuana because it is such a polarizing topic, which might affect their 
re-election” (G2-5, Illinois).  
“Politicians lean any direction that gets them elected. The populace 
needs educating & that’s difficult in a state that ranks 49th in education” 
(G1-21, Kentucky).   
As discussed in Chapter Four, the general notion in terms of medical cannabis is 
that the dominant Democratic position is to support medical cannabis, while the 
dominant Republican position is to oppose it. Respondents agreed that political 
ideology could influence whether or not medical cannabis legislation is supported. 
However, in some states, such as New Mexico, the support for medical cannabis is not 
necessarily defined by political parties, and bipartisan support was believed to be one of 
the reasons for the success of New Mexico’s medical cannabis law.  
“...especially bipartisan support” (G1-6, New Mexico).  
“Dems favour....Repubs don’t” (G1-11, Michigan).  
“Republican Governor Johnson had fought for it, but he was blocked by 
the Democratic legislature who wanted to pass it, but felt that 
Republican legislators would use it against him. Having Democratic 
Governor Richardson in office, who also supported the legislation, 
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created a safer environment for legislators and Democrats got behind 
the bill” (G1-19, New Mexico).  
 “Pretty straightforward- Dems [Democrats] are (mostly) in favour 
though not all. Republicans are fairly adamant in their opposition” (G2-
21, Illinois).  
Rather than scientific evidence driving their decision making, medical cannabis 
can be a personal issue for some politicians. Some support the legislation because they 
have used medical cannabis themselves or know of someone who has, and their 
personal experience rather than scientific evidence drives their support. As Black (2001) 
said, policymakers can have their own goals for policies other than scientific evidence 
and clinical effectiveness, and can focus on other types of evidence such as personal 
experience.  
“We have to deal with lots of politicians; we see their human side. 
Cannabis gets personal, so the politicians do as well” (G1-20, Illinois). 
The people as legislators: Influence of direct democracy. The state by state 
review in Chapter Four indicated that using the initiative process helped pass medical 
cannabis laws initially in some states and helped them gain momentum in other states. 
To date 10 of 17 state medical cannabis laws were passed by a ballot initiative and in 
some states may not have passed, or passed as quickly, if the attempts to pass a medical 
cannabis law were only focused on the legislative process. In Michigan, for example, 
several attempts to pass a medical cannabis law via the legislature were unsuccessful 
until the issue was placed on the ballot and passed.  
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The results from Groups One and Two indicated that a distinction needs to be 
made between states with a direct democracy process (i.e. ballot initiative) where 
constituents are given the power to pass laws, and the states where the legislative 
decisions are left up to the legislators. The general consensus amongst participants was 
that the two processes have a differing influence on medical cannabis policy. 
Participants believed that ballot initiatives were important as they were able to take 
politicians out of the equation, were easier to pass, helped move the issue along, and 
allowed people to make a decision regarding a particular law. However, the difficulty 
arises in states that do not have the initiative process, and the attempts to pass a medical 
cannabis initiative need to occur at the legislative level.  
“If the state has a hostile legislature but a ballot initiative process, you 
can go around the legislature. It can be expensive though depending on 
the number and size of media markets” (G1-3, Michigan).  
 “I think the ballot initiative was crucial for getting the medical 
marijuana on the books. The legislature never would have gone for it” 
(G2-16, Michigan).  
 “...they allow the issues to percolate to the top at the initiative of the 
people rather than the legislators” (G2-6, Kentucky).  
“It may assist with moving the legislature along” (G2-7, Illinois). 
According to the respondents, states with ballot initiatives usually fare better on 
passing legislation than states without, which must rely on the legislators to engage in a 
medical cannabis debate. However, only 17 U.S. states and the D.C. have an initiative 
 Medical Cannabis in the United States     280 
 
process, which means that 27 states must rely on their state legislatures to enact medical 
cannabis laws. 
“Without a ballot initiative process, Louisiana residents are left to 
depend upon legislators to even engage in a debate regarding medical 
cannabis. As a result, there is no debate” (G1-2, Louisiana).  
“In initiative states, medical marijuana almost always passes. When it 
must be approved by politicians, it’s always a struggle, and Illinois was 
a classic example” (G1-9, Illinois).  
“Obviously, states that allow voter initiatives fair [sic] much better on 
passing this type of legislation” (G1-21, Kentucky).  
“I feel that the initiative process is a much easier way to get medical 
cannabis available to patients since politicians generally feel the issue is 
too controversial and don’t want to take a tough vote like this” (G1-12, 
Illinois). 
However, as much as they can be beneficial, both processes are perceived as 
having their disadvantages, such as being costly and prone to abuse, and can put well-
funded special interest groups at an advantage because of their access to campaign 
professions, access to donor lists, and media strategies (Birkland, 2005; Braunstein, 
2004; Cushman, 2005; Magleby, 1998).  
“Ballot- Big money will be used to campaign for the passage of the 
initiative, however it does allow the electorate to have a say as to what 
will be passed. Drawback is there is not the big money to campaign 
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against the initiative. Legislative branch- leaves the decision of millions 
in the hands of a very few. They become educated as to the benefits this 
cannabis will have for “patients”. They forget to look at the other side of 
the debate from law enforcement, prosecutors, treatment and prevention 
professionals” (G1-4, New Mexico).   
A dubious method [ballot initiative] in some cases due to manipulation of 
voters” [G1-25, Louisiana].  
“As a former Californian, I’d say that ballot measures tend more often to 
be harmful than helpful, so I would not advocate for them as a means of 
passing legislation” (G2-15, Illinois).  
The influence of national-level advocacy organisations on state-level policy. 
State by state review in Chapter Four found that organised interest groups are more 
likely to have greater access to resources and make campaign contributions in order to 
advance their desired outcomes. Money was very important as it enabled the groups to 
reach a wider audience and have a bigger impact. In the states with medical cannabis 
laws, national organisations such as NORML were very prominent and engaged in a 
range of activities from lobbying to organising television and radio advertisements to 
support their cause. The majority of Group One and Group Two respondents agreed that 
the involvement of national advocacy organisations, such as MPP and NORML, had an 
impact on medical cannabis policy; mostly positive, some detrimental. The responses 
indicated that one of the main contributions of the national organizations was money.  
“They have a very strong presence in our state and funded staff to lobby 
the Governor and legislature to pass the legislation. I imagine they also 
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paid for some of the individuals who testified in support of the 
legislation” (G1-4, New Mexico).  
“They were important mainly in funding and keeping databases current. 
Also providing qualified spokesmen” (G1-16, Louisiana).  
“MPP played the leading role, financing and organizing the lobbying 
campaign and media efforts” (G1-9, Illinois).  
“Most states are convinced by the PR not the data. PR takes money, 
hence national pro use groups are powerful” (G2-11, Michigan).  
“These groups are very prominent in MI [Michigan]” (G2-17, 
Michigan).  
As discussed in Chapter Four, interest groups prefer to use direct initiatives and 
carefully consider where they focus their efforts (Boehmke, 2002). The approach and 
activities of most interest groups is determined by the group’s mission, strategic goals, 
objectives, and strategies and tactics (Leiden, 1995). Research has found that states with 
an initiative process have more interest groups (Boehmke, 2002). While they may have 
contributed to the debate and passing of medical cannabis laws in some states, national 
organisations such as MPP and NORML did not actively participate in all states and 
appeared somewhat selective about the states they put their resources into. For example, 
MPP played a large role in supporting the medical cannabis effort in Michigan, donating 
money as well as organising television advertisements and being active in the 
newspaper discussion of the issue, but were not very active in New Mexico. The 
participants also noted that MPP and NORML put resources into states such as 
Michigan, while they did not have a strong presence in other states. 
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“MPP funded our initiative” (G1-11, Michigan). 
  “I was leader of the state office of DPA, we led the fight. NORML was 
very helpful with information requests and behind-the scenes 
background information. MPP did not play a role” (G1-6, New Mexico). 
 “There is no NORML office in Coonville, Kentucky anymore & I believe 
they have not targeted Kentucky as a prudent place to spend their limited 
resources” (G1-21, Kentucky).  
“NORML played almost no role in Michigan. That law was written, 
funded, and passed by MPP” (G1-3, Michigan).  
“There are many of us who are either members of NORML Louisiana or 
are advocates...we are in our infant stage, though, and need more 
capacity-building and technical assistance from our national office” 
(G1-13, Kentucky). 
Interestingly, while Group One participants strongly believed that the national 
organisations played a role in the medical cannabis legislation, Group Two participants 
were not unanimous in this belief, some not even being aware of the presence of these 
organisations. Notably, the respondents were from states such as Kentucky and Illinois 
that do not have medical cannabis legislation or have not considered one. Also, the 
medical cannabis debate in states such as Kentucky has not been very active.    
“Probably very little except to the extent that they could influence local 
politicians” (G2-6, Kentucky).  
“Since I have not heard of them, perhaps very little” (G2-20, Kentucky).   
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“None that I can see” (G2-21, Illinois).  
The perception of the national organised groups can also have an influence on 
the role that they play. That is, if they are perceived as negative or supporting a cause 
not favoured by the general public, it may have a detrimental effect. More specifically, 
if the organisations were perceived as supporting general cannabis legalisation, their 
support detracted from the issue of medical cannabis: 
“They pushed to convince people that they were being denied a real 
treatment. It should be noted that the effort in California to make 
personal use (not medical) failed because of the public’s views of these 
organizations. They were simply too facile” (G2-11, Michigan). 
 “NORML’s primary focus on legalization in more progressive states 
provides little support for efforts to advance medical cannabis law 
reform in Louisiana” (G1-2, Louisiana).  
 “They are legalization activists talking medicine and are bad at it” (G1-
17, Louisiana).  
“They create problems because they are not reputable organizations” 
(G1-30, Illinois).  
Higher level opposition: The federal government. While the state by state 
review in Chapter Four showed that the federal government, and more specifically the 
ONDCP, were active in Michigan and New Mexico when the medical cannabis 
movement in those states gained momentum, the federal government was not identified 
as playing a major role in passing or failure to pass medical cannabis laws. The majority 
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of Group One study participants, however, saw the federal government, and more 
specifically the ONDCP, as having both positive and detrimental effects on the medical 
cannabis legislation process. It was noted that while opposing the law, the federal 
opposition to medical cannabis in states such as Michigan was not very effective. 
“ONDCP opposition is always a problem. They work with the 
opposition, both overtly and covertly. In Illinois, a former ONDCP 
official, Andrea Barthwell, also played a visible role in opposition” (G1-
9, Illinois).  
 “Diminishing effect, as most educated people realize that the War on 
Drugs is actually a War on Drug Users and is propped up by what I call 
“The Big Lie” that cannabis deserves to be a Schedule I narcotic and is 
more harmful than legal intoxicants, such as alcohol or nicotine” (G1-1, 
Illinois).  
“They opposed the law, but weren’t terribly vocal or effective” (G1-3, 
Michigan).  
While participants believed that the federal government can influence state 
politicians and their support of medical cannabis legislation, their direct involvement in 
the state debate was reported by a number of Group One participants. Different tactics 
such as using expert testimony, prominent public figures and threatening funding were 
reported as being used by the federal government officials to oppose state medical 
cannabis bills. 
“ONDCP sent an expert witness to testify in opposition to the legislation. 
Along with all the other experts, the policy makers turned a deaf ear to 
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the realities of legalizing marijuana. ONDCP testimony was helpful” 
(G1-4, New Mexico).  
 “We’ve had former DEA head Bensinger testify against us numerous 
times over the years and even appearing on a televised debate against 
myself. I recall Walters coming to Illinois to testify once too. Other than 
brief appearances and working behind the scenes not much involvement 
I’d imagine” (G1-12, Illinois).  
Group Two participants reported that the federal offices have constantly opposed 
medical cannabis legislation, but that their presence usually had little or no influence. 
Participants from states such as Kentucky and Louisiana, in particular, did not believe 
there was strong federal opposition to cannabis in their states.   
“The ONDCP is pretty quiet on this issues [sic], even though they paid 
the IOM for the Marijuana as Medicine study. The ONDCP’s real task is 
to formulate drug abuse policy. General McAfree decided to let the 
medical issue alone” (G2-11, Michigan).  
“Slightly more than MPP, etc? not aware of their involvement in my 
state either so practically zero effect” (G2-20, Kentucky).  
 “None to my knowledge but the federal offices have remained 
consistently opposed to such legislation” (G2-6, Kentucky).  
When they are active, participants in Group Two believed that federal offices 
such as the ONDCP can act as a voice of authority and back up opposition groups in the 
state.  
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“Much- voice of authority” (G2-10, Louisiana).   
“Provides cover for those in opposition” (G2-21, Illinois). 
 In some cases, while not having a direct impact and preventing legislation from 
passing, the presence of the federal officials and federal offices such the ONDCP can 
have a reverse effect, and ignite the efforts of the advocates. As one participant 
described: 
“He [the Drug Czar] and his entourage visited our statehouse; he spoke 
to the panel; left the room before anyone on our side spoke; we lost the 
vote. His presence (and his twenty person entourage) worked to motivate 
our patients. He also, by his presence, let the statehouse know we must 
really be a threat if a representative from the federal government came 
to Springfield Illinois” (G1-20, Illinois).  
The effectiveness and organisation of state-based organised groups. The 
extent to which advocates for both sides are organised has been found to contribute to 
the successful enactment of medical cannabis laws. The state by state review found that 
in Michigan, state based organised groups had a persistent and prominent involvement 
in the medical cannabis debate and lobbied for medical cannabis over a period of time, 
while the only state based organised opposition group was not formed until shortly 
before the medical cannabis issue went to ballot. The influence of state-based organised 
lobby and advocacy groups had been frequently mentioned by the Group One 
respondents, with eight out of 14 respondents believing that they played a role in 
ensuring the passing of medical cannabis laws in some states.  
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“These groups were effective in getting the legislation passed and spent 
significant amounts of money to ensure its passage” (G1-1, Illinois).  
“We won the debate, hands down. I don’t think it would’ve passed 
without a well-organized group” (G1-6, New Mexico).  
 “It wouldn’t be possible to introduce legislation and have a chance to 
pass this without lobby groups” (G1-24, Illinois).  
However, respondents, and in particular those based in states with no medical 
cannabis law,  believed that state-based organised lobby groups had little to no 
influence. 
 “It was minor. The ones that existed were largely funded by MPP. They 
were useful allies, but have little impact without MPP’s resources. The 
major thing they contributed was connections with local patients, 
doctors and other visible supporters” (G1-9, Illinois).  
The majority of Group Two participants was not aware of state-based organised 
groups in their state, and, along with some Group One participants, believed that state-
based organised groups were generally related to the national efforts, and would not 
have been successful without the support of national organisations.  
 “If we lobby groups in my state, they seem pretty invisible” (G2-12, 
Kentucky). 
 “They have not been well publicised in the media and so I am guessing 
very little” (G2-21, Illinois).  
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 “Generally they are related to the national pro efforts” (G2-11, 
Michigan). 
However, both Group One and Group Two participants noted that it was 
important for groups both supporting and opposing medical cannabis legislation to be 
well organised and work strategically, as it can influence how they are perceived by the 
public and the policymakers.  
“...they need to work carefully and strategically. The more professional 
the group the better” (G2-2, Illinois).  
“...the more you organize the better your chances are of being 
successful. It isn’t only the most important causes that get attention but 
those that have publicity and money” (G1-24, Illinois).  
“I don’t think it would’ve passed without a well-organized group” (G1-
6, New Mexico).  
Lack of good organisation can in turn be detrimental to a particular side of the 
debate. For example, a respondent from New Mexico (a state with a medical cannabis 
law) said:  
“The opposition had more bodies (i.e. law enforcement) but they weren’t 
as well organized” (G1-6, New Mexico).  
The perceived presence of state-based organised groups. According to the 
respondents, the effectiveness of state-based organised groups was limited by their level 
of presence (or lack of) in the states and their perceived effort to pass medical cannabis 
legislation. In states such as Kentucky, there are no state-based medical cannabis 
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advocacy groups, and the student-run NORML chapter also experienced problems and 
eventually ceased operation.  
“I’m not aware of a single state lobby group in Kentucky lobbying for 
cannabis law reform. There is no NORML chapter still in operation here 
& no other organized group has considered Kentucky a favourable place 
to spend their resources” (G1-21, Kentucky).  
“There are none in Louisiana” (G1-12, Louisiana). 
The role of money. While the state by state review found that the allocation of 
money to support either side of the argument can affect the policy process, the 
respondents were divided on how significant the influence of money was, as it differed 
amongst states. This was also noted in the state by state review, which found that more 
money was spent in Michigan which had the ballot initiative process than in New 
Mexico which does not have a ballot initiative process and where the medical cannabis 
debate occurred within the political system. The respondents also believed that medical 
cannabis proponents spent more money than opponents, and this was also found to be 
the case in the state review of Michigan.  
“Not enough money is funnelled to effective advocates for medical 
cannabis by either state or national organizations, such as MPP, DPA, 
etc. NORML is basically a non-profit run by mostly volunteers and is of 
limited effectiveness in this debate as described before. Philanthropists 
are not yet supporting medical cannabis legalization in IL they [sic] way 
they did in CA and other early MC states” (G1-1, Illinois).  
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 “Until a level playing field is established in terms of funding for 
advocacy groups opposed to the legalization of cannabis, states will 
continue to fall prey to the pro-cannabis funded movement” (G1-4, New 
Mexico).  
“I don’t believe much money is spent for OR against MMJ [medical 
cannabis] in Ky [Kentucky]” (G1-21, Kentucky).  
“It’s always about the money to be successful” (G1-11, Michigan).  
“Whichever lobby has the most money rules the day” (G2-1, New 
Mexico).  
How money is used. Those respondents who believed that money did play or 
continues to play a significant role in the medical cannabis debate frequently gave 
consideration to how that money is used by individuals both supporting and opposing 
the legislation. The respondents stated that some of the ways that money can be used is 
to influence opinions and fund efforts to support or oppose the legislation. 
 “Money enabled the hiring of professional lobbyists and assembling an 
effective lobbying and advocacy effort. Almost nothing gets passed in 
U.S. state legislatures without some money behind it” (G1-9, Illinois).   
 “Money has been a crucial resource in many ways; the hiring of 
lobbyists who have the relationship with legislators to get the bill 
introduced, funding patients’ presence at the Capitol, and supporting 
advocacy efforts” (G1-12, Illinois).  
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“Key politicians are being bought off by marijuana advocates” (G1-7, 
Illinois).  
City and county-level change. As noted in Chapter Four, over the years local 
governments have made it easier for the electorate to raise issues and voice their 
opinions, and at times issues at the local level have been acted on more quickly than at 
the state and federal level. In Michigan, first medical cannabis changes occurred at the 
city level, and there was also city activity in Illinois and Louisiana. The majority of 
respondents in this study believed that city-level change showed potential and helped 
pave the way for future, larger-scale change, and are a good place to start in terms of 
gaining momentum for the issue.  
“I think they begin to open up the debate and they are a good place to 
start” (G1-6, New Mexico).  
 “They clearly helped pave the way and illustrate public support. This 
was most obviously the case in Michigan” (G1-9, Illinois).  
 “There is less money involved in terms of lobbyists and the cities have 
been able to avoid any influence from either side. City councils are 
smaller than the general assembly and that is easier to change too” (G1-
12, Illinois). 
“City-level changes can have a huge impact and did in our area” (G2-
16, Michigan).  
However, the city-level changes also appeared to be linked to states with an 
initiative process and states where there is already medical cannabis activity at the state 
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level. Those states where there was little medical cannabis movement at the state level 
appeared to have little to no movement at the city level.  
“In New Mexico this was not an issue. It was a top-down process. The 
debate began with Johnson and gained momentum with Richardson” 
(G1-19, New Mexico).  
“No city in Louisiana has even addressed medical cannabis issues” (G1-
2, Louisiana).  
“I’m not aware of any city level initiatives in Kentucky, although I did 
pose the question to our new Mayor. He, like most politicians, only 
considered if the majority of voters would approve of a low enforcement 
law” (G1-21, Kentucky). 
Participants also believed that passing medical cannabis laws or ordinances at 
different levels would make the medical cannabis issue more complex and city-level 
changes would not necessarily lead to a successful implementation at the state level.  
 “It would be a good start. But what happens in Chicago sometimes does 
not affect downstate but if a few smaller progressive cities would do it 
that would help” (G2-7, Illinois).  
“I think it’s ridiculous to make changes at the city level. It’s too 
confusing and piecemeal” (G2-1, New Mexico).  
“City law cannot override state law so little impact likely” (G2-20, 
Kentucky).  
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“I think it is highly unlikely to play a role in this state” (G2-6, 
Kentucky).  
On the other hand, seven participants did not think separating the two aims had 
much (or any) influence for a number of reasons, including it being confusing and the 
influence of state law.  
“I think it’s ridiculous to make changes at the city level. It’s too 
confusing and piecemeal” (G2-1, New Mexico). 
Difference between states. As can be seen from the other themes mentioned 
previously, medical cannabis advocates and opposition groups are more active in some 
states than others and tend to choose where they will allocate their time and resources. 
According to four Group One respondents, factors such as debate, public support and 
perception, and the influence of other states may account for this. As mentioned in 
Chapter Four, it is also generally believed that there is little interest in medical cannabis 
in the Southern states, while the initiative process tends to be most popular in the 
Western states, but is not exclusively a western phenomenon (Matsusaka, 2005).  
“There is no NORML chapter still in operation here & no other 
organized group has considered Kentucky a favourable place to spend 
their resources…Kentucky is a rural, religious, and uneducated state. 
Change is slow to non-existent. I’ve written my legislators numerous 
times & have had no response” (G1-21, Kentucky).  
“Louisiana lawmakers mirror those of other deep southern states, and 
ignore medical cannabis as potentially beneficial to countless suffering 
patients.” (G1-2, Louisiana).  
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Need for activity. Lack of campaigning in a particular state generally leads to 
lack of funds and debate on the issue. In the state by state review, limited campaigning 
and debate was observed in states such as Kentucky and Louisiana, and as a result there 
was little public support. Meanwhile, states such as Michigan had a well organised, 
persistent medical cannabis effort, which eventually resulted in passing of the medical 
cannabis law in the state.  
“...there is little medical cannabis debate in Kentucky. There is no 
television coverage except National Programming & the Newspaper 
rarely covers stories or medical breakthroughs” (G1-21, Kentucky).  
“I heard nothing- pro or con during the last election cycle” (G2-10, 
Louisiana). 
“Very little debate to my knowledge” (G2-20, Kentucky). 
While there is need for activity and persistence in efforts, timing is also an 
important factor to consider. In the state by state review, timing was an important factor. 
It was noted that timing of political events does not happen by chance and politicians 
attempt to influence the timing in order to maximise benefits and draw public attention 
to a particular issue or draw it away. In New Mexico, for example, Gov. Johnson voiced 
his support for medical cannabis in his last term as a governor, when he was not up for 
re-election and the issue was not going to affect him being re-elected. As one Group 
One participant wrote: 
“The politicians don’t want to do anything closely controversial 
anywhere near an election, and State Reps. in Illinois run for re-election 
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every two years. Party leaders will only do it when it is the least 
problematic for them in terms of losing seats” (G1-12, Illinois). 
Media influence. The state by state review in Chapter Four found that how an 
issue is framed in the media can shape how individuals interpret and evaluate the issue 
(Lee et al., 2008). The media has also been found to be of particular influence in the 
democratic process. In states such as Michigan, the media kept the public actively 
involved in the issue. In terms of medical cannabis, the media was a forum where the 
proponents and opponents could debate and present their opinions. Five Group One 
respondents said that media presence and coverage can have an influence on the 
outcome of medical cannabis policy. How a particular issue is covered and portrayed by 
the media can also influence the outcome, with the media also having the ability to 
“cherry-pick” scientific evidence that is presented. No Group Two participants 
discussed media as a factor of influence in the medical cannabis debate.  
 “The mainstream media gives little attention to scientific evidence 
regarding cannabis. I’ve written & had published numerous letters in Ky 
[Kentucky] largest newspaper, the Courier-Journal, calling them out on 
their lack of coverage. They didn’t even cover Dr Tashkin’s 2005 cancer 
study(except for my letter) that should be front page news in a state with 
one of the highest cancer rates” (G1-21, Kentucky).  
“We end up losing momentum whenever there is significant media 
coverage that distorts the aim of the effort and instead tries to paint it as 
more of a drug legalization effort” (G1-24, Illinois).  
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In terms of medical cannabis, the participants also indicated that the media can 
work in reverse, with insufficient media coverage leading to less public support in 
states.  
“...there is simply not enough media coverage to even encourage public 
debate, much less support” (G1-2, Louisiana).  
The importance of knowledge/education. In Chapter One, it was discussed 
that scientific evidence can have an impact on policymaking, but not necessarily in the 
immediate or direct way that would be expected by the researchers (Black, 2001; 
Brownson et al., 2009). It was also noted that it was not enough for relevant research to 
just be available as evidence itself may not necessarily be used by the participants in the 
process or influence decision making (Birkland, 2005; Brownson et al., 2009; Hanney et 
al., 2003). Those involved in the medical cannabis debate in the states reviewed in this 
thesis believed that both physicians’ and politicians’ lack of knowledge about the 
medicinal properties of cannabis influenced the medical cannabis debate. The responses 
indicated that it is not enough to simply have scientific evidence, but that it needs to be 
actively used to educate individuals and groups involved in the policy process, such as 
politicians and the general public.  
 “The biggest factor influencing the absence of implementable law in 
Louisiana is lack of education regarding the medical value of cannabis... 
Even doctors lack knowledge of its medical value. Because it is illegal, 
they tend to ignore scientific/medical research study reports proving it to 
be a reasonably safe and effective medicine” (G1-2, Louisiana).  
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“We have had some decent progress in Illinois in attempting to 
implement medical cannabis, largely due to an effective push by 
advocacy groups that are supported by scientific and medical 
professionals” (G1-24, Illinois).  
However, the respondents also acknowledged that there were obstacles to 
educating individuals involved in the process, such as the need for more comprehensive 
studies and refusal by some physicians to share their data.  
“I am also trying to organize a North American Community-Based 
Clinical Cannabis Research Network to achieve the basic aims of 
developing evidence based treatment guidelines...but encountering much 
resistance from the major MC physicians, particularly in CA, who don’t 
want to “share” their data, etc.” (G1-1, Illinois).  
The influence of old laws. Four out of five states reviewed in Chapter One had 
medical cannabis or therapeutic research laws passed in the 1970s, which have not been 
effective. Some states such as New Mexico attempted to reinstate the old state law by 
making amendments to it, while states such as Michigan did not attempt to reinstate the 
old law but instead tried passing a new one. Group Two respondents did not discuss old 
state laws, but Group One respondents believed that the focus should not be on creating 
a new medical cannabis law, but reinforcing the already existing one.  
 “The problem isn’t making new laws, but honouring the current laws” 
(G1-5, Louisiana).  
“We’ve had an “inoperable” medical cannabis law in Illinois since 
1978. It is only a lack of political will to create a workable law...We 
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don’t need an initiative ~ we need Section 11 of the current law 
enforced” (G1-20, Illinois).  
However, there were also respondents who believed that the old laws were an 
impediment to passing new medical cannabis legislation. 
“...the State of IL DID pass a medical marijuana law in, I think, 1971, 
but since it called for “prescription” of cannabis and was never enacted 
through regulations, etc., it never went into effect. I think that having this 
history in IL is a definite barrier to passing a reasonable MC law 
currently and we would be better off if the earlier law had never been 
enacted” (G1-1, Illinois).  
The role of patient testimonies. It has been argued that the policy process can 
sometimes be more influenced by anecdotal rather than by scientific evidence. In terms 
of medical cannabis, the majority of evidence on cannabis as a medicine came from 
personal and historical accounts (Mack & Joy, 2000). In Michigan, for example, patient 
testimonies were prominent in the media, while in New Mexico patient testimonies 
were heard in the Senate and House of Representatives when there were attempts to 
pass a medical cannabis bill. There were also professionals and individuals testifying 
against medical cannabis to support the opposition’s arguments of negative effects of 
medical cannabis. Four Group One respondents said that patient and expert testimony 
can play a role in determining the outcome of legislation. For example, the ONDCP 
using professional/expert witnesses to testify against medical cannabis legislation. As 
one respondent put it:  
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“The Administrative Branch, Legislature, advocacy groups and patient 
testimony were the most compelling efforts and support that lead to the 
passing” (G1-4, New Mexico).  
The opposition of the law enforcement lobby. While the law enforcement 
lobby was not identified as one of the major factors in the medical cannabis debate in 
the state by state review, four Group One respondents from states that do not currently 
have a medical cannabis law believed it was one of the major factors preventing medical 
cannabis laws from passing in their states as it had the potential to influence legislators.  
“Cowardly legislators in fear of the law enforcement lobby (the latter 
should have been named as a factor in the prior sections – it is the most 
important source of opposition)” (G1-9, Illinois).  
“Illinois Partners Providing Marijuana Education and the law 
enforcement community were able to influence the legislators” (G1-30, 
Illinois). 
Public opinion and support. As can be observed through the themes discussed 
previously, public opinion can have an influence on the legislators and their decision to 
support or not support particular legislation. Public opinion can be particularly 
influential in states with an initiative process. As noted in the state by state review, 
medical cannabis opponents and proponents in Michigan frequently appealed to the 
public to support their cause, especially in the months preceding the placing of the issue 
on the ballot. Five Group One respondents believed that public support played a major 
role in the medical cannabis policy process. However, they also believed that public 
support played little role in states with only the legislative process.  
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“Most important in Michigan was public support” (G1-3, Michigan). 
“Legislation on this issue, sadly, is an illustration of how little role 
public sentiment often plays in the legislative process” (G1-9, Illinois).  
Religious organisations. While the involvement of religious organisations was 
reported in the state by state review, especially in Kentucky and Louisiana, it was not 
identified as a major factor. In this study, only one Group One respondent stated that 
religious organisations had a strong influence on medical cannabis legislation. The 
respondent also indicated that if the medical cannabis issue was brought up in the state, 
there would be opposition from conservative religious organisations.  
“If it were to be brought up by advocates, I would assume there would be 
push back from opponents (particularly from conservative religious 
organizations)” (G1-15, Louisiana).   
While Groups One and Two were analysed and their findings reported, an 
additional group, Group Three, was excluded from analysis. The following section will 
describe the group and the reasons behind its exclusion.  
Group Three 
Group Three participants were drawn from individuals currently involved in the 
state government sector (i.e. the governor, Representatives and Senators) in one of the 
five states reviewed. The participants were identified through publicly available sources 
such as government documents and state government websites, and online searches. 
Participants were selected for their involvement in the government sector, and their 
experience in the policy process. As they were not identified as being directly involved 
in the medical cannabis debate, it was anticipated that Group Three participants would 
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be able to provide an objective appraisal of the debate and factors influencing medical 
cannabis legislation. A search of the literature did not provide a clear guideline for the 
response rate in the interviews of politicians; therefore a specific response rate was not 
expected. However, being guided by the response rate for Group One and Two 
participants, a response rate of at least 10% would have been deemed acceptable to 
discuss in this thesis.  
 A total of 625 potential participants with publicly available email addresses 
were contacted via email and invited to complete the online Qualtrics survey. Of those, 
three responded to the email invitation and stated that they would be unable to 
participate. A total of 5 (0.8%) participants completed the online survey. As the number 
of responses was low it was concluded that the sample would not be representative of 
the group (politicians) as a whole, and Group Three was therefore excluded from further 
analysis.  
Perhaps an explanation for the low response rate can be found in the literature 
which suggests that elites such as politicians are unwilling to reveal their true beliefs in 
structured questionnaires because they feel that the differential nature of their political 
views cannot be adequately captured by the questions with fixed-choice options 
(Donsbach & Traugott, 2008). Politicians are busy people with time constraints and can 
also have distrust in the purpose of the research or the trustworthiness of the researcher. 
In this case, the researcher was from a relatively new university in a different country to 
the participants, which may have impacted on the response rate. It was also difficult to 
obtain direct contact details for the majority of participants, and the researcher had to 
contact their office in hope of establishing direct contact with potential participants. It is 
possible then that the questionnaire did not reach some potential participants. As noted 
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in the previous chapters, there are also many factors that politicians need to take into 
account when engaging in a public debate or taking a stance on a particular issue, and as 
such may have been reluctant to participate in research on medical cannabis.   
 In hindsight, it may have been better to attempt to make direct contact with this 
group of participants and establish rapport before interviewing them. Face-to-face 
interviewing would have been preferred, as the participants may have been weary of 
online surveys and may have held concerns about the security and data integrity 
(Rivera, Kozyreva, & Sarovskii, 2002; Sax, Gilmartin, & Bryant, 2003). However, face-
to-face interviewing was not possible for the purposes of this study due to money and 
time constraints, and the location of the researcher.  
Discussion 
There were some underlying differences between the respondents in terms of the 
demographic information. Just under half (48%) of Group one and 83 percent of Group 
Two respondents identified as Democrat, which supports the earlier assertion that 
Democrats generally tend to be in favour of medical cannabis, and the majority of 
participants in both groups indicated that they supported medical cannabis. While Group 
One participants were identified as participating in the medical cannabis process, the 
findings indicate that a majority of Group Two participants were also aware of the 
medical cannabis debate in their state. It indicates that even those that are not directly 
involved in the process have some knowledge of it, and have formed opinions on the 
issue.  
As the medical cannabis movement keeps gaining momentum, it is possible that 
a large percentage of the population will in some way be exposed to the medical 
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cannabis debate or have personal experience with it. This makes it important for 
evidence to be disseminated to the wider population, so that informed decisions can be 
formed. However, as discussed in Chapter One, there are a number of factors that play a 
role in the medical cannabis policy process, and evidence does not play as big a role as 
one might assume. While it is acknowledged that the findings of Group One and Two 
studies may be biased towards the views of medical cannabis supporters, some 
underlying themes have been identified. While the findings in this chapter were 
presented as themes, it should be noted that they are not independent of each other and 
actually interact as part of the policy process.  
The general consensus between research participants was that cannabis can be 
used effectively as a medicine, but there were no elaborate discussions in relation to 
specific disorders. An overwhelming majority of participants also agreed that further 
research on cannabis as a medicine was needed, particularly research addressing 
different routes of administration, appropriate dosage, side effects, and long-term 
effects. While those involved in the research field, such as Group Two participants, 
were more likely to call for more evidence on cannabis’ medicinal properties, it was 
also noted that the results may not have enough impact unless they are reaching and 
informing those involved in the policy making process. Group Two participants were 
also less optimistic in terms of the role scientific evidence plays in passing medical 
cannabis legislation, but this could be attributed to their belief that more evidence is 
needed. However, it is important that the evidence being disseminated to the public and 
those involved in the process remains objective, and that it be presented in a way that is 
easy to understand.  
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What also needs to be taken into consideration is the individual or the group, 
such as politicians, who the evidence is distributed to and what sort of evidence they 
require (Ritter, 2009). For example, Ritter (2009) found that politicians were interested 
in simple, uncomplicated information. In relation to understanding who the evidence is 
provided to, Davoudi (2006) stated that:  
When it comes to influencing policy, it should be noted that new 
evidence does not enter a pristine environment, it has to fit into the 
policy-makers’ general understanding of how the world works. Such 
understanding comes from a variety of sources ranging from scientific, 
systematic research evidence to anecdotal experiences and tacit and un-
codified knowledge. (p. 21).  
While the notion that scientific evidence should play a major role in influencing 
medical cannabis policy is ideal, it is also not realistic in the sense that there are other 
factors which play a role in the process and which need to be taken into consideration. 
The role of scientific evidence in informing policy also depends on a variety of factors, 
such as the government; context; how it is used and for what purpose; how it is 
presented and communicated; the direct policy process; and what individuals interested 
in the policy make of the science. While it might be argued that policy should be 
enacted on the basis of the scientific evidence, it needs to be understood that the 
legislative process is essentially political. Advocates of medical cannabis, or other drug 
law reform, while not losing sight of the evidence, also need to understand and engage 
in the political process. A change in researchers’ attitudes is also required, so that the 
sole focus is not just on generating research, but on making that research an influential 
part of the policy process.  
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The findings also indicate that there may be some differences between the 
factors which play a role in passing medical cannabis laws in states with the initiative 
process and those without. The results of this study indicate that a distinction needs to 
be made between the factors playing a role in medical cannabis policy formation in 
states with an initiative process and those without. While the participants thought that it 
may be easier to pass medical cannabis laws in states with an initiative process, there 
were also difficulties associated with it, such as cost and potential for the system to be 
abused by those who have monetary and organisational power. The question of who set 
the agenda and for what purpose is also another important question to consider with 
regards to the initiative process, as, according to Kousser and McCubbins (2005) “it 
does not allow for careful selection of those who set the agenda” (p. 20). Kousser and 
McCubbins suggested that, due to the flaws in the process, initiatives have the potential 
to lead to negative outcomes and poor implementation. This can be related back to the 
poor implementation of medical cannabis laws in some states and the difficulties 
experienced with implementing such laws which will be discussed later. Overall, while 
using the initiative process has helped in the passing of medical cannabis laws where 
they may not have passed otherwise, the ballot initiative process can also be abused. For 
example, money from outside organizations can often have a disproportionate influence 
on the process, which may or may not be consistent with what the evidence supports or 
what the majority of the electorate desire.  
The findings also indicate that influencing public opinion is a driver in 
instigating policy change, especially when concerning a polarising topic such as medical 
cannabis. Public support was rated as one of the top three factors of influence by both 
Group One and Group Two participants. According to the findings, laws are not likely 
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to work without the support of the public. As a result, influencing public opinion is one 
of the major focus points for those who are attempting to get a law passed.  
While the state by state review in Chapter Four showed that there were high-
profile organisations supporting medical cannabis, Group One and Two participants did 
not think that high-profile individuals played a significant role in the medical cannabis 
policy process. They ranked it as eight and seventh respectively, and indicated that other 
factors, such as legislative and public support, took precedence. Notably, Group One 
participants rated advocacy groups as the second most important factor influencing 
policy, while Group Two participants rated this as the second last. The difference could 
be attributed to the fact that Group One participants had a direct involvement in the 
process and possibly had had interactions with advocacy groups. Because Group One 
participants were selected based on their involvement in the medical cannabis debate in 
one of the five states under review, they may also have been medical cannabis 
advocates and may have seen their involvement in the process as important. Because 
Group Two participants were not involved in the medical cannabis debate, they may 
have taken a more objective view of the importance of advocacy groups and other 
factors.  
 Both Group One and Group Two participants placed the support in the 
legislature as one of the most important factors influencing policy. This is also linked to 
the influence of high profile individuals, as some politicians are very high profile and 
were known to actively support or oppose medical cannabis policy. While it is 
important to have support from the politicians, especially those well-known or well-
liked by the public, the support does not come easily as there are many factors 
politicians need to take into account when making policy-related decisions. If the aim is 
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to make policy making more evidence-based and educate politicians, then scientists 
should be aware of the political process and the factors, apart from scientific evidence, 
that politicians need to take into account.  
Patient testimonies were ranked by Group One participants as sixth out of nine 
factors influencing medical cannabis policy creation and last by Group Two 
participants. This could possibly be due to the fact that the evidence so far has been 
limited and inconclusive. Those participants who were researchers may also have been 
biased towards the role of scientific evidence. Nonetheless, as can be seen from a look 
at the process of how medical cannabis laws were created, as discussed in Chapter Four 
the role of anecdotal evidence should not be underestimated.  
Notably, Group Two participants rated money as the number one factor 
influencing medical cannabis policy. It was placed fourth by Group One participants, 
who were directly involved in the process. This tendency could be explained by the fact 
that only four (13%) Group One respondents participated in the medical cannabis debate 
in Michigan, while most resided in New Mexico, Illinois and Louisiana, which have no 
ballot initiative process or cannot put medical cannabis on the ballot. The results also 
indicated that the reason why some organisations or individuals supported medical 
cannabis policies was not due to science or compassion, but due to the belief that 
medical cannabis is a business and there are profits available. The influence of funding 
sources can then make it difficult for decision makers to remain objective.  
Taking into account the many factors participants identified as playing a role in 
the medical cannabis process, it can be said that the political process is composed of a 
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number of different factors and influences. These include political timing, legislative 
pressure, and party ideology.  
Unrelated political conflicts and instances when other pieces of legislation are 
used for a different purpose can also impact progress, as well as political “mind games” 
such as threatening funding and adapting to a particular environment in order to send a 
particular message. There are also different factors that policymakers need to take into 
account, which can diminish the perceived importance and influence of the scientific 
evidence. Overall, policy creation can be a long and difficult process, where persistence 
and a well-organised effort are of importance, as well as the interplay of different 
factors such as timing, political ideologies, and the context in which the policy creation 
is occurring.  
“One of the major issues that ultimately led to it being a 7 year fight 
were all the unrelated political conflicts and instances when other pieces 
of legislation were used to impact our progress, or when our bill was 
used to further another bill. Hostage situations (taking the bill hostage in 
exchange for another bill), timing issues, all unrelated to the merits of 
the bill but part of the political process” (G1-6, New Mexico).   
Study Limitations  
As with any research, there were some unavoidable limitations with this study. 
One noteworthy limitation was low response rates in the research groups. Although the 
findings of the study were intended to inform the researcher and there were no 
expectations in terms of acceptable response rates for the groups, previous research has 
found that an average response rate for online surveys to be around 33 percent and 56 
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percent for paper-based surveys. While the use of online surveys is increasing, little 
research is identified which can suggest what an appropriate expected response rate may 
be. According to Nulty (2008) “whether or not a response rate is adequate depends (in 
part) on the use that is being made of the data” (p. 307). Participants for this study were 
asked to provide their views on factors influencing the medical cannabis process, and it 
was therefore decided that, although limited in the number of respondents, Group One 
and Two participants were able to offer a valuable insight into the policy process from 
the view of those directly involved in it and those involved in the science based aspect 
of policy. The low response rate could be attributed to a number of reasons including an 
increase in the number of research studies during the past few decades and the number 
of requests participants may receive to participate in studies, overall decline in social 
participation, and participation not being viewed as worthwhile (Galea & Tracy, 2007). 
Research has shown that face-to-face interviews result in higher response rates, but this 
was difficult to achieve for the purpose of this thesis due to the researcher’s location and 
time and money constraints (Nulty, 2008). Future research may consider face-to-face 
interviews and increasing the sample size to try and achieve a higher response rate. 
There is also the issue of generalizability of the findings. In terms of Group One, 
individuals involved in the medical cannabis debate in the five U.S. states reviewed here 
are a unique sample, and the data obtained may not be applicable to other populations. 
Group Two participants were all researchers and had varying degrees of familiarity with 
the medical cannabis debate in the five U.S. states, and could be considered to have a 
more objective view of the topic due to lack of direct involvement. It is not possible to 
demonstrate that the sample was representative of the population; therefore caution 
must be exercised in generalising conclusions beyond the medical cannabis policy field. 
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However, it is important to note that this study was of an exploratory design and 
generalisability was not the aim of the study. The aim of this study was not to test a 
hypothesis, but obtaining an insight into the medical cannabis process and what 
happened in the five states under review from the perspective of those participating in 
the process and those observing it. This sample is therefore a very small proportion of 
everyone involved in the medical cannabis process in the U.S., either directly or 
indirectly, and research studies with a much larger sample size would be needed to 
ensure generalisability of the findings. The data collection was limited to only five 
representative U.S. states and future studies may want to look at replications of the 
study in different U.S. states and in the general population.  
There might be a potential for bias in the Group One sample of participants as 
they already had formed views on the medical cannabis issue, which were expressed in 
the public forum and identified in the literature review for each state. Nine (31%) of 
Group One participants also used cannabis for medical purposes, and eight (28%) used 
it recreationally. In contrast, no Group Two participant used cannabis for medical 
purposes, but 11 (48%) used it recreationally. However, the majority of participants in 
both groups supported medical cannabis legislation, and the sample may therefore be 
biased toward medical cannabis. According to Galea & Tracy (2007), potential 
participants are more likely to respond to surveys they are interested in and that have 
some personal value to them, which may explain more medical cannabis supporters 
completing the surveys. The sample was also biased in terms of political affiliation, 
with 48 percent of Group One participants and 83 percent of Group Two participants 
identifying themselves as Democrats. As discussed in the state by state review in 
Chapter Four, Democrats generally tend to be supporters of medical cannabis while 
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Republicans tend to oppose it. As such, the views of those involved in the study may 
greatly differ from the views expressed by those not involved, as the supports of 
medical cannabis legislation may have been more inclined to participate.  
Another potential limitation of this study is that it relied on self-reported 
responses, which can lead to potential bias in results (Donsbach & Traugott, 2008). 
Biases can be derived from participants’ experience of medical cannabis or recreational 
cannabis use, as well as their involvement in the debate; they may misreport their level 
of involvement or the importance of certain factors based on their personal opinion and 
experience, and may be inclined to provide socially accepted responses. Personal 
perceptions and opinions of the participants in this study may therefore not reflect the 
actual medical cannabis policy process and the importance of factors influencing such a 
process. However, self-report methods were considered as the most appropriate and 
realistic method for gathering the required information, due to the participants’ location, 
and for gathering information about the process itself from the perspective of those 
involved in it. It is therefore advisable that any future studies draw a random sample of 
the population.  
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Chapter 6- Group Four Study 
This chapter will outline in detail how the Group Four study was undertaken, 
provide details of the study design, and present Group Four findings. The purpose of 
this study was to further explore the themes developed through earlier studies and the 
state by state review, and obtain a general overview of the factors influencing alcohol, 
other drug, and medical cannabis policy from the perspective of individuals involved in 
the field.  
Sample 
Group Four participants were members of the ISSDP, and were chosen as 
individuals who had an interest in, and participated in, the drug policy field. It was 
anticipated that the participants would have sufficient experience to answer questions 
relating to the drug policy field and the processes and factors involved in enacting 
policy, without necessarily being directly involved in the medical cannabis debate. 
Their opinions were sought as experts on the drug policy process and it was anticipated 
that they would be able to provide an objective, informed view of the process. All 
participants were identified through the ISSDP 2010 conference registration list 
supplied to the researcher by ISSDP. All participants who were not personally involved 
with this study through providing feedback on the study to the researcher, and whose 
email addresses were available were invited to participate in a semi-structured telephone 
interview.  
 A total of 90 potential participants were invited to participate in the study. 
Nineteen individuals responded to say that they were unable to participate in the study 
for several reasons, including insufficient knowledge of medical cannabis policy, 
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insufficient knowledge of the drug policy field, and time constraints. The interviews 
were conducted with participants in the order that participants were available for 
interview. It was estimated that ten interviews would be able to provide a valuable 
insight into expert view of the policy process, and data saturation was reached after ten 
interviews. In qualitative studies, saturation is reached when no new or relevant 
information emerges from the data, and the information obtained from participants 
becomes repetitive (Given, 2008; Liamputtong & Ezzy, 2005; Mason, 2010; O'Leary, 
2004).  
In total, interviews were conducted over three months, with ten participants of 
whom five resided in the U.S., three in Australia, one in the Czech Republic, and one in 
France. Their occupations included professor, senior economist, consultant in social 
research and evaluation, researcher, PhD student, lecturer, and assistant policy advisor. 
All participants had research experience in drug policy, and five had studied policies on 
the use of cannabis as a medicine.  
Procedure 
Approval for the study was obtained from the ECU Human Research Ethics 
Committee prior to commencing the research. The following section will describe the 
procedures used in the development of the semi-structured interview schedule and how 
the interviews were conducted. The data collection period spanned from 16th February 
2011 to 22nd April 2011. 
According to Corbetta (2003), qualitative interviewing allows the researcher to 
gain an understanding of a subject’s perspective, “understanding his mental categories, 
his interpretations, his perceptions and feelings, and the motives underlying his actions” 
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(p. 264). It was expected that Group Four participants would be able to present an 
objective overview of the policy field and factors which play a role in influencing it, 
along with their experiences of working in that particular field. Qualitative interviewing 
also does not call for a representative sample, making it appropriate for Group Four 
participants who were all from similar fields and were members of ISSDP (Corbetta, 
2003).  
Telephone interviews, specifically, allowed the researcher to obtain more in-
depth data than questionnaires did, and allowed respondents to discuss their 
experiences, perceptions, and attitudes (Morrison et al., 2000; Stetson & Romeo, 1996). 
Telephone interviewing is a cost-effective way to cover a greater geographical area, 
which allowed the researcher to interview participants from four different countries and 
obtain a wider perspective of the policy process (Musselwhite, Cuff, McGregor, & 
King, 2007). It also allowed the researcher to arrange interview times across different 
time zones, at a time convenient to participants, and allowed for a dynamic interchange 
of information and allowed the researcher to clarify responses and discuss relevant 
issues (O'Leary, 2004). Protection of participants’ anonymity was also considered when 
selecting an appropriate interviewing method, and telephone interviewing allowed this. 
According to Musselwhite et al. (2007) “the anonymity associated with telephone 
contact may enable participants to be more forthcoming with their responses” (p. 1066). 
Due to low participant response rates for Groups One to Three, telephone interviews 
were utilised for Group Four interviews as they generally have better response rates 
than questionnaires (Glogowska, Young, & Lockyer, 2011).  
Interview questions. A semi-structured interview schedule (Appendix E) 
containing nine open-ended questions was used. Semi-structured interviews are the 
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most used interviewing format for qualitative research (DiCicco-Bloom & Crabtree, 
2006). According to O’Leary (2004), semi-structured interviewing “gives both the 
interviewer and the respondent ample freedom, while at the same time ensuring that all 
the relevant themes are dealt with and all the necessary information collected” (p. 270). 
The questions helped guide the interaction between the participants and the researcher, 
while still allowing participants an opportunity to raise and discuss pertinent issues 
(Liamputtong & Ezzy, 2005). Examples of questions included “What role do you think 
scientific evidence generally plays in policy-making?” and “In your opinion, which 
factors influenced the passing of medical cannabis legislation in 1511 U.S. states (such 
as California, Michigan, and New Mexico) since 1998?”  
The questions were based on themes derived from the state by state review and 
Phase I results. The questions sought to investigate the role of scientific evidence in 
medical cannabis policy, and identify the factors influencing general drug as well as 
medical cannabis policy. In semi-structured interviewing, the wording and order of the 
questions can be changed, depending on the interview and the participant (O'Leary, 
2004). Some questions were omitted due to participants’ lack of knowledge or inability 
to answer a question, while in certain cases questions were added in order to facilitate 
discussion. Probing (or prompting) was also used to encourage participants to provide 
more information or to clarify an issue (O'Leary, 2004).  
The interview process. Once the contact details of ISSDP members were 
obtained, they were emailed an information letter which outlined the nature of the study 
and invited them to voluntarily participate in it. The letter also informed participants 
11 At the time of the interviews being conducted, 15 U.S. states had enacted medical cannabis legislation. 
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that the study looked at the policy process underlying medical cannabis laws in the U.S., 
how problems and issues are recognised and raised, and how and why governments 
choose to act or not act on certain policies. The participants were advised that they had 
been identified as someone who could comment on the policy process due to their 
involvement with the ISSDP.  
Participants were asked to indicate their willingness to participate in the study by 
sending an email to the researcher stating their agreement. They were then contacted by 
the researcher to arrange a suitable interview time. Participants were informed that they 
were free to withdraw their consent and cease their involvement in the research project 
at any time. Participants were provided with contact details of the researcher, two 
supervisors, and an independent contact (ECU Research Ethics Officer) in case they had 
any questions about the study. Prior to the interview taking place, participants were sent 
a confirmation email, allowing them time to raise questions or concerns regarding the 
study. If a date change was necessary, participants were asked to indicate their 
availability and the interview was rescheduled to a more suitable time.  
All Group Four interviews were conducted at a time convenient to the 
participants and the researcher. The researcher obtained a quiet room with a speaker 
telephone, and interviews were recorded and transcribed verbatim. All interviews were 
completed in one sitting. Before interview questions were asked, the researcher 
explained the purpose of the interview, addressed the terms of confidentiality, explained 
the format of the interview, indicated how long the interview would take, and allowed 
participants to ask questions to clarify any concerns they had (Musselwhite, et al., 
2007). The researcher also attempted to set participants at ease by reviewing the aims of 
the interview and reassuring participants of their anonymity. Participants were also 
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reminded that the interview would be voice recorded for later transcription, and their 
consent was confirmed.  
The interview was voice recorded in order to preserve the data in its purest form, 
as it would have been difficult to write notes and keep track of the questions while 
maintaining a conversation with the interviewee (Glogowska, et al., 2011). The 
interviewer used a speaker telephone in a quiet room at ECU, and an audio-recording 
device with high sensitivity. One participant preferred using Skype (www.skype.com) 
for the interview and this was arranged. The Skype interview was recorded using audio-
recording software on the researcher’s computer.  
The interview began with generic questions in order to establish rapport with the 
participants and set them at ease (Musselwhite, et al., 2007). The interviews were kept 
at 30 to 40 minutes long, in order to minimise participant inconvenience (Glogowska, et 
al., 2011). One interview had missing data due to technical difficulties with the voice 
recorder. The participant invited the researcher to email them the missing questions, but 
no response was received. After the interview took place, the researcher allowed 
respondents time to add further information or discuss any pertinent issues.  
After the interviews were completed they were transcribed by the researcher, 
and audio files of telephone interviews were stored in a password protected computer in 
the researcher’s office at ECU and all further work was done using the transcripts. Only 
the researcher had access to the transcripts. All transcripts were numerically coded; each 
participant was assigned a different numerical code, and no identifying information was 
used. All transcripts were coded based on the participant’s group, and their interview 
number. For example, if the participant belonged to Group Four and was the fifth 
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participant interviewed, they were assigned the code “G4-5”. Transcripts and data were 
stored in a locked filing cabinet at ECU.  
Analysis 
After the accuracy of the transcripts was verified, by checking them against the 
audiotapes, they were analysed using thematic analysis, with a focus on maintaining the 
essence of the participants’ accounts (Liamputtong & Ezzy, 2005). Thematic analysis 
involves the identification of themes through reading and rereading of the data and 
coding of recurring themes appearing throughout (Liamputtong & Ezzy, 2005). For 
more information on thematic analysis and the steps used in the analysis process, please 
refer to Chapter Five, “Analysis” section.   
An audit trail consisting of how codes and themes are developed was kept in 
order to enhance the credibility of the research. Providing an audit trail ensured the 
rigour of the study, clearly and accurately documenting how the data were collected and 
analysed and how interpretations were made. In order to check the validity, the 
supervisors of the project reviewed the themes (Liamputtong & Ezzy, 2005). The 
researcher used a reflective journal (memoing) in order to recognise any research bias, 
which added to the authenticity of the information (Liamputtong & Ezzy, 2005). QSR 
International’s computer-assisted qualitative data analysis software, Nvivo 9, was also 
used to assist with the organisation and analysis of the data, and with keeping an audit 
trail (QSR International Pty Ltd, 2010). 
The following section outlines the findings from Group Four interviews, 
presented according to emerging themes.  
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Results 
Moderate but increasing role of scientific evidence. One of the major themes 
arising from the Group Four study was the influence of scientific evidence on general 
drug policy. The general consensus amongst participants was that the scientific evidence 
did and continued to play a role in the policy making process and the policy debate. 
However, as noted in the previous chapters, that role was generally believed to be 
limited and not to the level that researchers may have wanted. Those conducting 
research also hoped that evidence did play a role as that meant that they were serving 
their purpose and contributing to the process.  
 “You know, if you had a rating scale of 0 to 10 of how much role does 
science play in it...I would put it currently at about a 4 or a 5 in general 
alcohol and drug policy. We have seen, for example, increasing use of 
medications in treatment over the last decade- in part because of science 
and research, but it’s...I would put it maybe at a 4 ½ to 5...So I would 
say a moderate amount that is done in alcohol and drug treatment in 
general” (G4-4, U.S.).  
“I mean, my life sort of depends on it having an effect; because if it 
doesn’t, I’m just wasting my life. But it is kind of frustrating that....It 
seems like you have an effect maybe, but it’s a small effect; and it could 
really go either way” (G4-5, U.S.).  
“I think it plays a minor role to a moderate role. It can definitely 
motivate a change in policy, support a case for it, but in terms of 
implementing the best policy it’s not always then used” (G4-10, U.S.).  
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Participants also indicated that the impact of scientific evidence on policy had 
increased over the years and attributed this to an increase in research and an improved 
communication between researchers and policymakers.  
 “I do think it’s playing an increasing role. I do think in some areas of 
medicine and health care it plays a substantial role” (G4-4, U.S.).   
Scientific evidence: a range of roles. In regards to general policy making, roles 
of scientific evidence were varied and depended on a number of factors. Scientific 
evidence was found to motivate a change in policy and help shape policy; help get an 
issue onto an agenda and lead to a recognition of an issue; be a part of the policy 
discussion; influence and educate state legislators; and inform the process and the actors 
in it. The question that arises, however, is whether scientific evidence is used to 
implement the best policy, as this has not always been the case. As discussed in the 
earlier chapters, while scientific evidence may not have a direct impact on policy 
creation, it does enter the discussion and can help inform the policymakers. This 
supports Weiss’ “enlightenment model” that the impact of research on policy is not 
direct, but research is instead seen as one of several sources of information available to 
policymakers (Weiss, 1977, 1979). 
“It can definitely motivate a change in policy, support a case for it, but 
in terms of implementing the best policy it’s not always then used....I 
think what scientific research does more than anything is it helps modify 
existing policies” (G4-10, U.S.).  
“I think state legislators change their position based on the scientific 
evidence....I think scientific evidence is a part of the discussion. I’ve seen 
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legislatures go from incarceration to diversion treatment. I’ve seen 
legislatures go to needle exchange programs as a way of fighting the 
transmission of HIV. So, I have seen scientific evidence impact policy 
decision at the local and state levels” (G4-1, U.S.).  
Scientific evidence and agenda setting. According to Kingdon (1995) decision 
makers will prioritise those problems where someone like the administration or the 
scientific community can provide them with a constructive solution. However, three of 
Group Four participants argued that even with scientific evidence available, this did not 
play a significant role in agenda setting. The question that this view raises is, even if the 
evidence is brought to the attention of policymakers, will it make any difference to 
agenda setting?  
“I think — generally speaking- scientific evidence is very low in the 
hierarchy of influences on setting agenda. A low- fairly low- in hierarchy 
of influences that lead to governments paying attention to an issue” (G4-
2, Australia).  
“I don’t think it influences agenda setting. So if you think about how 
governments do business, the first thing is: it needs to be on their 
agenda. The second thing is: they need to look for solutions. And then the 
third thing is: they need to implement those solutions. So in terms of 
agenda setting- research has a very small role to play in agenda setting; 
that’s much more the area of public opinion, and media, and individual 
political concerns” (G4-8, Australia).  
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Factors influencing the role of scientific evidence. As discussed in Chapter 
One, Weiss listed the reasons for the limited use of research in policymaking as 
weaknesses in the research itself, conflicting demands on policy, and the discrepancy 
between what knowledge is needed by policymakers and what is provided by 
researchers (Weiss, 1977, 1979). Black (2001) listed these reasons as policymakers 
having their own goals for policies other than scientific evidence and clinical 
effectiveness, the dismissal of scientific evidence as irrelevant and not applicable, lack 
of consensus about scientific evidence and its interpretations, focus on other types of 
evidence such as personal experience, social environment not conductive to policy 
change, and poor quality of knowledge purveyors. Group Four participants also 
believed that there were a range of factors that influenced the use of science in policy 
formation, and whether or not it is used to influence policy. How the evidence is 
communicated to the public and other actors in the policy process was the most 
discussed factor of influence. Five participants indicated that the way the evidence is 
communicated can impact on whether or not it is used to influence a particular policy.  
Other factors included access to evidence and the type of research accessed; the 
availability of scientific evidence; who has access to the evidence and in what context; 
connections within the political field (how scientists are connected with the political 
field, who is responsible to whom, etc.); context and the time period; mass media and 
how it presents the scientific evidence; public perceptions of what evidence is; interest 
in scientific evidence; type of society the policy is made in; and the topic area. Overall, 
the participants did not believe that a single factor influences the impact of evidence on 
policymaking, but rather a number of different factors. However, all participants agreed 
that what is lacking is getting the right type of research to the wider public, who 
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generally tend to obtain their information from non-scientific sources, rather than 
scientific journals.  
“...There is a whole journal now here in the States about the therapeutic 
benefits of cannabis and the various studies that show the clinical studies 
of cannabis. And you can find lots of scientific articles in that journal. 
But I think that most doctors would say that that journal is probably not 
as well read or accepted as JMR or the New England Journal of 
Medicine, and you don’t see articles there; but does the average person 
know that? The quality of science is not dichotomous either and the 
average person isn’t necessarily able to decipher that” (G4-10, U.S.).  
 “You know, we’ve been busy funding science in the U.S. for the last 50 
years and we fund a ton of wonderful science, but there’s been almost 
very little attention given to how to communicate that science to the 
public....In fact, for those of us who get grants and research: we get the 
grant to do the research; we do the research; we do the research 
findings; if we’re lucky we get something that we can publish in a 
professional journal; and then we’re onto the next grant. There’s never 
any attention paid to get this information out to the public and try to 
communicate it to the broader community. And I think that’s then part of 
the problem in getting the public more aware of the science of alcohol 
and other drug policy” (G4-4, U.S.).  
Improving the use of scientific evidence in policy making. Bacci (2009) 
suggested that in order for research evidence to be used effectively in the policy 
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process, researchers and policymakers need to take a more collaborative approach 
instead of working in isolation. Bacci also suggested that policymakers need to be 
involved in all stages of research from the development of the research question to the 
implementation of the results. Group Four participants thought that the first step in 
improving the use of evidence is improving how the evidence is communicated to the 
individuals involved in policy making (such as the public and the politicians). The 
participants believed that scientific evidence needed to be reconciled so that it 
encompassed both sides of the debate and presented results in an objective way. They 
indicated that it was also important to make evidence easier to understand, and focus on 
translating it into the political field. This could be done, as Bacci (2009) suggested, by 
taking a more collaborative approach between researchers and policymakers.   
“If science is supposed to be objective and get information and present 
facts, we can’t force people to use those facts, unless we can educate 
them. So I really, really believe that if science was to become more 
important in affecting policy it needs to do a better job of communicating 
not just to the politicians but also to the layperson what the essential 
points are – and not doing it by overstating the findings, because that’s 
where we get ourselves into a lot of trouble with drug policy is things 
tend to get overstated...and be honest when the results aren’t clear” (G4-
10, U.S.).  
 “It’s how that evidence is manipulated, is packaged, is communicated to 
the people who can make use of it. In my view, we need to return to some 
kind of arrangement whereby there are structures, and resources, and 
known channels through which the research evidence can be- not just put 
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together- but packaged, and communicated, and used in the policy 
context at the national level” (G4-2, Australia).  
 “…I think in the future for us to get science to play a better role our 
ability to communicate effectively, and to communicate in a way that the 
public understands it, and to tailor the messaging so it’s something they 
can relate to their own lives- THAT makes a difference” (G4-4, U.S.).    
Other ways of improving the role of scientific evidence, as mentioned by the 
respondents, included more studies, apart from ideology; drawing more attention to 
science, “selling it”; making science more accessible; catering to policymakers’ 
interests; mixing science with politics by scientists becoming more aware of political 
issues and the political process; and providing objective information.  
“I think scientists and the organisations that promote science and that 
think that science should have more influence need to do a better job and 
invest more in communicating the science more effectively, and getting 
the science out to the public in vehicles. And if you’re going to try to 
communicate via mass media you have to be skilled at communicating in 
a way people can understand and that they will continue to pay attention. 
And I think that we haven’t done a lot of that. I think we’re moving in 
that direction and I think that’s going to be one of the factors that will 
determine how successful we are in making science more important in 
setting policies and developing the whole policy side of things” (G4-4, 
U.S.).  
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“I think the first thing is to do the kind of research that matters to policy 
makers. Most research that’s conducted in drug and alcohol is marginal 
to policy makers’ interests. So that’s problem number 1 – we’re studying 
the wrong things, because we’re not studying the things that policy 
makers are interested in or need to make decisions about... Now, we do 
efficacy trials all the time and we rarely do effectiveness trials. And 
politicians aren’t interested in efficacy so much; they’re much more 
interested in effectiveness. That is, if they rolled out this treatment, would 
it actually be used in a way in which it’s intended and produce the 
outcomes that the pollies were looking for?” (G4-8, Australia).   
Science and democracy. As mentioned in Chapter Two, one of the more 
prominent criticisms of the initiative process is that voters lack education and 
competence to make policy decisions (Burnett & Parry, 2014; Matsusaka, 2005). 
Research has shown that most voters are uninformed about public policy, politics and 
government, which raises the concern that damaging policies may be adopted as a result 
of voters lacking education. The question this raises is whether, in a democratic process, 
science should play a more important role than public opinion, or vice versa? And how 
restricting is the democratic process to evidence-based policy?  
 “…I think that there’s an optimisation here that hasn’t been done, and 
that is: If science is providing information that’s counter to what the 
general public wants to believe; and in democracy, should science be the 
one thing directing policy? I would like to believe science is very 
important and is more important than people that don’t understand the 
facts – that’s not democracy” (G4-10, U.S.).  
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Scientific evidence in the future: an increasing importance. Overall, Group 
Four participants were optimistic that if steps were taken to improve its use, the role of 
scientific evidence in the general policy making process will likely increase over time:   
 “You know, I couldn’t keep doing the work I do if I didn’t think it was 
going to increase” (G4-4, U.S.).  
 “I tend to think that in the future it will get better. That overtime- as 
people become more educated- they’ll have better scientific 
understanding of the theme and a better appreciation for scientific 
evidence, and a global willingness to defer to science when they need to” 
(G4-5, U.S.).   
Selective use of scientific evidence. The use and misuse of scientific evidence 
by the people involved in the policy field was another theme frequently discussed by 
Group Four participants. Participants addressed the issue of “cherry-picking” or the act 
of selectively using data that conform to a particular position in order to promote it, 
while ignoring cases or data that may contradict that position. Participants believed that 
science was used by the individuals involved in the policy making process to “sell” their 
position to the general public and gain support for the issue they were representing. This 
was also a major theme in the state by state review in this thesis, as well as Group One 
and Two studies. This was also described by Weiss (1991) as “research as arguments”, 
representing research to which an advocacy position has been added. The difficulty lies 
in overcoming the selective use of evidence, and Birkland (2005) and Ritter (2011) 
argued that to do this it would be important to bridge the gap between what research 
tells us and how citizens and government officials use that information.  
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 “I think that people prefer science that supports their position so it gets 
selectively reviewed and presented on every side of the issue” (G4-10, 
U.S.).  
 “Politicians, I believe, use the scientific evidence in the substance abuse 
field primarily in the way that we do characterise as “cherry picking”. 
In other words, selecting those bits of evidence that are consistent with a 
predetermined position. And, unfortunately, many public servants now 
find themselves taking the same approach” (G4-2, Australia).   
  “What’s very interesting is that sometimes the same scientific evidence 
or the same scientific theory is used in two different ways by two 
stakeholders, like lobbyists and politicians, that are actually opposed in 
the drug policy creation” (G4-9, France).  
Scientific evidence and medical cannabis. While not all participants were 
familiar with medical cannabis research and medical cannabis policy in some of the 
U.S. states, the majority agreed that there was insufficient scientific evidence supporting 
cannabis’ use as a medicine to warrant policy change. The respondents indicated that 
the evidence was usually mixed and could generally be considered limited. Similarly, 
the research evidence reviewed in Chapter Three has shown that cannabis and its 
constituents have therapeutic potential for a number of conditions, some for which the 
evidence is mixed and unclear. Most of the research evidence supports the use of 
cannabis in the treatment of chronic pain, spasticity, nausea and vomiting, and as an 
appetite simulant for AIDS-related wasting syndrome. The participants concluded that it 
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is difficult to make effective policy on medical cannabis when research is mixed or 
lacking.   
 “In the case of medical marijuana I think that there are certain areas 
where there’s lots of research; and there are certain areas where there is 
still a gaping hole. And so the science is not as developed as in other 
areas” (G4-10, U.S.).   
 “So the scientific research on dosage, on impact, for what conditions, 
really is not out there” (G4-1, U.S.).  
 “The science of cannabis and its effects as a medicine have been so 
poorly studied up to this point. It’s hard to make policy on cannabis as a 
medicine based on science because there’s so little science” (G4-4, 
U.S.).  
As a result, the participants believed that in the case of medical cannabis, 
scientific evidence has not been a main motivating factor for policy change.   
 “But the rest of the scientific evidence just doesn’t stack up in terms of 
the benefits of medicinal cannabis. So, given that states in America have 
approved medicinal cannabis; I don’t think it’s on the basis of scientific 
evidence, because if it was on the basis of that, they wouldn’t have 
approved it” (G4-8, Australia).    
 “There was no such crisis in those 15 states, besides, I guess, the 
gradual change in opinion in voters’ minds, where it eventually got to 
the point where you had these laws from so long ago that they didn’t 
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really match up with people’s opinions and their sense of compassion 
towards sick people” (G4-5, U.S.).  
While it was generally not considered to be the sole factor driving medical 
cannabis policy, the participants suggested that scientific evidence did play a role in the 
policy process by informing the process, rather than directly affecting it.    
 “It remains a very complicated process which the science informs, but 
doesn’t really decide political polemics about legalising recreational 
drug... intertwined with medicine and science....So, the science is a part 
of it, but science I don’t think overwhelms it- I gave it less than half of 
the contribution” (G4-1, U.S.).  
 “I think that in this case the research hasn’t been the motivating factor 
for the policy change. No. I think it’s been used in the discussion, but it 
has not been the motivating factor for policy change” (G4-10, U.S.).  
One participant also discussed the need to educate people and gain knowledge as 
something that should be the motivating factor for gathering evidence on medical 
cannabis.   
 “I don’t think it’s been done to warrant a policy change; I think that we 
generally need to know. In the U.S. there was a senate committee that 
was funded to look at the medicinal value of marijuana using clinical 
trials, and I think that that was completely appropriate and should have 
been then” (G4-10, U.S.).  
Factors influencing the use of science in medical cannabis policy. Similarly to 
general policy formation, the participants believed that there were certain factors which 
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influenced medical cannabis research, whether or not science was used in the medical 
cannabis policy process, and how the evidence was used. No one particular factor was 
identified, but rather a range of factors which were believed to influence the quality of 
scientific research and its role. Politics and the political nature of medical cannabis 
policy was the most frequently mentioned factor. Participants suggested that politics had 
the potential to interfere with the role science had in informing policy and could prevent 
medical cannabis research from occurring. Other factors mentioned by participants 
included limited research funding, the priority given to research (participants believed 
medical cannabis research was not seen as a priority by governments), restrictions 
placed on medical cannabis research due to the drug’s scheduling and difficulty in 
obtaining cannabis supplies for research purposes, communication between different 
actors in the policy process, religious groups, special interest groups, and the type of 
research conducted.   
 “I’d say it’s all political. I don’t think enough research has been done, 
but, that’s a political issue because of the scheduling issue in the U.S. 
...Unfortunately, because cannabis is classed as a Schedule I drug in the 
U.S., not a whole lot of research has been done. I think the way 
government sees it now is that it’s a non-issue because marijuana- 
cannabis- is still classified as a Schedule I drug and so they’re not 
funding research; people have a hard time getting any funding for 
research legally and doing it ethically” (G4-6, Australia).  
 “First, on a political level, it’s easier to make the argument that 
marijuana should remain illegal if there’s nothing good known about 
it…With regards to the second one: the importance of the special interest 
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groups. I do think that it will also kind of hinder the use of scientific 
evidence, unless that scientific evidence can be framed in such a way as 
being beneficial to those special interest groups; to the police, the prison 
guards. In that sense, if it could be framed as their asset, then they could 
gain some significant allies. But generally, I think those groups are 
going to be against a lot of scientific evidence and also the use of 
scientific evidence” (G4-7, U.S.).  
“...there’s not a whole lot of priority in really funding research on 
medical cannabis and what it can do. There is some, but it’s not going to 
get a lot of federal funds, it’s not going to get a lot of state funds. These 
are tough budget times; it’s not going to get a top priority.... And the 
politics can really interfere with the science” (G4-1, U.S.).  
 “… in the United States, as an addiction researcher for 35 years, we 
have not been able to research cannabis. It’s been impossible to get 
supplies of it; the National Institute on Drug Abuse wouldn’t fund it... 
until the last, I don’t know, 5 to 8 years, it simply was a topic you 
couldn’t do research on and so we kind of ignored it” (G4-4, U.S.).   
Improving the use of scientific evidence in medical cannabis policy. After it 
was suggested that scientific evidence does not play a significant enough role in relation 
to medical cannabis policies, participants suggested a total of six different ways of 
improving medical cannabis research and giving it a more important role in medical 
cannabis policy making. Conducting more definitive medical cannabis studies was the 
most popular suggestion, discussed by six participants. This was closely followed by the 
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need to improve upon how science is communicated to the general public and the 
individuals involved in the policy process. Participants also mentioned the need to 
conduct more studies, and conduct them away from ideology. Re-scheduling of 
cannabis was also discussed, as one participant believed it would allow access to the 
drug in order to conduct more studies and obtain more funding. Lastly, two participants 
suggested that researchers needed to conduct research that is relevant to politicians and 
policymakers:  
 “I think it would be very helpful to do some definitive scientific studies 
that would look into medical marijuana, and in terms of the health 
condition, in terms of what it is. You know, we think “Marijuana. What is 
it, marijuana?” THC, I mean, the dosage levels, delivery...Is smoking the 
best way to get the medicine to you?” (G4-1, U.S.).  
 “I think with cannabis as medicine there are a few steps before that that 
we also need to be doing, which is documenting clearly what cannabis is 
useful for, and documenting with carefully designed research trials to 
articulate how cannabis produces whatever beneficial effects it does 
produce, and what proportion of the population benefit from the pain 
relief or which kinds of pain, why it produces pain relief. I mean, all of 
those....With cannabis, we have the problem of: we don’t have the 
science yet. And so...we need more basic, and applied, and clinical 
science” (G4-4, U.S.).     
However, despite acknowledging that re-scheduling cannabis at the federal level 
is an important step towards improving medical cannabis science and its influence on 
medical cannabis policy, it has to be acknowledged that re-scheduling is a difficult 
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process. As suggested by one participant, the federal government would not reschedule 
cannabis until there was sufficient evidence for its medicinal properties. However, 
scientific evidence alone would not likely lead to cannabis’ re-scheduling, as the federal 
government had to consider other factors, such as international treaties it is signed onto:  
 “In the U.S., while we have states changing laws the federal government 
is not going to change its law until it has more scientific evidence. And 
so perhaps this is just the way that evidence will come out” (G4-10, 
U.S.).  
 “I think that a lot of other things have to happen for the federal 
government to do it, because it wouldn’t just be an issue of science given 
the international treaties it’s signed onto. The fact that cannabis has 
been rated as a top ten dangerous drug internationally not just in the 
U.S. — that would have to be addressed for the U.S. federal government 
to change its policy because I don’t see it as being willing to change its 
policy and go against the international laws, violate international 
treaties. That doesn’t promote its other interests in seeking other people 
to comply with international treaties” (G4-10, U.S.).  
Selective use of medical cannabis research. While participant views regarding 
the influence of scientific evidence in passing medical cannabis policies were mixed, it 
was agreed that scientific evidence can be used in different ways by different 
individuals in the field. Group Four participants indicated that the evidence can be used 
selectively by individuals involved in medical cannabis policy to further or support a 
position, as well as to influence public opinion. As discussed earlier in the chapter, 
selective use of evidence, or “cherry-picking”, is not solely limited to medical cannabis, 
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but is happening across the drug policy field. However, with cannabis being a 
contentious issue, proponents and opponents selectively using the currently available 
evidence was one of the major factors playing a role in the medical cannabis debate in 
the states reviewed in Chapter Four.  
 “The public definitely heard that there is some evidence for medical 
marijuana, and the IOM report provided some additional evidence that 
there might be therapeutic benefits. It wasn’t that it said that definitively, 
but there were a couple of statements that the advocacy groups could 
pull out. And the other side of that too, because the IOM said we should 
not make marijuana available for medicinal purposes, right now we 
don’t have enough science... the people who were against policy change 
pulled that line out. The people who wanted policy change pulled 
different lines out. And both presented that information to the public, and 
the question is: which one was the public listening to?” (G4-10, U.S).   
 “And on the other side of things- I think that this is a big enough issue 
and it’s gotten enough attention- that I don’t think that advocates on 
either side are basing their opinions on the scientific evidence. I think 
that they’re picking their facts to fit their side…” (G4-7, U.S.).   
Is cannabis a medicine? Participants also brought up uncertainties over medical 
cannabis and whether or not it could be considered a medicine as well as the availability 
of other medicine that could be used instead of cannabis. Undefined aspects of medical 
cannabis, such as dose, purity, and distribution need to be explored further through 
research in order for effective laws to be created. Participants also believed that medical 
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cannabis policies in some states were not clearly defined, especially in terms of how the 
medical cannabis program should be implemented. As discussed in the earlier chapters, 
there are differences in state medical cannabis laws in terms of the conditions covered, 
the amount of cannabis allowed for medical use, and how cannabis is distributed.  One 
of the themes that came up in this study was, if cannabis is a medicine, why is it not 
treated as such. This would mean following the FDA approval process for new medicine 
as well as having well-defined laws.  
 “If it’s a medicine, we aren’t really treating it like medicine....I think 
most of medical marijuana policies are ludicrous. Because they don’t 
give a good definition of disease, they don’t give good definition of 
dosage, there’s really no way to know the purity and delivery...It’s 
bizarre...through some clubs in California you ‘grow your own’ in some 
states... you grow 3 or 4 plants.” (G4-1, U.S.).  
 “Whether or not marijuana is the preferred medicine is still debated 
because of other issues such as route of administration and the 
availability of other medicines that could meet the same goal” (G4-10, 
U.S.).    
Differences between medical cannabis and other areas of policy. It was 
suggested by the participants that there was a difference between medical cannabis and 
other drug policy, as well as medical cannabis and other medicines. The same rules did 
not apply to cannabis as a medicine and other medicines, such as the required FDA 
approval. The participants thought that there was a difference in the amount of research 
available for medical cannabis and other drugs, and that people were more likely to be 
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opinionated on the issue of medical cannabis. While some participants believed that 
there was not enough scientific evidence to show cannabis can be effective as a 
medicine, others believed that scientific evidence could play a more important role in 
informing medical cannabis policy than other policy areas. Alternatively, it was also 
suggested that science would not be as influential a factor in medical cannabis policy 
formation as it is in other drug policy areas. There was also a notable difference in the 
power the law enforcement lobby had in medical cannabis policy and other areas of 
medical research.   
 “I would say one of the differences is in a lot of the cases where we try to 
do a policy change, cigarettes for example, there were just volumes of 
research to promote or substantiate a policy change. In the case of 
medical marijuana I think that there are certain areas where there’s lots 
of research; and there are certain areas where there is still a gaping 
hole. And so the science is not as developed as in other areas” (G4-10, 
U.S.).   
“So, I think- in other areas of medicine in general- there’s a greater 
potential for science to play a role... up to this point anyway.  I mean 
maybe it will change with cannabis as we get good studies – if we do. 
And in other areas of medicine there is a more direct relationship. I 
mean, there’s medicine where it’s equally as hysterical. Things like, in 
the United States, the stem cell research and anything to do with 
abortion. I mean those things generate the same kind of hysteria and 
emotionality as cannabis. But, for the most part, in other areas of 
medicine there’s more direct application of science” (G4-4, U.S.).    
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“I don’t think you’d advocate growing penicillin. It’s a ridiculous way 
they approach the matters. So I think the medical marijuana policy is not 
a good medical policy; it’s not a good health policy” (G4-1, U.S.). 
Framing the issue. Group Four participants also discussed different ways of 
how the medical cannabis issue was portrayed by both supporters and opponents. 
Generally, it was found that portraying medical cannabis as a human suffering and 
compassionate issue contributed to the successful passing of some medical cannabis 
laws. The participants also agreed that it was important to differentiate medical cannabis 
from legalisation of recreational cannabis in order to pass medical cannabis laws. 
Separating medical cannabis from the broader legalisation issue has played a major role 
in the medical cannabis policy debate. This also has political importance as medical 
cannabis can be seen as an issue of compassion and is generally more accepted by the 
public, while drug legalisation is more controversial and there is generally less 
acceptance.  
 “I think the attempt to make it a medical- human suffering- definition has 
played a role...perhaps medical marijuana passing where 
legalisation/decriminalisation did not. So I think the attempt to 
differentiate them probably has played some success in medicalisation” 
(G4-1, U.S.).   
 “Personally, I think that many of these advocates for legalisation of 
marijuana are being a little disingenuous by saying “No, no, we’re not 
necessarily going for legalisation of marijuana for everyone today; 
we’re just going for medical marijuana.” And so I think that their 
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arguments are a little disingenuous; whether they’re right or they’re 
wrong. But, I do think it can be very effective” (G4-7, U.S.).  
 “Well, you know the saying, that with respect to drug policy, you should 
probably restrain from using the term ‘legalisation’ in case you wanted 
to push through something which is really useful and acceptable by the 
public and decision makers....” (G4-3, Czech Republic).  
Science vs. politics. Another common theme in the Group Four study was the 
interplay of science and politics in the policy creation process. Politics can impede the 
use of science in the policy process and can sometimes overwhelm it. As a result, it was 
implied by some participants that scientists conducting research should be more aware 
of political issues and the political process in order to make science an essential factor 
in informed policy creation.  
 “I think right now there’s still a lot of fear and a lot of politics-driven 
issues that are affecting policy; more so than scientific evidence” (G4-6, 
Australia).  
  “I think that probably scientists have to be more aware of political 
issues, political debates, and things like that. Because, in my PhD I 
showed that the scientific evidence...that the translation of scientific 
evidence in politics, how it’s framed and things like that, is done by 
political actors. Rather, political actors translate scientific evidence 
rather than scientists themselves” (G4-9, France).  
Interest: who stands to win or lose? Participants also considered interest 
groups, or who stands to win or lose if a particular law is passed or fails to pass, as one 
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of the factors influencing policy formation. Group Four participants discussed the role 
of interest groups and suggested that, especially in terms of medical cannabis, there 
were various groups and organisations who stood to win if the law were passed as well 
as those who stood to lose both power and financially. Interest groups can have political 
significance when they try to influence public policy, propose new laws, or persuade 
government officials to act in their interest. Over the years, the activism and influence 
of interest groups has expanded, and they now play a significant role in the U.S. 
political system (Singh, 2003). As discussed in the state by state review, pharmaceutical 
groups also stood to lose money if cannabis was legalised and suggestions were made 
that the reluctance to adopt new drug laws came mainly from the pharmaceutical 
industry’s concern that they would suffer significant monetary loss should cannabis be 
legalised (Andrews, 2007a; R. E. Martin, 2007).  
 “I think that the business- cannabis as a business- has definitely played a 
role. The profits that are available... because the business has continued 
to push forward a desire to see policies change and for them to operate 
more freely. I think that there has been a huge role” (G4-10, U.S.).   
 “...it wasn’t so much an argument about medicine/no medicine; it was an 
argument about economics of distribution” (G4-4, U.S.).  
“Because the DEA agents with the police already have a position, and 
they’re already powerful, and they already exist and have interests- they 
are in a much better position to fight for those interests than people who 
may have a benefit sometime in the future and don’t really have 
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something concrete to grab onto, and don’t really have those levers of 
power to work with” (G4-7, U.S.).   
The influence of public opinion. The participants believed that, especially in 
the medical cannabis field, public opinion was taken into account by the individuals 
involved in policy creation. However, they also believed that the role could be reversed 
and public opinion be influenced by those in the policy creation field. Public opinion 
also had an effect on the use of evidence in policy formation, as sometimes public 
support for a particular issue was seen as more important than the scientific evidence 
available. As discussed in Chapter Four, public opinion is also likely to play more of a 
role in states with an initiative process, while science tends to have more impact when a 
law is being passed by the legislature.     
 “You know...they give you all the organising you want to and if the 
public wasn’t crying out- then nothing would happen” (G4-5, U.S.).  
 “In my mind, in cases...once the public gets involved, evidence may be 
wielded as a weapon by one side or the other; but they’re not making 
their decisions based on the science. The only time that I really think that 
science is going to be used by policy makers is when it’s the 
policymakers who are making the decision; not when the politicians are 
appealing to the people. And so...in cases where a committee is making a 
decision pretty much behind closed doors, or if it’s something that 
people [don’t] really care about or don’t really have an opinion about 
most of the time; then science will play a large role. But, in cases where 
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people are really excited and really fired up, I don’t think that science 
plays that large of a role” (G4-7, U.S.).  
Ballot initiative vs. legislature. The participants also agreed with previous 
findings that there is a difference between factors involved in passing medical cannabis 
laws via a ballot initiative and those passed by the legislature. The participants were 
inclined to believe that giving constituents the power to pass laws contributed to the 
success of passing medical cannabis legislation in some U.S. states, especially in the 
early stages, as the voters were more willing to have policies changed. Five participants 
believed that public support of an issue was important, but diminished the role that 
scientific evidence played in influencing policy. Conversely, participants suggested that 
medical cannabis laws passed by the legislative process were more thought out and 
were more likely to be informed by scientific evidence. 
 “A real problem is that you can go through the state legislative process 
where you may have some scientific evidence about medical marijuana. 
Other states, since they went through a ballot initiative, it became more 
of a popular referendum than a scientific discussion” (G4-1, U.S.).  
 “The fact that it happened initially through ballot initiatives is no 
coincidence. There have been proposals in the legislatures- even in the 
federal government- to decriminalise recreational use of marijuana or to 
allow things for medicinal purposes, and none of that gets by legislature. 
And it really was... it’s going directly to the populace and appealing to 
the populace that caused some of these initiatives initially to pass, and 
that gained momentum” (G4-10, U.S.).  
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 “I think that the states that adopted laws through voter referendum 
initiative process, which was the first grouping of state medical 
marijuana laws, they relied more on advocates using science to promote 
a position. I think in the legislatures- when they were passed by 
legislative bodies- there was an opportunity to consider a broader look 
at science.... And some of the legislatures, such as Hawaii which passed 
the law in 2000, saw this coming in their state and went about it more 
judiciously through the legislature as opposed to allowing it to get 
usurped and put on as a ballot initiative” (G4-10, U.S.). 
The initiative process enables citizens to put an issue on the political agenda 
which may not be seen as important by the decision makers, and allows the general 
public to make decisions away from the influence of government. However, some may 
think that with voter initiatives, all that has to be done in order to pass a law is convince 
the public. This in essence reduces the use of scientific evidence as intended by 
researchers, with scientific evidence potentially used as a means of convincing the 
public to support a particular issue rather than informing it and increasing its 
knowledge.  
 “So a lot of these things have happened by a voter initiative and so they 
just sort of have to convince the public. So to the extent that scientific 
evidence is used to help convince the public that there are people with a 
medical need out there, then I suppose it’s having an effect; but it’s 
probably an indirect one. There seems to be a lot of demagoguery on 
either side in that kind of environment” (G4-5, U.S.).  
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Factors politicians have to take into account. As discussed in the earlier 
chapters, there are many factors other than evidence that politicians need to take into 
account when making policy-related decisions. Factors such as getting re-elected, how 
they are perceived, political ideology and funding are very important in influencing 
politicians whether or not to support specific legislation. Group Four participants 
mentioned that, in terms of medical cannabis, politicians usually look at more than just 
proof of the therapeutic benefits of the drug, but instead consider other factors such as 
efficacy, alternative medication, and economic advantages/disadvantages. Interestingly, 
the most commonly mentioned factor was scientific evidence. However, the participants 
concurred that scientific evidence plays a significant role when it is the policymakers 
who are making the decision, such as when laws are passed by the legislative process, 
rather than when a law is passed via the initiative process. Otherwise, the politicians 
look to the decisions that are supported by the public and that will get them re-elected. 
The participants also acknowledged the roles of various other factors, including funds, 
extreme events, global perception of drugs and international standing, public perception, 
ideology, lobby groups, laws in other states, policy advice that they receive, 
politics/policy issues, and public health issues.   
 “The only time that I really think that science is going to be used by 
policy makers is when it’s the policymakers who are making the 
decision; not when the politicians are appealing to the people (G4-7, 
U.S).     
 “What do I think they make their decisions based on? Whoever donates 
to their political campaigns and whatever they need to do to get re-
elected is my cynical answer” (G4-4, U.S.).  
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 “The largest thing that comes into account for them is- can this come 
back at them? If they make this decision, can there be something 
concrete and high-profile, something with a perception of dread and the 
unknown that really, really amplifies...that makes something coming out 
of it to be really dramatic. The politicians’ perception that this could 
come back to bite them. I think it definitely suggests that a politician be 
cautious that they go to status quo, that they don’t try and allow more 
medical trials because it’s a lot harder to be dinged for a nebulous 
inaction that for a specific concrete action” (G4-7, U.S.).   
  “They need to take into account the various pressure groups who are 
always trying to influence them in one direction or another....They need 
to take into account the kind of policy advice they receive from the public 
service; the quality and nature of which is incredibly variable, depending 
on a lot of factors” (G4-2, Australia).  
State differences. The responses of Group Four participants indicated that there 
were differences between U.S. states that could determine whether legislation, such as 
medical cannabis, was passed or not. These differences mainly focused on whether or 
not a state had a ballot initiative process, as well as how the state attempted to pass 
legislation. It was suggested that the U.S. allowed variety in terms of how policy is 
made and implemented within a state, and the way that scientific evidence is used. As 
seen in the state by state review, medical cannabis advocates and opposition groups can 
be more active in some states than others and tend to choose where they will allocate 
their time and resources. States were also found to be inclined to follow happenings in 
other states and improve on previously passed legislation; such was the case in relation 
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to medical cannabis legislation. As discussed in Chapter Four, policymakers should 
look to other states to creating effective medical cannabis laws, which may then lead to 
a more uniform approach to medical cannabis across the states.  
 “Dependent on the state, dependent on the time- some states would move 
toward medical marijuana and then back off. Some states you grow your 
own; some states you don’t. Michigan has a real problem in, it doesn’t 
know how to deliver the medical marijuana....I think in some states it 
may be one of those elements [influencing policy] may be stronger than 
in others” (G4-1, U.S.).  
 “… I think that some knowledge was gained in the preliminary ones that 
helped legislatures devise policies that meet the needs of all constituents, 
not just the advocates for change” (G4-10, U.S.).   
  “I think the success that California has had- being the first state to pass 
a medical marijuana proposition. So other states have seen that and said 
“Oh, look! We can do that”. I think it’s greatly affected it. I don’t know 
if any other state would have had the idea. I mean, 1998 was pretty 
early. So, it’s been more reasonable than the past five to seven years, but 
I think California’s passage greatly affected the rest of the states” (G4-6, 
Australia).  
Anecdotal evidence and testimonials. Another theme discussed by Group Four 
participants was the use of anecdotal evidence and patient testimonials in the medical 
cannabis debate. Participants believed that, in terms of medical cannabis policy, 
anecdotal evidence was widely used and played an influential role. Participants also 
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suggested that patient testimonies on the use of cannabis as a medicine were used to 
portray a particular image of cannabis as a medicine and the individuals using the drug 
for medical purposes, in order to influence policy.   
 “Lots of information was reported to the average person through the 
newspapers and through the media. And the source of that information 
was largely anecdotal. That doesn’t mean that it wasn’t valid or useful, 
but from a scientific perspective it wouldn’t be viewed as rigorous as a 
large informed study. But there were no large informed studies, so that’s 
what they had to draw on” (G4-10, U.S.).   
 “.. I don’t think that, in the United States at least, we’re discussing 
matters of medical fact very much. We’re using a lot of anecdote, but I 
don’t know how much we’re using factual data....” (G4-7, U.S.).  
 “I think in all of those states, and certainly in California, you have these 
testimonials of people who were in general community law abiding, 
productive citizens, who use cannabis to control nausea or pain and 
have gotten what they see as being great relief from it. And they give 
emotional testimonials to the benefits of cannabis. I think those also play 
a big role.” (G4-4-, U.S.).  
Politics and policy. There are also politics-driven factors which can drive 
policy, more so than scientific evidence. According to Kingdon (1995), the politics 
stream comprises political issues such as election results, interest groups and public 
opinion that need to be taken into account. Group Four participants also suggested that 
the nature of politics and the political system can affect scientific evidence and its 
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ability to inform policy. Issues such as political ideology are another aspect of the 
process that was mentioned by participants who believed that medical cannabis policy 
was driven and affected by ideology, more than by scientific evidence.   
“Well, I think the cannabis policy is far more politicised and the result of 
a 30, 40, 50 year battle of ideologies...” (G4-4, U.S.).  
 “I guess one of the really big impediments to using the scientific evidence 
in thinking about medical cannabis is the highly political aspect of it. By 
political, I’m thinking of party politics. And I’m also thinking of issues of 
power more broadly- about who controls whom in society” (G4-2, 
Australia).  
 “I think there’s also the political ideology that plays a major role. I 
think...you have a bit of libertarian ideology in the United States. One of 
the...political movements in the U.S. right now is libertarianism. In 
which the governments should not interfere with the daily lives of its 
citizens....And I think libertarianism has been an increasing force in 
medical marijuana policy. That the government shouldn’t interfere; that 
medical marijuana often becomes a part of the 
legalisation/decriminalisation rubric. So, that kind of policy discussion 
probably is stronger than the medical/scientific discussion” (G4-1, 
U.S.).  
The role of advocates. Similarly to Groups One and Two, Group Four 
respondents rated advocacy groups as playing a major role in the creation of medical 
cannabis policies. The respondents believed that advocacy groups for both sides were 
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effective in raising the awareness of the issue and influencing public opinion. According 
to participants, one of the reasons why advocates played an important role was their 
ability to “sell” the issue to the public and policymaker. The question raised, however, 
is how much of the advocacy groups’ stance is based on scientific evidence. As 
previously mentioned, both medical cannabis opponents and proponents tend to 
selectively use scientific evidence to support their arguments, ignoring the bigger 
picture.  
 “I think that advocacy in this area makes a big difference; it clearly has 
in the case of marijuana. Because things that people might do and talk 
about at the federal level they can’t do, because of international 
agreements or unwillingness, can be done at a more grassroots level, 
and our structure of government at the States allows that. So advocacy 
has definitely played a role. And when I say advocacy I should be clear; 
I don’t just mean advocacy for people changing the law- I mean 
advocacy for people opposed to the law” (G4-10, U.S.).  
 “I think...advocacy is very, very strong. Advocacy of medical marijuana 
and drug policy is strong in the United States- as for being so extreme on 
general drug policy laws....So in terms of taking the research out and 
selling it to the media and to the public and to policymakers- I think 
they’ve done a really good job” (G4-3, Czech Republic).  
 “I think that their dogged efforts are bearing fruit. I think that these 
things take a long time, but...I think they’re having an effect on public 
opinion; maybe using some scientific evidence- at least the scientific 
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evidence that they favour. But some evidence anyway to change people’s 
minds about things” (G4-5, U.S.).   
While the participants believed that advocates play a role in the policy making 
process, they suggested that they are not always necessarily basing their arguments on 
scientific evidence. Additionally, participants stated that advocates sometimes used 
scientific evidence to further their position, even if that position was not always based 
on science.   
 “I think the science was used for advocacy purposes and not presented 
by scientists per se. Some scientists were the ones presenting it, but 
again it was used to promote a position as opposed to comprehensively 
review everything we know and what we don’t know and whether it was 
enough to make decisions” (G4-10, U.S.).     
 “And on the other side of things, I think that this is a big enough issue – 
and it’s gotten enough attention – that I don’t think that advocates on 
either side are basing their opinions on the scientific evidence. I think 
that they’re picking their facts to fit their side” (G4-7, U.S.).  
The importance of what is advocated. Participants suggested that some medical 
cannabis advocates advocated for both medical and recreational use of cannabis. Not 
making a distinction between medical and recreational use of the drug could hurt its 
chances of being made legally available for medical purposes, as medical use of 
cannabis is generally more accepted than general legalisation.   
 “But I think the groups that are advocating for medicalisation have also 
tended to advocate for legalisation. I think that they have done some 
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attempts to separate, and that has been successful for medical 
marijuana…” (G4-1, U.S.).   
 “I find that many people who are on the pro-medical marijuana side 
are...they make a strong argument for medical marijuana, but they also 
make strong arguments for legalisation of marijuana for everybody…” 
(G4-7, U.S.).  
Perceptions, morals, and ideology. Apart from evidence, there are also factors 
such as how an issue is perceived, people’s morals and ideology that those involved in 
policy creation need to consider. Even factors such as how drug users are generally 
perceived can influence whether or not a medical cannabis policy will be passed. Are 
medical cannabis users seen as drug users or is a more compassionate stance taken and 
they are viewed as people who are suffering and are in need of a medicine? Group Four 
respondents mentioned the role of individual belief systems and their perceptions of 
politicians and drug users. According to the respondents, even factors such as fear were 
influential in passing or failing to pass medical cannabis policies. When we look at the 
history of medical cannabis in the U.S., it has been viewed as different things at 
different points in time, such as a medicine in the early 1900s, an evil drug in the 1930s, 
and again as a potential medicine in recent times.  
 “Fear was a big part of it- if you smoke pot you’ll be a heroin addict. 
Belief systems are still out there in the community and amongst some 
conservative parents groups and all of that that you still heard...So there 
are both of those” (G4-4, U.S.).  
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 “And so I still think that the first most important thing is the conception 
or the construction of the people who use drugs. And the second thing is 
the construction of the politicians, insofar as what makes a good leader. 
And I think that construction of what makes a good leader is 
changing....These constructions play a much larger role than the science 
behind it....So I guess the main factor- one of the main factors- would be 
how the users of drugs are viewed- are they constructed as the other, are 
they constructed as good or bad, weak or strong?” (G4-7, U.S.).  
 “Now, linked to that is the issue of morals and values that different 
people hold about the appropriateness or otherwise of using cannabis 
under any circumstances. And that- those moral issues- don’t apply to a 
lot of other medications” (G4-2, Australia).    
The role of organised networks. The role of organised networks, such as 
NORML, was also mentioned by Group Four participants who stated that organisations 
played a role in the passage of medical cannabis legislation in some states. However, the 
participants also believed that organised groups only had an effect when they worked in 
conjunction with public opinion. It also depends on how well organised the networks 
are and where they chose to focus their efforts.  
“Well, I mean, the Soros Foundation, you know...I’m sure you’ve run 
across that...has played a major role. As well as, of course, NORML, as 
an organisation that played a major role” (G4-1, U.S.).  
 “...but also organised groups. Like, California in particular has a really 
good organised network of people in the medical marijuana – or even 
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marijuana generally – reform community.  And these people are really 
well organised and they’re really motivated, and they make things 
happen in their state, in conjunction with the public opinion. ...they give 
you all the organising you want to and if the public wasn’t crying out- 
then nothing would happen. So I think you need those things” (G4-5, 
U.S.).  
Overall, it was concluded that policy making is an ongoing, complicated process 
depending on a number of different factors. The factors are required to come together in 
order for a change to occur or a policy to be created and passed. It was also suggested 
by Group Four participants that the process is multidisciplinary, and required 
individuals in different fields and levels to work together.   
“...it remains a very complicated process which the science informs, but 
doesn’t really decide political polemics...I mean, there’s no clear 
answer. It’s a very mixed bag of polemics. In some ways, yeah, you have 
to always be a part of the political process. It’s a never-ending process” 
(G4-1, U.S.).    
  “…that there are what I call a policy network or existing communities 
that are ...in these networks there are scientists, there are lawyers, there 
are politicians, there are also medical practitioners...that are working 
together to do some research, to find some evidence to unearth, to 
impact policies” (G4-9, France).  
Discussion  
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Group Four participants were sought for their expert opinion on the drug policy 
process. One of the major themes to come out of the study is the need for further 
research into medical cannabis. However, what is important when conducting such 
research is that it is the type of research that matters to policy makers. Otherwise, it will 
be difficult for the evidence to enter the policymaking arena and have major influence. 
In order to identify the type of research required by the policymakers, a collaborative 
approach between those involved in policymaking and the researchers is needed. 
However, this is no easy feat.  
While there has been a significant progress in the use of technology and social 
media over recent years, ways of presenting and communicating the evidence has not 
followed suit. Ritter (2006) found that politicians most commonly sourced information 
by consulting an expert or technical reports, monographs and bulletins. Accessing the 
internet and using statistical data were the other two most common sources of 
information. A question then arises is why, with all the information available to them, 
are the politicians not following the evidence? Researchers also need to make the 
evidence more accessible, and to do this there needs to be a shift in how we 
communicate with those we would like to inform, such as increasing the use of internet 
and social media to promote research findings. If scientific evidence is to play a bigger 
role in the policy making process, we need to look beyond the evidence into how we 
can promote it and disseminate it effectively. As one Group Four participant said that 
“the evidence alone never speaks for itself” (G4-2, Australia).   
Another theme that was raised by Group Four participants was the issue of direct 
democracy and whether policy decisions should be left up to the public, which can 
oftentimes be uninformed but expected to make important decisions. In terms of ballot 
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initiatives, care needs to be taken that they do not become more a popular referendum 
than a scientific discussion. Most Group Four participants were also inclined to believe 
that advocacy groups played more of a role in the laws passed via the ballot initiative. 
The participants also felt that the legislative process met the needs of the constituents 
rather than the advocates and also tended to be more influenced by the evidence. There 
is also an indication that states which pass the laws through the legislature have more 
scientific debate. The findings also suggest that, with the laws passed through the 
legislative process, there was an opportunity to consider science more broadly. As one 
participant stated:   
And now it’s becoming more common to see these as legislative 
processes which have thought through the implications of access and 
supply, as well as how do you reconcile this with the prohibition on 
recreational use. And those sorts of issues and the nuances were not so 
well thought through in the initial ballot initiatives. (G4-10, U.S.). 
The highly political aspect of medical cannabis can also be an impediment to the 
use of evidence. There is the issue of federal versus state power, where direct 
democracy measures have created a conflict between state and federal governments 
(Ferraiolo, 2008; Hall & Degenhardt, 2003; McDonough, 2000; Pickerill & Chen, 
2008). The question that arose is whether states should be able to decide for themselves 
whether to legalise cannabis for medical use or if the federal government should 
regulate this area of policy (Pickerill & Chen, 2008). There are also interest groups who 
play a major role in states with the initiative process, and who have both monetary and 
organisational power to have a big impact on public opinion as well as policy creation.  
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In terms of politicians, evidence may not have a direct effect on agenda setting 
or politician support. There are a number of factors politicians need to take into account, 
with one of the most important being getting re-elected. As previously mentioned, 
politicians need to carefully consider the timing of their decisions to support or oppose 
particular legislation. Politicians also need to consider the impact and benefit of their 
decisions, and what happens in the future. Other factors include, but are not limited to 
campaign funding (who provides support for their re-election and how the decision to 
support or oppose particular legislation will impact fund raising); how they are 
perceived; international standing; lobby, pressure, and interest groups; political 
ideology; what happened and is happening in other states; public opinion; scientific 
evidence; and the policy advice they receive. Scientists interested in informing policy 
need to consider these factors and create the sort of evidence that fits in with what 
politicians need and are looking for. For example, one Group Four participant suggested 
that: 
They [politicians] are looking for the sound bites. And scientists 
need to be aware of that. Sometimes you can only get a politician’s 
attention for 5 or 10 minutes and need to reveal and tell a general gist in 
that 5 to 10, and be OK with the fact that you can’t give all the qualifiers 
and the nuances and you weren’t able to do this and that and that...We 
as scientists sometimes want to provide all the situation, and we can’t 
communicate that in the attention span of either the politicians or of the 
average person. (G4-10, U.S.).  
Findings also indicate that media can filter scientific evidence, and can be 
selective as to what is or is not put forward to the public. One participant said that “the 
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public does not have direct access to scientific evidence. It’s all filtered- primarily 
through the mass media” (G4-2). What needs to be considered then is how well the 
media filters the evidence and whether or not it is done in an objective way. Another 
question to be considered is where the media gets its information from and what its 
sources of “scientific evidence” are. 
While a number of factors play a role it the policy process, in terms of medical 
cannabis one question deserves significant attention: if cannabis is a medicine, why is it 
not being treated as such? The evidence indicates that cannabis does have potential as a 
treatment for some debilitating medical conditions. However, the findings of this study 
indicate that cannabis is not treated as a medicine in the sense that the process of 
making it legally available has been different from the process other medicines have to 
go through, such as the FDA approval process. Medical cannabis is not obtained from a 
normal drug store as other medicines are, but is instead grown by individuals or 
distributed by special dispensaries. As a result, it is difficult to determine what “medical 
grade” cannabis is and what appropriate dosages are, as it is left to the individual and 
not a medical professional to determine these. In Los Angeles alone, it is estimated that 
there are around 750 medical cannabis dispensaries (Linthicum, 2012). In order to 
regulate the distribution of medical cannabis and after complaints and calls for 
restrictions from the mayor, the police chief, the city’s attorney office, and the residents’ 
groups, a city ordinance was passed to shut down most of the dispensaries (Linthicum, 
2012). The federal government also got involved and started issuing letters to 
dispensaries stating that they are violating federal drug laws and that, despite the state’s 
medical cannabis law, federal law takes precedence over state law. The potential 
negative effect of this is that patients unable to grow their own cannabis or obtain it 
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from a dispensary may expose themselves to risk by obtaining it from the black market, 
where the quality of the drug is difficult to control. This would not be an issue if 
cannabis were recognised as a medicine and obtained in the same way other medicines 
are.  
There is, however, a difference between medical cannabis and other medicines: 
cannabis is not recognised as a medicine by the FDA. As previously discussed, all 
medicines in the U.S. must be approved by the FDA; in order for cannabis to be 
approved as a medicine, it needs to go through the FDA approval process. In order for a 
medicine to be approved it needs to be proven that it is safe and effective, and that its 
benefits outweigh the risks (Federal Food, Drug, and Cosmetic Act, 2000). So why is 
cannabis not approved by the FDA? According to the FDA, evaluations by several 
departments have concluded that “no scientific studies supported medical use of 
marijuana for treatment in the U.S., and no animal or human data supported the safety 
or efficacy of marijuana for general medical use” (FDA, 2006). The results from the 
literature review conducted in Chapter Two indicate otherwise; there are clinical trials 
which have shown that cannabis has medicinal value and potential to be used as a 
medicine for some medical conditions.  
However, the difficulties arise in relation to how the appropriate dosage would 
be determined, what an appropriate route of administration would be, and what the 
ingredients of medical cannabis would be. Moreover, as stated in Chapter One, there are 
still many unidentified components of medical cannabis, making it difficult to approve 
it as a medicine. The research so far has not clarified these issues, as one Group Four 
participant put it:  
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I think one of the major issues of medical marijuana is, if it is 
going to be “medicalised” we really haven’t gone to the process of 
defining dose, purity, how we manage and how we distribute it. Medical 
marijuana rendered to a real problem of how you would distribute it, 
how you would label it, define it, decide on a dosage level. In most 
states, the delivery mechanism is difficult. In a few states, you grow your 
own. Well, that’s kind of complicated. I mean, would you grow your own 
penicillin? It has some real quality problems”. (G4-1, U.S.).  
If medical cannabis laws are to be driven by science, then scientific research 
needs to be enabled by re-classifying cannabis, providing funding for such research, and 
allowing researchers access to medical-grade cannabis. Doctors need to be able to 
prescribe the drug and determine the right dosage for the patient, and this will not be 
possible as long as cannabis remains in Schedule I of the CSA. Cohen (2006) speculated 
that, had cannabis not been included in the CSA and was taxed and regulated as are 
alcohol and tobacco, “every ‘medical marijuana’ case would have been moot. And 
under this scenario, as long as smoked marijuana was not advertised as a FDA-approved 
pharmaceutical....it would undoubtedly have become one of this century’s premier 
herbal medications” (p. 22).    
Study limitations 
As with the previous studies, there were some unavoidable limitations with the 
Group Four study. One noteworthy limitation was generalisability. In Group Four, the 
sample was varied and consisted of ISSDP members from three continents, the U.S., 
Australia, and Europe, who conducted drug policy research. The individuals had 
varying degrees of familiarity with the medical cannabis debate, but all conducted 
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research on drug policy. It is not possible to demonstrate that the sample was 
representative of the population; therefore caution must be exercised in generalising 
conclusions beyond the medical cannabis policy or policy field. Because it is such a 
specific and somewhat controversial topic, there was also potential for bias, especially 
due to a small sample size. However, the participants were chosen for a specific 
purpose, and that is due to their expertise in the area of drug policy. As such, we cannot 
make generalisations about the total population from this sample because it is not 
representative.      
The participants were identified through an ISSDP-supplied contact list and 
were asked to participate due to their experience in the drug policy area. While the study 
sample may have been biased due to non-random selection, as they were not identified 
as being directly involved in the medical cannabis debate it was anticipated that Group 
Four participants would be able to provide an objective appraisal of the medical 
cannabis policy process. Literature suggests that elites such as politicians and experts 
are busy people with time constraints and can also have distrust in the purpose of the 
research or the trustworthiness of the researcher. The researcher therefore attempted to 
make direct contact with this group of participants and establish rapport before 
interviewing them. Face-to-face interviewing would have been preferred but was not 
possible for the purposes of this study due to money and time constraints, and the 
location of the researcher. As Nulty (2008) said, “whether or not a response rate is 
adequate depends (in part) on the use that is being made of the data” (p. 307). In this 
case, the data were treated as expert opinion on a particular topic, providing insight into 
expert views of the medical cannabis policy process in addition to already established 
findings. To decrease bias and to reach generalisability of data, future studies may want 
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to increase sample size and identify experts from a range of sources, rather than 
participation in one particular group such as the ISSDP.  
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Chapter 7- Discussion  
This study aimed to identify the main issues pertaining to the development of 
medical cannabis policies in the U.S. This study was conducted in two stages. The first 
stage was a state by state review of the medical cannabis debate in five representative 
U.S. states to identify which factors played a role in the passing or failure to pass 
medical cannabis laws in those states. The second part of the study involved using a 
questionnaire and telephone interviews to further explore the factors which influenced 
the medical cannabis policy process from the perspective of those directly involved in 
the process, researchers not directly involved, and drug policy experts. This discussion 
section is framed around the central research questions and the themes and sub-themes 
that emerge from what has been presented in the previous chapters of this thesis. That 
is, it will pull together the themes and sub-themes that emerge across the whole of the 
study to discuss the overarching themes and answer the three research questions.  
The literature review completed in Chapter Three indicated that cannabis has 
medicinal properties, but further research is required to explore the efficacy and 
effectiveness of cannabis in the treatment of specific medical conditions, identify which 
conditions the use of cannabis is best suited for, the appropriate route of administration 
and dosage, and the long-term consequences. While the long-term effects of medical 
cannabis use are difficult to assess it was also noted that this can be experienced with 
other conventional medication and is not considered a major problem in the medical use 
of cannabis. For conditions which aren’t always successfully treated by other medicines, 
medical cannabis may also be a beneficial addition to treatment or management of the 
condition (Zajicek, et al., 2003). Therefore, further studies of medical cannabis are 
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encouraged. In relation to the importance of increasing knowledge of medical cannabis, 
Strang et al. wrote:  
In its absence, public policy will continue to be made with 
premature foreclosure of debate in the face of uncertainty by using 
arbitrary rules about which side in the debate bears the burden of proof- 
those who defend the status quo or those who wish to reform our 
cannabis laws. (p. 110).  
 One way to overcome the issue of mixed and unclear evidence would be to 
conduct more research into cannabis as a medicine, especially smoked cannabis. 
However, the difficulty lies in cannabis being a Schedule I substance in the CSA, 
making it difficult to obtain research-grade cannabis and conduct studies. This issue is 
discussed in detail throughout the thesis, and more specifically in Chapter Six. The 
history of drug policy in the U.S. also shows that it is a complex process, and while 
there were some shifts at the state level towards recognition of medical cannabis, the 
attempts have largely been ignored by the federal government who maintain that there is 
currently no evidence to support cannabis’ rescheduling. However, the fact that the drug 
is placed in Schedule I creates a barrier to research. This has been summed up by the 
Martin and Rashidian (2014) statement that “Cannabis is a Schedule I because there is 
not enough federally approved research, but there is not enough federally approved 
research because cannabis is a Schedule I” (p.29). Therefore, the first step towards 
evidence playing a bigger role in medical cannabis would be for it to be rescheduled. In 
the absence of that, other ways of giving evidence more prominence in the medical 
cannabis debate need to be explored. As one Group Four participant put it:  
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“I think in the future- especially if we can think about re-
classifying or rescheduling drugs that are currently scheduled as 
Schedule I- I think scientific evidence will play more of a factor....I would 
say it’s got to be reclassed. It’s got to be rescheduled. People need to 
have access to it in order to do studies, and studies need to be funded 
and backed by policy or backed by U.S. federal government” (G4-6, 
Australia). 
What also needs to be addressed is the sort of research that is being done. In 
terms of medical cannabis, it may be wise to separate the whole plant from its 
compounds. It is highly unlikely that due to side-effects associated with it, smoked 
cannabis will ever be approved as a medicine by the FDA, but there is potential for 
other compounds to be made into pharmaceutical products (Hall & Degenhardt, 2009; 
Martin & Rashidian, 2014). In the absence of a pharmaceutical product, the role of 
whole plant cannabis also needs to be further explored, especially in the light of state 
medical cannabis initiatives which have legalised smoked cannabis for medicinal use. It 
is also important to consider how the use of evidence in policymaking can be approved, 
and this is discussed next.  
Kingdon (1995) described policy formation as the result of three processes or 
“streams”; the problem stream, the policy stream and the politics stream. The problem 
stream is related to matters requiring the attention of decision makers. It is important to 
note that not all problems are given such attention. The policy stream involves proposals 
for change. This implies that before a problem can reach the decision making agenda, 
decision makers need to be given at least one solution to the problem. Kingdon states 
that decision makers will prioritise problems where someone like the administration or 
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the scientific community can provide them with a constructive solution. The politics 
stream comprises issues such as election results, interest groups and public opinion that 
need to be considered. The three streams are independent of each other and for the most 
part operate independently, until they come together and a “window of opportunity” 
opens for policy change. For scientific evidence to influence the policy agenda, 
information would need to be readily available when “windows of opportunity” open 
(Kingdon, 1995). 
Another issue that needs to be recognised is that evidence is used in different 
ways by the actors in the process. Cherry-picking, or selective use of evidence, was a 
frequently occurring theme throughout this study and is discussed in more depth in 
Chapter Four (p. 239). What this study found is that the three main arguments 
frequently used for opposing medical cannabis legalisation were unproven safety and 
effectiveness of cannabis as a medicine, cannabis as a “gateway drug” that leads to use 
of more serious drugs, and sending the wrong message to the public that cannabis is safe 
for recreational use. Medical cannabis opponents argue that there are already medicines 
available that can treat symptoms and conditions for which cannabis has been shown to 
be effective while supporters argue that cannabis can be used as a medicine for a range 
of medical conditions including some which have not had strong scientific support. 
Supporters also argue that cannabis has less abuse potential than drugs such as alcohol, 
tobacco, and cocaine. In essence, evidence is used as ammunition in the fight, but there 
is little acknowledgement by either side of the complexities and incompleteness of the 
research evidence. As the debate tends to be oversimplified, what usually seems to be 
omitted is the rational middle ground, one which objectively assesses the benefits and 
costs of cannabis use.  
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This lends support to Weiss’ (1991) assertion that one of the ways the research 
enters the policy field is as research to which an advocacy position has been added and 
used by policymakers and/or interest groups to support their position. The problem that 
arises when research enters the policy field in such a way is that the some findings tend 
to get selectively lost as they give way to findings that support a particular argument 
(Weiss, 1991). This problem can be overcome by bridging the gap between what 
knowledge is needed by policymakers and what is provided by researchers, as well as 
what the research tells us and how the information gets used by the policymakers 
(Ritter, 2011; Weiss, 1977, 1979). There are also concerns about what sort of evidence 
is deemed “acceptable” by policymakers, who can select evidence that suits specific 
political agendas and to seek justification for their decision on policy (Bacchi, 2009; 
Nagel, 1990; Weiss, 1998, 1999). This is made more complex by the nature of evidence 
available which is often vast, uneven in quality and inaccessible to policymakers 
(Brownson et al., 2009; Davies et al., 2000). More medical cannabis research is also 
needed to assist creation of more evidence-based policies and making the evidence more 
accessible to policymakers and the public (Strang, Witton, & Hall, 2000).  
However, having a debate about the evidence may not necessarily be a bad 
thing. In an article that can still be applied to what we have seen in the medical cannabis 
debate to date, Majone (1979) said that “The real problem facing regulating bodies 
today is not the existence of conflicting expert opinions, but the inability of existing 
procedures to channel disagreement toward constructive purposes” (p. 572). While 
Majone recognised that regulatory decisions are increasingly based on arguments and 
judgements about competing benefits and risks rather than facts, he also encouraged this 
conflict as a way to educate the public. Because public opinion plays a significant role 
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in influencing policy, it is important to consider how well informed the public is and 
what sort of information they are getting. 
Ideally, scientific evidence should always be incorporated in selecting and 
implementing programs, developing policies, and evaluating progress (Brownson, et al., 
2011). The approval of any drug for medical use should also ideally be based on 
evidence rather than political considerations (Cohen, 2010). However, this study is 
consistent with the literature which finds that the policy process is inherently political 
and does not rely solely on research evidence (Anderson, 2003; Brownson et al., 2009; 
Brownson et al., 2011; Pentz, et al., 2004; Ritter, 2011). If research evidence was used 
to drive policy, then cannabis would be recommended only for use as a medicine for the 
conditions that the evidence supports, with some flexibility in relation to a conservative 
or liberal interpretation of the research evidence. Smoked cannabis would also not be 
the preferred route of administration. However, this is not the case in those states which 
have enacted medical cannabis laws. For example, in New Mexico, medical conditions 
included in the law go beyond the scope of currently available evidence and is also open 
to adding other medical condition as approved by the NMDH. This supports Weiss’ 
“enlightenment model” that the impact of research on policy is not direct, but research 
is instead seen as one of several sources of information available to policymakers 
(Weiss, 1977, 1979). The other factors which were found to influence the medical 
cannabis policy process are discussed next.   
 The findings of this study have indicated that scientific evidence does play a 
role in the policy process, but not as significant a role as one may think, or as scientists 
may like. While scientific evidence is one factor of influence, it is often not used in the 
manner scientists would prefer but rather as ammunition to support an already adopted 
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position. Contrary to what is generally believed, the medical cannabis process appears 
to be less medically and more politically driven, and scientific evidence tends to fall 
behind in its level of influence (Black, 2001). In this study, it is suggested that political 
issues play a more central role than evidence. Factors such as the decoupling of medical 
cannabis from wider moves to decriminalise or legalise cannabis are important, as are 
anecdotal reports of those who have or could potentially benefit from medical cannabis, 
and organised, well-funded advocacy groups. National advocacy groups can play an 
important role, especially in states with a ballot initiative process. The success or failure 
of a law can also depend upon context, timing, and persistence. As the U.S. is a 
democratic republic, it is important to consider public opinion, which tends to play more 
of a role in the states with a ballot initiative process. Public opinion is also taken into 
account by politicians making policy decisions, amongst other factors that they need to 
take into account, such as whether making a certain decision will work in their favour or 
against them. While the support of powerful politicians can be important, as in the case 
of New Mexico, lack of such support does not prevent such laws being enacted, as the 
case of Michigan illustrates.  
There are many factors which need to be taken into consideration when looking 
at the political process and how certain laws are enacted. When questioned about the 
factors influencing the medical cannabis process, there was no major difference noted in 
terms of the importance of the factors. Depending on the person and the context, 
generally all the factors identified in this thesis were rated as important. While the 
factors mentioned in Chapters Four to Six can affect the policy process, they are not 
free-standing and there is a relationship between the factors. There is a complex 
relationship between science, public opinion, and political action and the decisions in 
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the policymaking process are the cumulative result of interactions between the many 
actors involved in the process (Kingdon, 1995; Sabatier, 1999; Speck, 2010; Wolf, 
2000). In the case of medical cannabis, media coverage can influence public opinion, 
which in turn can influence political actors. For example, the review of the five states 
indicated that there was significant media coverage of the medical cannabis debate in 
Michigan.This resulted in national organisations putting their efforts into passing a 
medical cannabis law in that state. As the law was passed by a ballot initiative, the 
public had to be informed in order to make a decision and vote for or against the issue. 
The national advocacy organisations used media in order to promote their stance, and 
while the opposition attempted the same, it did not do it on a large scale. In New 
Mexico, there was a similar relationship between the media and the public, except that 
New Mexico does not have the ballot initiative process, and the focus there was on 
getting the support of the politicians. It is evident, based on the previous discussion of 
what politicians take into account, that they took heed of public opinion whilst deciding 
whether or not to pass a medical cannabis law. While it is difficult to conclude that had 
media portrayed the issue differently or not portrayed it at all, it would not affect the 
public’s perspective on the issue and that the laws would have been passed anyway, it is 
also possible that the interplay between the three factors positively influenced the 
outcome.  
Kingdon (1995) viewed the three policy streams in his model as separate until 
they come together to create a policy “window of opportunity”. Kingdon viewed these 
three streams as largely independent of each other. While going beyond agenda setting, 
the findings of this study indicate that the different factors co-exist and interact in 
multiple ways. Some argue that a single framework cannot explain all its facets and it is 
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difficult to reach consensus on which is the “best” or most satisfactory approach 
(Anderson, 2003; Weible et al., 2012). This thesis did not focus on a particular 
framework instead adopted the approach of the Institute of Medicine (IOM) (1999) 
study which recommend commencing policy analysis by describing what happened with 
no predetermined framework identified. However, future studies may use a framework 
to attempt to explain the policy process. One framework, based on Kingdon’s (1995) 
policy stream model, that could potentially prove a good explanation for the medical 
cannabis policy process is described by Howlett, McConnell, and Perl (2013) as “A 
Five Stream ‘Confluence’ Model”. This incorporates five different streams and involves 
thinking about policymaking as a sequence of stages of the policy process, and sees the 
streams as interacting and nested within others. 
 It would be difficult for the factors identified in this thesis not to interact. For 
example, in relation to scientific evidence and limited access to it by the general public, 
the media plays a role by filtering the evidence and presenting it to the public who then 
make their opinions known, and these opinions are then taken into account by 
politicians. Advocates also play a role in disseminating the evidence, as do the 
researchers themselves. This then creates a set of interactions, which, although not 
entirely predictable in terms of the outcome, have the ability to change the policy 
making process. However, timing is important and can determine the success or failure 
of the interaction. Researchers should understand that these factors should not be 
interpreted individually as they do not make the policy process on their own, but are 
rather part of a complex, interactive, and ongoing process, dependent on context and 
time. The goal is to draw lessons from each of the factors and their interactions and 
identify how science can best be part of the interplay. 
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The context in which a law change is proposed, finding the right timing, and 
most importantly, persistence, are also important factors to consider. In the states with 
medical cannabis laws reviewed here, the advocacy efforts have been widespread. 
Medical cannabis laws were not created overnight and were the result of persistent 
effort by medical cannabis supporters to put the issue in the public arena, raise public 
support and, in the case of Michigan, get the issue on the ballot. In the case of New 
Mexico, medical cannabis supporters were constantly introducing medical cannabis 
bills, sometimes more than one at a time. However, while the efforts in Illinois have 
been just as persistent, a medical cannabis law is yet to be passed. Kentucky and 
Louisiana have never had such efforts.  
This is where the question of timing comes in. Throughout the literature, there 
are references made to the importance of timing in the political context: when a 
particular issue is introduced, when announcements are made and when bills are 
introduced (Gibson, 1999; Kingdon, 1995). Gibson (1999) argued that the timing of 
political events did not happen by chance, with politicians attempting to influence the 
timing in order to maximise benefits and draw public attention to a particular issue or 
draw it away if needed. In the case of New Mexico, this was evident in Gov. Johnson’s 
decision to support medical cannabis in his last term as a governor, when he was not up 
for re-election. His views continued to cause controversy, and an article published in the 
Chicago Tribune noted that Gov. Johnson did not make his position on drug use clear 
until his second term as a governor. This decision, however, had consequences as his 
approval rating dropped by 11 points. It is therefore not enough to just put an issue 
forward but to identify the right time to do so, based on careful consideration of factors 
such as public support and sentiment and likelihood and desire of being re-elected. The 
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findings in this thesis support Kingdon’s assertion that policy change occurs when a 
“window of opportunity” opens for policy change. Timing was therefore an important 
factor in medical cannabis policy creation.  
Also related to timing is the change in the perceptions of medical cannabis. As 
discussed in Chapter One’s history of medical cannabis, the public perceptions of the 
drug have undergone change in the past 100 years. For example, previous to 1914, 
cannabis was readily available in the U.S. (Grinspoon, 2000; IOM, 1999; Ruiz, et al., 
2007). Then, gradually, in the context of major social reforms, the Harrison Act saw the 
federal government not only collecting taxes and ensuring registration of drug users, but 
also the prosecution of doctors that prescribed the drugs (McBride, et al., 2009; Musto, 
1999). Cannabis’ recreational use increased and it became popular among minorities, 
including African-Americans and Mexican immigrants, who were feared as a source of 
crime and deviant social behaviour (Musto, 1999). This saw the emergence of reports of 
negative effects of cannabis and the drug being viewed as evil, which subsequently led 
to cannabis use being prohibited in every state by 1937 (Gieringer et al., 2008; Mack & 
Joy, 2000; Marshall, 2005; Musto, 1999). Despite an increase in cannabis use in the 
1960s, which was also a period of economic growth in the U.S. and the drug becoming 
a political issue, associated with anti-war protests,  it remained legal under federal law 
until the CSA was created in 1970 (Musto, 1999). What then followed is an attempt by 
activists to portray the use of the drug as a medical necessity, starting with Robert 
Randall's use of the "medical defence to defend himself against cannabis charges 
(Gieringer et al., 2008), followed by the creation of the NORML organisation. One 
Group Two participant said:  
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“My impression is that the medical cannabis movement (i.e. 
smoked cannabis, not THC pills) is partly an effort to show that cannabis 
is a benign substance…” (G2-3, Illinois).  
Since then the federal government has maintained that cannabis deserves its 
Schedule I classification, and that there is no evidence to show otherwise. However, 
there were shifts in 1978 when New Mexico became the first state to pass legislation 
recognising cannabis as a medicine and subsequently 34 states had enacted legislation 
which allowed their health departments to conduct research on the effectiveness of 
cannabis as a medicine under the IND program (Koch, 1999; Werner, 2001). However, 
the IND program was terminated and has not been revived since. Despite the lobbying 
effort, it was not until 1996 that California became the first state to legalise the 
cultivation, possession and use of cannabis for medical purposes that the medical 
cannabis movement gained momentum and the public recognised the need for cannabis 
as a medicine (MPP, 2013; Zeese 1999).  
Michigan and New Mexico’s medical cannabis laws came to pass following the 
first such law passed in California in 1996. States such as Michigan and New Mexico 
also had ineffective medical cannabis and therapeutic research laws from 1978 which 
they were trying to revive. Some medical cannabis laws are similar to that of California 
while there are also variations in the state laws. New Mexico’s law was the first in the 
country to specifically instruct the state to develop and implement a cannabis production 
and distribution system, in response to criticism of the California law which led to 
difficulties in medical cannabis production and distribution. In New Mexico, there were 
regular calls from the medical cannabis proponents and the Department of Health to 
model New Mexico’s medical cannabis program on Hawaii and Oregon’s, as they were 
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deemed to be the most effective. Due to the states being subjected to similar pressures 
and the expanding amount of information available, it can be said that policymakers are 
looking to other political systems for knowledge and ideas that they can apply to their 
jurisdictions, as was the case with New Mexico’s legislature (Dolowitz & Marsh, 2000; 
Wolf, 2000). Wolf (2000) noted that there is no such thing as  “best public 
administration” but there are instead good and better practices which need to be 
identified on the basis of national needs and the requirements for adaptation to the 
political and administrative context in which they are to be applied. While there are 
variations in state approaches to medical cannabis issues, policymakers should look to 
other states to determine those parts of medical cannabis laws that have proven to be 
effective, and apply it to their law. This will then, perhaps, lead to a more uniform 
approach to medical cannabis laws across the states. However, policy transfer is not an 
“all or nothing” process and the type of transfer likely to occur is subject to a number of 
factors such as the actors involved in the process, the resources and time available to 
them, and the nature of the problem they face (Dolowitz & Marsh, 2000).  
Some may argue that it was not by coincidence that the first medical cannabis 
law was passed by the ballot initiative process. As Watts (2010) notes, the past two 
decades saw an increase in initiatives in the U.S. The initiative process is useful in cases 
where law makers are unwilling to enact or consider a law that the citizens want, and in 
the case of medical cannabis, after the attempts to reschedule cannabis since the CSA 
have failed, attention turned to state measures (Watts, 2010).  As discussed in Chapter 
Two, the initiative process has largely become influenced by money and large interest 
groups, but ultimately must involve mass audiences in order to place an issue on the 
ballot and win on election day (Boehmke & Bowen, 2010; Braunstein, 2004; Magleby, 
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1998). The issue, however, is that the literature has found that voters often lack 
education and competence to make policy decisions which allows for the elites to 
influence voters’ choice (Burnett & Parry, 2014; Matsusaka, 2005).  
So if the voters are uninformed about public policy, politics and government, 
damaging policy may be adopted as a result. If the goal is to make more evidence-based 
policy, then it is important to consider, especially in states with the initiative process, 
the role science plays in informing the public and how scientific information can be 
made more accessible to them. This view is also supported by Sabatier (1988) who 
encouraged policy debates in order for policymakers to broaden their perspectives 
beyond the ideological concerns and self-interest. Sabatier (1988) said that exposure to 
competing views and justifying one’s position in a public forum would lead to a more 
thought out policy. Therefore, as suggested by Majone (1979) steps need to be taken 
encourage conflict about the evidence and a process where alternatives are encouraged, 
particularly when the evidence is mixed. As Majone (1979) concluded:  
By ensuring the representation of conflicting opinions and the 
examination of a wide range of alternatives, well-designed procedures 
can greatly improve not only the rationality but also the legitimacy of 
regulatory decisions. (p. 580).  
The results from the group studies discussed in Chapters Five and Six indicate 
the participants’ beliefs that scientific evidence enters the debate more when the medical 
cannabis laws are passed by the legislature than by the initiative process. The 
participants also noted a difference in the factors influencing the debate at the legislative 
and initiative level. They can also lead to different outcomes and improvements upon 
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the laws in other states, such as New Mexico’s law being the first in the country to 
specifically instruct the state to develop and implement a cannabis production and 
distribution system, in order to assist patients in obtaining the drug (Lynn and Erin 
Compassionate Use Act, 2007; MPP, 2013). Based on the findings in this study, a better 
way of approaching medical cannabis policy may be to move the debate to the 
legislature. There has already been an increase in states passing medical cannabis laws 
through the legislative process, and this may be the way to go in order to increase the 
use of science in the medical cannabis policy field (MPP, 2013). After all, government 
elites tend to be more reflective of their constituents’ views because of their greater 
electoral accountability and exposure to opponents’ views, whereas interest groups, who 
largely influence the initiative process, tend to be more extreme in their views than their 
constituents (Sabatier, 1988).  
Conclusion  
This thesis looked at the medical cannabis process in five representative U.S. 
states and sought to identify the role of scientific evidence in the medical cannabis 
policy process and other factors of influence. It provided an in-depth view of the 
medical cannabis process in five representative states, and individual experiences of the 
medical cannabis policy process through the eyes of those who were directly involved 
in it. It also examined the process from the views of those not directly involved in the 
process but conducting research in the alcohol and other drug field, and those 
individuals who have expertise in drug policy research. This thesis also drew attention 
to areas that need to be addressed by future research, such as the limitations of the 
currently available scientific evidence, the need for further studies, and increasing the 
role of scientific evidence in what is essentially a medical field. 
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The study found that, despite the expectation that the same rules would apply to 
cannabis as other medicine, the medical cannabis process appears to be less medically 
and more politically driven, and scientific evidence tends to fall behind in its level of 
influence. Factors such as political ideology, the initiative process in some states, 
political timing, and interest groups tend to play a role in the process and more so than 
scientific evidence. While this study recommended more research into cannabis as a 
medicine, it is recognised that this is made difficult by cannabis being placed in 
Schedule I of the Controlled Substances Act. Cannabis’ rescheduling would potentially 
lead to more studies, especially long-term studies which are lacking. However, it is 
unlikely that cannabis will be rescheduled in the near future, so the attention needs to be 
turned to how the evidence can be used to assure that effective medical cannabis laws 
are passed and that there is a more uniform approach across the states passing such 
laws. There are also opportunities to improve the laws and how they are implemented, 
through taking a more evidence-based approach. This study suggests that the first step 
to doing this is for the debate to shift to the legislative process and for more systematic 
effort being dedicated to educating the public and the policymakers. A collaborative 
approach between researchers and policymakers is also recommended.  
Although a controversial issue and still in the early stages of scientific 
exploration, the topic of cannabis and its role as a medicine is nonetheless an important 
one. It is an issue which should be further explored on both an individual and political 
level, in order to develop successful laws which would benefit society and increase 
knowledge of what it takes to create an effective law. It should also be questioned why, 
if cannabis is a medicine, it is not treated as such, and what could be done to enable its 
treatment as a medicine, such as undergoing the FDA approval process, giving 
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physicians the ability to prescribe it, and controlling it in the same way other medicines 
are controlled.  
It is hoped that this thesis will be viewed as an observation of the medical 
cannabis process, not only from the researcher’s point of view but from the views of 
those who participated in the process, researched the process, or observed the changes 
in medical cannabis laws over the years. It is anticipated that, by reporting the results of 
this research, the main factors influencing the policy formation process can be identified 
and that information used by researchers and those involved in the policy process as a 
guide to improving the role of evidence in the medical cannabis movement. Ideally, 
scientific evidence would be incorporated into all levels of policy decision-making and 
the researchers would work collaboratively with policymakers to provide the knowledge 
that is needed by the policymakers, while not losing sight of the best evidence.  
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Appendix A- Questionnaire for Group One 
 
Factors Influencing Medical Cannabis Policy Development in the United States 
Dear participant,  
Thank you for agreeing to take part in this study of the processes that led, or did 
not lead, to the enactment of medicinal cannabis legislation in Michigan, New Mexico, 
Illinois, Kentucky, and Louisiana.  
 
Please note that you will remain anonymous and no responses will be 
attributed to any individual.  
 
Through the review of the published media reports relating to medical cannabis, 
you have been identified as having actively participated in the medical cannabis debate 
in one of the following states: a) Michigan; b) New Mexico; c) Illinois; d) Kentucky; or 
e) Louisiana.  
Please indicate which state you were MOST ACTIVELY participating in during 
the 2000-2010 time period (select ONE).  
___ Michigan 
___ New Mexico 
___ Illinois 
___ Kentucky 
 Medical Cannabis in the United States     442 
 
___ Louisiana 
___ More than one state * 
     * Because of the nature of these questions, we ask that you specify one state 
where you had most involvement by selecting it below: 
 
___ Michigan           ___New Mexico          ___ Illinois          ___ Kentucky          
___Louisiana 
 
As you answer the following questions, could you please answer in relation to 
the state you specified. Should you wish to make additional comments in relation to 
other states, please refer to Section 3 “Additional comments”. 
 
 
 
This section relates to your opinions on medical cannabis and the medical 
cannabis debate in your state. For the following statements, please indicate if you 
strongly agree, agree, disagree, strongly disagree or do not know by circling the 
letter (a, b, c, d, or e) that best reflects your view.  
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SECTION 1 
 
1. I support legislation to make cannabis legally available for medicinal purposes  
a) Strongly Agree 
b) Agree 
c) Disagree 
d) Strongly Disagree 
e) Don’t know 
2. Cannabis can be used effectively as a medicine 
a) Strongly Agree 
b) Agree 
c) Disagree 
d) Strongly Disagree 
e) Don’t know 
3. Cannabis is a gateway to the use of other illicit drugs 
a) Strongly Agree 
b) Agree 
c) Disagree 
d) Strongly Disagree 
e) Don’t know 
4. More research is needed on cannabis as a medicine 
a) Strongly Agree 
b) Agree 
c) Disagree 
d) Strongly Disagree 
e) Don’t know 
5. Scientific evidence plays an important role in the passing of medical cannabis 
legislation 
a) Strongly Agree 
b) Agree 
c) Disagree 
d) Strongly Disagree 
e) Don’t know 
6. Laws to allow the use of cannabis as a medicine should be implemented in all 
U.S. States 
a) Strongly Agree 
b) Agree 
c) Disagree 
d) Strongly Disagree 
e) Don’t know 
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7. Laws to allow the use of cannabis as a medicine should be implemented at the 
federal level 
a) Strongly Agree 
b) Agree 
c) Disagree 
d) Strongly Disagree 
e) Don’t know 
8. It is important to separate medical cannabis legalization from the broader drug 
legalization agenda 
a) Strongly Agree 
b) Agree 
c) Disagree 
d) Strongly Disagree 
e) Don’t know 
For Items 9-17, consider how important each of the following is to whether 
medical cannabis legislation is enacted or not: 
9. Advocacy groups  
a) Very Important 
b) Somewhat Important 
c) Somewhat Unimportant 
d) Very Unimportant 
e) Don’t know 
10. The extent to which advocacy groups are well organized  
a) Very Important 
b) Somewhat Important 
c) Somewhat Unimportant  
d) Very Unimportant 
e) Don’t know  
11. Politicians  
a) Very Important 
b) Somewhat Important 
c) Somewhat Unimportant 
d) Very Unimportant 
e) Don’t know 
12. The amount of money available to both legalization advocates and opponents 
a) Very Important 
b) Somewhat Important 
c) Somewhat Unimportant 
d) Very Unimportant 
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e) Don’t know 
13. Testimonies from people who have used cannabis as a medicine  
a) Very Important 
b) Somewhat Important 
c) Somewhat Unimportant 
d) Very Unimportant 
e) Don’t know 
14. The support of the executive branch of the state government (i.e., the governor)  
a) Very Important 
b) Somewhat Important 
c) Somewhat Unimportant 
d) Very Unimportant 
e) Don’t know 
15. The support of the legislative branch of the state government (Senate and the 
House of Representatives)  
a) Very Important 
b) Somewhat Important 
c) Somewhat Unimportant 
d) Very Unimportant 
e) Don’t know 
16. Public support  
a) Very Important 
b) Somewhat Important 
c) Somewhat Unimportant 
d) Very Unimportant  
e) Don’t know 
17. The media  
a) Very Important 
b) Very Unimportant 
c) Somewhat Unimportant 
d) Very Unimportant 
e) Don’t know 
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The following set of questions will enable us to group responses and to sort 
the data collected. Please note that you will remain anonymous and no responses 
will be attributed to any individual.  
18. In the table below, please rate (by marking the corresponding box) the following 
in terms of the level of influence you believe they have on medical cannabis 
legislation (0= no influence, 5= some influence, 10=very high influence).                                      
 
                                                 No                 Very Little          Some              Very       
                                             Influence           Influence          Influence          High 
                                                                                                                         Influence                                                                                                                 
 0 1 2 3 4 5 6 7 8 9 10 
Advocacy groups            
High-profile individuals            
Money            
Lobbyists            
Opposition groups            
Patient testimonies            
Support in the legislature            
Public support            
Media support            
 
19. Have you or anyone you know used cannabis for medical purposes or 
recreational use? (You can give more than one response). 
a) Yes, I have personally used cannabis for medical purposes 
b) Yes, I know someone who has used cannabis for medical purposes 
c) No 
d) Yes, I have used cannabis for recreational purposes 
e) Yes, I know someone who has used cannabis for recreational purposes 
f) I opt not to disclose this information  
 
20. Which of the following most accurately describes your political affiliation? 
a) Democrat 
b) Republican 
c) Other ____________ please specify 
You have now completed the first section of the questionnaire. 
 Medical Cannabis in the United States     447 
 
SECTION 2 
The following section will provide you with an opportunity to expand on the 
answers you provided in the first section of this questionnaire.  There is no limit on 
the length of your answer. If more space is required, simply attach as many pages 
as you need. Please answer to the best of your ability.  
 
The first part of this section contains general questions relating to the 
medical cannabis debate and the factors influencing medical cannabis legislation.  
1) In your opinion, which factors influenced the passing or failure to pass medical 
cannabis legislation in your state?  
 
 
 
 
2) Does scientific evidence play a role in the medical cannabis debate in your state? 
If so, what role does it play? 
 
 
3) Does the separating of medical cannabis from the broader aim of cannabis 
legalization have an impact on the medical cannabis debate in your state? If so, 
what impact does it have? 
 
4) Please describe the role politicians played or are playing in the medical cannabis 
debate in your state. 
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The second part of this section consists of more specific questions relating to 
factors influencing the medical cannabis debate in Michigan, New Mexico, Illinois, 
Kentucky, and Louisiana.   
5) What effect did or does the involvement of national advocacy organizations, 
such as the Marijuana Policy Project (MPP) and the National Organization for 
the Reform of Marijuana Laws (NORML), have on the medical cannabis debate 
in your state? 
 
 
6) What effect did or does the involvement of the Office of National Drug Control 
Policy (the “Drug Czar”) have on the medical cannabis debate in your state? 
 
 
7) What are your views on the way money was or is used in your state, in relation 
to the medical cannabis debate? 
 
 
 
8) Some U.S. states have a ballot initiative process for proposing a new law or a 
constitutional amendment at the state level. Other states do not have the 
initiative process and rely on the legislative branch of government.  
 
What are your views on the effect these differing processes have on the medical 
cannabis debate in your state?  
 
 
 
 
9) What are your views on the role state-based organized lobby groups had on the 
medical cannabis debate in your state? 
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10) In some U.S. states, city-level changes to medical cannabis legislation preceded 
changes at the state level. 
 
What are your views on the effect city-level changes have on the state-level 
medical cannabis legislation? 
 
 
END OF QUESTIONNAIRE 
Thank you for taking your time to participate in this study. We appreciate 
your responses.  
If you would like to leave comments regarding this questionnaire or would 
like further information, please contact Jelica Grbic (researcher) by telephone 
(+61 86304 2654 or +381 61 422 345 397) or email (jgrbic@our.ecu.edu.au).  
If you would like to obtain further information regarding the results of the 
study, a summary will be made available to you by the researcher upon request.   
 
SECTION 3 
Additional Comments 
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Appendix B- Additional Questions for Group Two  
 
Dear participant, 
 
Thank you for agreeing to take part in this study of the processes that led, or did not 
lead, to the enactment of medicinal cannabis legislation in Michigan, New Mexico, 
Illinois, Kentucky, and Louisiana. You have the option of saving your answer and re-
opening the site to complete the questionnaire at a later time (no later than January 
14th 2011). 
  
Please note that you will remain anonymous and no responses will be attributed to any 
individual. 
  
Through the review of publicly available data, you have been identified as a researcher 
in the alcohol and other drug field, currently receiving a grant from the NIAAA, NIDA, 
or SAMHSA* in one of the following states: a) Michigan; b) New Mexico; c) Illinois; 
d) Kentucky; or e) Louisiana. 
  
* Please disregard this survey if you are not currently or have not in the 
past conducted research funded by NIAAA, NIDA or SAMHSA. 
  
  
  
Please indicate which state you currently conduct alcohol and other 
drug related research in (select ONE).  
Michigan 
New Mexico 
Illinois 
Kentucky 
Louisiana 
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Please indicate your awareness of the medical cannabis debate in your state 
Very aware 
Somewhat aware 
Neither aware nor unaware 
Somewhat unaware 
Very unaware 
 
Please indicate the level of your involvement in the medical cannabis debate in 
your state 
Very involved 
Somewhat involved 
Neither involved nor uninvolved 
Somewhat uninvolved 
Very uninvolved 
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Appendix C- Informational Email  
 
Subject name: Factors Influencing Medical Cannabis Policy Development in the United 
States 
 
Dear (Potential Research Participant’s Name) 
My name is Jelica Grbic, and I am a PhD student in the Faculty of Computing, 
Health and Science at Edith Cowan University (ECU), Western Australia. I am 
conducting research under the supervision of Dr. David Ryder (Faculty of Computing 
Health and Science, ECU) and Professor Perilou Goddard (Department of Psychology, 
Northern Kentucky University).  
You are invited to participate in a research study looking at the policy process 
underlying medical cannabis laws in the U.S.A, aiming to identify how problems and 
issues are recognized and raised, and how and why governments choose to act or not act 
on certain policies. Through a review of the literature, you have been identified as 
someone who could comment on the policy process, and we are interested in hearing 
about your experiences.  
As a participant in this study, you will be asked to answer questions through an 
internet survey. The survey can be accessed on the following link 
http://ecupsych.qualtrics.com/SE/?SID=SV_0HCbC6H8BbrdRQM . 
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The questions will ask you about the medical cannabis policy process which lead 
to laws being passed or not passed.   
Participation in this research project is voluntary, and will take approximately 1 
hour of your time. You will not be asked to provide any personally-identifying 
information. There are no anticipated risks or discomforts related to this research, 
except for the time you take to answer the research questions. You may decline to 
answer any questions presented during the study if you wish to do so. You will be free 
to withdraw your consent and cease your involvement in the research project at any 
time.  
Due to the nature of your involvement in the policy creation field, you will be 
identified in the research project, but not identified by the questionnaire. However, 
should you wish to do so, you will be able to request anonymity, upon which the 
researcher will remove all the identifying information relating to you from the project, 
and your information will be presented using numerical codes. The data with identifying 
information will be kept for a period of five years following the completion of the 
research, after which it will be destroyed. The data will be securely locked in an office 
in Edith Cowan University, to which only the researcher and the supervisors will have 
access. 
The benefits of participation in this study include an opportunity to raise issues 
relevant to you, and offer your perspective on the medical cannabis policy process. You 
will also gain insight into what challenges helped shape your experiences and ways in 
which this occurred. You will also be able to express your wishes for future policy 
development.  
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If, after receiving this email, you have any questions about this study or would 
like additional information to assist you in reaching a decision about participation, 
please feel free to contact me or either of my supervisors using the information supplied 
below. If you would like to obtain the final results of this research, you may also contact 
me on the numbers/email supplied below. If you wish to speak to someone independent 
of this research, please contact the Postgraduate Coordinator in Public Health (ECU) 
Kim Clark, whose contact details are supplied below.  
This research has been approved by the Human Research and Ethics Committee 
at Edith Cowan University.  
If upon reading the information presented here you wish to participate in this 
research project, please reply to this email and indicate your consent by writing the 
following into the e-mail message: “I have read the above information regarding this 
research study on medical cannabis policy in the U.S, and consent to participate in this 
study”.  
 
Thank you for your interest in this research and for your assistance.  
 
Regards 
Jelica Grbic 
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Researcher’s contact details 
Jelica Grbic 
PhD Candidate  
Faculty of Computing, Health and Science 
Edith Cowan University 
Telephone:  (08) 6304 2654 
Mobile: +61422345397 
Email: jgrbic@student.ecu.edu.au 
 
Supervisors 
Dr David Ryder  
Coordinator of Clinical Psychology Courses  
School of Psychology and Social Science  
Edith Cowan University, JOONDALUP 
Telephone:   (08) 6304 5452  
Facsimile:      (08) 6304 5834  
Email:   david.ryder@ecu.edu.au 
 
 
Professor Perilou Goddard, Ph.D. 
Department of Psychology 
Northern Kentucky University 
BEP 355, Nunn Drive 
Highland Heights, KY 41099 
Telephone:  859 572 5463 
Facsimile:    859 572 6085 
Email: goddard@nku.edu 
 
Independent Contact 
Kim Gifkins 
Research Ethics Officer 
Edith Cowan University, JOONDALUP 
Telephone:  (08) 6304 2170 
Facsimile:    (08) 6304 2661 
Email: research.ethics@ecu.edu.au 
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Appendix D- Information Letter  
 
Subject name:  Factors Influencing Medical Cannabis Policy Development in the United 
States 
Dear   
My name is Jelica Grbic, and I am a PhD student in the Faculty of Computing, 
Health and Science at Edith Cowan University (ECU), Western Australia. I am 
conducting research under the supervision of Dr. David Ryder (Faculty of Computing 
Health and Science, ECU) and Professor Perilou Goddard (Department of Psychology, 
Northern Kentucky University).  
You are invited to participate in a research study looking at the policy process 
underlying medical cannabis laws in the U.S.A, aiming to identify how problems and 
issues are recognized and raised, and how and why governments choose to act or not act 
on certain policies. Through a review of the literature, you have been identified as 
someone who could comment on the policy process, and we are interested in hearing 
about your experiences.  
As a participant in this study, you will be asked to answer questions included in 
this letter. After completion we ask that you return the questionnaire to us in an 
envelope provided by December 10th 2010. The questions will ask you about the 
medical cannabis policy process which lead to laws being passed or not passed.   
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Participation in this research project is voluntary, and will take approximately 1 
hour of your time. You will not be asked to provide any personally-identifying 
information. There are no anticipated risks or discomforts related to this research, 
except for the time you take to answer the research questions. You may decline to 
answer any questions presented during the study if you wish to do so. You will be free 
to withdraw your consent and cease your involvement in the research project at any 
time.  
Due to the nature of your involvement in the policy creation field, you will be 
identified in the research project, but not identified by the questionnaire. However, 
should you wish to do so, you will be able to request anonymity, upon which the 
researcher will remove all the identifying information relating to you from the project, 
and your information will be presented using numerical codes. The data with identifying 
information will be kept for a period of five years following the completion of the 
research, after which it will be destroyed. The data will be securely locked in an office 
in Edith Cowan University, to which only the researcher and the supervisors will have 
access. 
The benefits of participation in this study include an opportunity to raise issues 
relevant to you, and offer your perspective on the medical cannabis policy process. You 
will also gain insight into what challenges helped shape your experiences and ways in 
which this occurred. You will also be able to express your wishes for future policy 
development.  
If, after receiving this mail, you have any questions about this study or would 
like additional information to assist you in reaching a decision about participation, 
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please feel free to contact me or either of my supervisors using the information supplied 
below. If you would like to obtain the final results of this research, you may also contact 
me on the numbers/email supplied below. If you wish to speak to someone independent 
of this research, please contact the Postgraduate Coordinator in Public Health (ECU) 
Kim Clark, whose contact details are supplied below.  
This research has been approved by the Human Research and Ethics Committee 
at Edith Cowan University.  
If upon reading the information presented here you wish to participate in this 
research project, please indicate your consent by writing the following statement on the 
tear-off docket below: “I have read the above information regarding this research 
study on medical cannabis policy in the U.S, and consent to participate in this 
study”.  
Thank you for your interest in this research and for your assistance.  
Regards 
Jelica Grbic 
 
 
Please write your consent here and return with the questionnaire.  
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Researcher’s contact details 
Jelica Grbic 
PhD Candidate  
Faculty of Computing, Health and Science 
Edith Cowan University 
Telephone:  (08) 6304 2654 
Mobile: +61422345397 
Email: jgrbic@student.ecu.edu.au 
 
Supervisors 
Dr David Ryder  
Coordinator of Clinical Psychology Courses  
School of Psychology and Social Science  
Edith Cowan University, JOONDALUP 
Telephone:   (08) 6304 5452  
Facsimile:      (08) 6304 5834  
Email:   david.ryder@ecu.edu.au 
 
 
 
Professor Perilou Goddard, Ph.D. 
Department of Psychology 
Northern Kentucky University 
BEP 355, Nunn Drive 
Highland Heights, KY 41099 
Telephone:  859 572 5463 
Facsimile:    859 572 6085 
Email: goddard@nku.edu 
 
Independent Contact 
Kim Gifkins 
Research Ethics Officer 
Edith Cowan University, JOONDALUP 
Telephone:  (08) 6304 2170 
Facsimile:    (08) 6304 2661 
Email: research.ethics@ecu.edu.au 
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Appendix E- Group Four Interview Questions 
 
Semi-Structured Interview Schedule 
Demographic information 
What is your current occupation?  
Have you ever conducted research into drug policy?  
Prompt: Please tell me a bit more about your research. What did your 
research mainly focus on?  
Have you ever studied policies on the use of cannabis as a medicine? 
 
1) What role do you think scientific evidence generally plays in policy-making?  
Prompt: How do you think scientific evidence influences government 
recognition of a particular issue as requiring consideration and / or action? 
Prompt:  More specifically, what role do you think scientific evidence plays 
in policies related to alcohol and other drugs?  
Prompt: What role do you think scientific evidence plays in passing medical 
cannabis policies?  
2) How do you think scientific evidence is used by individuals directly or indirectly 
involved in policy creation (e.g. politicians, lobbyists, and the voting public)? 
Prompt: Can you please give specific examples to illustrate the view you 
have just given?  
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3) It is a belief held by some medical cannabis opponents that insufficient research 
has been conducted on medical cannabis to warrant a policy change. What is 
your opinion on this?  
4) Which factors influence the policy making process? And specifically, drug 
policy related process?  
Prompt: Which factors are important for politicians to take into account 
when making policy-related decisions?  
5) What are some of the notable differences between the role scientific evidence 
plays in general and medical cannabis-related policy making? 
6) In your opinion, which factors influenced the passing of medical cannabis 
legislation in 15 US states (such as California, Michigan, and New Mexico) 
since 1998?  
7) What role do you think the scientific evidence played in passing medical 
cannabis laws in 15 US states?  
8) In your opinion, what role will scientific evidence play in the future in relation 
to policy making?  
9) It has been said that scientific evidence does not play a significant enough role in 
informing alcohol and other drug policies. Do you agree with this statement and 
if you do, what do you think we can do to improve its significance?  
Prompt: Can you suggest how we might give scientific evidence a more 
significant role in informing policy on the use of cannabis as a medicine?  
 
